<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy - Tsujimoto, H - 2020 | Cochrane Library</title> <meta content="Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy - Tsujimoto, H - 2020 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012467.pub3/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy - Tsujimoto, H - 2020 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012467.pub3/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD012467.pub3" name="dc.identifier" scheme="DOI"/> <meta content="Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy" name="citation_title"/> <meta content="Hiraku Tsujimoto" name="citation_author"/> <meta content="Hyogo Prefectural Amagasaki General Medical Center" name="citation_author_institution"/> <meta content="hira_to_ber3598@yahoo.co.jp" name="citation_author_email"/> <meta content="Yasushi Tsujimoto" name="citation_author"/> <meta content="School of Public Health in the Graduate School of Medicine, Kyoto University" name="citation_author_institution"/> <meta content="Yukihiko Nakata" name="citation_author"/> <meta content="Shimane University" name="citation_author_institution"/> <meta content="Tomoko Fujii" name="citation_author"/> <meta content="Monash University" name="citation_author_institution"/> <meta content="Sei Takahashi" name="citation_author"/> <meta content="Mai Akazawa" name="citation_author"/> <meta content="Shiga University of Medical Science Hospital" name="citation_author_institution"/> <meta content="Yuki Kataoka" name="citation_author"/> <meta content="Hyogo Prefectural Amagasaki General Medical Center" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="12" name="citation_issue"/> <meta content="10.1002/14651858.CD012467.pub3" name="citation_doi"/> <meta content="2020" name="citation_date"/> <meta content="2020/12/14" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012467.pub3/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012467.pub3/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012467.pub3/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Acute Kidney Injury [mortality, *therapy]; Anticoagulants [*administration &amp; dosage, adverse effects]; Bias; Blood Coagulation [*drug effects]; *Catheter Obstruction [etiology]; Citric Acid [administration &amp; dosage, adverse effects]; Continuous Renal Replacement Therapy [adverse effects, *instrumentation, mortality]; Filtration [instrumentation]; Hemorrhage [chemically induced, prevention &amp; control]; Heparin [administration &amp; dosage, adverse effects]; Heparin, Low-Molecular-Weight [administration &amp; dosage, adverse effects]; Kidney [physiology]; Patient Dropouts; Randomized Controlled Trials as Topic; Recovery of Function [drug effects]; Thrombocytopenia [prevention &amp; control]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012467.pub3&amp;doi=10.1002/14651858.CD012467.pub3&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012467.pub3&amp;doi=10.1002/14651858.CD012467.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012467.pub3&amp;doi=10.1002/14651858.CD012467.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012467.pub3&amp;doi=10.1002/14651858.CD012467.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012467.pub3&amp;doi=10.1002/14651858.CD012467.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012467.pub3&amp;doi=10.1002/14651858.CD012467.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012467.pub3&amp;doi=10.1002/14651858.CD012467.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012467.pub3&amp;doi=10.1002/14651858.CD012467.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012467.pub3&amp;doi=10.1002/14651858.CD012467.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012467.pub3&amp;doi=10.1002/14651858.CD012467.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012467.pub3&amp;doi=10.1002/14651858.CD012467.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012467.pub3&amp;doi=10.1002/14651858.CD012467.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012467.pub3&amp;doi=10.1002/14651858.CD012467.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012467.pub3&amp;doi=10.1002/14651858.CD012467.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012467.pub3&amp;doi=10.1002/14651858.CD012467.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012467.pub3&amp;doi=10.1002/14651858.CD012467.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012467.pub3&amp;doi=10.1002/14651858.CD012467.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012467.pub3&amp;doi=10.1002/14651858.CD012467.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012467.pub3&amp;doi=10.1002/14651858.CD012467.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012467.pub3&amp;doi=10.1002/14651858.CD012467.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012467.pub3&amp;doi=10.1002/14651858.CD012467.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012467.pub3&amp;doi=10.1002/14651858.CD012467.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012467.pub3&amp;doi=10.1002/14651858.CD012467.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774054000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774081000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000"}};Liferay.authToken="jU9oKp1Y";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD012467\x2epub3\x26doi\x3d10\x2e1002\x2f14651858\x2eCD012467\x2epub3\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012467\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012467\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1559916434000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANS","ru","ms","ja","hr","fa","fr"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD012467.pub3",title:"Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy",firstPublishedDate:"Dec 14, 2020 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Kidney and Transplant Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738735355000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=jU9oKp1Y&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012467.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD012467.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD012467.pub3/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD012467.pub3/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012467.pub3%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD012467.PUB3" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ja&quot;,&quot;title&quot;:&quot;一般語訳&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]},{&quot;param&quot;: &quot;comments&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Comments&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD012467.pub3/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD012467.PUB3" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD012467.pub3/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD012467.pub3/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>3166 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD012467.pub3" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012467.pub3/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012467.pub3/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012467.pub3/full#CD012467-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012467.pub3/full#CD012467-sec-0219"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012467.pub3/full#CD012467-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012467.pub3/full#CD012467-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012467.pub3/full#CD012467-sec-0014"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012467.pub3/full#CD012467-sec-0015"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012467.pub3/full#CD012467-sec-0044"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012467.pub3/full#CD012467-sec-0213"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012467.pub3/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012467.pub3/appendices#CD012467-sec-0224"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012467.pub3/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012467.pub3/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/table_n/CD012467StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/table_n/CD012467StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012467.pub3/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012467.pub3/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012467.pub3/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD012467.pub3/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD012467.pub3/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD012467.pub3/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2020 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> <div class="inline-status-wrapper"> <ul class="cochrane-status"> <li aria-label="There has been an important change to the conclusions of the review." class="status-item up-to-date custom-tooltip" data-status="conclusionchanged" title="There has been an important change to the conclusions of the review."> <a class="btn secondary" href="information#history">Conclusions changed</a> </li> </ul> </div> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy </h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012467.pub3/information#CD012467-cr-0004"><i class="icon corresponding-author fa fa-envelope"></i>Hiraku Tsujimoto</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012467.pub3/information#CD012467-cr-0005">Yasushi Tsujimoto</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012467.pub3/information#CD012467-cr-0006">Yukihiko Nakata</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012467.pub3/information#CD012467-cr-0007">Tomoko Fujii</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012467.pub3/information#CD012467-cr-0008">Sei Takahashi</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012467.pub3/information#CD012467-cr-0009">Mai Akazawa</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012467.pub3/information#CD012467-cr-0010">Yuki Kataoka</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/information/en#CD012467-sec-0237">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 14 December 2020 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD012467.pub3">https://doi.org/10.1002/14651858.CD012467.pub3</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD012467-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD012467-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD012467-abs-0013">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD012467-abs-0009">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD012467-abs-0011">Français</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD012467-abs-0003">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD012467-abs-0001" lang="en"> <section id="CD012467-sec-0001"> <h3 class="title" id="CD012467-sec-0001">Background</h3> <p>Acute kidney injury (AKI) is a major comorbidity in hospitalised patients. Patients with severe AKI require continuous renal replacement therapy (CRRT) when they are haemodynamically unstable. CRRT is prescribed assuming it is delivered over 24 hours. However, it is interrupted when the extracorporeal circuits clot and the replacement is required. The interruption may impair the solute clearance as it causes under dosing of CRRT. To prevent the circuit clotting, anticoagulation drugs are frequently used. </p> </section> <section id="CD012467-sec-0002"> <h3 class="title" id="CD012467-sec-0002">Objectives</h3> <p>To assess the benefits and harms of pharmacological interventions for preventing clotting in the extracorporeal circuits during CRRT. </p> </section> <section id="CD012467-sec-0003"> <h3 class="title" id="CD012467-sec-0003">Search methods</h3> <p>We searched the Cochrane Kidney and Transplant Register of Studies up to 12 September 2019 through contact with the Information Specialist using search terms relevant to this review. Studies in the Register are identified through searches of CENTRAL, MEDLINE, and EMBASE, conference proceedings, the International Clinical Trials Register (ICTRP) Search Portal and ClinicalTrials.gov. </p> </section> <section id="CD012467-sec-0004"> <h3 class="title" id="CD012467-sec-0004">Selection criteria</h3> <p>We selected randomised controlled trials (RCTs or cluster RCTs) and quasi‐RCTs of pharmacological interventions to prevent clotting of extracorporeal circuits during CRRT. </p> </section> <section id="CD012467-sec-0005"> <h3 class="title" id="CD012467-sec-0005">Data collection and analysis</h3> <p>Data were abstracted and assessed independently by two authors. Dichotomous outcomes were calculated as risk ratio (RR) with 95% confidence intervals (CI). The primary review outcomes were major bleeding, successful prevention of clotting (no need of circuit change in the first 24 hours for any reason), and death. Evidence certainty was determined using the Grading of Recommendation Assessment, Development, and Evaluation (GRADE) approach. </p> </section> <section id="CD012467-sec-0006"> <h3 class="title" id="CD012467-sec-0006">Main results</h3> <p>A total of 34 completed studies (1960 participants) were included in this review. We identified seven ongoing studies which we plan to assess in a future update of this review. No included studies were free from risk of bias. We rated 30 studies for performance bias and detection bias as high risk of bias. We rated 18 studies for random sequence generation,Ã‚Â Ã‚Â six studies for the allocation concealment, three studies for performance bias, three studies for detection bias,Ã‚Â  nine studies for attrition bias,Ã‚Â 14 studies for selective reporting and nine studies for the other potential source of bias, as having low risk of bias. </p> <p>We identified eight studies (581 participants) that compared citrate with unfractionated heparin (UFH). Compared to UFH, citrate probably reduces major bleeding (RR 0.22, 95% CI 0.08 to 0.62; moderate certainty evidence) and probably increases successful prevention of clotting (RR 1.44, 95% CI 1.10 to 1.87; moderate certainty evidence). Citrate may have little or no effect on death at 28 days (RR 1.06, 95% CI 0.86 to 1.30, moderate certainty evidence). Citrate versus UFH may reduce the number of participants who drop out of treatment due to adverse events (RR 0.47, 95% CI 0.15 to 1.49; low certainty evidence). Compared to UFH, citrate may make little or no difference to the recovery of kidney function (RR 1.04, 95% CI 0.89 to 1.21; low certainty evidence). Compared to UFH, citrate may reduceÃ‚Â thrombocytopenia (RR 0.39, 95% CI 0.14 to 1.03; low certainty evidence). It was uncertain whether citrate reduces a cost to health care services because of inadequate data. </p> <p>For low molecular weight heparin (LMWH) versus UFH, six studies (250 participants) were identified. Compared to LMWH, UFH may reduce major bleeding (0.58, 95% CI 0.13 to 2.58; low certainty evidence). It is uncertain whether UFH versus LMWH reduces death at 28 days or leads to successful prevention of clotting. Compared to LMWH, UFH may reduce the number of patient dropouts from adverse events (RR 0.29, 95% CI 0.02 to 3.53; low certainty evidence). It was uncertain whether UFH versus LMWH leads to the recovery of kidney function because no included studies reported this outcome. It was uncertain whether UFH versus LMWH leads to thrombocytopenia. It was uncertain whether UFH reduces a cost to health care services because of inadequate data. </p> <p>For the comparison of UFH to no anticoagulation, one study (10 participants) was identified. It is uncertain whether UFH compare to no anticoagulation leads to more major bleeding. It is uncertain whether UFH improves successful prevention of clotting in the first 24 hours, death at 28 days, the number of patient dropouts due to adverse events, recovery of kidney function, thrombocytopenia, or cost to health care services because no study reported these outcomes. </p> <p>For the comparison ofÃ‚Â citrate to no anticoagulation,Ã‚Â no completed study was identified. </p> </section> <section id="CD012467-sec-0007"> <h3 class="title" id="CD012467-sec-0007">Authors' conclusions</h3> <p>Currently,Ã‚Â available evidence does not support the overall superiority of any anticoagulant to another. Compared to UFH, citrate probably reduces major bleeding and prevents clotting and probably has little or no effect on death at 28 days. For other pharmacological anticoagulation methods, there is no available data showing overall superiority to citrate or no pharmacological anticoagulation. Further studies are needed to identify patient populations in which CRRT should commence with no pharmacological anticoagulation or with citrate. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD012467-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD012467-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD012467-abs-0014">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD012467-abs-0010">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD012467-abs-0012">Français</a> </li> <li class="section-language"> <a class="" href="full/hr#CD012467-abs-0008">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ja#CD012467-abs-0007">日本語</a> </li> <li class="section-language"> <a class="" href="full/ms#CD012467-abs-0006">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/ru#CD012467-abs-0005">Русский</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD012467-abs-0004">简体中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD012467-abs-0002" lang="en"> <h3>Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy </h3> <p><b>What is the issue?</b> <br/>Acute kidney injury (AKI) is a major comorbidity in hospitalised patients. Patients with severe AKI require renal replacement therapy. Continuous renal replacement therapy (CRRT) is a type of blood dialysis therapy that is generally used for critically ill patients in the intensive care unit. Due to the slow clearance of waste products, CRRT typically runs continuously for 24 hours. Clotting in the dialysis circuits requires immediate circuit changes and leads to treatment interruption and inadequate treatment. The aim of this review was to evaluate the effectiveness and safety of different medications to prevent clotting of circuits in CRRT. </p> <p><b>What did we do?</b><br/>We searched the Cochrane Kidney and Transplant Specialised Register up to 12 September 2019. We summarized the results of 34 randomised controlled trials with 1960Ã‚Â participants in this review. </p> <p><b>What did we find?</b> </p> <p>Citrate probably reduces majorÃ‚Â bleeding (e.g. the need for blood transfusion or surgery) and increases filter patency compared to heparin without changing death. For the other pharmacological comparisons, only inadequate data or low‐quality data were available. </p> <p><b>Conclusions</b> </p> <p>The most effective anti‐clotting options for CRRT remain uncertain; however, citrate or no anticoagulation seems to be reasonable options to prevent the clotting of circuits in CRRT. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD012467-sec-0219" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD012467-sec-0219"></div> <h3 class="title" id="CD012467-sec-0220">Implications for practice</h3> <section id="CD012467-sec-0220"> <p>Available evidence does not support theÃ‚Â overall superiority of any anticoagulant to another, or to no anticoagulation. For bleeding and filter patency, citrate probably has lower bleeding and filter clotting risks compared to UFH. All other anticoagulants including LMWH were not proven to reduce or increaseÃ‚Â the risk of bleeding nor successfully prevent clotting compared to citrate. For death, compared to UFH, citrate probably makes little or no difference. It was uncertain whether citrate compared to LMWH reduces death. Citrate would be the first choice of pharmacological anticoagulation for CRRT; however, it was uncertain whether citrate compares to no anticoagulation increases or reduces bleeding, successfully prevent clotting or mortality. </p> </section> <h3 class="title" id="CD012467-sec-0221">Implications for research</h3> <section id="CD012467-sec-0221"> <p>More comprehensive data on the relative effectiveness (including cost‐effective analysis) of either citrate or UFH against other pharmacological or no anticoagulants are needed. In addition, further studies are needed to identify patient populations that commence CRRT with no pharmacological anticoagulation, with citrate or with UFH. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD012467-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD012467-sec-0008"></div> <div class="table" id="CD012467-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Citrate versus unfractionated heparin for continuous renal replacement therapy</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Citrate versus UFH for CRRT</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> CRRT<br/><b>Setting:</b> ICU<br/><b>Intervention:</b> citrate<br/><b>Comparison:</b> UFH </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>No. of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with UFH</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with citrate</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Major bleeding</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>102 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>22 per 1,000<br/>(8 to 63) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.22<br/>(0.08 to 0.62) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>535 (7)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE <sup>1 2</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Death at 28 days</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>384 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>407 per 1,000<br/>(330 to 500) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.06<br/>(0.86 to 1.30) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>462 (5)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE <sup>3</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Successful prevention of clotting</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>257 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>370 per 1,000<br/>(283 to 481) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.44<br/>(1.10 to 1.87) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>88 (3)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE <sup>2</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Treatment cessation due to adverse events</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>141 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>66 per 1,000<br/>(21 to 211) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.47<br/>(0.15 to 1.49) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>412 (3)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>2 4</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Recovery of kidney function</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>583 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>607 per 1,000<br/>(519 to 706) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.04<br/>(0.89 to 1.21) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>214 (2)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>2 4</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Thrombocytopenia</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>78 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>30 per 1,000<br/>(11 to 80) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.39<br/>(0.14 to 1.03) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>412 (3)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>2 4</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cost to health care services</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>UFH:</b> unfractionated heparin; <b>CRRT:</b> continuous renal replacement therapy; <b>ICU:</b> intensive care unit; <b>CI:</b> confidence interval; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p>Reasons for downgrading the evidence</p> <p><sup>1</sup> Indirectness: including bleeding events of unclear severity </p> <p><sup>2</sup> Study limitations </p> <p><sup>3</sup> Imprecision: risk estimate consistent with both appreciable benefit and harm </p> <p><sup>4</sup> Imprecision: risk estimate includes null effect and estimate consistent with both appreciable benefit and harm </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD012467-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Unfractionated heparin versus low molecular weight heparin for continuous renal replacement therapy</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>UFH versus LMWH for CRRT</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> CRRT<br/><b>Setting:</b> ICU<br/><b>Intervention:</b> UFH<br/><b>Comparison:</b> LMWH </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>No. of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with LMWH</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with UFH</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Major bleeding</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>103 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>60 per 1,000<br/>(13 to 267) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.58<br/>(0.13 to 2.58) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>153 (5)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1 2 3</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Death: unknown time frame</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>857 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>669 per 1,000<br/>(437 to 1,000) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.78<br/>(0.51 to 1.18) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29 (1)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>1 3 4</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Successful prevention of clotting</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>760 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>722 per 1,000<br/>(532 to 996) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.95<br/>(0.70 to 1.31) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>54 (1)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>1 3 4</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Treatment cessation due to adverse events</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>105 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>31 per 1,000<br/>(2 to 372) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.29<br/>(0.02 to 3.53) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>77 (2)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1 3</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Recovery of kidney function</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>not reported</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Thrombocytopenia</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>127 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>72 per 1,000<br/>(25 to 207) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.57<br/>(0.20 to 1.63) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>124 (2)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>1 3 4</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cost to health care services</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>UFH:</b> unfractionated heparin; <b>LMWH:</b> low molecular weight heparin; <b>CRRT:</b> continuous renal replacement therapy; <b>ICU:</b> intensive care unit; <b>CI:</b> confidence interval; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p>Reasons for downgrading the evidence</p> <p><sup>1</sup> Study limitations </p> <p><sup>2</sup> Severe heterogeneity: point estimates varied widely </p> <p><sup>3</sup> Imprecision: risk estimate includes null effect and estimate consistent with both appreciable benefit and harm </p> <p><sup>4</sup> Total number of events small </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD012467-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Unfractionated heparin versus no pharmacological anticoagulation for continuous renal replacement therapy</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>UFH versus no pharmacological anticoagulation for CRRT</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> CRRT<br/><b>Setting:</b> ICU<br/><b>Intervention:</b> UFH<br/><b>Comparison:</b> no anticoagulation </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>No. of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with no anticoagulation</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with UFH</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Major bleeding</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>200 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>100 per 1,000<br/>(10 to 934) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.50<br/>(0.05 to 4.67) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10 (1)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>1 2 3</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Death at 28 days</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>not reported</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Successful prevention of clotting</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>not reported</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Treatment cessation due of adverse events</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>not reported</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Recovery of kidney function</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>not reported</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Thrombocytopenia</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>not reported</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cost to health care services</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>not reported</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>UFH:</b> unfractionated heparin; <b>CRRT:</b> continuous renal replacement therapy; <b>ICU:</b> intensive care unit; <b>CI:</b> confidence interval; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p>Reasons for downgrading the evidence</p> <p><sup>1</sup> Study limitations </p> <p><sup>2</sup> Imprecision: risk estimate includes null effect and estimate consistent with both appreciable benefit and harm </p> <p><sup>3</sup> Total number of events small </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD012467-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD012467-sec-0009"></div> <section id="CD012467-sec-0010"> <h3 class="title" id="CD012467-sec-0010">Description of the condition</h3> <p>Acute kidney injury (AKI) occurs in 11% to 18% of admitted patients (<a href="./references#CD012467-bbs2-0064" title="FujiiT , UchinoS , TakinamiM , BellomoR . Subacute kidney injury in hospitalized patients. Clinical Journal of The American Society of Nephrology: CJASN2014;9(3):457-61. [MEDLINE: 24311710]">Fujii 2014</a>; <a href="./references#CD012467-bbs2-0095" title="ZengX , McMahonGM , BrunelliSM , BatesDW , WaikarSS . Incidence, outcomes, and comparisons across definitions of AKI in hospitalized individuals. Clinical Journal of The American Society of Nephrology: CJASN2014;9(1):12-20. [MEDLINE: 24178971]">Zeng 2014</a>) and contributes to about 1.7 million deaths every year (<a href="./references#CD012467-bbs2-0078" title="MehtaRL , CerdaJ , BurdmannEA , TonelliM , Garcia-GarciaG , JhaV , et al. International Society of Nephrology's 0by25 initiative for acute kidney injury (zero preventable deaths by 2025): a human rights case for nephrology. Lancet2015;6736(9987):2616-43. [MEDLINE: 25777661]">Mehta 2015</a>). A large prospective multinational survey showed that around 40% to 50% of intensive care unit (ICU) patients had AKI and that death increased with AKI severity, as defined by the Kidney Disease Improving Global Outcomes (KDIGO) classification (<a href="./references#CD012467-bbs2-0070" title="HosteEA , BagshawSM , BellomoR , CelyCM , ColmanR , CruzDN , et al. Epidemiology of acute kidney injury in critically ill patients: the multinational AKI-EPI study. Intensive Care Medicine2015;41(8):1411-23. [MEDLINE: 26162677]">Hoste 2015</a>; <a href="./references#CD012467-bbs2-0079" title="NisulaS , KaukonenKM , VaaraST , KorhonenAM , PoukkanenM , KarlssonS , et al. Incidence, risk factors and 90-day mortality of patients with acute kidney injury in Finnish intensive care units: the FINNAKI study. [Erratum in: Intensive Care Med. 2013 Apr;39(4):798]. Intensive Care Medicine2013;39(3):420-8. [MEDLINE: 23291734]">Nisula 2013</a>). </p> <p>According to the US nationwide survey on World Kidney Day, AKI is the most common reason for nephrology consultation among hospitalised patients (<a href="./references#CD012467-bbs2-0075" title="KoynerJL , CerdaJ , GoldsteinSL , JaberBL , LiuKD , SheaJA , et al. The daily burden of acute kidney injury: a survey of U.S. nephrologists on World Kidney Day. American Journal of Kidney Diseases2014;64(3):394-401. [MEDLINE: 24815216]">Koyner 2014</a>). The survey estimated that nephrologists in the USA handle about 4.5 million AKI consults each year (<a href="./references#CD012467-bbs2-0075" title="KoynerJL , CerdaJ , GoldsteinSL , JaberBL , LiuKD , SheaJA , et al. The daily burden of acute kidney injury: a survey of U.S. nephrologists on World Kidney Day. American Journal of Kidney Diseases2014;64(3):394-401. [MEDLINE: 24815216]">Koyner 2014</a>). Notably, 958,000 of those consults required intermittent haemodialysis and 304,000 required some form of renal replacement therapy (RRT) (continuous RRT (CRRT) or slow low‐efficiency dialysis) annually (<a href="./references#CD012467-bbs2-0075" title="KoynerJL , CerdaJ , GoldsteinSL , JaberBL , LiuKD , SheaJA , et al. The daily burden of acute kidney injury: a survey of U.S. nephrologists on World Kidney Day. American Journal of Kidney Diseases2014;64(3):394-401. [MEDLINE: 24815216]">Koyner 2014</a>). Furthermore, the Centers for Disease Control and Prevention in the USA reported that the number of patients with a diagnosis of AKI who faced an extension of hospital stay rose from 18/100,000 to 365/100,000 between 1980 and 2005 (<a href="./references#CD012467-bbs2-0061" title="Centers for Disease Control and Prevention (CDC). Hospitalization discharge diagnoses for kidney disease - United States 1980-2005. MMWR - Morbidity &amp; Mortality Weekly Report2008;57(12):309-12. [MEDLINE: 18368005]">CDC 2008</a>; <a href="./references#CD012467-bbs2-0081" title="ParikhCR , KoynerJL . Chapter 30: Biomarkers in acute and chronic kidney diseases. In: SkoreckiK , ChertowGM , MarsdenPA , TaalMW , YU, AS, editors(s). Brenner and Rector's The Kidney. 10th edition. Philadelphia: Elsevier, 2016:926-955.e10. [ISBN: 978-1455748365]">Parikh 2016</a>). In addition, 5% to 6% of patients in the ICU required RRT or AKI (<a href="./references#CD012467-bbs2-0081" title="ParikhCR , KoynerJL . Chapter 30: Biomarkers in acute and chronic kidney diseases. In: SkoreckiK , ChertowGM , MarsdenPA , TaalMW , YU, AS, editors(s). Brenner and Rector's The Kidney. 10th edition. Philadelphia: Elsevier, 2016:926-955.e10. [ISBN: 978-1455748365]">Parikh 2016</a>). In Japan, a nationwide survey in 2011 revealed that 6478 (3.9%) out of 165,815 ICU patients who were hospitalised for at least three days received CRRT (<a href="./references#CD012467-bbs2-0071" title="IwagamiM , YasunagaH , NoiriE , HoriguchiH , FushimiK , MatsubaraT , at al. Current state of continuous renal replacement therapy for acute kidney injury in Japanese intensive care units in 2011: analysis of a national administrative database. Nephrology Dialysis Transplantation2015;30(6):988-95. [MEDLINE: 25795153]">Iwagami 2015</a>). Of these patients, the average duration of CRRT was 4 and 6 days for 3201 survivors and 3277 non‐survivors, respectively (<a href="./references#CD012467-bbs2-0071" title="IwagamiM , YasunagaH , NoiriE , HoriguchiH , FushimiK , MatsubaraT , at al. Current state of continuous renal replacement therapy for acute kidney injury in Japanese intensive care units in 2011: analysis of a national administrative database. Nephrology Dialysis Transplantation2015;30(6):988-95. [MEDLINE: 25795153]">Iwagami 2015</a>). </p> <p>CRRT is a type of extracorporeal RRT provided continuously. In general, the indication of CRRT is a kidney failureÃ‚Â with haemodynamic instability (<a href="./references#CD012467-bbs2-0078" title="MehtaRL , CerdaJ , BurdmannEA , TonelliM , Garcia-GarciaG , JhaV , et al. International Society of Nephrology's 0by25 initiative for acute kidney injury (zero preventable deaths by 2025): a human rights case for nephrology. Lancet2015;6736(9987):2616-43. [MEDLINE: 25777661]">Mehta 2015</a>; <a href="./references#CD012467-bbs2-0084" title="RoncoC , RicciZ , BellomoR , D’intiniV . Renal replacement therapy. In: VincentJL , AbrahamE , KochanekP , MooreFA , FinkMP , editors(s). Textbook of Critical Care. 6th edition. Philadelphia: Elsevier/Saunders, 2011:894-901. [ISBN: 978-1437713671]">Ronco 2011</a>). The comparison between intermittent versus CRRT for AKI patients was inconclusivelyÃ‚Â discussedÃ‚Â in other reviewsÃ‚Â (<a href="./references#CD012467-bbs2-0082" title="RabindranathKS , AdamsJ , MacLeodAM , MuirheadN . Intermittent versus continuous renal replacement therapy for acute renal failure in adults. Cochrane Database of Systematic Reviews2007, Issue 3. Art. No: CD003773. [DOI: 10.1002/14651858.CD003773.pub3]">Rabindranath 2007</a>; <a href="./references#CD012467-bbs2-0094" title="WangAY , BellomoR . Renal replacement therapy in the ICU: intermittent hemodialysis, sustained low-efficiency dialysis or continuous renal replacement therapy?Current Opinion in Critical Care2018;24(6):437-42. [MEDLINE: 30247213]">Wang 2018</a>).Ã‚Â Due to the slow clearance of solute or water, CRRT typically runs over 24 hours with the requisite duration of at least 16 hours/day (<a href="./references#CD012467-bbs2-0089" title='UchinoS , FealyN , BaldwinI , MorimatsuH , BellomoR . Continuous is not continuous: the incidence and impact of circuit "down-time" on uraemic control during continuous veno-venous haemofiltration. Intensive Care Medicine2003;29(4):575-8. [MEDLINE: 12577144]'>Uchino 2003</a>). Modalities of CRRT are continuous venovenous haemofiltration (CVVH), continuous venovenous haemodialysis (CVVHD), continuous venovenous haemodiafiltration (CVVHDF) and slow continuous ultrafiltration (SCUF) (<a href="./references#CD012467-bbs2-0080" title="ParikhA , ChawlaLS . Chapter 18: Continuous renal replacement therapy. In: ParrilloJE , DellingerRP , editors(s). Critical Care Medicine: Principles of Diagnosis and Management in the Adult. 4th edition. Philadelphia: Elsevier/Saunders, 2014:237-54. [ISBN: 978-0-323-08929-6]">Parikh 2014</a>). Each of these modalities has its own unique features. CVVH is dependent on the convective removal of plasma solute across a semipermeable membrane while CVVHD relies on a diffusion‐based process (<a href="./references#CD012467-bbs2-0080" title="ParikhA , ChawlaLS . Chapter 18: Continuous renal replacement therapy. In: ParrilloJE , DellingerRP , editors(s). Critical Care Medicine: Principles of Diagnosis and Management in the Adult. 4th edition. Philadelphia: Elsevier/Saunders, 2014:237-54. [ISBN: 978-0-323-08929-6]">Parikh 2014</a>). CVVHDF uses a combination of both convective removal and a diffusion‐based process. In contrast, SCUF uses only ultrafiltration employed on a continuous basis (<a href="./references#CD012467-bbs2-0080" title="ParikhA , ChawlaLS . Chapter 18: Continuous renal replacement therapy. In: ParrilloJE , DellingerRP , editors(s). Critical Care Medicine: Principles of Diagnosis and Management in the Adult. 4th edition. Philadelphia: Elsevier/Saunders, 2014:237-54. [ISBN: 978-0-323-08929-6]">Parikh 2014</a>). Ultrafiltration uses hydrostatic pressure and is dependent on the convective removal of plasma water from blood across the semipermeable membrane (<a href="./references#CD012467-bbs2-0080" title="ParikhA , ChawlaLS . Chapter 18: Continuous renal replacement therapy. In: ParrilloJE , DellingerRP , editors(s). Critical Care Medicine: Principles of Diagnosis and Management in the Adult. 4th edition. Philadelphia: Elsevier/Saunders, 2014:237-54. [ISBN: 978-0-323-08929-6]">Parikh 2014</a>). All modalities use extracorporeal circuits including the dialyser filter (with a built‐in semipermeable membrane) (<a href="./references#CD012467-bbs2-0080" title="ParikhA , ChawlaLS . Chapter 18: Continuous renal replacement therapy. In: ParrilloJE , DellingerRP , editors(s). Critical Care Medicine: Principles of Diagnosis and Management in the Adult. 4th edition. Philadelphia: Elsevier/Saunders, 2014:237-54. [ISBN: 978-0-323-08929-6]">Parikh 2014</a>).Ã‚Â  </p> <p>Although CRRT is prescribed assuming it is provided over 24 hours, "down‐time" can occur due to the clotting in the extracorporeal circuits (<a href="./references#CD012467-bbs2-0089" title='UchinoS , FealyN , BaldwinI , MorimatsuH , BellomoR . Continuous is not continuous: the incidence and impact of circuit "down-time" on uraemic control during continuous veno-venous haemofiltration. Intensive Care Medicine2003;29(4):575-8. [MEDLINE: 12577144]'>Uchino 2003</a>). To achieve the optimal intensity of 20 to 25 mL/kg/hour in RRT for AKI (<a href="./references#CD012467-bbs2-0073" title="Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group. KDIGO Clinical Practice Guideline for Acute Kidney Injury. Kidney international - Supplement2012;2(1):1-138. [DOI: 10.1038/kisup.2012.1]">KDIGO 2012</a>; <a href="./references#CD012467-bbs2-0083" title="RENAL Replacement Therapy Study Investigators, BellomoR , CassA , ColeL , FinferS , GallagherM , et al. Intensity of continuous renal-replacement therapy in critically ill patients. New England Journal of Medicine2009;361(17):1627-38. [MEDLINE: 19846848]">RENAL Replacement Therapy Study Investigators 2009</a>; <a href="./references#CD012467-bbs2-0091" title="VA/NIH Acute Renal Failure Trial Network, PalevskyPM , ZhangJH , O'ConnorTZ , ChertowGM , CrowleyST , et al. Intensity of renal support in critically ill patients with acute kidney injury. [Erratum in: N Engl J Med. 2009 Dec 10;361(24):2391]. New England Journal of Medicine2008;359(1):7-20. [MEDLINE: 18492867]">VA/NIH Acute Renal Failure Trial Network 2008</a>), it is crucial to reduce unexpected downtime. An observational study reported downtime of around one to three hours/day (<a href="./references#CD012467-bbs2-0089" title='UchinoS , FealyN , BaldwinI , MorimatsuH , BellomoR . Continuous is not continuous: the incidence and impact of circuit "down-time" on uraemic control during continuous veno-venous haemofiltration. Intensive Care Medicine2003;29(4):575-8. [MEDLINE: 12577144]'>Uchino 2003</a>; <a href="./references#CD012467-bbs2-0092" title="VesconiS , CruzDN , FumagalliR , Kindgen-MillesD , MontiG , MarinhoA , et al. Delivered dose of renal replacement therapy and mortality in critically ill patients with acute kidney injury. Critical Care (London, England)2009;13(2):R57. [MEDLINE: 19368724]">Vesconi 2009</a>). Clotting in the extracorporeal circuits requires immediate circuit changes and leads to an increase in the workload of medical staff and the cost of treatment (<a href="./references#CD012467-bbs2-0065" title="GattasDJ , RajbhandariD , BradfordC , BuhrH , LoS , BellomoR . A randomized controlled trial of regional citrate versus regional heparin anticoagulation for continuous renal replacement therapy in critically ill adults. Critical Care Medicine2015;43(8):1622-9. [MEDLINE: 25853591]">Gattas 2015a</a>). Frequent circuit changes can cause futile downtime of the treatment. </p> </section> <section id="CD012467-sec-0011"> <h3 class="title" id="CD012467-sec-0011">Description of the intervention</h3> <p>Non‐pharmacological and pharmacological approaches provide two possible ways to prevent clotting in the circuits during CRRT. Non‐pharmacological interventions to prevent clotting include reducing blood viscosity inside the haemofilter (including the pre‐dilution method of fluid replacement and saline flush), reducing blood‐air contact to protect the site from excessive clotting, and the selection and the positionÃ‚Â of the catheter (<a href="./references#CD012467-bbs2-0063" title="DaviesH , LeslieG . Maintaining the CRRT circuit: non-anticoagulant alternatives. Australian Critical Care2006;19(4):133-8. [MEDLINE: 17165492]">Davies 2006</a>; <a href="./references#CD012467-bbs2-0072" title="JoannidisM , Oudemans-van StraatenHM . Clinical review: patency of the circuit in continuous renal replacement therapy. Critical Care (London, England)2007;11(4):218. [MEDLINE: 17634148]">Joannidis 2007a</a>; <a href="./references#CD012467-bbs2-0073" title="Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group. KDIGO Clinical Practice Guideline for Acute Kidney Injury. Kidney international - Supplement2012;2(1):1-138. [DOI: 10.1038/kisup.2012.1]">KDIGO 2012</a>;Ã‚Â <a href="./references#CD012467-bbs2-0074" title="KirwanCJ , Ã‚Â  JacksonL , Ã‚Â  ProwleJR . A continuous renal replacement therapy protocol on the updated Nikkiso Aquarius Platform using regional citrate as first-line anticoagulation significantly improves filter life span but the position of the vascular access is key. Blood Purification2018;45(1-3):129-30. [MEDLINE: 29402829]">Kirwan 2018</a>). In this review, we didÃ‚Â not address these non‐pharmacological interventions. </p> <p>The pharmacological approach involves using an array of drugs including intravenous anticoagulants (e.g. unfractionated heparin (UFH), low‐molecular‐weight heparin (LMWH), nafamostat mesilate, argatroban, and citrate), oral anticoagulants (warfarin) and antiplatelet agents, as well as coagulation monitoring (activated coagulation time (ACT) or activated prothrombin time (APTT)). It should be noted here that up to 60% of patients treated with CRRT in large multinational studies did not receive any form of pharmacological anticoagulation (<a href="./references#CD012467-bbs2-0083" title="RENAL Replacement Therapy Study Investigators, BellomoR , CassA , ColeL , FinferS , GallagherM , et al. Intensity of continuous renal-replacement therapy in critically ill patients. New England Journal of Medicine2009;361(17):1627-38. [MEDLINE: 19846848]">RENAL Replacement Therapy Study Investigators 2009</a>: <a href="./references#CD012467-bbs2-0091" title="VA/NIH Acute Renal Failure Trial Network, PalevskyPM , ZhangJH , O'ConnorTZ , ChertowGM , CrowleyST , et al. Intensity of renal support in critically ill patients with acute kidney injury. [Erratum in: N Engl J Med. 2009 Dec 10;361(24):2391]. New England Journal of Medicine2008;359(1):7-20. [MEDLINE: 18492867]">VA/NIH Acute Renal Failure Trial Network 2008</a>). Clotting in the extracorporeal circuits sometimes results in blood loss in the circuits (<a href="./references#CD012467-bbs2-0072" title="JoannidisM , Oudemans-van StraatenHM . Clinical review: patency of the circuit in continuous renal replacement therapy. Critical Care (London, England)2007;11(4):218. [MEDLINE: 17634148]">Joannidis 2007a</a>). Conversely, a multinational survey reported that bleeding complications occurred in 3.3% of patients (<a href="./references#CD012467-bbs2-0090" title="UchinoS , BellomoR , MorimatsuH , MorgeraS , SchetzM , TanI , et al. Continuous renal replacement therapy: a worldwide practice survey: the Beginning and Ending Supportive Therapy for the Kidney (B.E.S.T. Kidney) Investigators. Intensive Care Medicine2007;33(9):1563-70. [MEDLINE: 17594074]">Uchino 2007</a>). Thus, it is critical to address the issue of efficacy and safety of pharmacological interventions for preventing clotting in the circuits in CRRT. </p> </section> <section id="CD012467-sec-0012"> <h3 class="title" id="CD012467-sec-0012">How the intervention might work</h3> <p>The contact of blood with the foreign surface of the circuit may result in the activation of a coagulation pathway (<a href="./references#CD012467-bbs2-0073" title="Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group. KDIGO Clinical Practice Guideline for Acute Kidney Injury. Kidney international - Supplement2012;2(1):1-138. [DOI: 10.1038/kisup.2012.1]">KDIGO 2012</a>). To prevent this, anticoagulation or antiplatelets are usually used. Systematic anticoagulation or antiplatelets can be a double‐edged sword as they raised the risk of bleeding. Therefore, techniques such as regional anticoagulation have been developed that can prevent clotting in the circuits but will not affect the patient's systemic coagulation system. Citrate forms a chelate with calcium and works as an anticoagulant regionally in the circuits. Citrate is expected to reduce the risk of bleeding compared with systemic administration, because it is metabolised into bicarbonate in the liver, skeletal muscles and renal cortex into bicarbonate (<a href="./references#CD012467-bbs2-0085" title="SchilderL , NurmohamedSA , BoschFH , PurmerIM , den BoerSS , KleppeCG , et al. Citrate anticoagulation versus systemic heparinisation in continuous venovenous hemofiltration in critically ill patients with acute kidney injury: a multi-center randomized clinical trial. Critical Care (London, England)2014;18(4):472. [MEDLINE: 25128022]">Schilder 2014</a>). As accumulated citrate leads to hypocalcaemia, and calcium supplementation may be required. Using short half‐life anticoagulants may be an alternative to the regional anticoagulation, e.g. nafamostat mesilate. For instance, anticoagulation can be achieved with nafamostat mesilate without increasing bleeding complications (<a href="./references#CD012467-bbs2-0077" title="MaruyamaY , YoshidaH , UchinoS , YokoyamaK , YamamotoH , TakinamiM , et al. Nafamostat mesilate as an anticoagulant during continuous veno-venous hemodialysis: a three-year retrospective cohort study. International Journal of Artificial Organs2011;34(7):571-6. [MEDLINE: 21786254]">Maruyama 2011</a>). </p> </section> <section id="CD012467-sec-0013"> <h3 class="title" id="CD012467-sec-0013">Why it is important to do this review</h3> <p>There are various methods to prevent clotting in the circuits, and the method of choice may differ across countries. Therefore, it is important to systematically summarize the benefits and harms of all the pharmacological methods. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD012467-sec-0014" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD012467-sec-0014"></div> <p>To assess the benefits and harms of pharmacological interventions for preventing clotting in the extracorporeal circuits during CRRT. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD012467-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD012467-sec-0015"></div> <section id="CD012467-sec-0016"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD012467-sec-0017"> <h4 class="title">Types of studies</h4> <p>All randomised controlled trials (RCTs or cluster RCTs) and quasi‐RCTs (RCTs in which allocation to treatment was obtained by alternation, use of alternate medical records, date of birth or other predictable methods) looking at pharmacological interventions for preventing clotting of extracorporeal circuits during CRRT. </p> </section> <section id="CD012467-sec-0018"> <h4 class="title">Types of participants</h4> <section id="CD012467-sec-0019"> <h5 class="title">Inclusion criteria</h5> <p>We included all AKI patients receiving CRRT in the ICU regardless of age or sex.</p> </section> <section id="CD012467-sec-0020"> <h5 class="title">Exclusion criteria</h5> <p>We excluded patients who received dialysis treatment before admission to the ICU.</p> </section> </section> <section id="CD012467-sec-0021"> <h4 class="title">Types of interventions</h4> <p> <ol id="CD012467-list-0001"> <li> <p>Citrate versus UFH</p> </li> <li> <p>Citrate versus LMWH</p> </li> <li> <p>Citrate versus nafamostat mesilate</p> </li> <li> <p>Citrate versus argatroban</p> </li> <li> <p>Citrate versus warfarin</p> </li> <li> <p>Citrate versus no pharmacological anticoagulation</p> </li> <li> <p>UFH versus LMWH</p> </li> <li> <p>UFH versus nafamostat mesilate</p> </li> <li> <p>UFH versus argatroban</p> </li> <li> <p>UFH versus warfarin</p> </li> <li> <p>UFH versus no pharmacological anticoagulation</p> </li> <li> <p>LMWH versus nafamostat mesilate</p> </li> <li> <p>LMWH versus argatroban</p> </li> <li> <p>LMWH versus warfarin</p> </li> <li> <p>LMWH versus no pharmacological anticoagulation</p> </li> <li> <p>Nafamostat mesilate versus argatroban</p> </li> <li> <p>Nafamostat mesilate versus warfarin</p> </li> <li> <p>Nafamostat mesilate versus no pharmacological anticoagulation</p> </li> <li> <p>Argatroban versus warfarin</p> </li> <li> <p>Argatroban versus no pharmacological anticoagulation</p> </li> <li> <p>Warfarin versus no pharmacological anticoagulation</p> </li> <li> <p>Systematic anticoagulation versus regional anticoagulation</p> </li> <li> <p>Antiplatelet agents versus no antiplatelet agents</p> </li> <li> <p>Activated coagulation time (ACT) monitoring versus activated prothrombin time (APTT) monitoring </p> </li> </ol> </p> <p>We considered all comparisons listed above. We also considered following other pharmacological interventions identified during our search. </p> <p> <ol id="CD012467-list-0002"> <li> <p>Bivalirudin versus UFH</p> </li> <li> <p>UFH versus UFH plus protamine</p> </li> <li> <p>UFH plus protamine versus citrate</p> </li> <li> <p>UFH plus protamine versus LMWH</p> </li> <li> <p>Hirudin versus UFH</p> </li> <li> <p>Citrate plus LMWH versus citrate</p> </li> <li> <p>Citrate plus LMWH versus LMWH</p> </li> </ol> </p> <p>We excluded studies comparing different doses of the same pharmacological intervention (e.g. high‐dose UFH versus low‐dose UFH). </p> </section> <section id="CD012467-sec-0022"> <h4 class="title">Types of outcome measures</h4> <section id="CD012467-sec-0023"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD012467-list-0003"> <li> <p>Major bleeding: incidence of major bleeding, defined as bleeding requiring blood transfusion, or as defined by the authors </p> </li> <li> <p>Successful prevention of clotting: successful prevention of clotting is defined as no need for circuit change in the first 24 hours for any reason. If a study did not report the outcome with the timeframe of 24 hours, we adopted other time frames used in the study. </p> </li> <li> <p>Death: death from any cause at day 28. If a study did not report an outcome with the timeframe of 28 days, we adopted hospital death, ICU death or death within the study period in this order of priority. </p> </li> </ul> </p> </section> <section id="CD012467-sec-0024"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD012467-list-0004"> <li> <p>Early termination with blood loss in the circuits: early termination was defined as the full prescribed dose that was not administered in the first 24 hours for any reason, and blood loss was defined as a failure to return blood for any reason </p> </li> <li> <p>Catheter thrombotic event: incidence of catheter malfunction presumed due to thrombosis was defined as a failure to achieve a blood flow despite positional changes of the participants and additional saline flush or both, or as defined by the study authors </p> </li> <li> <p>Recovery of kidney function: numbers of participants free of RRT after discontinuing CRRT at day 28 </p> </li> <li> <p>Thrombocytopenia: defined as emergent platelet count &lt; 150,000/Ã‚ÂµL (150 x 10<sup>9</sup>/L) after starting CRRT, or as defined by the study authors </p> </li> <li> <p>Adverse events</p> <ul id="CD012467-list-0005"> <li> <p>Number of patients who dropped out of treatment because of adverse events (technique or patient‐dependent factors) </p> </li> <li> <p>Number of patients experiencing any adverse events</p> </li> </ul> </li> <li> <p>Hypocalcaemia: as defined by the study authors</p> </li> <li> <p>Hypercalcaemia: as defined by the study authors</p> </li> <li> <p>Hypernatraemia: as defined by the study authors</p> </li> <li> <p>Metabolic disturbances: such as acidosis or alkalosis as defined by the study authors</p> </li> <li> <p>Cost to health care services</p> <ul id="CD012467-list-0006"> <li> <p>Types and number of dialyser filters and circuits</p> </li> <li> <p>Use/no use of anticoagulation</p> </li> <li> <p>Types of anticoagulation</p> </li> <li> <p>All costsÃ‚Â were reported in dollar valuesÃ‚Â using theÃ‚Â Foreign Exchange Rates on 31Ã‚Â December 2018 which was reported by theÃ‚Â Board of Governors of the Federal Reserve System. </p> </li> </ul> </li> <li> <p>Other adverse events: including allergic reactions, urticaria, and anaphylaxis (<a href="./references#CD012467-bbs2-0093" title="WangY , IvanyJN , PerkovicV , GallagherMP , WoodwardM , JardineMJ . Anticoagulants and antiplatelet agents for preventing central venous haemodialysis catheter malfunction in patients with end-stage kidney disease. Cochrane Database of Systematic Reviews2016, Issue 4. Art. No: CD009631. [DOI: 10.1002/14651858.CD009631.pub2]">Wang 2016</a>). </p> </li> </ul> </p> </section> </section> </section> <section id="CD012467-sec-0025"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD012467-sec-0026"> <h4 class="title">Electronic searches</h4> <p>We searched the <a href="http://kidneyandtransplant.cochrane.org/cochrane-kidney-and-transplant-specialised-register" target="_blank">Cochrane Kidney and Transplant Register of Studies</a> up to 12 September 2019 through contact with the Information Specialist using search terms relevant to this review. The Register contains studies identified from the following sources. </p> <p> <ol id="CD012467-list-0007"> <li> <p>Monthly searches of the Cochrane Central Register of Controlled Trials (CENTRAL)</p> </li> <li> <p>Weekly searches of MEDLINE OVID SP</p> </li> <li> <p>Handsearching of kidney‐related journals and the proceedings of major kidney conferences</p> </li> <li> <p>Searching of the current year of EMBASE OVID SP</p> </li> <li> <p>Weekly current awareness alerts for selected kidney and transplant journals</p> </li> <li> <p>Searches of the International Clinical Trials Register (ICTRP) Search Portal and ClinicalTrials.gov.</p> </li> </ol> </p> <p>Studies contained in the Register are identified through searches of CENTRAL, MEDLINE, and EMBASE based on the scope of Cochrane Kidney and Transplant. Details of search strategies, as well as a list of handsearched journals, conference proceedings and current awareness alerts, are available on the <a href="https://kidneyandtransplant.cochrane.org/cochrane-kidney-and-transplant-specialised-register" target="_blank">Cochrane Kidney and Transplant website</a>. </p> <p>See <a href="./appendices#CD012467-sec-0225">Appendix 1</a> for search terms used in strategies for this review. </p> </section> <section id="CD012467-sec-0027"> <h4 class="title">Searching other resources</h4> <p> <ol id="CD012467-list-0008"> <li> <p>Reference lists of review articles, relevant studies and clinical practice guidelines.</p> </li> <li> <p>Letters seeking information about unpublished or incomplete studies to investigators known to be involved in previous studies. </p> </li> </ol> </p> </section> </section> <section id="CD012467-sec-0028"> <h3 class="title" id="CD012467-sec-0028">Data collection and analysis</h3> <section id="CD012467-sec-0029"> <h4 class="title">Selection of studies</h4> <p>The search strategy described was used to obtain titles and abstracts of studies that may be relevant to the review. The titles and abstracts were screened independently by two authors, who discarded studies that were not applicable; however, studies and reviews with potentially relevant data or information on studies were retained initially. Two authors independently assessed retrieved abstracts and, if necessary, the full text of these studies to determine which studies satisfied the inclusion criteria. The two authors compared their lists and any differences in opinion between the two authors was resolved by discussion and, where this failed, through arbitration by a third author. </p> </section> <section id="CD012467-sec-0030"> <h4 class="title">Data extraction and management</h4> <p>Data extraction was carried out independently by two authors using standard data extraction forms (<a href="./appendices#CD012467-sec-0226">Appendix 2</a>). Differences in opinion on data collection was resolved by discussion and, where this failed, through arbitration by a third author. Studies reported in non‐English language journals were translated before assessment. Where more than one publication of one study existed, reports were grouped together and the publication with the most complete data was used in the analyses. Where relevant outcomes were only published in earlier versions, these data were used. Any discrepancy between published versions was highlighted. </p> </section> <section id="CD012467-sec-0031"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>The following items were independently assessed by two authors using the risk of bias assessment tool (<a href="./references#CD012467-bbs2-0069" title="HigginsJP , Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.">Higgins 2011</a>) (see <a href="./appendices#CD012467-sec-0227">Appendix 3</a>). </p> <p> <ul id="CD012467-list-0009"> <li> <p>Was there adequate sequence generation (selection bias)?</p> </li> <li> <p>Was allocation adequately concealed (selection bias)?</p> </li> <li> <p>Was knowledge of the allocated interventions adequately prevented during the study?</p> <ul id="CD012467-list-0010"> <li> <p>Participants and personnel (performance bias)</p> </li> <li> <p>Outcome assessors (detection bias)</p> </li> </ul> </li> <li> <p>Were incomplete outcome data adequately addressed (attrition bias)?</p> </li> <li> <p>Are reports of the study free of suggestion of selective outcome reporting (reporting bias)? </p> </li> <li> <p>Was the study apparently free of other problems that could put it at a risk of bias?</p> </li> </ul> </p> </section> <section id="CD012467-sec-0032"> <h4 class="title">Measures of treatment effect</h4> <p>For dichotomous outcomes (e.g. death, major bleeding, hypocalcaemia, hypersensitivity reaction, other adverse events) results were expressed as risk ratio (RR) with 95% confidence intervals (CI). </p> <p>We basically used the number of all participants who underwent randomised allocation as a denominator of their event risk calculation. </p> <p>For outcomes being presumed as adverse events of interventions (e.g. major bleeding, metabolic disturbances, hypernatraemia, hypocalcaemia, hypercalcaemia, thrombocytopenia, catheter thrombotic event, or any adverse events), we used the number of all participants who underwent intervention after randomised allocation as a denominator of their event risk calculation. </p> </section> <section id="CD012467-sec-0033"> <h4 class="title">Unit of analysis issues</h4> <p>We assessed unit of analysis issues in the included studies in three possible ways in which they might arise. </p> <section id="CD012467-sec-0034"> <h5 class="title">Multiple enrolments of the same participants from either individually randomised or cross‐over studies </h5> <p>If there were multiple enrolments of circuits used by the same individual following a need for repeated CRRT using new circuits (e.g. clotting of circuits), unit of analysis issues might arise. We considered to address them by first assessing each included study for any evidence of multiple enrolments (e.g. number of circuits exceeded the number of participants). We considered excluding those with multiple enrolments by entering the data of only the first circuit. However, such information was not available, and we performed our analysis based on whatever data the authors provided, using the total number of circuits as the denominator according to a priori defined protocol. </p> </section> <section id="CD012467-sec-0035"> <h5 class="title">Clustering at the level of the enrolled units in cluster‐randomized trials</h5> <p>In dealing with cluster‐RCTs, for dichotomous data, we applied the design effect and calculated the effective sample size and number of events using the intra‐cluster correlation coefficient among each unit (ICC) and the average cluster size, as described in Chapter 16.3.5 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD012467-bbs2-0069" title="HigginsJP , Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.">Higgins 2011</a>). If the ICC had not been reported, we used the ICC of a similar study as a substitute. For continuous data only, the sample size was reduced; means and standard deviations remained unchanged (<a href="./references#CD012467-bbs2-0069" title="HigginsJP , Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.">Higgins 2011</a>). </p> </section> <section id="CD012467-sec-0036"> <h5 class="title">Multiple comparisons</h5> <p>All intervention groups that were relevant to this review were included.</p> </section> </section> <section id="CD012467-sec-0037"> <h4 class="title">Dealing with missing data</h4> <p>Any further information required from the original author was requested by written correspondence (e.g. emailing corresponding author) and any relevant information obtained in this manner was included in the review. Evaluation of important numerical data, such as screened, randomised patients as well as intention‐to‐treat, as‐treated and per‐protocol populations, was carefully performed. Attrition rates, for example drop‐outs, losses to follow‐up and withdrawals, were investigated. Issues of missing data and imputation methods (for example, last‐observation‐carried‐forward) was critically appraised (<a href="./references#CD012467-bbs2-0069" title="HigginsJP , Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.">Higgins 2011</a>). </p> </section> <section id="CD012467-sec-0038"> <h4 class="title">Assessment of heterogeneity</h4> <p>We first assessed the heterogeneity by visual inspection of the forest plot. We quantified statistical heterogeneity using the I<sup>2</sup> statistic, which described the percentage of total variation across studies that was due to heterogeneity rather than sampling error (<a href="./references#CD012467-bbs2-0068" title="HigginsJP , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta-analyses. BMJ2003;327(7414):557-60. [MEDLINE: 12958120]">Higgins 2003</a>). A guide to the interpretation of I<sup>2</sup> values was as follows. </p> <p> <ul id="CD012467-list-0011"> <li> <p>0% to 40%: might not be important</p> </li> <li> <p>30% to 60%: moderate heterogeneity</p> </li> <li> <p>50% to 90%: substantial heterogeneity</p> </li> <li> <p>75% to 100%: considerable heterogeneity.</p> </li> </ul> </p> <p>The importance of the observed value of I<sup>2</sup> depends on the magnitude and direction of treatment effects and the strength of evidence for heterogeneity (e.g. P‐value from the Chi<sup>2</sup> test, or a confidence interval for I<sup>2</sup>) (<a href="./references#CD012467-bbs2-0069" title="HigginsJP , Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.">Higgins 2011</a>). </p> </section> <section id="CD012467-sec-0039"> <h4 class="title">Assessment of reporting biases</h4> <p>If possible, funnel plots were used to assess for the potential existence of small study bias (<a href="./references#CD012467-bbs2-0069" title="HigginsJP , Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.">Higgins 2011</a>). </p> </section> <section id="CD012467-sec-0040"> <h4 class="title">Data synthesis</h4> <p>Data were pooled using the random‐effects model, but the fixed‐effect model was also used to ensure robustness of the model chosen and susceptibility to outliers. </p> </section> <section id="CD012467-sec-0041"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>Subgroup analysis was planned to explore possible sources of heterogeneity for the primary outcomes if sufficient studies were available. Heterogeneity among participants could be related to age (≥ 18 years or &lt; 18 years) and prior condition (elderly patients, duration after a major operation, presence of liver disease, disseminated intravascular coagulopathy or other diseases of coagulation‐fibrinolysis system). Heterogeneity in treatments could be related to a prior or combined agent(s) used (e.g. protamine for UFH) and the agent, dose and duration of therapy (intensity of RRT, target APTT or ACT). Adverse effects were tabulated and assessed with descriptive techniques, as they were likely to be different for the various agents used. Where possible, the risk difference with 95% CI was calculated for adverse events, either compared to no treatment or to another agent. </p> </section> <section id="CD012467-sec-0042"> <h4 class="title">Sensitivity analysis</h4> <p>We planned to conduct sensitivity analyses in order to explore the influence of the following factors on effect size; however, sufficient data were not available to determine the influence of these factors on the effect size. </p> <p> <ul id="CD012467-list-0012"> <li> <p>Repeating the analysis excluding unpublished studies</p> </li> <li> <p>Repeating the analysis taking account of risk of bias, as specified</p> </li> <li> <p>Repeating the analysis excluding any very long or large studies to establish how much they dominate the results </p> </li> <li> <p>Repeating the analysis excluding studies using the following filters: diagnostic criteria, language of publication, source of funding (industry versus other), and country. </p> </li> </ul> </p> </section> <section id="CD012467-sec-0043"> <h4 class="title">Summary of findings and assessment of the certainty of the evidence</h4> <p>We presented the main results of the review in 'Summary of findings' tables. These tables present key information concerning the quality of the evidence, the magnitude of the effects of the interventions examined, and the sum of the available data for the main outcomes (<a href="./references#CD012467-bbs2-0086" title="SchÃƒÂ¼nemannHJ , OxmanAD , HigginsJP , VistGE , GlasziouP , GuyattGH . Chapter 11: Presenting results and 'Summary of findings' tables. In: Higgins JP, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.">Schunemann 2011a</a>). The 'Summary of findings' tables also includes an overall grading of the evidence related to each of the main outcomes using the GRADE (Grades of Recommendation, Assessment, Development, and Evaluation) approach (<a href="./references#CD012467-bbs2-0066" title="GuyattGH , OxmanAD , VistGE , KunzR , Falck-YtterY , Alonso-CoelloP , et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ2008;336(7650):924-6. [MEDLINE: 18436948]">GRADE 2008</a>; <a href="./references#CD012467-bbs2-0067" title="GuyattG , OxmanAD , AklEA , KunzR , VistG , BrozekJ , et al. GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. Journal of Clinical Epidemiology2011;64(4):383-94. [MEDLINE: 21195583]">GRADE 2011</a>). The GRADE approach defined the quality of a body of evidence as to the extent to which one could be confident that an estimate of effect or association is close to the true quantity of specific interest. The quality of a body of evidence involves consideration of within‐trial risk of bias (methodological quality), directness of evidence, heterogeneity, precision of effect estimates and risk of publication bias (<a href="./references#CD012467-bbs2-0087" title="SchÃƒÂ¼nemannHJ , OxmanAD , HigginsJP , DeeksJJ , GlasziouP , GuyattGH . Chapter 12: Interpreting results and drawing conclusions. In: Higgins JP, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.">Schunemann 2011b</a>). We presented the following outcomes in the 'Summary of findings' tables. </p> <p> <ul id="CD012467-list-0013"> <li> <p>Major bleeding</p> </li> <li> <p>Death at 28 days</p> </li> <li> <p>Successful prevention of clotting in the first 24 hours</p> </li> <li> <p>Dropped out of treatment because of adverse events</p> </li> <li> <p>Recovery of kidney function</p> </li> <li> <p>Thrombocytopenia</p> </li> <li> <p>Cost to health care services</p> </li> </ul> </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD012467-sec-0044" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD012467-sec-0044"></div> <section id="CD012467-sec-0045"> <h3 class="title">Description of studies</h3> <section id="CD012467-sec-0046"> <h4 class="title">Results of the search</h4> <p>Our searches identified 67Ã‚Â unique records from the electronic search and 12 unique records from other sources at the initial search on 16 January 2017. Update search identified four and two records, on 1 May 2018 and 12 September 2019, respectively. After the screening steps, a total of 43 reports of 34Ã‚Â completed studies were eligible to be included in this review (<a href="#CD012467-fig-0001">Figure 1</a>). There were a total of 1960Ã‚Â randomised participants with 3218Ã‚Â observations (reported unit of outcome measurements including multiple measuring of the outcomes from the same participants due to the primary study design). We identified fourÃ‚Â ongoing studies (<a href="./references#CD012467-bbs2-0057" title="KimDK . Circuit survival and efficacy for middle molecular-weight solute elimination between nafamostat infusion and heparinized saline priming. www.clinicaltrials.gov/ct2/show/NCT01486485 (first received 6 December 2011). ">NCT01486485</a>; <a href="./references#CD012467-bbs2-0058" title="NCT01839578. Regional citrate versus systemic heparin anticoagulation for super high-flux continuous hemodialysis in septic shock: effect on middle molecular weight molecules clearances. www.clinicaltrials.gov/ct2/show/NCT01839578 (first received 25 April 2013). ">NCT01839578</a>; <a href="./references#CD012467-bbs2-0059" title="ZarbockA . Regional citrate versus systemic heparin anticoagulation for continuous renal replacement therapy in critically ill patients with acute kidney injury. www.clinicaltrials.gov/ct2/show/NCT02669589 (first received 1 February 2016). ">NCT02669589</a>; <a href="./references#CD012467-bbs2-0060" title="ArcaroliJ . Clinical evaluation of use of prismocitrate 18 in patients undergoing acute continuous renal replacement therapy (CRRT). www.clinicaltrials.gov/ct2/show/NCT02860130 (first received 9 August 2016). ">NCT02860130</a>) and one study awaiting classification (a completed study but its results have not published) (<a href="./references#CD012467-bbs2-0056" title="SrisawatN . Immunomodulation effect of regional citrate anticoagulation in acute kidney injury requiring continuous renal replacement therapy. www.clinicaltrials.gov/ct2/show/NCT02423642 (first received 22 April 2015). ">NCT02423642</a>) which will be assessed in a future update of this review. </p> <div class="figure" id="CD012467-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Flow chart of study selection" data-id="CD012467-fig-0001" src="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/image_n/nCD012467-FIG-01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Flow chart of study selection</p> </div> </div> </div> </section> <section id="CD012467-sec-0047"> <h4 class="title">Included studies</h4> <p>Study characteristics including the dose of each intervention are individually shown in <a href="./references#CD012467-sec-0244" title="">Characteristics of included studies</a>. </p> <p> <ul id="CD012467-list-0014"> <li> <p>Eight studies compared citrate versus UFH (<a href="./references#CD012467-bbs2-0003" title="BetjesMG , OosteromD , vanAgterenM , vande WeteringJ . Regional citrate versus heparin anticoagulation during venovenous hemofiltration in patients at low risk for bleeding: similar hemofilter survival but significantly less bleeding [abstract no: TH-FC107]. Journal of the American Society of Nephrology2006;17(Abstracts):24A. [CENTRAL: CN-00671866] BetjesMG , vanOosteromD , vanAgterenM , vande WeteringJ . Regional citrate versus heparin anticoagulation during venovenous hemofiltration in patients at low risk for bleeding: similar hemofilter survival but significantly less bleeding. Journal of Nephrology2007;20(5):602-8. [MEDLINE: 17918147]">Betjes 2007</a>; <a href="./references#CD012467-bbs2-0005" title="SchilderL , NurmohamedS , BoschFH , PurmerIM , den BoerSS , KleppeCG , et al. Citrate anticoagulation versus systemic heparinisation in continuous venovenous hemofiltration in critically ill patients with acute kidney injury: a multi-center randomized clinical trial. Critical Care (London, England)2014;18(4):472. [MEDLINE: 25128022]SchilderL , NurmohamedSA , ter WeePM , PaauwNJ , GirbesAR , BeishuizenA , et al. Citrate confers less filter-induced complement activation and neutrophil degranulation than heparin when used for anticoagulation during continuous venovenous haemofiltration in critically ill patients. BMC Nephrology2014;15:19. [MEDLINE: 24438360]SchilderL , NurmohamedSA , ter WeePM , PaauwNJ , GirbesAR , BeishuizenA , et al. Putative novel mediators of acute kidney injury in critically ill patients: handling by continuous venovenous hemofiltration and effect of anticoagulation modalities. BMC Nephrology2015;16:178. [MEDLINE: 26519056]SchilderL , NurmohamedSA , ter WeePM , PaauwNJ , GirbesAR , BeishuizenA , et al. The plasma level and biomarker value of neutrophil gelatinase-associated lipocalin in critically ill patients with acute kidney injury are not affected by continuous venovenous hemofiltration and anticoagulation applied. Critical Care (London, England)2014;18(2):R78. [MEDLINE: 24755339]">CASH 2014</a>; <a href="./references#CD012467-bbs2-0015" title="HetzelGR , SchmitzM , WissingH , RiesW , SchottG , HeeringPJ , et al. Regional citrate versus systemic heparin for anticoagulation in critically ill patients on continuous venovenous haemofiltration: a prospective randomized multicentre trial. Nephrology Dialysis Transplantation2011;26(1):232-9. [MEDLINE: 20876598]">Hetzel 2011</a>; <a href="./references#CD012467-bbs2-0019" title="KutsogiannisDJ , GibneyRT , StolleryD , GaoJ . Regional citrate versus systemic heparin anticoagulation for continuous renal replacement in critically ill patients. Kidney International2005;67(6):2361-7. [MEDLINE: 15882280]">Kutsogiannis 2005</a>; <a href="./references#CD012467-bbs2-0023" title="MonchiM , BerghmansD , LedouxD , CanivetJL , DuboisB , DamasP . Citrate vs. heparin for anticoagulation in continuous venovenous hemofiltration: a prospective randomized study. Intensive Care Medicine2004;30(2):260-5. [MEDLINE: 14600809]">Monchi 2004</a>; <a href="./references#CD012467-bbs2-0028" title="StuckerF , PonteB , TatawJ , MartinPY , WozniakH , PuginJ , et al. Efficacy and safety of citrate-based anticoagulation compared to heparin in patients with acute kidney injury requiring continuous renal replacement therapy: a randomized controlled trial. Critical Care (London, England)2015;19(1):91. [MEDLINE: 25881975]StuckerF , PuginJ , TattawJ , PonteB , BrochardL , MartinP , et al. Citrate-based anticoagulation in patients with AKI in the intensive care unit: a safe and efficacious method [abstract no: 0379]. Intensive Care Medicine2013;39(Suppl 2):S320. [EMBASE: 71446324]">Stucker 2015</a>; <a href="./references#CD012467-bbs2-0029" title="TiranathanagulK , JearnsujitwimolO , SusantitaphongP , KijkriengkraikulN , LeelahavanichkulA , SrisawatN , et al. Regional citrate anticoagulation reduces polymorphonuclear cell degranulation in critically ill patients treated with continuous venovenous hemofiltration. Therapeutic Apheresis &amp; Dialysis2011;15(6):556-64. [MEDLINE: 22107692]">Tiranathanagul 2011</a>; <a href="./references#CD012467-bbs2-0007" title="CuiW , DengX , LvS , HuQ , ZhangK . The observation on the comprehensive effect of extracorporeal citrate anticoagulation protocol in continuous blood purification. Journal of Qiqihar University of Medicine2011;32(12):1884. ">Cui 2011</a>). </p> </li> <li> <p>Three studies compared citrate versus UFH plus protamine (<a href="./references#CD012467-bbs2-0010" title="FealyN , BaldwinI , JohnstoneM , EgiM , BellomoR . A pilot randomized controlled crossover study comparing regional heparinization to regional citrate anticoagulation for continuous venovenous hemofiltration. International Journal of Artificial Organs2007;30(4):301-7. [MEDLINE: 17520566]">Fealy 2007</a>; <a href="./references#CD012467-bbs2-0011" title="BrainMJ , RoodenburgOS , AdamsN , McCrackenP , HockingsL , MusgraveS , et al. Randomised trial of software algorithm driven regional citrate anticoagulation versus heparin in continuous renal replacement therapy: the Filter Life in Renal Replacement Therapy pilot trial. Critical Care &amp; Resuscitation2014;16(2):131-7. [MEDLINE: 24888284]">FLIRRT 2014</a>; <a href="./references#CD012467-bbs2-0013" title="GattasDJ , RajbhandariD , BradfordC , BuhrH , LoS , BellomoR . A randomized controlled trial of regional citrate versus regional heparin anticoagulation for continuous renal replacement therapy in critically ill adults. Critical Care Medicine2015;43(8):1622-9. [MEDLINE: 25853591]">Gattas 2015</a>). </p> </li> <li> <p>One study compared citrate versus LMWH (<a href="./references#CD012467-bbs2-0024" title="Oudemans-van StraatenHM , BosmanRJ , KoopmansM , van derVoortPH , WesterJP , van derSpoelJI , et al. Citrate anticoagulation for continuous venovenous hemofiltration. Critical Care Medicine2009;37(2):545-52. [MEDLINE: 19114912]">Oudemans‐van Straaten 2009</a>). </p> </li> <li> <p>Six studies compared UFH versus LMWH (<a href="./references#CD012467-bbs2-0012" title="GarcesEO , VictorinoJA , ThomeFS , RohsigLM , DornellesE , LouzadaM , et al. Enoxaparin versus unfractioned heparin as anticoagulant for continuous venovenous hemodialysis: a randomized open-label trial. Renal Failure2010;32(3):320-7. [MEDLINE: 20370447]">Garces 2010</a>; <a href="./references#CD012467-bbs2-0016" title="JoannidisM , KountchevJ , GroteA , BellmanR , WiedermannCJ . Unfractioned versus low-molecular-weight heparin for anticoagulation in hemofiltration [abstract no: SU-PO880]. Journal of the American Society of Nephrology2003;14(Nov):728-9A. [CENTRAL: CN-00583249] JoannidisM , KountchevJ , RauchenzaunerM , SchusterschitzN , UlmerH , MayrA , et al. Enoxaparin vs. unfractionated heparin for anticoagulation during continuous veno-venous hemofiltration: a randomized controlled crossover study. Intensive Care Medicine2007;33(9):1571-9. [MEDLINE: 17563874]KountchevJ , GroteA , BellmannR , WiedermannC , JoannidisM . Unfractioned versus low-molecular-weight heparin (enoxaparin) for anticoagulation in CVVH [abstract no: MP459]. In: 41st Congress. European Renal Association. European Dialysis and Transplantation Association; 2004 May 15-18; Lisbon, Portugal. 2004:384. [CENTRAL: CN-00509287] ">Joannidis 2007</a>; <a href="./references#CD012467-bbs2-0026" title="ReevesJH , CummingAR , GallagherL , O'BrienJL , SantamariaJD . A controlled trial of low-molecular-weight heparin (dalteparin) versus unfractionated heparin as anticoagulant during continuous venovenous hemodialysis with filtration. Critical Care Medicine1999;27(10):2224-8. [MEDLINE: 10548211]">Reeves 1999</a>; <a href="./references#CD012467-bbs2-0027" title="ReevesJH , GraanM . Randomised controlled trial: enoxaparin versus heparin in continuous renal replacement therapy [abstract no: 41]. Blood Purification2003;21(2):203. [CENTRAL: CN-00757740] ">Reeves 2003</a>; <a href="./references#CD012467-bbs2-0031" title="vanDoornKJ , HubloueI , VerbeelenD . Urea exchange efficacy during unfractionated heparin anticoagulation versus low molecular weight heparin (dalteparin) anticoagulation in continuous veno-venous hemofiltration [abstract]. In: 41st Congress. European Renal Association. European Dialysis and Transplantation Association; 2004 May 15-18; Lisbon, Portugal. 2004:384. [CENTRAL: CN-00509250] vanDoornKJ , HubloueI , VerbeelenD . Urea exchange efficacy during unfractionated heparin anticoagulation versus low molecular weight heparin (dalteparin) anticoagulation in continuous veno-venous hemofiltration [abstract no: 33]. Blood Purification2004;22(2):243. [CENTRAL: CN-01658168] ">van Doorn 2004</a>; <a href="./references#CD012467-bbs2-0033" title="VictorinoJA , OteroE , RohsigL , DornellesE , LouzadaM , StifftJ , et al. Low molecular weight heparin (LMWH) versus non-fractionated heparin (NFH) as anticoagulation system in continuous veno-veno hemodialysis (CVVH) in patients with acute renal (ARF) and respiratory failure (RF) [abstract no: 128]. In: American Thoracic Society International Conference; 2007 May 18-23; San Francisco (CA). 2007. [CENTRAL: CN-00645386] ">Victorino 2007</a>). </p> </li> <li> <p>Two studies compared nafamostat mesilate versus no anticoagulation (<a href="./references#CD012467-bbs2-0006" title="ChoiJY , KangYJ , JangHM , JungHY , ChoJH , ParkSH , et al. Nafamostat mesilate as an anticoagulant during continuous renal replacement therapy in patients with high bleeding risk: a randomized clinical trial. Medicine2015;94(52):e2392. [MEDLINE: 26717390]">Choi 2015</a>; <a href="./references#CD012467-bbs2-0021" title="LeeYK , LeeHW , ChoiKH , KimBS . Ability of nafamostat mesilate to prolong filter patency during continuous renal replacement therapy in patients at high risk of bleeding: a randomized controlled study. PLoS ONE [Electronic Resource]2014;9(10):e108737. [MEDLINE: 25302581]LeeYK , LeeHW , ChoiKH , KimBS . The effect of nafamostat mesilate in prolonging filter patency with patients on continuous renal replacement therapy [abstract no: MP403]. Nephrology Dialysis Transplantation2013;28(Suppl 1):i425. [EMBASE: 71076312]">Lee 2014b</a>). </p> </li> <li> <p>One study compared UFH vs UFH plus protamine versus no anticoagulation (<a href="./references#CD012467-bbs2-0002" title="BellomoR , TeedeH , BoyceN . Anticoagulant regimens in acute continuous hemodiafiltration: a comparative study. Intensive Care Medicine1993;19(6):329-32. [MEDLINE: 8227722]">Bellomo 1993</a>). </p> </li> <li> <p>One studies compared prostaglandin I<sub> 2</sub> (PGI<sub>2</sub>) versus UFH (<a href="./references#CD012467-bbs2-0001" title="ArcangeliA , RoccaB , SalvatoriG , CianciaM , De CristofaroR , AntonelliM . Heparin versus prostacyclin in continuous hemodiafiltration for acute renal failure: effects on platelet function in the systemic circulation and across the filter. Thrombosis Research2010;126(1):24-31. [MEDLINE: 20185164]">Arcangeli 2010</a>). </p> </li> <li> <p>One study compared prostaglandin I<sub> 2</sub> (PGI<sub>2</sub>) versus UFH plus PGI<sub>2</sub> versus UFH (<a href="./references#CD012467-bbs2-0020" title="LangeneckerSA , FelfernigM , WerbaA , MuellerCM , ChiariA , ZimpferM . Anticoagulation with prostacyclin and heparin during continuous venovenous hemofiltration. Critical Care Medicine1994;22(11):1774-81. [MEDLINE: 7956281]">Langenecker 1994</a>). </p> </li> <li> <p>One study compared UFH plus PGI<sub>2</sub> versus UFH (<a href="./references#CD012467-bbs2-0004" title="BirnbaumJ , SpiesCD , KlotzE , HeinOV , MorgeraS , SchinkT , et al. Iloprost for additional anticoagulation in continuous renal replacement therapy--a pilot study. Renal Failure2007;29(3):271-7. [MEDLINE: 17497439]">Birnbaum 2007</a>). </p> </li> <li> <p>One study compared UFH plus protamine plus PGI<sub>2</sub> versus UFH (<a href="./references#CD012467-bbs2-0009" title="FabbriLP , NuceraM , Al MalyanM , BecchiC . Regional anticoagulation and antiaggregation for CVVH in critically ill patients: a prospective, randomized, controlled pilot study. Acta Anaesthesiologica Scandinavica2010;54(1):92-7. [MEDLINE: 19650808]">Fabbri 2010</a>). </p> </li> <li> <p>One study compared UFH plus prostaglandin E<sub>1</sub> (PGE<sub>1</sub>) versus UFH plus PGI<sub>2</sub> versus UFH (<a href="./references#CD012467-bbs2-0018" title="Kozek-LangeneckerSA , SpissCK , GamsjagerT , DomenigC , ZimpferM . Anticoagulation with prostaglandins and unfractionated heparin during continuous venovenous haemofiltration: a randomized controlled trial. Wiener Klinische Wochenschrift2002;114(3):96-101. [MEDLINE: 12060975]">Kozek‐Langenecker 2002</a>). </p> </li> <li> <p>One study compared UFH versus UFH plus tirofiban (<a href="./references#CD012467-bbs2-0022" title="LinkA , GirndtM , SelejanS , RbahR , BohmM . Tirofiban preserves platelet loss during continuous renal replacement therapy in a randomised prospective open-blinded pilot study. Critical Care (London, England)2008;12(4):R111. [MEDLINE: 18759963]">Link 2008</a>). </p> </li> <li> <p>One study compared bivalirudin versus UFH (<a href="./references#CD012467-bbs2-0017" title="KiserTH , MacLarenR , FishDN , HassellKL , TeitelbaumI . Bivalirudin versus unfractionated heparin for prevention of hemofilter occlusion during continuous renal replacement therapy. Pharmacotherapy2010;30(11):1117-26. [MEDLINE: 20973685]">Kiser 2010</a>). </p> </li> <li> <p>Two study compared hirudin versus UFH (<a href="./references#CD012467-bbs2-0032" title="Vargas HeinO , vonHeymannC , LippsM , ZiemerS , RoncoC , NeumayerHH , et al. Hirudin versus heparin for anticoagulation in continuous renal replacement therapy. Intensive Care Medicine2001;27(4):673-9. [MEDLINE: 11403068]">Vargas Hein 2001</a>; <a href="./references#CD012467-bbs2-0014" title="HeinOV , vonHeymannC , DiehlT , ZiemerS , RoncoC , MorgeraS , et al. Intermittent hirudin versus continuous heparin for anticoagulation in continuous renal replacement therapy. Renal Failure2004;26(3):297-303. [MEDLINE: 15354980]">Hein 2004</a>). </p> </li> <li> <p>One study compared low molecular weight dextran versus placebo (vehicle)Ã‚Â (<a href="./references#CD012467-bbs2-0025" title="PalevskyPM , BurrR , MorelandL , TokiwaY , GreenbergA . Failure of low molecular weight dextran to prevent clotting during continuous renal replacement therapy. ASAIO Journal1995;41(4):847-9. [MEDLINE: 8589465]">Palevsky 1995</a>). </p> </li> <li> <p>One study compared dalteparin (LMWH) versus nadroparin (LMWH) (<a href="./references#CD012467-bbs2-0008" title="dePontAC , Oudemans-van StraatenHM , RoozendaalKJ , ZandstraDF . Nadroparin versus dalteparin anticoagulation in high-volume, continuous venovenous hemofiltration: a double-blind, randomized, crossover study. Critical Care Medicine2000;28(2):421-5. [MEDLINE: 10708177]">de Pont 2000</a>) </p> </li> <li> <p>One study compared citrate vs LMWH versus citrate plus LMWH (<a href="./references#CD012467-bbs2-0034" title="WuB , ZhangK , XuB , JiD , LiuZ , GongD . Randomized controlled trial to evaluate regional citrate anticoagulation plus low-dose of dalteparin in continuous veno-venous hemofiltration. Blood Purification2015;39(4):306-12. [MEDLINE: 26022434]ZhangK , GongD , JiD , XuB , IIuZ . Regional citrate plus low dose of low molecular weight heparins: a safe and more efficacy anticoagulation protocol for continuous veno - venous hemofiltration [abstract no: 71]. In: CCRT 2012. 17th International Conference on CRRT; 2012 Feb 14-17; San Diego (CA). 2012. [CENTRAL: CN-01658175] ">Wu 2015b</a>). </p> </li> <li> <p>One study compared UFH plus protamine versus LMWH (<a href="./references#CD012467-bbs2-0030" title="van derVoortPH , GerritsenRT , KuiperMA , EgbersPH , KingmaWP , BoermaEC . Filter run time in CVVH: pre- versus post-dilution and nadroparin versus regional heparin-protamine anticoagulation. Blood Purification2005;23(3):175-80. [MEDLINE: 15711037]">van der Voort 2005</a>). </p> </li> </ul> </p> </section> <section id="CD012467-sec-0048"> <h4 class="title">Excluded studies</h4> <p>Twenty‐oneÃ‚Â studies were excluded.</p> <p> <ul id="CD012467-list-0015"> <li> <p>Effect of prostacyclin (PGI<sub>2</sub>) on platelets function (<a href="./references#CD012467-bbs2-0040" title="Kozek-LangeneckerSA , SpissCK , Michalek-SaubererA , FelfernigM , ZimpferM . Effect of prostacyclin on platelets, polymorphonuclear cells, and heterotypic cell aggregation during hemofiltration. Critical Care Medicine2003;31(3):864-8. [MEDLINE: 12626998]">Kozek‐Langenecker 2003</a>) </p> </li> <li> <p>Twenty‐nine consecutive patients with septic shock and treated by CVVH (<a href="./references#CD012467-bbs2-0041" title="LafargueM , Joannes-BoyauO , HonorePM , GaucheB , GrandH , FleureauC , et al. Acquired deficit of antithrombin and role of supplementation in septic patients during continuous veno-venous hemofiltration. ASAIO Journal2008;54(1):124-8. [MEDLINE: 18204328]">Lafargue 2008</a>) </p> </li> <li> <p>Two circuit configurations with different administration dilutions of UFH (<a href="./references#CD012467-bbs2-0042" title="LeslieGD , JacobsIG , ClarkeGM . Proximally delivered dilute heparin does not improve circuit life in continuous venovenous haemodiafiltration. Intensive Care Medicine1996;22(11):1261-4. [MEDLINE: 9120123]">Leslie 1996</a>) </p> </li> <li> <p>Different dose of PGE<sub>1</sub> (<a href="./references#CD012467-bbs2-0039" title="Kozek-LangeneckerSA , KettnerSC , OismuellerC , GonanoC , SpeiserW , ZimpferM . Anticoagulation with prostaglandin E1 and unfractionated heparin during continuous venovenous hemofiltration. Critical Care Medicine1998;26(7):1208-12. [MEDLINE: 9671370]">Kozek‐Langenecker 1998</a>) </p> </li> <li> <p>Anticoagulation for patients with multiple organ disorder (<a href="./references#CD012467-bbs2-0043" title="LinXM , Qin ZM ChenL . The comparing research of anticoagulation with sodium citrate or heparin in continuous venovenous hemodiafiltration. Chinese Journal of Practical Internal Medicine2007;27(S1):194-6. ">Lin 2007</a>) </p> </li> <li> <p>Heparin rinse of the circuit before the CRRT procedure (<a href="./references#CD012467-bbs2-0047" title="Opatrny K Jr, PolanskaK , KrouzeckyA , VitL , NovakI , KasalE . The effect of heparin rinse on the biocompatibility of continuous veno-venous hemodiafiltration. International Journal of Artificial Organs2002;25(6):520-8. [MEDLINE: 12117291]">Opatrny 2002b</a>) </p> </li> <li> <p>Filtration flow speed (<a href="./references#CD012467-bbs2-0048" title="Oudemans-van StraatenHM , vanSchilfgaardeM , MolenaarPJ , WesterJP , LeyteA . Hemostasis during low molecular weight heparin anticoagulation for continuous venovenous hemofiltration: a randomized cross-over trial comparing two hemofiltration rates. Critical Care (London, England)2009;13(6):R193. [MEDLINE: 19958532]">Oudemans‐van Straaten 2009a</a>) </p> </li> <li> <p>Albumin (human blood preparations) priming of the circuit (<a href="./references#CD012467-bbs2-0049" title="ReevesJH , SealPF , VossAL , O'ConnorC . Albumin priming does not prolong hemofilter life. ASAIO Journal1997;43(3):193-6. [MEDLINE: 9152490]">Reeves 1997</a>) </p> </li> <li> <p>CVVHF on blood heparin levels (as measured by anti‐Factor Xa activity) (<a href="./references#CD012467-bbs2-0051" title="SingerM , McNallyT , ScreatonG , MackieI , MachinS , CohenSL . Heparin clearance during continuous veno-venous haemofiltration. Intensive Care Medicine1994;20(3):212-5. [MEDLINE: 8014289]">Singer 1994</a>) </p> </li> <li> <p>Catheter locking fluid (<a href="./references#CD012467-bbs2-0053" title="BruyereR , Soudry-FaureA , CapellierG , BinquetC , NadjiA , TornerS , et al. Comparison of heparin to citrate as a catheter locking solution for non-tunneled central venous hemodialysis catheters in patients requiring renal replacement therapy for acute renal failure (VERROU-REA study): study protocol for a randomized controlled trial. Trials [Electronic Resource]2014;15(1):449. [MEDLINE: 25409678]">VERROU‐REA 2014</a>) </p> </li> <li> <p>Anticoagulation method of sustained low‐efficiency dialysis (one of the intermittent dialysis methods) (<a href="./references#CD012467-bbs2-0044" title="Jansen van DoornKJ , VerpootenG , VerbruggheW , JorensP . Comparison of slow efficiency daily dialysis (SLEDD) with unfractionated heparin versus citrasate in critically ill patients. www.clinicaltrials.gov/ct2/show/NCT01228292 (first received 26 October 2010). ">NCT01228292</a>; <a href="./references#CD012467-bbs2-0052" title="TingliW , LingZ , YunyingS , PingF . Safety and efficacy of regional citrate anticoagulation in sustained low efficiency dialysis [abstract no: SP442]. Nephrology Dialysis Transplantation2014;29(Suppl 3):iii220. [EMBASE: 71492069]">Tingli 2014</a>; <a href="./references#CD012467-bbs2-0055" title="WangT , ZhangL , ChenZ , FuP . Evaluation of the application of regional citrate anticoagulation in sustained low efficiency hemodialysis. Chung-Hua Nei Ko Tsa Chih [Chinese Journal of Internal Medicine]2014;53(12):953-6. [MEDLINE: 25623561]">Wang 2014b</a>) </p> </li> <li> <p>Different doses of citrate (<a href="./references#CD012467-bbs2-0037" title="AnsteyC , CampbellV , RichardsonA . A comparison between two dilute citrate solutions (15 vs. 18 mmol/l) in continuous renal replacement therapy: the Base Excess and Renal Substitution Solution study. Blood Purification2016;42(3):194-201. [MEDLINE: 27352175]">Anstey 2016</a>; <a href="./references#CD012467-bbs2-0046" title="BoerW . Magnesium balance of citrate-based continuous venovenous hemofiltration, effect of citrate dose. www.clinicaltrials.gov/ct2/show/NCT02194569 (first received 18 July 2014). ">NCT02194569</a>) </p> </li> <li> <p>Anticoagulation of high‐dose dialysis (not continuous) (<a href="./references#CD012467-bbs2-0054" title="WangY , ChenXM , SunXF , XiangJ . A study of the dosage of argatroban for anticoagulation effect in the patients undergoing high volume hemofiltration. Zhongguo Wei Zhong Bing Ji Jiu Yi Xue [Chinese Critical Care Medicine]2009;21(4):240-2. [MEDLINE: 19374795]">Wang 2009e</a>) </p> </li> <li> <p>Different doses of LMWH (<a href="./references#CD012467-bbs2-0050" title="RobinsonS , ZincukA , LarsenUL , EkstromC , ToftP . A feasible strategy for preventing blood clots in critically ill patients with acute kidney injury (FBI): study protocol for a randomized controlled trial. Trials [Electronic Resource]2014;15(1):226. [MEDLINE: 24925372]">Robinson 2014</a>) </p> </li> <li> <p>Concentration of unfractionated heparin (<a href="./references#CD012467-bbs2-0045" title="GolperTA , SikaM . A comparison of dilute versus concentrated heparin for CRRT anticoagulation. www.clinicaltrials.gov/ct2/show/NCT01318811 (first received 18 March 2011). ">NCT01318811</a>) </p> </li> <li> <p>Clearance of thromboxane A2 (<a href="./references#CD012467-bbs2-0036" title="AmbrÃƒÂ³s ChecaA , SÃƒÂ¡nchez-Izquierdo RieraJA , PÃƒÂ©rez VelaJL , Alted LopezE , SÃƒÂ¡nchez CasadoM , Cobo CastelianosP . Changes in respiratory parameters in patients with severe multiple trauma with continuous haemofiltration [abstract no: 118]. Medicina Intensiva1995;19(Suppl 1):32. [CENTRAL: CN-00724914] PÃƒÂ©rez VelaJL , SÃƒÂ¡nchez-Izquierdo RieraJA , OrtuÃƒÂ±o de SoloB , Caballero CubedoR , SÃƒÂ¡nchez CasadoM , Alted LopezE . Depuration capacity of thromboxane A2 in continuous haemofiltration in patients with severe multiple trauma [abstract no: 345] [Capacidad de depuracion de tromboxano A2 por hemofiltracion continua en pacientes politraumatizados severos]. Medicina Intensiva1996;20(Suppl 1):101. [CENTRAL: CN-00740493] SÃƒÂ¡nchez-Izquierdo RieraJA , PÃƒÂ©rez VelaJL , OrtuÃƒÂ±o de SoloB , Alted LopezE , Vaquerizo AlonsoC , Novillo-Fertreil VazquezP . Depuration capacity of leukotriene B4 in continuous haemofiltration in patients with severe multiple trauma [abstract no: 210]. Medicina Intensiva1996;20(Suppl 1):63. [CENTRAL: CN-00740492] ">Ambros Checa 1995</a>) </p> </li> <li> <p>Different doses of UFH (<a href="./references#CD012467-bbs2-0038" title="HenrikssonBA . Evaluation of lifespan in AN69ST with two different heparinization strategies. www.isrctn.com/ISRCTN01121161 (first received 13 March 2013). ">ISRCTN01121161</a>) </p> </li> <li> <p>Argatroban versus lepirudin on critically ill heparin‐induced thrombocytopenia (HIT) patients (<a href="./references#CD012467-bbs2-0035" title="TreschanTA , SchaeferMS , GeibJ , BahlmannA , BrezinaT , WernerP , et al. Argatroban versus lepirudin in critically ill patients (Alicia): a randomized controlled trial. Critical Care (London, England)2014;18(5):588. [CENTRAL: CN-01112878] [MEDLINE: 25344113]">ALicia 2014</a>). </p> </li> </ul> </p> </section> </section> <section id="CD012467-sec-0049"> <h3 class="title">Risk of bias in included studies</h3> <p>None of the included studies were free from risk of bias. Risk of bias assessment for included studies are shown in <a href="#CD012467-fig-0002">Figure 2</a>; <a href="#CD012467-fig-0003">Figure 3</a>. The details of the assessment for each study are shown in <a href="./references#CD012467-sec-0244" title="">Characteristics of included studies</a>. The summary of judgment across each domain is shown below. </p> <div class="figure" id="CD012467-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD012467-fig-0002" src="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/image_n/nCD012467-FIG-02.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <div class="figure" id="CD012467-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD012467-fig-0003" src="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/image_n/nCD012467-FIG-03.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <section id="CD012467-sec-0050"> <h4 class="title">Allocation</h4> <section id="CD012467-sec-0051"> <h5 class="title">Random sequence generation</h5> <p>We judged 18 studies (53%) as having low risk of bias (<a href="./references#CD012467-bbs2-0002" title="BellomoR , TeedeH , BoyceN . Anticoagulant regimens in acute continuous hemodiafiltration: a comparative study. Intensive Care Medicine1993;19(6):329-32. [MEDLINE: 8227722]">Bellomo 1993</a>; <a href="./references#CD012467-bbs2-0003" title="BetjesMG , OosteromD , vanAgterenM , vande WeteringJ . Regional citrate versus heparin anticoagulation during venovenous hemofiltration in patients at low risk for bleeding: similar hemofilter survival but significantly less bleeding [abstract no: TH-FC107]. Journal of the American Society of Nephrology2006;17(Abstracts):24A. [CENTRAL: CN-00671866] BetjesMG , vanOosteromD , vanAgterenM , vande WeteringJ . Regional citrate versus heparin anticoagulation during venovenous hemofiltration in patients at low risk for bleeding: similar hemofilter survival but significantly less bleeding. Journal of Nephrology2007;20(5):602-8. [MEDLINE: 17918147]">Betjes 2007</a>; <a href="./references#CD012467-bbs2-0005" title="SchilderL , NurmohamedS , BoschFH , PurmerIM , den BoerSS , KleppeCG , et al. Citrate anticoagulation versus systemic heparinisation in continuous venovenous hemofiltration in critically ill patients with acute kidney injury: a multi-center randomized clinical trial. Critical Care (London, England)2014;18(4):472. [MEDLINE: 25128022]SchilderL , NurmohamedSA , ter WeePM , PaauwNJ , GirbesAR , BeishuizenA , et al. Citrate confers less filter-induced complement activation and neutrophil degranulation than heparin when used for anticoagulation during continuous venovenous haemofiltration in critically ill patients. BMC Nephrology2014;15:19. [MEDLINE: 24438360]SchilderL , NurmohamedSA , ter WeePM , PaauwNJ , GirbesAR , BeishuizenA , et al. Putative novel mediators of acute kidney injury in critically ill patients: handling by continuous venovenous hemofiltration and effect of anticoagulation modalities. BMC Nephrology2015;16:178. [MEDLINE: 26519056]SchilderL , NurmohamedSA , ter WeePM , PaauwNJ , GirbesAR , BeishuizenA , et al. The plasma level and biomarker value of neutrophil gelatinase-associated lipocalin in critically ill patients with acute kidney injury are not affected by continuous venovenous hemofiltration and anticoagulation applied. Critical Care (London, England)2014;18(2):R78. [MEDLINE: 24755339]">CASH 2014</a>; <a href="./references#CD012467-bbs2-0006" title="ChoiJY , KangYJ , JangHM , JungHY , ChoJH , ParkSH , et al. Nafamostat mesilate as an anticoagulant during continuous renal replacement therapy in patients with high bleeding risk: a randomized clinical trial. Medicine2015;94(52):e2392. [MEDLINE: 26717390]">Choi 2015</a>; <a href="./references#CD012467-bbs2-0009" title="FabbriLP , NuceraM , Al MalyanM , BecchiC . Regional anticoagulation and antiaggregation for CVVH in critically ill patients: a prospective, randomized, controlled pilot study. Acta Anaesthesiologica Scandinavica2010;54(1):92-7. [MEDLINE: 19650808]">Fabbri 2010</a>; <a href="./references#CD012467-bbs2-0011" title="BrainMJ , RoodenburgOS , AdamsN , McCrackenP , HockingsL , MusgraveS , et al. Randomised trial of software algorithm driven regional citrate anticoagulation versus heparin in continuous renal replacement therapy: the Filter Life in Renal Replacement Therapy pilot trial. Critical Care &amp; Resuscitation2014;16(2):131-7. [MEDLINE: 24888284]">FLIRRT 2014</a>; <a href="./references#CD012467-bbs2-0012" title="GarcesEO , VictorinoJA , ThomeFS , RohsigLM , DornellesE , LouzadaM , et al. Enoxaparin versus unfractioned heparin as anticoagulant for continuous venovenous hemodialysis: a randomized open-label trial. Renal Failure2010;32(3):320-7. [MEDLINE: 20370447]">Garces 2010</a>; <a href="./references#CD012467-bbs2-0013" title="GattasDJ , RajbhandariD , BradfordC , BuhrH , LoS , BellomoR . A randomized controlled trial of regional citrate versus regional heparin anticoagulation for continuous renal replacement therapy in critically ill adults. Critical Care Medicine2015;43(8):1622-9. [MEDLINE: 25853591]">Gattas 2015</a>; <a href="./references#CD012467-bbs2-0018" title="Kozek-LangeneckerSA , SpissCK , GamsjagerT , DomenigC , ZimpferM . Anticoagulation with prostaglandins and unfractionated heparin during continuous venovenous haemofiltration: a randomized controlled trial. Wiener Klinische Wochenschrift2002;114(3):96-101. [MEDLINE: 12060975]">Kozek‐Langenecker 2002</a>; <a href="./references#CD012467-bbs2-0019" title="KutsogiannisDJ , GibneyRT , StolleryD , GaoJ . Regional citrate versus systemic heparin anticoagulation for continuous renal replacement in critically ill patients. Kidney International2005;67(6):2361-7. [MEDLINE: 15882280]">Kutsogiannis 2005</a>; <a href="./references#CD012467-bbs2-0021" title="LeeYK , LeeHW , ChoiKH , KimBS . Ability of nafamostat mesilate to prolong filter patency during continuous renal replacement therapy in patients at high risk of bleeding: a randomized controlled study. PLoS ONE [Electronic Resource]2014;9(10):e108737. [MEDLINE: 25302581]LeeYK , LeeHW , ChoiKH , KimBS . The effect of nafamostat mesilate in prolonging filter patency with patients on continuous renal replacement therapy [abstract no: MP403]. Nephrology Dialysis Transplantation2013;28(Suppl 1):i425. [EMBASE: 71076312]">Lee 2014b</a>; <a href="./references#CD012467-bbs2-0022" title="LinkA , GirndtM , SelejanS , RbahR , BohmM . Tirofiban preserves platelet loss during continuous renal replacement therapy in a randomised prospective open-blinded pilot study. Critical Care (London, England)2008;12(4):R111. [MEDLINE: 18759963]">Link 2008</a>; <a href="./references#CD012467-bbs2-0023" title="MonchiM , BerghmansD , LedouxD , CanivetJL , DuboisB , DamasP . Citrate vs. heparin for anticoagulation in continuous venovenous hemofiltration: a prospective randomized study. Intensive Care Medicine2004;30(2):260-5. [MEDLINE: 14600809]">Monchi 2004</a>; <a href="./references#CD012467-bbs2-0024" title="Oudemans-van StraatenHM , BosmanRJ , KoopmansM , van derVoortPH , WesterJP , van derSpoelJI , et al. Citrate anticoagulation for continuous venovenous hemofiltration. Critical Care Medicine2009;37(2):545-52. [MEDLINE: 19114912]">Oudemans‐van Straaten 2009</a>; <a href="./references#CD012467-bbs2-0025" title="PalevskyPM , BurrR , MorelandL , TokiwaY , GreenbergA . Failure of low molecular weight dextran to prevent clotting during continuous renal replacement therapy. ASAIO Journal1995;41(4):847-9. [MEDLINE: 8589465]">Palevsky 1995</a>; <a href="./references#CD012467-bbs2-0026" title="ReevesJH , CummingAR , GallagherL , O'BrienJL , SantamariaJD . A controlled trial of low-molecular-weight heparin (dalteparin) versus unfractionated heparin as anticoagulant during continuous venovenous hemodialysis with filtration. Critical Care Medicine1999;27(10):2224-8. [MEDLINE: 10548211]">Reeves 1999</a>; <a href="./references#CD012467-bbs2-0028" title="StuckerF , PonteB , TatawJ , MartinPY , WozniakH , PuginJ , et al. Efficacy and safety of citrate-based anticoagulation compared to heparin in patients with acute kidney injury requiring continuous renal replacement therapy: a randomized controlled trial. Critical Care (London, England)2015;19(1):91. [MEDLINE: 25881975]StuckerF , PuginJ , TattawJ , PonteB , BrochardL , MartinP , et al. Citrate-based anticoagulation in patients with AKI in the intensive care unit: a safe and efficacious method [abstract no: 0379]. Intensive Care Medicine2013;39(Suppl 2):S320. [EMBASE: 71446324]">Stucker 2015</a>; <a href="./references#CD012467-bbs2-0030" title="van derVoortPH , GerritsenRT , KuiperMA , EgbersPH , KingmaWP , BoermaEC . Filter run time in CVVH: pre- versus post-dilution and nadroparin versus regional heparin-protamine anticoagulation. Blood Purification2005;23(3):175-80. [MEDLINE: 15711037]">van der Voort 2005</a>); 15 studies (44%) (<a href="./references#CD012467-bbs2-0001" title="ArcangeliA , RoccaB , SalvatoriG , CianciaM , De CristofaroR , AntonelliM . Heparin versus prostacyclin in continuous hemodiafiltration for acute renal failure: effects on platelet function in the systemic circulation and across the filter. Thrombosis Research2010;126(1):24-31. [MEDLINE: 20185164]">Arcangeli 2010</a>; <a href="./references#CD012467-bbs2-0004" title="BirnbaumJ , SpiesCD , KlotzE , HeinOV , MorgeraS , SchinkT , et al. Iloprost for additional anticoagulation in continuous renal replacement therapy--a pilot study. Renal Failure2007;29(3):271-7. [MEDLINE: 17497439]">Birnbaum 2007</a>; <a href="./references#CD012467-bbs2-0007" title="CuiW , DengX , LvS , HuQ , ZhangK . The observation on the comprehensive effect of extracorporeal citrate anticoagulation protocol in continuous blood purification. Journal of Qiqihar University of Medicine2011;32(12):1884. ">Cui 2011</a>; <a href="./references#CD012467-bbs2-0008" title="dePontAC , Oudemans-van StraatenHM , RoozendaalKJ , ZandstraDF . Nadroparin versus dalteparin anticoagulation in high-volume, continuous venovenous hemofiltration: a double-blind, randomized, crossover study. Critical Care Medicine2000;28(2):421-5. [MEDLINE: 10708177]">de Pont 2000</a>; <a href="./references#CD012467-bbs2-0010" title="FealyN , BaldwinI , JohnstoneM , EgiM , BellomoR . A pilot randomized controlled crossover study comparing regional heparinization to regional citrate anticoagulation for continuous venovenous hemofiltration. International Journal of Artificial Organs2007;30(4):301-7. [MEDLINE: 17520566]">Fealy 2007</a>; <a href="./references#CD012467-bbs2-0015" title="HetzelGR , SchmitzM , WissingH , RiesW , SchottG , HeeringPJ , et al. Regional citrate versus systemic heparin for anticoagulation in critically ill patients on continuous venovenous haemofiltration: a prospective randomized multicentre trial. Nephrology Dialysis Transplantation2011;26(1):232-9. [MEDLINE: 20876598]">Hetzel 2011</a>; <a href="./references#CD012467-bbs2-0016" title="JoannidisM , KountchevJ , GroteA , BellmanR , WiedermannCJ . Unfractioned versus low-molecular-weight heparin for anticoagulation in hemofiltration [abstract no: SU-PO880]. Journal of the American Society of Nephrology2003;14(Nov):728-9A. [CENTRAL: CN-00583249] JoannidisM , KountchevJ , RauchenzaunerM , SchusterschitzN , UlmerH , MayrA , et al. Enoxaparin vs. unfractionated heparin for anticoagulation during continuous veno-venous hemofiltration: a randomized controlled crossover study. Intensive Care Medicine2007;33(9):1571-9. [MEDLINE: 17563874]KountchevJ , GroteA , BellmannR , WiedermannC , JoannidisM . Unfractioned versus low-molecular-weight heparin (enoxaparin) for anticoagulation in CVVH [abstract no: MP459]. In: 41st Congress. European Renal Association. European Dialysis and Transplantation Association; 2004 May 15-18; Lisbon, Portugal. 2004:384. [CENTRAL: CN-00509287] ">Joannidis 2007</a>; <a href="./references#CD012467-bbs2-0017" title="KiserTH , MacLarenR , FishDN , HassellKL , TeitelbaumI . Bivalirudin versus unfractionated heparin for prevention of hemofilter occlusion during continuous renal replacement therapy. Pharmacotherapy2010;30(11):1117-26. [MEDLINE: 20973685]">Kiser 2010</a>; <a href="./references#CD012467-bbs2-0020" title="LangeneckerSA , FelfernigM , WerbaA , MuellerCM , ChiariA , ZimpferM . Anticoagulation with prostacyclin and heparin during continuous venovenous hemofiltration. Critical Care Medicine1994;22(11):1774-81. [MEDLINE: 7956281]">Langenecker 1994</a>; <a href="./references#CD012467-bbs2-0027" title="ReevesJH , GraanM . Randomised controlled trial: enoxaparin versus heparin in continuous renal replacement therapy [abstract no: 41]. Blood Purification2003;21(2):203. [CENTRAL: CN-00757740] ">Reeves 2003</a>; <a href="./references#CD012467-bbs2-0029" title="TiranathanagulK , JearnsujitwimolO , SusantitaphongP , KijkriengkraikulN , LeelahavanichkulA , SrisawatN , et al. Regional citrate anticoagulation reduces polymorphonuclear cell degranulation in critically ill patients treated with continuous venovenous hemofiltration. Therapeutic Apheresis &amp; Dialysis2011;15(6):556-64. [MEDLINE: 22107692]">Tiranathanagul 2011</a>; <a href="./references#CD012467-bbs2-0031" title="vanDoornKJ , HubloueI , VerbeelenD . Urea exchange efficacy during unfractionated heparin anticoagulation versus low molecular weight heparin (dalteparin) anticoagulation in continuous veno-venous hemofiltration [abstract]. In: 41st Congress. European Renal Association. European Dialysis and Transplantation Association; 2004 May 15-18; Lisbon, Portugal. 2004:384. [CENTRAL: CN-00509250] vanDoornKJ , HubloueI , VerbeelenD . Urea exchange efficacy during unfractionated heparin anticoagulation versus low molecular weight heparin (dalteparin) anticoagulation in continuous veno-venous hemofiltration [abstract no: 33]. Blood Purification2004;22(2):243. [CENTRAL: CN-01658168] ">van Doorn 2004</a>; <a href="./references#CD012467-bbs2-0032" title="Vargas HeinO , vonHeymannC , LippsM , ZiemerS , RoncoC , NeumayerHH , et al. Hirudin versus heparin for anticoagulation in continuous renal replacement therapy. Intensive Care Medicine2001;27(4):673-9. [MEDLINE: 11403068]">Vargas Hein 2001</a>; <a href="./references#CD012467-bbs2-0033" title="VictorinoJA , OteroE , RohsigL , DornellesE , LouzadaM , StifftJ , et al. Low molecular weight heparin (LMWH) versus non-fractionated heparin (NFH) as anticoagulation system in continuous veno-veno hemodialysis (CVVH) in patients with acute renal (ARF) and respiratory failure (RF) [abstract no: 128]. In: American Thoracic Society International Conference; 2007 May 18-23; San Francisco (CA). 2007. [CENTRAL: CN-00645386] ">Victorino 2007</a>; <a href="./references#CD012467-bbs2-0034" title="WuB , ZhangK , XuB , JiD , LiuZ , GongD . Randomized controlled trial to evaluate regional citrate anticoagulation plus low-dose of dalteparin in continuous veno-venous hemofiltration. Blood Purification2015;39(4):306-12. [MEDLINE: 26022434]ZhangK , GongD , JiD , XuB , IIuZ . Regional citrate plus low dose of low molecular weight heparins: a safe and more efficacy anticoagulation protocol for continuous veno - venous hemofiltration [abstract no: 71]. In: CCRT 2012. 17th International Conference on CRRT; 2012 Feb 14-17; San Diego (CA). 2012. [CENTRAL: CN-01658175] ">Wu 2015b</a>) as unclear risk of bias. One study (3%) (<a href="./references#CD012467-bbs2-0014" title="HeinOV , vonHeymannC , DiehlT , ZiemerS , RoncoC , MorgeraS , et al. Intermittent hirudin versus continuous heparin for anticoagulation in continuous renal replacement therapy. Renal Failure2004;26(3):297-303. [MEDLINE: 15354980]">Hein 2004</a>) was judged to be at high risk of bias because inappropriate block randomisation. </p> </section> <section id="CD012467-sec-0052"> <h5 class="title">Allocation concealment</h5> <p>We judged six studies (17%) (<a href="./references#CD012467-bbs2-0005" title="SchilderL , NurmohamedS , BoschFH , PurmerIM , den BoerSS , KleppeCG , et al. Citrate anticoagulation versus systemic heparinisation in continuous venovenous hemofiltration in critically ill patients with acute kidney injury: a multi-center randomized clinical trial. Critical Care (London, England)2014;18(4):472. [MEDLINE: 25128022]SchilderL , NurmohamedSA , ter WeePM , PaauwNJ , GirbesAR , BeishuizenA , et al. Citrate confers less filter-induced complement activation and neutrophil degranulation than heparin when used for anticoagulation during continuous venovenous haemofiltration in critically ill patients. BMC Nephrology2014;15:19. [MEDLINE: 24438360]SchilderL , NurmohamedSA , ter WeePM , PaauwNJ , GirbesAR , BeishuizenA , et al. Putative novel mediators of acute kidney injury in critically ill patients: handling by continuous venovenous hemofiltration and effect of anticoagulation modalities. BMC Nephrology2015;16:178. [MEDLINE: 26519056]SchilderL , NurmohamedSA , ter WeePM , PaauwNJ , GirbesAR , BeishuizenA , et al. The plasma level and biomarker value of neutrophil gelatinase-associated lipocalin in critically ill patients with acute kidney injury are not affected by continuous venovenous hemofiltration and anticoagulation applied. Critical Care (London, England)2014;18(2):R78. [MEDLINE: 24755339]">CASH 2014</a>: <a href="./references#CD012467-bbs2-0011" title="BrainMJ , RoodenburgOS , AdamsN , McCrackenP , HockingsL , MusgraveS , et al. Randomised trial of software algorithm driven regional citrate anticoagulation versus heparin in continuous renal replacement therapy: the Filter Life in Renal Replacement Therapy pilot trial. Critical Care &amp; Resuscitation2014;16(2):131-7. [MEDLINE: 24888284]">FLIRRT 2014</a>: <a href="./references#CD012467-bbs2-0013" title="GattasDJ , RajbhandariD , BradfordC , BuhrH , LoS , BellomoR . A randomized controlled trial of regional citrate versus regional heparin anticoagulation for continuous renal replacement therapy in critically ill adults. Critical Care Medicine2015;43(8):1622-9. [MEDLINE: 25853591]">Gattas 2015</a>; <a href="./references#CD012467-bbs2-0023" title="MonchiM , BerghmansD , LedouxD , CanivetJL , DuboisB , DamasP . Citrate vs. heparin for anticoagulation in continuous venovenous hemofiltration: a prospective randomized study. Intensive Care Medicine2004;30(2):260-5. [MEDLINE: 14600809]">Monchi 2004</a>; <a href="./references#CD012467-bbs2-0028" title="StuckerF , PonteB , TatawJ , MartinPY , WozniakH , PuginJ , et al. Efficacy and safety of citrate-based anticoagulation compared to heparin in patients with acute kidney injury requiring continuous renal replacement therapy: a randomized controlled trial. Critical Care (London, England)2015;19(1):91. [MEDLINE: 25881975]StuckerF , PuginJ , TattawJ , PonteB , BrochardL , MartinP , et al. Citrate-based anticoagulation in patients with AKI in the intensive care unit: a safe and efficacious method [abstract no: 0379]. Intensive Care Medicine2013;39(Suppl 2):S320. [EMBASE: 71446324]">Stucker 2015</a>; <a href="./references#CD012467-bbs2-0030" title="van derVoortPH , GerritsenRT , KuiperMA , EgbersPH , KingmaWP , BoermaEC . Filter run time in CVVH: pre- versus post-dilution and nadroparin versus regional heparin-protamine anticoagulation. Blood Purification2005;23(3):175-80. [MEDLINE: 15711037]">van der Voort 2005</a>) as having low risk of bias; 17 studies (50%) (<a href="./references#CD012467-bbs2-0001" title="ArcangeliA , RoccaB , SalvatoriG , CianciaM , De CristofaroR , AntonelliM . Heparin versus prostacyclin in continuous hemodiafiltration for acute renal failure: effects on platelet function in the systemic circulation and across the filter. Thrombosis Research2010;126(1):24-31. [MEDLINE: 20185164]">Arcangeli 2010</a>; <a href="./references#CD012467-bbs2-0002" title="BellomoR , TeedeH , BoyceN . Anticoagulant regimens in acute continuous hemodiafiltration: a comparative study. Intensive Care Medicine1993;19(6):329-32. [MEDLINE: 8227722]">Bellomo 1993</a>; <a href="./references#CD012467-bbs2-0004" title="BirnbaumJ , SpiesCD , KlotzE , HeinOV , MorgeraS , SchinkT , et al. Iloprost for additional anticoagulation in continuous renal replacement therapy--a pilot study. Renal Failure2007;29(3):271-7. [MEDLINE: 17497439]">Birnbaum 2007</a>; <a href="./references#CD012467-bbs2-0006" title="ChoiJY , KangYJ , JangHM , JungHY , ChoJH , ParkSH , et al. Nafamostat mesilate as an anticoagulant during continuous renal replacement therapy in patients with high bleeding risk: a randomized clinical trial. Medicine2015;94(52):e2392. [MEDLINE: 26717390]">Choi 2015</a>; <a href="./references#CD012467-bbs2-0012" title="GarcesEO , VictorinoJA , ThomeFS , RohsigLM , DornellesE , LouzadaM , et al. Enoxaparin versus unfractioned heparin as anticoagulant for continuous venovenous hemodialysis: a randomized open-label trial. Renal Failure2010;32(3):320-7. [MEDLINE: 20370447]">Garces 2010</a>; <a href="./references#CD012467-bbs2-0015" title="HetzelGR , SchmitzM , WissingH , RiesW , SchottG , HeeringPJ , et al. Regional citrate versus systemic heparin for anticoagulation in critically ill patients on continuous venovenous haemofiltration: a prospective randomized multicentre trial. Nephrology Dialysis Transplantation2011;26(1):232-9. [MEDLINE: 20876598]">Hetzel 2011</a>; <a href="./references#CD012467-bbs2-0016" title="JoannidisM , KountchevJ , GroteA , BellmanR , WiedermannCJ . Unfractioned versus low-molecular-weight heparin for anticoagulation in hemofiltration [abstract no: SU-PO880]. Journal of the American Society of Nephrology2003;14(Nov):728-9A. [CENTRAL: CN-00583249] JoannidisM , KountchevJ , RauchenzaunerM , SchusterschitzN , UlmerH , MayrA , et al. Enoxaparin vs. unfractionated heparin for anticoagulation during continuous veno-venous hemofiltration: a randomized controlled crossover study. Intensive Care Medicine2007;33(9):1571-9. [MEDLINE: 17563874]KountchevJ , GroteA , BellmannR , WiedermannC , JoannidisM . Unfractioned versus low-molecular-weight heparin (enoxaparin) for anticoagulation in CVVH [abstract no: MP459]. In: 41st Congress. European Renal Association. European Dialysis and Transplantation Association; 2004 May 15-18; Lisbon, Portugal. 2004:384. [CENTRAL: CN-00509287] ">Joannidis 2007</a>; <a href="./references#CD012467-bbs2-0018" title="Kozek-LangeneckerSA , SpissCK , GamsjagerT , DomenigC , ZimpferM . Anticoagulation with prostaglandins and unfractionated heparin during continuous venovenous haemofiltration: a randomized controlled trial. Wiener Klinische Wochenschrift2002;114(3):96-101. [MEDLINE: 12060975]">Kozek‐Langenecker 2002</a>; <a href="./references#CD012467-bbs2-0019" title="KutsogiannisDJ , GibneyRT , StolleryD , GaoJ . Regional citrate versus systemic heparin anticoagulation for continuous renal replacement in critically ill patients. Kidney International2005;67(6):2361-7. [MEDLINE: 15882280]">Kutsogiannis 2005</a>; <a href="./references#CD012467-bbs2-0020" title="LangeneckerSA , FelfernigM , WerbaA , MuellerCM , ChiariA , ZimpferM . Anticoagulation with prostacyclin and heparin during continuous venovenous hemofiltration. Critical Care Medicine1994;22(11):1774-81. [MEDLINE: 7956281]">Langenecker 1994</a>; <a href="./references#CD012467-bbs2-0022" title="LinkA , GirndtM , SelejanS , RbahR , BohmM . Tirofiban preserves platelet loss during continuous renal replacement therapy in a randomised prospective open-blinded pilot study. Critical Care (London, England)2008;12(4):R111. [MEDLINE: 18759963]">Link 2008</a>; <a href="./references#CD012467-bbs2-0025" title="PalevskyPM , BurrR , MorelandL , TokiwaY , GreenbergA . Failure of low molecular weight dextran to prevent clotting during continuous renal replacement therapy. ASAIO Journal1995;41(4):847-9. [MEDLINE: 8589465]">Palevsky 1995</a>; <a href="./references#CD012467-bbs2-0026" title="ReevesJH , CummingAR , GallagherL , O'BrienJL , SantamariaJD . A controlled trial of low-molecular-weight heparin (dalteparin) versus unfractionated heparin as anticoagulant during continuous venovenous hemodialysis with filtration. Critical Care Medicine1999;27(10):2224-8. [MEDLINE: 10548211]">Reeves 1999</a>; <a href="./references#CD012467-bbs2-0027" title="ReevesJH , GraanM . Randomised controlled trial: enoxaparin versus heparin in continuous renal replacement therapy [abstract no: 41]. Blood Purification2003;21(2):203. [CENTRAL: CN-00757740] ">Reeves 2003</a>; <a href="./references#CD012467-bbs2-0029" title="TiranathanagulK , JearnsujitwimolO , SusantitaphongP , KijkriengkraikulN , LeelahavanichkulA , SrisawatN , et al. Regional citrate anticoagulation reduces polymorphonuclear cell degranulation in critically ill patients treated with continuous venovenous hemofiltration. Therapeutic Apheresis &amp; Dialysis2011;15(6):556-64. [MEDLINE: 22107692]">Tiranathanagul 2011</a>; <a href="./references#CD012467-bbs2-0031" title="vanDoornKJ , HubloueI , VerbeelenD . Urea exchange efficacy during unfractionated heparin anticoagulation versus low molecular weight heparin (dalteparin) anticoagulation in continuous veno-venous hemofiltration [abstract]. In: 41st Congress. European Renal Association. European Dialysis and Transplantation Association; 2004 May 15-18; Lisbon, Portugal. 2004:384. [CENTRAL: CN-00509250] vanDoornKJ , HubloueI , VerbeelenD . Urea exchange efficacy during unfractionated heparin anticoagulation versus low molecular weight heparin (dalteparin) anticoagulation in continuous veno-venous hemofiltration [abstract no: 33]. Blood Purification2004;22(2):243. [CENTRAL: CN-01658168] ">van Doorn 2004</a>; <a href="./references#CD012467-bbs2-0033" title="VictorinoJA , OteroE , RohsigL , DornellesE , LouzadaM , StifftJ , et al. Low molecular weight heparin (LMWH) versus non-fractionated heparin (NFH) as anticoagulation system in continuous veno-veno hemodialysis (CVVH) in patients with acute renal (ARF) and respiratory failure (RF) [abstract no: 128]. In: American Thoracic Society International Conference; 2007 May 18-23; San Francisco (CA). 2007. [CENTRAL: CN-00645386] ">Victorino 2007</a>) as unclear risk of bias, and 11 studies (32%) (<a href="./references#CD012467-bbs2-0003" title="BetjesMG , OosteromD , vanAgterenM , vande WeteringJ . Regional citrate versus heparin anticoagulation during venovenous hemofiltration in patients at low risk for bleeding: similar hemofilter survival but significantly less bleeding [abstract no: TH-FC107]. Journal of the American Society of Nephrology2006;17(Abstracts):24A. [CENTRAL: CN-00671866] BetjesMG , vanOosteromD , vanAgterenM , vande WeteringJ . Regional citrate versus heparin anticoagulation during venovenous hemofiltration in patients at low risk for bleeding: similar hemofilter survival but significantly less bleeding. Journal of Nephrology2007;20(5):602-8. [MEDLINE: 17918147]">Betjes 2007</a>; <a href="./references#CD012467-bbs2-0007" title="CuiW , DengX , LvS , HuQ , ZhangK . The observation on the comprehensive effect of extracorporeal citrate anticoagulation protocol in continuous blood purification. Journal of Qiqihar University of Medicine2011;32(12):1884. ">Cui 2011</a>; <a href="./references#CD012467-bbs2-0008" title="dePontAC , Oudemans-van StraatenHM , RoozendaalKJ , ZandstraDF . Nadroparin versus dalteparin anticoagulation in high-volume, continuous venovenous hemofiltration: a double-blind, randomized, crossover study. Critical Care Medicine2000;28(2):421-5. [MEDLINE: 10708177]">de Pont 2000</a>; <a href="./references#CD012467-bbs2-0009" title="FabbriLP , NuceraM , Al MalyanM , BecchiC . Regional anticoagulation and antiaggregation for CVVH in critically ill patients: a prospective, randomized, controlled pilot study. Acta Anaesthesiologica Scandinavica2010;54(1):92-7. [MEDLINE: 19650808]">Fabbri 2010</a>; <a href="./references#CD012467-bbs2-0010" title="FealyN , BaldwinI , JohnstoneM , EgiM , BellomoR . A pilot randomized controlled crossover study comparing regional heparinization to regional citrate anticoagulation for continuous venovenous hemofiltration. International Journal of Artificial Organs2007;30(4):301-7. [MEDLINE: 17520566]">Fealy 2007</a>; <a href="./references#CD012467-bbs2-0014" title="HeinOV , vonHeymannC , DiehlT , ZiemerS , RoncoC , MorgeraS , et al. Intermittent hirudin versus continuous heparin for anticoagulation in continuous renal replacement therapy. Renal Failure2004;26(3):297-303. [MEDLINE: 15354980]">Hein 2004</a>; <a href="./references#CD012467-bbs2-0017" title="KiserTH , MacLarenR , FishDN , HassellKL , TeitelbaumI . Bivalirudin versus unfractionated heparin for prevention of hemofilter occlusion during continuous renal replacement therapy. Pharmacotherapy2010;30(11):1117-26. [MEDLINE: 20973685]">Kiser 2010</a>; <a href="./references#CD012467-bbs2-0021" title="LeeYK , LeeHW , ChoiKH , KimBS . Ability of nafamostat mesilate to prolong filter patency during continuous renal replacement therapy in patients at high risk of bleeding: a randomized controlled study. PLoS ONE [Electronic Resource]2014;9(10):e108737. [MEDLINE: 25302581]LeeYK , LeeHW , ChoiKH , KimBS . The effect of nafamostat mesilate in prolonging filter patency with patients on continuous renal replacement therapy [abstract no: MP403]. Nephrology Dialysis Transplantation2013;28(Suppl 1):i425. [EMBASE: 71076312]">Lee 2014b</a>; <a href="./references#CD012467-bbs2-0024" title="Oudemans-van StraatenHM , BosmanRJ , KoopmansM , van derVoortPH , WesterJP , van derSpoelJI , et al. Citrate anticoagulation for continuous venovenous hemofiltration. Critical Care Medicine2009;37(2):545-52. [MEDLINE: 19114912]">Oudemans‐van Straaten 2009</a>; <a href="./references#CD012467-bbs2-0032" title="Vargas HeinO , vonHeymannC , LippsM , ZiemerS , RoncoC , NeumayerHH , et al. Hirudin versus heparin for anticoagulation in continuous renal replacement therapy. Intensive Care Medicine2001;27(4):673-9. [MEDLINE: 11403068]">Vargas Hein 2001</a>; <a href="./references#CD012467-bbs2-0034" title="WuB , ZhangK , XuB , JiD , LiuZ , GongD . Randomized controlled trial to evaluate regional citrate anticoagulation plus low-dose of dalteparin in continuous veno-venous hemofiltration. Blood Purification2015;39(4):306-12. [MEDLINE: 26022434]ZhangK , GongD , JiD , XuB , IIuZ . Regional citrate plus low dose of low molecular weight heparins: a safe and more efficacy anticoagulation protocol for continuous veno - venous hemofiltration [abstract no: 71]. In: CCRT 2012. 17th International Conference on CRRT; 2012 Feb 14-17; San Diego (CA). 2012. [CENTRAL: CN-01658175] ">Wu 2015b</a>) as high risk of bias. </p> </section> </section> <section id="CD012467-sec-0053"> <h4 class="title">Blinding</h4> <section id="CD012467-sec-0054"> <h5 class="title">Performance bias</h5> <p>We judged three studies (9%) (<a href="./references#CD012467-bbs2-0008" title="dePontAC , Oudemans-van StraatenHM , RoozendaalKJ , ZandstraDF . Nadroparin versus dalteparin anticoagulation in high-volume, continuous venovenous hemofiltration: a double-blind, randomized, crossover study. Critical Care Medicine2000;28(2):421-5. [MEDLINE: 10708177]">de Pont 2000</a>; <a href="./references#CD012467-bbs2-0009" title="FabbriLP , NuceraM , Al MalyanM , BecchiC . Regional anticoagulation and antiaggregation for CVVH in critically ill patients: a prospective, randomized, controlled pilot study. Acta Anaesthesiologica Scandinavica2010;54(1):92-7. [MEDLINE: 19650808]">Fabbri 2010</a>; <a href="./references#CD012467-bbs2-0017" title="KiserTH , MacLarenR , FishDN , HassellKL , TeitelbaumI . Bivalirudin versus unfractionated heparin for prevention of hemofilter occlusion during continuous renal replacement therapy. Pharmacotherapy2010;30(11):1117-26. [MEDLINE: 20973685]">Kiser 2010</a>) as having low risk of bias; one study (3%) (<a href="./references#CD012467-bbs2-0018" title="Kozek-LangeneckerSA , SpissCK , GamsjagerT , DomenigC , ZimpferM . Anticoagulation with prostaglandins and unfractionated heparin during continuous venovenous haemofiltration: a randomized controlled trial. Wiener Klinische Wochenschrift2002;114(3):96-101. [MEDLINE: 12060975]">Kozek‐Langenecker 2002</a>) as unclear risk of bias, and 30 studies (81%) (<a href="./references#CD012467-bbs2-0001" title="ArcangeliA , RoccaB , SalvatoriG , CianciaM , De CristofaroR , AntonelliM . Heparin versus prostacyclin in continuous hemodiafiltration for acute renal failure: effects on platelet function in the systemic circulation and across the filter. Thrombosis Research2010;126(1):24-31. [MEDLINE: 20185164]">Arcangeli 2010</a>; <a href="./references#CD012467-bbs2-0002" title="BellomoR , TeedeH , BoyceN . Anticoagulant regimens in acute continuous hemodiafiltration: a comparative study. Intensive Care Medicine1993;19(6):329-32. [MEDLINE: 8227722]">Bellomo 1993</a>; <a href="./references#CD012467-bbs2-0003" title="BetjesMG , OosteromD , vanAgterenM , vande WeteringJ . Regional citrate versus heparin anticoagulation during venovenous hemofiltration in patients at low risk for bleeding: similar hemofilter survival but significantly less bleeding [abstract no: TH-FC107]. Journal of the American Society of Nephrology2006;17(Abstracts):24A. [CENTRAL: CN-00671866] BetjesMG , vanOosteromD , vanAgterenM , vande WeteringJ . Regional citrate versus heparin anticoagulation during venovenous hemofiltration in patients at low risk for bleeding: similar hemofilter survival but significantly less bleeding. Journal of Nephrology2007;20(5):602-8. [MEDLINE: 17918147]">Betjes 2007</a>; <a href="./references#CD012467-bbs2-0004" title="BirnbaumJ , SpiesCD , KlotzE , HeinOV , MorgeraS , SchinkT , et al. Iloprost for additional anticoagulation in continuous renal replacement therapy--a pilot study. Renal Failure2007;29(3):271-7. [MEDLINE: 17497439]">Birnbaum 2007</a>; <a href="./references#CD012467-bbs2-0005" title="SchilderL , NurmohamedS , BoschFH , PurmerIM , den BoerSS , KleppeCG , et al. Citrate anticoagulation versus systemic heparinisation in continuous venovenous hemofiltration in critically ill patients with acute kidney injury: a multi-center randomized clinical trial. Critical Care (London, England)2014;18(4):472. [MEDLINE: 25128022]SchilderL , NurmohamedSA , ter WeePM , PaauwNJ , GirbesAR , BeishuizenA , et al. Citrate confers less filter-induced complement activation and neutrophil degranulation than heparin when used for anticoagulation during continuous venovenous haemofiltration in critically ill patients. BMC Nephrology2014;15:19. [MEDLINE: 24438360]SchilderL , NurmohamedSA , ter WeePM , PaauwNJ , GirbesAR , BeishuizenA , et al. Putative novel mediators of acute kidney injury in critically ill patients: handling by continuous venovenous hemofiltration and effect of anticoagulation modalities. BMC Nephrology2015;16:178. [MEDLINE: 26519056]SchilderL , NurmohamedSA , ter WeePM , PaauwNJ , GirbesAR , BeishuizenA , et al. The plasma level and biomarker value of neutrophil gelatinase-associated lipocalin in critically ill patients with acute kidney injury are not affected by continuous venovenous hemofiltration and anticoagulation applied. Critical Care (London, England)2014;18(2):R78. [MEDLINE: 24755339]">CASH 2014</a>; <a href="./references#CD012467-bbs2-0006" title="ChoiJY , KangYJ , JangHM , JungHY , ChoJH , ParkSH , et al. Nafamostat mesilate as an anticoagulant during continuous renal replacement therapy in patients with high bleeding risk: a randomized clinical trial. Medicine2015;94(52):e2392. [MEDLINE: 26717390]">Choi 2015</a>; <a href="./references#CD012467-bbs2-0007" title="CuiW , DengX , LvS , HuQ , ZhangK . The observation on the comprehensive effect of extracorporeal citrate anticoagulation protocol in continuous blood purification. Journal of Qiqihar University of Medicine2011;32(12):1884. ">Cui 2011</a>; <a href="./references#CD012467-bbs2-0010" title="FealyN , BaldwinI , JohnstoneM , EgiM , BellomoR . A pilot randomized controlled crossover study comparing regional heparinization to regional citrate anticoagulation for continuous venovenous hemofiltration. International Journal of Artificial Organs2007;30(4):301-7. [MEDLINE: 17520566]">Fealy 2007</a>; <a href="./references#CD012467-bbs2-0011" title="BrainMJ , RoodenburgOS , AdamsN , McCrackenP , HockingsL , MusgraveS , et al. Randomised trial of software algorithm driven regional citrate anticoagulation versus heparin in continuous renal replacement therapy: the Filter Life in Renal Replacement Therapy pilot trial. Critical Care &amp; Resuscitation2014;16(2):131-7. [MEDLINE: 24888284]">FLIRRT 2014</a>; <a href="./references#CD012467-bbs2-0012" title="GarcesEO , VictorinoJA , ThomeFS , RohsigLM , DornellesE , LouzadaM , et al. Enoxaparin versus unfractioned heparin as anticoagulant for continuous venovenous hemodialysis: a randomized open-label trial. Renal Failure2010;32(3):320-7. [MEDLINE: 20370447]">Garces 2010</a>; <a href="./references#CD012467-bbs2-0013" title="GattasDJ , RajbhandariD , BradfordC , BuhrH , LoS , BellomoR . A randomized controlled trial of regional citrate versus regional heparin anticoagulation for continuous renal replacement therapy in critically ill adults. Critical Care Medicine2015;43(8):1622-9. [MEDLINE: 25853591]">Gattas 2015</a>; <a href="./references#CD012467-bbs2-0014" title="HeinOV , vonHeymannC , DiehlT , ZiemerS , RoncoC , MorgeraS , et al. Intermittent hirudin versus continuous heparin for anticoagulation in continuous renal replacement therapy. Renal Failure2004;26(3):297-303. [MEDLINE: 15354980]">Hein 2004</a>; <a href="./references#CD012467-bbs2-0015" title="HetzelGR , SchmitzM , WissingH , RiesW , SchottG , HeeringPJ , et al. Regional citrate versus systemic heparin for anticoagulation in critically ill patients on continuous venovenous haemofiltration: a prospective randomized multicentre trial. Nephrology Dialysis Transplantation2011;26(1):232-9. [MEDLINE: 20876598]">Hetzel 2011</a>; <a href="./references#CD012467-bbs2-0016" title="JoannidisM , KountchevJ , GroteA , BellmanR , WiedermannCJ . Unfractioned versus low-molecular-weight heparin for anticoagulation in hemofiltration [abstract no: SU-PO880]. Journal of the American Society of Nephrology2003;14(Nov):728-9A. [CENTRAL: CN-00583249] JoannidisM , KountchevJ , RauchenzaunerM , SchusterschitzN , UlmerH , MayrA , et al. Enoxaparin vs. unfractionated heparin for anticoagulation during continuous veno-venous hemofiltration: a randomized controlled crossover study. Intensive Care Medicine2007;33(9):1571-9. [MEDLINE: 17563874]KountchevJ , GroteA , BellmannR , WiedermannC , JoannidisM . Unfractioned versus low-molecular-weight heparin (enoxaparin) for anticoagulation in CVVH [abstract no: MP459]. In: 41st Congress. European Renal Association. European Dialysis and Transplantation Association; 2004 May 15-18; Lisbon, Portugal. 2004:384. [CENTRAL: CN-00509287] ">Joannidis 2007</a>; <a href="./references#CD012467-bbs2-0019" title="KutsogiannisDJ , GibneyRT , StolleryD , GaoJ . Regional citrate versus systemic heparin anticoagulation for continuous renal replacement in critically ill patients. Kidney International2005;67(6):2361-7. [MEDLINE: 15882280]">Kutsogiannis 2005</a><a href="./references#CD012467-bbs2-0020" title="LangeneckerSA , FelfernigM , WerbaA , MuellerCM , ChiariA , ZimpferM . Anticoagulation with prostacyclin and heparin during continuous venovenous hemofiltration. Critical Care Medicine1994;22(11):1774-81. [MEDLINE: 7956281]">Langenecker 1994</a>; <a href="./references#CD012467-bbs2-0021" title="LeeYK , LeeHW , ChoiKH , KimBS . Ability of nafamostat mesilate to prolong filter patency during continuous renal replacement therapy in patients at high risk of bleeding: a randomized controlled study. PLoS ONE [Electronic Resource]2014;9(10):e108737. [MEDLINE: 25302581]LeeYK , LeeHW , ChoiKH , KimBS . The effect of nafamostat mesilate in prolonging filter patency with patients on continuous renal replacement therapy [abstract no: MP403]. Nephrology Dialysis Transplantation2013;28(Suppl 1):i425. [EMBASE: 71076312]">Lee 2014b</a>; <a href="./references#CD012467-bbs2-0022" title="LinkA , GirndtM , SelejanS , RbahR , BohmM . Tirofiban preserves platelet loss during continuous renal replacement therapy in a randomised prospective open-blinded pilot study. Critical Care (London, England)2008;12(4):R111. [MEDLINE: 18759963]">Link 2008</a>; <a href="./references#CD012467-bbs2-0023" title="MonchiM , BerghmansD , LedouxD , CanivetJL , DuboisB , DamasP . Citrate vs. heparin for anticoagulation in continuous venovenous hemofiltration: a prospective randomized study. Intensive Care Medicine2004;30(2):260-5. [MEDLINE: 14600809]">Monchi 2004</a>; <a href="./references#CD012467-bbs2-0024" title="Oudemans-van StraatenHM , BosmanRJ , KoopmansM , van derVoortPH , WesterJP , van derSpoelJI , et al. Citrate anticoagulation for continuous venovenous hemofiltration. Critical Care Medicine2009;37(2):545-52. [MEDLINE: 19114912]">Oudemans‐van Straaten 2009</a>; <a href="./references#CD012467-bbs2-0025" title="PalevskyPM , BurrR , MorelandL , TokiwaY , GreenbergA . Failure of low molecular weight dextran to prevent clotting during continuous renal replacement therapy. ASAIO Journal1995;41(4):847-9. [MEDLINE: 8589465]">Palevsky 1995</a>; <a href="./references#CD012467-bbs2-0026" title="ReevesJH , CummingAR , GallagherL , O'BrienJL , SantamariaJD . A controlled trial of low-molecular-weight heparin (dalteparin) versus unfractionated heparin as anticoagulant during continuous venovenous hemodialysis with filtration. Critical Care Medicine1999;27(10):2224-8. [MEDLINE: 10548211]">Reeves 1999</a>; <a href="./references#CD012467-bbs2-0027" title="ReevesJH , GraanM . Randomised controlled trial: enoxaparin versus heparin in continuous renal replacement therapy [abstract no: 41]. Blood Purification2003;21(2):203. [CENTRAL: CN-00757740] ">Reeves 2003</a>; <a href="./references#CD012467-bbs2-0028" title="StuckerF , PonteB , TatawJ , MartinPY , WozniakH , PuginJ , et al. Efficacy and safety of citrate-based anticoagulation compared to heparin in patients with acute kidney injury requiring continuous renal replacement therapy: a randomized controlled trial. Critical Care (London, England)2015;19(1):91. [MEDLINE: 25881975]StuckerF , PuginJ , TattawJ , PonteB , BrochardL , MartinP , et al. Citrate-based anticoagulation in patients with AKI in the intensive care unit: a safe and efficacious method [abstract no: 0379]. Intensive Care Medicine2013;39(Suppl 2):S320. [EMBASE: 71446324]">Stucker 2015</a>; <a href="./references#CD012467-bbs2-0029" title="TiranathanagulK , JearnsujitwimolO , SusantitaphongP , KijkriengkraikulN , LeelahavanichkulA , SrisawatN , et al. Regional citrate anticoagulation reduces polymorphonuclear cell degranulation in critically ill patients treated with continuous venovenous hemofiltration. Therapeutic Apheresis &amp; Dialysis2011;15(6):556-64. [MEDLINE: 22107692]">Tiranathanagul 2011</a>; <a href="./references#CD012467-bbs2-0030" title="van derVoortPH , GerritsenRT , KuiperMA , EgbersPH , KingmaWP , BoermaEC . Filter run time in CVVH: pre- versus post-dilution and nadroparin versus regional heparin-protamine anticoagulation. Blood Purification2005;23(3):175-80. [MEDLINE: 15711037]">van der Voort 2005</a>; <a href="./references#CD012467-bbs2-0031" title="vanDoornKJ , HubloueI , VerbeelenD . Urea exchange efficacy during unfractionated heparin anticoagulation versus low molecular weight heparin (dalteparin) anticoagulation in continuous veno-venous hemofiltration [abstract]. In: 41st Congress. European Renal Association. European Dialysis and Transplantation Association; 2004 May 15-18; Lisbon, Portugal. 2004:384. [CENTRAL: CN-00509250] vanDoornKJ , HubloueI , VerbeelenD . Urea exchange efficacy during unfractionated heparin anticoagulation versus low molecular weight heparin (dalteparin) anticoagulation in continuous veno-venous hemofiltration [abstract no: 33]. Blood Purification2004;22(2):243. [CENTRAL: CN-01658168] ">van Doorn 2004</a>; <a href="./references#CD012467-bbs2-0032" title="Vargas HeinO , vonHeymannC , LippsM , ZiemerS , RoncoC , NeumayerHH , et al. Hirudin versus heparin for anticoagulation in continuous renal replacement therapy. Intensive Care Medicine2001;27(4):673-9. [MEDLINE: 11403068]">Vargas Hein 2001</a>; <a href="./references#CD012467-bbs2-0033" title="VictorinoJA , OteroE , RohsigL , DornellesE , LouzadaM , StifftJ , et al. Low molecular weight heparin (LMWH) versus non-fractionated heparin (NFH) as anticoagulation system in continuous veno-veno hemodialysis (CVVH) in patients with acute renal (ARF) and respiratory failure (RF) [abstract no: 128]. In: American Thoracic Society International Conference; 2007 May 18-23; San Francisco (CA). 2007. [CENTRAL: CN-00645386] ">Victorino 2007</a>; <a href="./references#CD012467-bbs2-0034" title="WuB , ZhangK , XuB , JiD , LiuZ , GongD . Randomized controlled trial to evaluate regional citrate anticoagulation plus low-dose of dalteparin in continuous veno-venous hemofiltration. Blood Purification2015;39(4):306-12. [MEDLINE: 26022434]ZhangK , GongD , JiD , XuB , IIuZ . Regional citrate plus low dose of low molecular weight heparins: a safe and more efficacy anticoagulation protocol for continuous veno - venous hemofiltration [abstract no: 71]. In: CCRT 2012. 17th International Conference on CRRT; 2012 Feb 14-17; San Diego (CA). 2012. [CENTRAL: CN-01658175] ">Wu 2015b</a>) as high risk of bias due to open‐label design. </p> </section> <section id="CD012467-sec-0055"> <h5 class="title">Detection bias</h5> <p>We judged three studies (9%) (<a href="./references#CD012467-bbs2-0008" title="dePontAC , Oudemans-van StraatenHM , RoozendaalKJ , ZandstraDF . Nadroparin versus dalteparin anticoagulation in high-volume, continuous venovenous hemofiltration: a double-blind, randomized, crossover study. Critical Care Medicine2000;28(2):421-5. [MEDLINE: 10708177]">de Pont 2000</a>; <a href="./references#CD012467-bbs2-0009" title="FabbriLP , NuceraM , Al MalyanM , BecchiC . Regional anticoagulation and antiaggregation for CVVH in critically ill patients: a prospective, randomized, controlled pilot study. Acta Anaesthesiologica Scandinavica2010;54(1):92-7. [MEDLINE: 19650808]">Fabbri 2010</a>; <a href="./references#CD012467-bbs2-0017" title="KiserTH , MacLarenR , FishDN , HassellKL , TeitelbaumI . Bivalirudin versus unfractionated heparin for prevention of hemofilter occlusion during continuous renal replacement therapy. Pharmacotherapy2010;30(11):1117-26. [MEDLINE: 20973685]">Kiser 2010</a>) as having low risk of bias; one study (3%) (<a href="./references#CD012467-bbs2-0018" title="Kozek-LangeneckerSA , SpissCK , GamsjagerT , DomenigC , ZimpferM . Anticoagulation with prostaglandins and unfractionated heparin during continuous venovenous haemofiltration: a randomized controlled trial. Wiener Klinische Wochenschrift2002;114(3):96-101. [MEDLINE: 12060975]">Kozek‐Langenecker 2002</a>) as unclear risk of bias, and 30 studies (88%) (<a href="./references#CD012467-bbs2-0001" title="ArcangeliA , RoccaB , SalvatoriG , CianciaM , De CristofaroR , AntonelliM . Heparin versus prostacyclin in continuous hemodiafiltration for acute renal failure: effects on platelet function in the systemic circulation and across the filter. Thrombosis Research2010;126(1):24-31. [MEDLINE: 20185164]">Arcangeli 2010</a>; <a href="./references#CD012467-bbs2-0002" title="BellomoR , TeedeH , BoyceN . Anticoagulant regimens in acute continuous hemodiafiltration: a comparative study. Intensive Care Medicine1993;19(6):329-32. [MEDLINE: 8227722]">Bellomo 1993</a>; <a href="./references#CD012467-bbs2-0003" title="BetjesMG , OosteromD , vanAgterenM , vande WeteringJ . Regional citrate versus heparin anticoagulation during venovenous hemofiltration in patients at low risk for bleeding: similar hemofilter survival but significantly less bleeding [abstract no: TH-FC107]. Journal of the American Society of Nephrology2006;17(Abstracts):24A. [CENTRAL: CN-00671866] BetjesMG , vanOosteromD , vanAgterenM , vande WeteringJ . Regional citrate versus heparin anticoagulation during venovenous hemofiltration in patients at low risk for bleeding: similar hemofilter survival but significantly less bleeding. Journal of Nephrology2007;20(5):602-8. [MEDLINE: 17918147]">Betjes 2007</a>; <a href="./references#CD012467-bbs2-0004" title="BirnbaumJ , SpiesCD , KlotzE , HeinOV , MorgeraS , SchinkT , et al. Iloprost for additional anticoagulation in continuous renal replacement therapy--a pilot study. Renal Failure2007;29(3):271-7. [MEDLINE: 17497439]">Birnbaum 2007</a>; <a href="./references#CD012467-bbs2-0005" title="SchilderL , NurmohamedS , BoschFH , PurmerIM , den BoerSS , KleppeCG , et al. Citrate anticoagulation versus systemic heparinisation in continuous venovenous hemofiltration in critically ill patients with acute kidney injury: a multi-center randomized clinical trial. Critical Care (London, England)2014;18(4):472. [MEDLINE: 25128022]SchilderL , NurmohamedSA , ter WeePM , PaauwNJ , GirbesAR , BeishuizenA , et al. Citrate confers less filter-induced complement activation and neutrophil degranulation than heparin when used for anticoagulation during continuous venovenous haemofiltration in critically ill patients. BMC Nephrology2014;15:19. [MEDLINE: 24438360]SchilderL , NurmohamedSA , ter WeePM , PaauwNJ , GirbesAR , BeishuizenA , et al. Putative novel mediators of acute kidney injury in critically ill patients: handling by continuous venovenous hemofiltration and effect of anticoagulation modalities. BMC Nephrology2015;16:178. [MEDLINE: 26519056]SchilderL , NurmohamedSA , ter WeePM , PaauwNJ , GirbesAR , BeishuizenA , et al. The plasma level and biomarker value of neutrophil gelatinase-associated lipocalin in critically ill patients with acute kidney injury are not affected by continuous venovenous hemofiltration and anticoagulation applied. Critical Care (London, England)2014;18(2):R78. [MEDLINE: 24755339]">CASH 2014</a>; <a href="./references#CD012467-bbs2-0006" title="ChoiJY , KangYJ , JangHM , JungHY , ChoJH , ParkSH , et al. Nafamostat mesilate as an anticoagulant during continuous renal replacement therapy in patients with high bleeding risk: a randomized clinical trial. Medicine2015;94(52):e2392. [MEDLINE: 26717390]">Choi 2015</a>; <a href="./references#CD012467-bbs2-0007" title="CuiW , DengX , LvS , HuQ , ZhangK . The observation on the comprehensive effect of extracorporeal citrate anticoagulation protocol in continuous blood purification. Journal of Qiqihar University of Medicine2011;32(12):1884. ">Cui 2011</a>; <a href="./references#CD012467-bbs2-0010" title="FealyN , BaldwinI , JohnstoneM , EgiM , BellomoR . A pilot randomized controlled crossover study comparing regional heparinization to regional citrate anticoagulation for continuous venovenous hemofiltration. International Journal of Artificial Organs2007;30(4):301-7. [MEDLINE: 17520566]">Fealy 2007</a>; <a href="./references#CD012467-bbs2-0011" title="BrainMJ , RoodenburgOS , AdamsN , McCrackenP , HockingsL , MusgraveS , et al. Randomised trial of software algorithm driven regional citrate anticoagulation versus heparin in continuous renal replacement therapy: the Filter Life in Renal Replacement Therapy pilot trial. Critical Care &amp; Resuscitation2014;16(2):131-7. [MEDLINE: 24888284]">FLIRRT 2014</a>; <a href="./references#CD012467-bbs2-0012" title="GarcesEO , VictorinoJA , ThomeFS , RohsigLM , DornellesE , LouzadaM , et al. Enoxaparin versus unfractioned heparin as anticoagulant for continuous venovenous hemodialysis: a randomized open-label trial. Renal Failure2010;32(3):320-7. [MEDLINE: 20370447]">Garces 2010</a>; <a href="./references#CD012467-bbs2-0013" title="GattasDJ , RajbhandariD , BradfordC , BuhrH , LoS , BellomoR . A randomized controlled trial of regional citrate versus regional heparin anticoagulation for continuous renal replacement therapy in critically ill adults. Critical Care Medicine2015;43(8):1622-9. [MEDLINE: 25853591]">Gattas 2015</a>; <a href="./references#CD012467-bbs2-0014" title="HeinOV , vonHeymannC , DiehlT , ZiemerS , RoncoC , MorgeraS , et al. Intermittent hirudin versus continuous heparin for anticoagulation in continuous renal replacement therapy. Renal Failure2004;26(3):297-303. [MEDLINE: 15354980]">Hein 2004</a>; <a href="./references#CD012467-bbs2-0015" title="HetzelGR , SchmitzM , WissingH , RiesW , SchottG , HeeringPJ , et al. Regional citrate versus systemic heparin for anticoagulation in critically ill patients on continuous venovenous haemofiltration: a prospective randomized multicentre trial. Nephrology Dialysis Transplantation2011;26(1):232-9. [MEDLINE: 20876598]">Hetzel 2011</a>; <a href="./references#CD012467-bbs2-0016" title="JoannidisM , KountchevJ , GroteA , BellmanR , WiedermannCJ . Unfractioned versus low-molecular-weight heparin for anticoagulation in hemofiltration [abstract no: SU-PO880]. Journal of the American Society of Nephrology2003;14(Nov):728-9A. [CENTRAL: CN-00583249] JoannidisM , KountchevJ , RauchenzaunerM , SchusterschitzN , UlmerH , MayrA , et al. Enoxaparin vs. unfractionated heparin for anticoagulation during continuous veno-venous hemofiltration: a randomized controlled crossover study. Intensive Care Medicine2007;33(9):1571-9. [MEDLINE: 17563874]KountchevJ , GroteA , BellmannR , WiedermannC , JoannidisM . Unfractioned versus low-molecular-weight heparin (enoxaparin) for anticoagulation in CVVH [abstract no: MP459]. In: 41st Congress. European Renal Association. European Dialysis and Transplantation Association; 2004 May 15-18; Lisbon, Portugal. 2004:384. [CENTRAL: CN-00509287] ">Joannidis 2007</a>; <a href="./references#CD012467-bbs2-0019" title="KutsogiannisDJ , GibneyRT , StolleryD , GaoJ . Regional citrate versus systemic heparin anticoagulation for continuous renal replacement in critically ill patients. Kidney International2005;67(6):2361-7. [MEDLINE: 15882280]">Kutsogiannis 2005</a>; <a href="./references#CD012467-bbs2-0020" title="LangeneckerSA , FelfernigM , WerbaA , MuellerCM , ChiariA , ZimpferM . Anticoagulation with prostacyclin and heparin during continuous venovenous hemofiltration. Critical Care Medicine1994;22(11):1774-81. [MEDLINE: 7956281]">Langenecker 1994</a>; <a href="./references#CD012467-bbs2-0021" title="LeeYK , LeeHW , ChoiKH , KimBS . Ability of nafamostat mesilate to prolong filter patency during continuous renal replacement therapy in patients at high risk of bleeding: a randomized controlled study. PLoS ONE [Electronic Resource]2014;9(10):e108737. [MEDLINE: 25302581]LeeYK , LeeHW , ChoiKH , KimBS . The effect of nafamostat mesilate in prolonging filter patency with patients on continuous renal replacement therapy [abstract no: MP403]. Nephrology Dialysis Transplantation2013;28(Suppl 1):i425. [EMBASE: 71076312]">Lee 2014b</a>; <a href="./references#CD012467-bbs2-0022" title="LinkA , GirndtM , SelejanS , RbahR , BohmM . Tirofiban preserves platelet loss during continuous renal replacement therapy in a randomised prospective open-blinded pilot study. Critical Care (London, England)2008;12(4):R111. [MEDLINE: 18759963]">Link 2008</a>; <a href="./references#CD012467-bbs2-0023" title="MonchiM , BerghmansD , LedouxD , CanivetJL , DuboisB , DamasP . Citrate vs. heparin for anticoagulation in continuous venovenous hemofiltration: a prospective randomized study. Intensive Care Medicine2004;30(2):260-5. [MEDLINE: 14600809]">Monchi 2004</a>; <a href="./references#CD012467-bbs2-0024" title="Oudemans-van StraatenHM , BosmanRJ , KoopmansM , van derVoortPH , WesterJP , van derSpoelJI , et al. Citrate anticoagulation for continuous venovenous hemofiltration. Critical Care Medicine2009;37(2):545-52. [MEDLINE: 19114912]">Oudemans‐van Straaten 2009</a>; <a href="./references#CD012467-bbs2-0025" title="PalevskyPM , BurrR , MorelandL , TokiwaY , GreenbergA . Failure of low molecular weight dextran to prevent clotting during continuous renal replacement therapy. ASAIO Journal1995;41(4):847-9. [MEDLINE: 8589465]">Palevsky 1995</a>; <a href="./references#CD012467-bbs2-0026" title="ReevesJH , CummingAR , GallagherL , O'BrienJL , SantamariaJD . A controlled trial of low-molecular-weight heparin (dalteparin) versus unfractionated heparin as anticoagulant during continuous venovenous hemodialysis with filtration. Critical Care Medicine1999;27(10):2224-8. [MEDLINE: 10548211]">Reeves 1999</a>; <a href="./references#CD012467-bbs2-0027" title="ReevesJH , GraanM . Randomised controlled trial: enoxaparin versus heparin in continuous renal replacement therapy [abstract no: 41]. Blood Purification2003;21(2):203. [CENTRAL: CN-00757740] ">Reeves 2003</a>; <a href="./references#CD012467-bbs2-0028" title="StuckerF , PonteB , TatawJ , MartinPY , WozniakH , PuginJ , et al. Efficacy and safety of citrate-based anticoagulation compared to heparin in patients with acute kidney injury requiring continuous renal replacement therapy: a randomized controlled trial. Critical Care (London, England)2015;19(1):91. [MEDLINE: 25881975]StuckerF , PuginJ , TattawJ , PonteB , BrochardL , MartinP , et al. Citrate-based anticoagulation in patients with AKI in the intensive care unit: a safe and efficacious method [abstract no: 0379]. Intensive Care Medicine2013;39(Suppl 2):S320. [EMBASE: 71446324]">Stucker 2015</a>; <a href="./references#CD012467-bbs2-0029" title="TiranathanagulK , JearnsujitwimolO , SusantitaphongP , KijkriengkraikulN , LeelahavanichkulA , SrisawatN , et al. Regional citrate anticoagulation reduces polymorphonuclear cell degranulation in critically ill patients treated with continuous venovenous hemofiltration. Therapeutic Apheresis &amp; Dialysis2011;15(6):556-64. [MEDLINE: 22107692]">Tiranathanagul 2011</a>; <a href="./references#CD012467-bbs2-0030" title="van derVoortPH , GerritsenRT , KuiperMA , EgbersPH , KingmaWP , BoermaEC . Filter run time in CVVH: pre- versus post-dilution and nadroparin versus regional heparin-protamine anticoagulation. Blood Purification2005;23(3):175-80. [MEDLINE: 15711037]">van der Voort 2005</a>; <a href="./references#CD012467-bbs2-0031" title="vanDoornKJ , HubloueI , VerbeelenD . Urea exchange efficacy during unfractionated heparin anticoagulation versus low molecular weight heparin (dalteparin) anticoagulation in continuous veno-venous hemofiltration [abstract]. In: 41st Congress. European Renal Association. European Dialysis and Transplantation Association; 2004 May 15-18; Lisbon, Portugal. 2004:384. [CENTRAL: CN-00509250] vanDoornKJ , HubloueI , VerbeelenD . Urea exchange efficacy during unfractionated heparin anticoagulation versus low molecular weight heparin (dalteparin) anticoagulation in continuous veno-venous hemofiltration [abstract no: 33]. Blood Purification2004;22(2):243. [CENTRAL: CN-01658168] ">van Doorn 2004</a>; <a href="./references#CD012467-bbs2-0032" title="Vargas HeinO , vonHeymannC , LippsM , ZiemerS , RoncoC , NeumayerHH , et al. Hirudin versus heparin for anticoagulation in continuous renal replacement therapy. Intensive Care Medicine2001;27(4):673-9. [MEDLINE: 11403068]">Vargas Hein 2001</a>; <a href="./references#CD012467-bbs2-0033" title="VictorinoJA , OteroE , RohsigL , DornellesE , LouzadaM , StifftJ , et al. Low molecular weight heparin (LMWH) versus non-fractionated heparin (NFH) as anticoagulation system in continuous veno-veno hemodialysis (CVVH) in patients with acute renal (ARF) and respiratory failure (RF) [abstract no: 128]. In: American Thoracic Society International Conference; 2007 May 18-23; San Francisco (CA). 2007. [CENTRAL: CN-00645386] ">Victorino 2007</a>; <a href="./references#CD012467-bbs2-0034" title="WuB , ZhangK , XuB , JiD , LiuZ , GongD . Randomized controlled trial to evaluate regional citrate anticoagulation plus low-dose of dalteparin in continuous veno-venous hemofiltration. Blood Purification2015;39(4):306-12. [MEDLINE: 26022434]ZhangK , GongD , JiD , XuB , IIuZ . Regional citrate plus low dose of low molecular weight heparins: a safe and more efficacy anticoagulation protocol for continuous veno - venous hemofiltration [abstract no: 71]. In: CCRT 2012. 17th International Conference on CRRT; 2012 Feb 14-17; San Diego (CA). 2012. [CENTRAL: CN-01658175] ">Wu 2015b</a>) as high risk of bias regarding the outcomes detection, assessment or follow‐up due to unblinded design. </p> </section> </section> <section id="CD012467-sec-0056"> <h4 class="title">Incomplete outcome data</h4> <p>We judged nine studies (26%) as having low risk of bias (<a href="./references#CD012467-bbs2-0001" title="ArcangeliA , RoccaB , SalvatoriG , CianciaM , De CristofaroR , AntonelliM . Heparin versus prostacyclin in continuous hemodiafiltration for acute renal failure: effects on platelet function in the systemic circulation and across the filter. Thrombosis Research2010;126(1):24-31. [MEDLINE: 20185164]">Arcangeli 2010</a>; <a href="./references#CD012467-bbs2-0005" title="SchilderL , NurmohamedS , BoschFH , PurmerIM , den BoerSS , KleppeCG , et al. Citrate anticoagulation versus systemic heparinisation in continuous venovenous hemofiltration in critically ill patients with acute kidney injury: a multi-center randomized clinical trial. Critical Care (London, England)2014;18(4):472. [MEDLINE: 25128022]SchilderL , NurmohamedSA , ter WeePM , PaauwNJ , GirbesAR , BeishuizenA , et al. Citrate confers less filter-induced complement activation and neutrophil degranulation than heparin when used for anticoagulation during continuous venovenous haemofiltration in critically ill patients. BMC Nephrology2014;15:19. [MEDLINE: 24438360]SchilderL , NurmohamedSA , ter WeePM , PaauwNJ , GirbesAR , BeishuizenA , et al. Putative novel mediators of acute kidney injury in critically ill patients: handling by continuous venovenous hemofiltration and effect of anticoagulation modalities. BMC Nephrology2015;16:178. [MEDLINE: 26519056]SchilderL , NurmohamedSA , ter WeePM , PaauwNJ , GirbesAR , BeishuizenA , et al. The plasma level and biomarker value of neutrophil gelatinase-associated lipocalin in critically ill patients with acute kidney injury are not affected by continuous venovenous hemofiltration and anticoagulation applied. Critical Care (London, England)2014;18(2):R78. [MEDLINE: 24755339]">CASH 2014</a>; <a href="./references#CD012467-bbs2-0013" title="GattasDJ , RajbhandariD , BradfordC , BuhrH , LoS , BellomoR . A randomized controlled trial of regional citrate versus regional heparin anticoagulation for continuous renal replacement therapy in critically ill adults. Critical Care Medicine2015;43(8):1622-9. [MEDLINE: 25853591]">Gattas 2015</a>; <a href="./references#CD012467-bbs2-0015" title="HetzelGR , SchmitzM , WissingH , RiesW , SchottG , HeeringPJ , et al. Regional citrate versus systemic heparin for anticoagulation in critically ill patients on continuous venovenous haemofiltration: a prospective randomized multicentre trial. Nephrology Dialysis Transplantation2011;26(1):232-9. [MEDLINE: 20876598]">Hetzel 2011</a>; <a href="./references#CD012467-bbs2-0016" title="JoannidisM , KountchevJ , GroteA , BellmanR , WiedermannCJ . Unfractioned versus low-molecular-weight heparin for anticoagulation in hemofiltration [abstract no: SU-PO880]. Journal of the American Society of Nephrology2003;14(Nov):728-9A. [CENTRAL: CN-00583249] JoannidisM , KountchevJ , RauchenzaunerM , SchusterschitzN , UlmerH , MayrA , et al. Enoxaparin vs. unfractionated heparin for anticoagulation during continuous veno-venous hemofiltration: a randomized controlled crossover study. Intensive Care Medicine2007;33(9):1571-9. [MEDLINE: 17563874]KountchevJ , GroteA , BellmannR , WiedermannC , JoannidisM . Unfractioned versus low-molecular-weight heparin (enoxaparin) for anticoagulation in CVVH [abstract no: MP459]. In: 41st Congress. European Renal Association. European Dialysis and Transplantation Association; 2004 May 15-18; Lisbon, Portugal. 2004:384. [CENTRAL: CN-00509287] ">Joannidis 2007</a>; <a href="./references#CD012467-bbs2-0017" title="KiserTH , MacLarenR , FishDN , HassellKL , TeitelbaumI . Bivalirudin versus unfractionated heparin for prevention of hemofilter occlusion during continuous renal replacement therapy. Pharmacotherapy2010;30(11):1117-26. [MEDLINE: 20973685]">Kiser 2010</a>; <a href="./references#CD012467-bbs2-0022" title="LinkA , GirndtM , SelejanS , RbahR , BohmM . Tirofiban preserves platelet loss during continuous renal replacement therapy in a randomised prospective open-blinded pilot study. Critical Care (London, England)2008;12(4):R111. [MEDLINE: 18759963]">Link 2008</a>; <a href="./references#CD012467-bbs2-0024" title="Oudemans-van StraatenHM , BosmanRJ , KoopmansM , van derVoortPH , WesterJP , van derSpoelJI , et al. Citrate anticoagulation for continuous venovenous hemofiltration. Critical Care Medicine2009;37(2):545-52. [MEDLINE: 19114912]">Oudemans‐van Straaten 2009</a>; <a href="./references#CD012467-bbs2-0028" title="StuckerF , PonteB , TatawJ , MartinPY , WozniakH , PuginJ , et al. Efficacy and safety of citrate-based anticoagulation compared to heparin in patients with acute kidney injury requiring continuous renal replacement therapy: a randomized controlled trial. Critical Care (London, England)2015;19(1):91. [MEDLINE: 25881975]StuckerF , PuginJ , TattawJ , PonteB , BrochardL , MartinP , et al. Citrate-based anticoagulation in patients with AKI in the intensive care unit: a safe and efficacious method [abstract no: 0379]. Intensive Care Medicine2013;39(Suppl 2):S320. [EMBASE: 71446324]">Stucker 2015</a>); six studies (18%) (<a href="./references#CD012467-bbs2-0002" title="BellomoR , TeedeH , BoyceN . Anticoagulant regimens in acute continuous hemodiafiltration: a comparative study. Intensive Care Medicine1993;19(6):329-32. [MEDLINE: 8227722]">Bellomo 1993</a>; <a href="./references#CD012467-bbs2-0007" title="CuiW , DengX , LvS , HuQ , ZhangK . The observation on the comprehensive effect of extracorporeal citrate anticoagulation protocol in continuous blood purification. Journal of Qiqihar University of Medicine2011;32(12):1884. ">Cui 2011</a>; <a href="./references#CD012467-bbs2-0018" title="Kozek-LangeneckerSA , SpissCK , GamsjagerT , DomenigC , ZimpferM . Anticoagulation with prostaglandins and unfractionated heparin during continuous venovenous haemofiltration: a randomized controlled trial. Wiener Klinische Wochenschrift2002;114(3):96-101. [MEDLINE: 12060975]">Kozek‐Langenecker 2002</a>; <a href="./references#CD012467-bbs2-0031" title="vanDoornKJ , HubloueI , VerbeelenD . Urea exchange efficacy during unfractionated heparin anticoagulation versus low molecular weight heparin (dalteparin) anticoagulation in continuous veno-venous hemofiltration [abstract]. In: 41st Congress. European Renal Association. European Dialysis and Transplantation Association; 2004 May 15-18; Lisbon, Portugal. 2004:384. [CENTRAL: CN-00509250] vanDoornKJ , HubloueI , VerbeelenD . Urea exchange efficacy during unfractionated heparin anticoagulation versus low molecular weight heparin (dalteparin) anticoagulation in continuous veno-venous hemofiltration [abstract no: 33]. Blood Purification2004;22(2):243. [CENTRAL: CN-01658168] ">van Doorn 2004</a>; <a href="./references#CD012467-bbs2-0033" title="VictorinoJA , OteroE , RohsigL , DornellesE , LouzadaM , StifftJ , et al. Low molecular weight heparin (LMWH) versus non-fractionated heparin (NFH) as anticoagulation system in continuous veno-veno hemodialysis (CVVH) in patients with acute renal (ARF) and respiratory failure (RF) [abstract no: 128]. In: American Thoracic Society International Conference; 2007 May 18-23; San Francisco (CA). 2007. [CENTRAL: CN-00645386] ">Victorino 2007</a>; <a href="./references#CD012467-bbs2-0034" title="WuB , ZhangK , XuB , JiD , LiuZ , GongD . Randomized controlled trial to evaluate regional citrate anticoagulation plus low-dose of dalteparin in continuous veno-venous hemofiltration. Blood Purification2015;39(4):306-12. [MEDLINE: 26022434]ZhangK , GongD , JiD , XuB , IIuZ . Regional citrate plus low dose of low molecular weight heparins: a safe and more efficacy anticoagulation protocol for continuous veno - venous hemofiltration [abstract no: 71]. In: CCRT 2012. 17th International Conference on CRRT; 2012 Feb 14-17; San Diego (CA). 2012. [CENTRAL: CN-01658175] ">Wu 2015b</a>) as unclear risk of bias. Nineteen studies (56%) (<a href="./references#CD012467-bbs2-0003" title="BetjesMG , OosteromD , vanAgterenM , vande WeteringJ . Regional citrate versus heparin anticoagulation during venovenous hemofiltration in patients at low risk for bleeding: similar hemofilter survival but significantly less bleeding [abstract no: TH-FC107]. Journal of the American Society of Nephrology2006;17(Abstracts):24A. [CENTRAL: CN-00671866] BetjesMG , vanOosteromD , vanAgterenM , vande WeteringJ . Regional citrate versus heparin anticoagulation during venovenous hemofiltration in patients at low risk for bleeding: similar hemofilter survival but significantly less bleeding. Journal of Nephrology2007;20(5):602-8. [MEDLINE: 17918147]">Betjes 2007</a>; <a href="./references#CD012467-bbs2-0004" title="BirnbaumJ , SpiesCD , KlotzE , HeinOV , MorgeraS , SchinkT , et al. Iloprost for additional anticoagulation in continuous renal replacement therapy--a pilot study. Renal Failure2007;29(3):271-7. [MEDLINE: 17497439]">Birnbaum 2007</a>; <a href="./references#CD012467-bbs2-0006" title="ChoiJY , KangYJ , JangHM , JungHY , ChoJH , ParkSH , et al. Nafamostat mesilate as an anticoagulant during continuous renal replacement therapy in patients with high bleeding risk: a randomized clinical trial. Medicine2015;94(52):e2392. [MEDLINE: 26717390]">Choi 2015</a>; <a href="./references#CD012467-bbs2-0008" title="dePontAC , Oudemans-van StraatenHM , RoozendaalKJ , ZandstraDF . Nadroparin versus dalteparin anticoagulation in high-volume, continuous venovenous hemofiltration: a double-blind, randomized, crossover study. Critical Care Medicine2000;28(2):421-5. [MEDLINE: 10708177]">de Pont 2000</a>; <a href="./references#CD012467-bbs2-0009" title="FabbriLP , NuceraM , Al MalyanM , BecchiC . Regional anticoagulation and antiaggregation for CVVH in critically ill patients: a prospective, randomized, controlled pilot study. Acta Anaesthesiologica Scandinavica2010;54(1):92-7. [MEDLINE: 19650808]">Fabbri 2010</a>; <a href="./references#CD012467-bbs2-0010" title="FealyN , BaldwinI , JohnstoneM , EgiM , BellomoR . A pilot randomized controlled crossover study comparing regional heparinization to regional citrate anticoagulation for continuous venovenous hemofiltration. International Journal of Artificial Organs2007;30(4):301-7. [MEDLINE: 17520566]">Fealy 2007</a>; <a href="./references#CD012467-bbs2-0011" title="BrainMJ , RoodenburgOS , AdamsN , McCrackenP , HockingsL , MusgraveS , et al. Randomised trial of software algorithm driven regional citrate anticoagulation versus heparin in continuous renal replacement therapy: the Filter Life in Renal Replacement Therapy pilot trial. Critical Care &amp; Resuscitation2014;16(2):131-7. [MEDLINE: 24888284]">FLIRRT 2014</a>; <a href="./references#CD012467-bbs2-0012" title="GarcesEO , VictorinoJA , ThomeFS , RohsigLM , DornellesE , LouzadaM , et al. Enoxaparin versus unfractioned heparin as anticoagulant for continuous venovenous hemodialysis: a randomized open-label trial. Renal Failure2010;32(3):320-7. [MEDLINE: 20370447]">Garces 2010</a>; <a href="./references#CD012467-bbs2-0014" title="HeinOV , vonHeymannC , DiehlT , ZiemerS , RoncoC , MorgeraS , et al. Intermittent hirudin versus continuous heparin for anticoagulation in continuous renal replacement therapy. Renal Failure2004;26(3):297-303. [MEDLINE: 15354980]">Hein 2004</a>; <a href="./references#CD012467-bbs2-0019" title="KutsogiannisDJ , GibneyRT , StolleryD , GaoJ . Regional citrate versus systemic heparin anticoagulation for continuous renal replacement in critically ill patients. Kidney International2005;67(6):2361-7. [MEDLINE: 15882280]">Kutsogiannis 2005</a>; <a href="./references#CD012467-bbs2-0020" title="LangeneckerSA , FelfernigM , WerbaA , MuellerCM , ChiariA , ZimpferM . Anticoagulation with prostacyclin and heparin during continuous venovenous hemofiltration. Critical Care Medicine1994;22(11):1774-81. [MEDLINE: 7956281]">Langenecker 1994</a>; <a href="./references#CD012467-bbs2-0021" title="LeeYK , LeeHW , ChoiKH , KimBS . Ability of nafamostat mesilate to prolong filter patency during continuous renal replacement therapy in patients at high risk of bleeding: a randomized controlled study. PLoS ONE [Electronic Resource]2014;9(10):e108737. [MEDLINE: 25302581]LeeYK , LeeHW , ChoiKH , KimBS . The effect of nafamostat mesilate in prolonging filter patency with patients on continuous renal replacement therapy [abstract no: MP403]. Nephrology Dialysis Transplantation2013;28(Suppl 1):i425. [EMBASE: 71076312]">Lee 2014b</a>; <a href="./references#CD012467-bbs2-0023" title="MonchiM , BerghmansD , LedouxD , CanivetJL , DuboisB , DamasP . Citrate vs. heparin for anticoagulation in continuous venovenous hemofiltration: a prospective randomized study. Intensive Care Medicine2004;30(2):260-5. [MEDLINE: 14600809]">Monchi 2004</a>; <a href="./references#CD012467-bbs2-0025" title="PalevskyPM , BurrR , MorelandL , TokiwaY , GreenbergA . Failure of low molecular weight dextran to prevent clotting during continuous renal replacement therapy. ASAIO Journal1995;41(4):847-9. [MEDLINE: 8589465]">Palevsky 1995</a>; <a href="./references#CD012467-bbs2-0026" title="ReevesJH , CummingAR , GallagherL , O'BrienJL , SantamariaJD . A controlled trial of low-molecular-weight heparin (dalteparin) versus unfractionated heparin as anticoagulant during continuous venovenous hemodialysis with filtration. Critical Care Medicine1999;27(10):2224-8. [MEDLINE: 10548211]">Reeves 1999</a>; <a href="./references#CD012467-bbs2-0027" title="ReevesJH , GraanM . Randomised controlled trial: enoxaparin versus heparin in continuous renal replacement therapy [abstract no: 41]. Blood Purification2003;21(2):203. [CENTRAL: CN-00757740] ">Reeves 2003</a>; <a href="./references#CD012467-bbs2-0029" title="TiranathanagulK , JearnsujitwimolO , SusantitaphongP , KijkriengkraikulN , LeelahavanichkulA , SrisawatN , et al. Regional citrate anticoagulation reduces polymorphonuclear cell degranulation in critically ill patients treated with continuous venovenous hemofiltration. Therapeutic Apheresis &amp; Dialysis2011;15(6):556-64. [MEDLINE: 22107692]">Tiranathanagul 2011</a>; <a href="./references#CD012467-bbs2-0030" title="van derVoortPH , GerritsenRT , KuiperMA , EgbersPH , KingmaWP , BoermaEC . Filter run time in CVVH: pre- versus post-dilution and nadroparin versus regional heparin-protamine anticoagulation. Blood Purification2005;23(3):175-80. [MEDLINE: 15711037]">van der Voort 2005</a>; <a href="./references#CD012467-bbs2-0032" title="Vargas HeinO , vonHeymannC , LippsM , ZiemerS , RoncoC , NeumayerHH , et al. Hirudin versus heparin for anticoagulation in continuous renal replacement therapy. Intensive Care Medicine2001;27(4):673-9. [MEDLINE: 11403068]">Vargas Hein 2001</a>) were judged to be at high risk of bias because of considerable lost to follow‐up (≥ 10%) or outcome reporting from the same participants with biased number of multiple enrolments possibly due to treatment cessation during cross‐over or multiple enrolment. </p> </section> <section id="CD012467-sec-0057"> <h4 class="title">Selective reporting</h4> <p>We judged 14 studies (41%) as having low risk of bias (<a href="./references#CD012467-bbs2-0005" title="SchilderL , NurmohamedS , BoschFH , PurmerIM , den BoerSS , KleppeCG , et al. Citrate anticoagulation versus systemic heparinisation in continuous venovenous hemofiltration in critically ill patients with acute kidney injury: a multi-center randomized clinical trial. Critical Care (London, England)2014;18(4):472. [MEDLINE: 25128022]SchilderL , NurmohamedSA , ter WeePM , PaauwNJ , GirbesAR , BeishuizenA , et al. Citrate confers less filter-induced complement activation and neutrophil degranulation than heparin when used for anticoagulation during continuous venovenous haemofiltration in critically ill patients. BMC Nephrology2014;15:19. [MEDLINE: 24438360]SchilderL , NurmohamedSA , ter WeePM , PaauwNJ , GirbesAR , BeishuizenA , et al. Putative novel mediators of acute kidney injury in critically ill patients: handling by continuous venovenous hemofiltration and effect of anticoagulation modalities. BMC Nephrology2015;16:178. [MEDLINE: 26519056]SchilderL , NurmohamedSA , ter WeePM , PaauwNJ , GirbesAR , BeishuizenA , et al. The plasma level and biomarker value of neutrophil gelatinase-associated lipocalin in critically ill patients with acute kidney injury are not affected by continuous venovenous hemofiltration and anticoagulation applied. Critical Care (London, England)2014;18(2):R78. [MEDLINE: 24755339]">CASH 2014</a>; <a href="./references#CD012467-bbs2-0006" title="ChoiJY , KangYJ , JangHM , JungHY , ChoJH , ParkSH , et al. Nafamostat mesilate as an anticoagulant during continuous renal replacement therapy in patients with high bleeding risk: a randomized clinical trial. Medicine2015;94(52):e2392. [MEDLINE: 26717390]">Choi 2015</a>; <a href="./references#CD012467-bbs2-0013" title="GattasDJ , RajbhandariD , BradfordC , BuhrH , LoS , BellomoR . A randomized controlled trial of regional citrate versus regional heparin anticoagulation for continuous renal replacement therapy in critically ill adults. Critical Care Medicine2015;43(8):1622-9. [MEDLINE: 25853591]">Gattas 2015</a>; <a href="./references#CD012467-bbs2-0014" title="HeinOV , vonHeymannC , DiehlT , ZiemerS , RoncoC , MorgeraS , et al. Intermittent hirudin versus continuous heparin for anticoagulation in continuous renal replacement therapy. Renal Failure2004;26(3):297-303. [MEDLINE: 15354980]">Hein 2004</a>; <a href="./references#CD012467-bbs2-0015" title="HetzelGR , SchmitzM , WissingH , RiesW , SchottG , HeeringPJ , et al. Regional citrate versus systemic heparin for anticoagulation in critically ill patients on continuous venovenous haemofiltration: a prospective randomized multicentre trial. Nephrology Dialysis Transplantation2011;26(1):232-9. [MEDLINE: 20876598]">Hetzel 2011</a>; <a href="./references#CD012467-bbs2-0017" title="KiserTH , MacLarenR , FishDN , HassellKL , TeitelbaumI . Bivalirudin versus unfractionated heparin for prevention of hemofilter occlusion during continuous renal replacement therapy. Pharmacotherapy2010;30(11):1117-26. [MEDLINE: 20973685]">Kiser 2010</a>; <a href="./references#CD012467-bbs2-0019" title="KutsogiannisDJ , GibneyRT , StolleryD , GaoJ . Regional citrate versus systemic heparin anticoagulation for continuous renal replacement in critically ill patients. Kidney International2005;67(6):2361-7. [MEDLINE: 15882280]">Kutsogiannis 2005</a>; <a href="./references#CD012467-bbs2-0021" title="LeeYK , LeeHW , ChoiKH , KimBS . Ability of nafamostat mesilate to prolong filter patency during continuous renal replacement therapy in patients at high risk of bleeding: a randomized controlled study. PLoS ONE [Electronic Resource]2014;9(10):e108737. [MEDLINE: 25302581]LeeYK , LeeHW , ChoiKH , KimBS . The effect of nafamostat mesilate in prolonging filter patency with patients on continuous renal replacement therapy [abstract no: MP403]. Nephrology Dialysis Transplantation2013;28(Suppl 1):i425. [EMBASE: 71076312]">Lee 2014b</a>; <a href="./references#CD012467-bbs2-0023" title="MonchiM , BerghmansD , LedouxD , CanivetJL , DuboisB , DamasP . Citrate vs. heparin for anticoagulation in continuous venovenous hemofiltration: a prospective randomized study. Intensive Care Medicine2004;30(2):260-5. [MEDLINE: 14600809]">Monchi 2004</a>; <a href="./references#CD012467-bbs2-0024" title="Oudemans-van StraatenHM , BosmanRJ , KoopmansM , van derVoortPH , WesterJP , van derSpoelJI , et al. Citrate anticoagulation for continuous venovenous hemofiltration. Critical Care Medicine2009;37(2):545-52. [MEDLINE: 19114912]">Oudemans‐van Straaten 2009</a>; <a href="./references#CD012467-bbs2-0028" title="StuckerF , PonteB , TatawJ , MartinPY , WozniakH , PuginJ , et al. Efficacy and safety of citrate-based anticoagulation compared to heparin in patients with acute kidney injury requiring continuous renal replacement therapy: a randomized controlled trial. Critical Care (London, England)2015;19(1):91. [MEDLINE: 25881975]StuckerF , PuginJ , TattawJ , PonteB , BrochardL , MartinP , et al. Citrate-based anticoagulation in patients with AKI in the intensive care unit: a safe and efficacious method [abstract no: 0379]. Intensive Care Medicine2013;39(Suppl 2):S320. [EMBASE: 71446324]">Stucker 2015</a>; <a href="./references#CD012467-bbs2-0029" title="TiranathanagulK , JearnsujitwimolO , SusantitaphongP , KijkriengkraikulN , LeelahavanichkulA , SrisawatN , et al. Regional citrate anticoagulation reduces polymorphonuclear cell degranulation in critically ill patients treated with continuous venovenous hemofiltration. Therapeutic Apheresis &amp; Dialysis2011;15(6):556-64. [MEDLINE: 22107692]">Tiranathanagul 2011</a>; <a href="./references#CD012467-bbs2-0032" title="Vargas HeinO , vonHeymannC , LippsM , ZiemerS , RoncoC , NeumayerHH , et al. Hirudin versus heparin for anticoagulation in continuous renal replacement therapy. Intensive Care Medicine2001;27(4):673-9. [MEDLINE: 11403068]">Vargas Hein 2001</a>; <a href="./references#CD012467-bbs2-0034" title="WuB , ZhangK , XuB , JiD , LiuZ , GongD . Randomized controlled trial to evaluate regional citrate anticoagulation plus low-dose of dalteparin in continuous veno-venous hemofiltration. Blood Purification2015;39(4):306-12. [MEDLINE: 26022434]ZhangK , GongD , JiD , XuB , IIuZ . Regional citrate plus low dose of low molecular weight heparins: a safe and more efficacy anticoagulation protocol for continuous veno - venous hemofiltration [abstract no: 71]. In: CCRT 2012. 17th International Conference on CRRT; 2012 Feb 14-17; San Diego (CA). 2012. [CENTRAL: CN-01658175] ">Wu 2015b</a>); three studies (11%) (<a href="./references#CD012467-bbs2-0004" title="BirnbaumJ , SpiesCD , KlotzE , HeinOV , MorgeraS , SchinkT , et al. Iloprost for additional anticoagulation in continuous renal replacement therapy--a pilot study. Renal Failure2007;29(3):271-7. [MEDLINE: 17497439]">Birnbaum 2007</a>; <a href="./references#CD012467-bbs2-0008" title="dePontAC , Oudemans-van StraatenHM , RoozendaalKJ , ZandstraDF . Nadroparin versus dalteparin anticoagulation in high-volume, continuous venovenous hemofiltration: a double-blind, randomized, crossover study. Critical Care Medicine2000;28(2):421-5. [MEDLINE: 10708177]">de Pont 2000</a>; <a href="./references#CD012467-bbs2-0009" title="FabbriLP , NuceraM , Al MalyanM , BecchiC . Regional anticoagulation and antiaggregation for CVVH in critically ill patients: a prospective, randomized, controlled pilot study. Acta Anaesthesiologica Scandinavica2010;54(1):92-7. [MEDLINE: 19650808]">Fabbri 2010</a>) as unclear risk of bias, and 17 studies (50%) (<a href="./references#CD012467-bbs2-0001" title="ArcangeliA , RoccaB , SalvatoriG , CianciaM , De CristofaroR , AntonelliM . Heparin versus prostacyclin in continuous hemodiafiltration for acute renal failure: effects on platelet function in the systemic circulation and across the filter. Thrombosis Research2010;126(1):24-31. [MEDLINE: 20185164]">Arcangeli 2010</a>; <a href="./references#CD012467-bbs2-0002" title="BellomoR , TeedeH , BoyceN . Anticoagulant regimens in acute continuous hemodiafiltration: a comparative study. Intensive Care Medicine1993;19(6):329-32. [MEDLINE: 8227722]">Bellomo 1993</a>; <a href="./references#CD012467-bbs2-0003" title="BetjesMG , OosteromD , vanAgterenM , vande WeteringJ . Regional citrate versus heparin anticoagulation during venovenous hemofiltration in patients at low risk for bleeding: similar hemofilter survival but significantly less bleeding [abstract no: TH-FC107]. Journal of the American Society of Nephrology2006;17(Abstracts):24A. [CENTRAL: CN-00671866] BetjesMG , vanOosteromD , vanAgterenM , vande WeteringJ . Regional citrate versus heparin anticoagulation during venovenous hemofiltration in patients at low risk for bleeding: similar hemofilter survival but significantly less bleeding. Journal of Nephrology2007;20(5):602-8. [MEDLINE: 17918147]">Betjes 2007</a>: <a href="./references#CD012467-bbs2-0007" title="CuiW , DengX , LvS , HuQ , ZhangK . The observation on the comprehensive effect of extracorporeal citrate anticoagulation protocol in continuous blood purification. Journal of Qiqihar University of Medicine2011;32(12):1884. ">Cui 2011</a>; <a href="./references#CD012467-bbs2-0010" title="FealyN , BaldwinI , JohnstoneM , EgiM , BellomoR . A pilot randomized controlled crossover study comparing regional heparinization to regional citrate anticoagulation for continuous venovenous hemofiltration. International Journal of Artificial Organs2007;30(4):301-7. [MEDLINE: 17520566]">Fealy 2007</a>; <a href="./references#CD012467-bbs2-0011" title="BrainMJ , RoodenburgOS , AdamsN , McCrackenP , HockingsL , MusgraveS , et al. Randomised trial of software algorithm driven regional citrate anticoagulation versus heparin in continuous renal replacement therapy: the Filter Life in Renal Replacement Therapy pilot trial. Critical Care &amp; Resuscitation2014;16(2):131-7. [MEDLINE: 24888284]">FLIRRT 2014</a>; <a href="./references#CD012467-bbs2-0012" title="GarcesEO , VictorinoJA , ThomeFS , RohsigLM , DornellesE , LouzadaM , et al. Enoxaparin versus unfractioned heparin as anticoagulant for continuous venovenous hemodialysis: a randomized open-label trial. Renal Failure2010;32(3):320-7. [MEDLINE: 20370447]">Garces 2010</a>; <a href="./references#CD012467-bbs2-0016" title="JoannidisM , KountchevJ , GroteA , BellmanR , WiedermannCJ . Unfractioned versus low-molecular-weight heparin for anticoagulation in hemofiltration [abstract no: SU-PO880]. Journal of the American Society of Nephrology2003;14(Nov):728-9A. [CENTRAL: CN-00583249] JoannidisM , KountchevJ , RauchenzaunerM , SchusterschitzN , UlmerH , MayrA , et al. Enoxaparin vs. unfractionated heparin for anticoagulation during continuous veno-venous hemofiltration: a randomized controlled crossover study. Intensive Care Medicine2007;33(9):1571-9. [MEDLINE: 17563874]KountchevJ , GroteA , BellmannR , WiedermannC , JoannidisM . Unfractioned versus low-molecular-weight heparin (enoxaparin) for anticoagulation in CVVH [abstract no: MP459]. In: 41st Congress. European Renal Association. European Dialysis and Transplantation Association; 2004 May 15-18; Lisbon, Portugal. 2004:384. [CENTRAL: CN-00509287] ">Joannidis 2007</a>; <a href="./references#CD012467-bbs2-0018" title="Kozek-LangeneckerSA , SpissCK , GamsjagerT , DomenigC , ZimpferM . Anticoagulation with prostaglandins and unfractionated heparin during continuous venovenous haemofiltration: a randomized controlled trial. Wiener Klinische Wochenschrift2002;114(3):96-101. [MEDLINE: 12060975]">Kozek‐Langenecker 2002</a>; <a href="./references#CD012467-bbs2-0020" title="LangeneckerSA , FelfernigM , WerbaA , MuellerCM , ChiariA , ZimpferM . Anticoagulation with prostacyclin and heparin during continuous venovenous hemofiltration. Critical Care Medicine1994;22(11):1774-81. [MEDLINE: 7956281]">Langenecker 1994</a>; <a href="./references#CD012467-bbs2-0022" title="LinkA , GirndtM , SelejanS , RbahR , BohmM . Tirofiban preserves platelet loss during continuous renal replacement therapy in a randomised prospective open-blinded pilot study. Critical Care (London, England)2008;12(4):R111. [MEDLINE: 18759963]">Link 2008</a>; <a href="./references#CD012467-bbs2-0025" title="PalevskyPM , BurrR , MorelandL , TokiwaY , GreenbergA . Failure of low molecular weight dextran to prevent clotting during continuous renal replacement therapy. ASAIO Journal1995;41(4):847-9. [MEDLINE: 8589465]">Palevsky 1995</a>; <a href="./references#CD012467-bbs2-0026" title="ReevesJH , CummingAR , GallagherL , O'BrienJL , SantamariaJD . A controlled trial of low-molecular-weight heparin (dalteparin) versus unfractionated heparin as anticoagulant during continuous venovenous hemodialysis with filtration. Critical Care Medicine1999;27(10):2224-8. [MEDLINE: 10548211]">Reeves 1999</a>; <a href="./references#CD012467-bbs2-0027" title="ReevesJH , GraanM . Randomised controlled trial: enoxaparin versus heparin in continuous renal replacement therapy [abstract no: 41]. Blood Purification2003;21(2):203. [CENTRAL: CN-00757740] ">Reeves 2003</a>; <a href="./references#CD012467-bbs2-0030" title="van derVoortPH , GerritsenRT , KuiperMA , EgbersPH , KingmaWP , BoermaEC . Filter run time in CVVH: pre- versus post-dilution and nadroparin versus regional heparin-protamine anticoagulation. Blood Purification2005;23(3):175-80. [MEDLINE: 15711037]">van der Voort 2005</a>; <a href="./references#CD012467-bbs2-0031" title="vanDoornKJ , HubloueI , VerbeelenD . Urea exchange efficacy during unfractionated heparin anticoagulation versus low molecular weight heparin (dalteparin) anticoagulation in continuous veno-venous hemofiltration [abstract]. In: 41st Congress. European Renal Association. European Dialysis and Transplantation Association; 2004 May 15-18; Lisbon, Portugal. 2004:384. [CENTRAL: CN-00509250] vanDoornKJ , HubloueI , VerbeelenD . Urea exchange efficacy during unfractionated heparin anticoagulation versus low molecular weight heparin (dalteparin) anticoagulation in continuous veno-venous hemofiltration [abstract no: 33]. Blood Purification2004;22(2):243. [CENTRAL: CN-01658168] ">van Doorn 2004</a>; <a href="./references#CD012467-bbs2-0033" title="VictorinoJA , OteroE , RohsigL , DornellesE , LouzadaM , StifftJ , et al. Low molecular weight heparin (LMWH) versus non-fractionated heparin (NFH) as anticoagulation system in continuous veno-veno hemodialysis (CVVH) in patients with acute renal (ARF) and respiratory failure (RF) [abstract no: 128]. In: American Thoracic Society International Conference; 2007 May 18-23; San Francisco (CA). 2007. [CENTRAL: CN-00645386] ">Victorino 2007</a>) as carrying high risk of bias because death or their protocol‐defined safety‐related outcomes were not reported. </p> </section> <section id="CD012467-sec-0058"> <h4 class="title">Other potential sources of bias</h4> <p>We assessed the reporting of financial conflict of interest (COI) by author‐reported information and the possibility of academic COI judged by the relative number of included studies from the same research group for particular interventions. We judged nine studies (26%) (<a href="./references#CD012467-bbs2-0001" title="ArcangeliA , RoccaB , SalvatoriG , CianciaM , De CristofaroR , AntonelliM . Heparin versus prostacyclin in continuous hemodiafiltration for acute renal failure: effects on platelet function in the systemic circulation and across the filter. Thrombosis Research2010;126(1):24-31. [MEDLINE: 20185164]">Arcangeli 2010</a>; <a href="./references#CD012467-bbs2-0006" title="ChoiJY , KangYJ , JangHM , JungHY , ChoJH , ParkSH , et al. Nafamostat mesilate as an anticoagulant during continuous renal replacement therapy in patients with high bleeding risk: a randomized clinical trial. Medicine2015;94(52):e2392. [MEDLINE: 26717390]">Choi 2015</a>; <a href="./references#CD012467-bbs2-0011" title="BrainMJ , RoodenburgOS , AdamsN , McCrackenP , HockingsL , MusgraveS , et al. Randomised trial of software algorithm driven regional citrate anticoagulation versus heparin in continuous renal replacement therapy: the Filter Life in Renal Replacement Therapy pilot trial. Critical Care &amp; Resuscitation2014;16(2):131-7. [MEDLINE: 24888284]">FLIRRT 2014</a>; <a href="./references#CD012467-bbs2-0012" title="GarcesEO , VictorinoJA , ThomeFS , RohsigLM , DornellesE , LouzadaM , et al. Enoxaparin versus unfractioned heparin as anticoagulant for continuous venovenous hemodialysis: a randomized open-label trial. Renal Failure2010;32(3):320-7. [MEDLINE: 20370447]">Garces 2010</a>; <a href="./references#CD012467-bbs2-0013" title="GattasDJ , RajbhandariD , BradfordC , BuhrH , LoS , BellomoR . A randomized controlled trial of regional citrate versus regional heparin anticoagulation for continuous renal replacement therapy in critically ill adults. Critical Care Medicine2015;43(8):1622-9. [MEDLINE: 25853591]">Gattas 2015</a>; <a href="./references#CD012467-bbs2-0017" title="KiserTH , MacLarenR , FishDN , HassellKL , TeitelbaumI . Bivalirudin versus unfractionated heparin for prevention of hemofilter occlusion during continuous renal replacement therapy. Pharmacotherapy2010;30(11):1117-26. [MEDLINE: 20973685]">Kiser 2010</a>: <a href="./references#CD012467-bbs2-0023" title="MonchiM , BerghmansD , LedouxD , CanivetJL , DuboisB , DamasP . Citrate vs. heparin for anticoagulation in continuous venovenous hemofiltration: a prospective randomized study. Intensive Care Medicine2004;30(2):260-5. [MEDLINE: 14600809]">Monchi 2004</a>; <a href="./references#CD012467-bbs2-0029" title="TiranathanagulK , JearnsujitwimolO , SusantitaphongP , KijkriengkraikulN , LeelahavanichkulA , SrisawatN , et al. Regional citrate anticoagulation reduces polymorphonuclear cell degranulation in critically ill patients treated with continuous venovenous hemofiltration. Therapeutic Apheresis &amp; Dialysis2011;15(6):556-64. [MEDLINE: 22107692]">Tiranathanagul 2011</a>; <a href="./references#CD012467-bbs2-0034" title="WuB , ZhangK , XuB , JiD , LiuZ , GongD . Randomized controlled trial to evaluate regional citrate anticoagulation plus low-dose of dalteparin in continuous veno-venous hemofiltration. Blood Purification2015;39(4):306-12. [MEDLINE: 26022434]ZhangK , GongD , JiD , XuB , IIuZ . Regional citrate plus low dose of low molecular weight heparins: a safe and more efficacy anticoagulation protocol for continuous veno - venous hemofiltration [abstract no: 71]. In: CCRT 2012. 17th International Conference on CRRT; 2012 Feb 14-17; San Diego (CA). 2012. [CENTRAL: CN-01658175] ">Wu 2015b</a>) as having low risk of bias; 12 studies (35%) (<a href="./references#CD012467-bbs2-0002" title="BellomoR , TeedeH , BoyceN . Anticoagulant regimens in acute continuous hemodiafiltration: a comparative study. Intensive Care Medicine1993;19(6):329-32. [MEDLINE: 8227722]">Bellomo 1993</a>; <a href="./references#CD012467-bbs2-0003" title="BetjesMG , OosteromD , vanAgterenM , vande WeteringJ . Regional citrate versus heparin anticoagulation during venovenous hemofiltration in patients at low risk for bleeding: similar hemofilter survival but significantly less bleeding [abstract no: TH-FC107]. Journal of the American Society of Nephrology2006;17(Abstracts):24A. [CENTRAL: CN-00671866] BetjesMG , vanOosteromD , vanAgterenM , vande WeteringJ . Regional citrate versus heparin anticoagulation during venovenous hemofiltration in patients at low risk for bleeding: similar hemofilter survival but significantly less bleeding. Journal of Nephrology2007;20(5):602-8. [MEDLINE: 17918147]">Betjes 2007</a>; <a href="./references#CD012467-bbs2-0004" title="BirnbaumJ , SpiesCD , KlotzE , HeinOV , MorgeraS , SchinkT , et al. Iloprost for additional anticoagulation in continuous renal replacement therapy--a pilot study. Renal Failure2007;29(3):271-7. [MEDLINE: 17497439]">Birnbaum 2007</a>; <a href="./references#CD012467-bbs2-0007" title="CuiW , DengX , LvS , HuQ , ZhangK . The observation on the comprehensive effect of extracorporeal citrate anticoagulation protocol in continuous blood purification. Journal of Qiqihar University of Medicine2011;32(12):1884. ">Cui 2011</a>; <a href="./references#CD012467-bbs2-0008" title="dePontAC , Oudemans-van StraatenHM , RoozendaalKJ , ZandstraDF . Nadroparin versus dalteparin anticoagulation in high-volume, continuous venovenous hemofiltration: a double-blind, randomized, crossover study. Critical Care Medicine2000;28(2):421-5. [MEDLINE: 10708177]">de Pont 2000</a>; <a href="./references#CD012467-bbs2-0009" title="FabbriLP , NuceraM , Al MalyanM , BecchiC . Regional anticoagulation and antiaggregation for CVVH in critically ill patients: a prospective, randomized, controlled pilot study. Acta Anaesthesiologica Scandinavica2010;54(1):92-7. [MEDLINE: 19650808]">Fabbri 2010</a>; <a href="./references#CD012467-bbs2-0010" title="FealyN , BaldwinI , JohnstoneM , EgiM , BellomoR . A pilot randomized controlled crossover study comparing regional heparinization to regional citrate anticoagulation for continuous venovenous hemofiltration. International Journal of Artificial Organs2007;30(4):301-7. [MEDLINE: 17520566]">Fealy 2007</a>; <a href="./references#CD012467-bbs2-0024" title="Oudemans-van StraatenHM , BosmanRJ , KoopmansM , van derVoortPH , WesterJP , van derSpoelJI , et al. Citrate anticoagulation for continuous venovenous hemofiltration. Critical Care Medicine2009;37(2):545-52. [MEDLINE: 19114912]">Oudemans‐van Straaten 2009</a>; <a href="./references#CD012467-bbs2-0025" title="PalevskyPM , BurrR , MorelandL , TokiwaY , GreenbergA . Failure of low molecular weight dextran to prevent clotting during continuous renal replacement therapy. ASAIO Journal1995;41(4):847-9. [MEDLINE: 8589465]">Palevsky 1995</a>; <a href="./references#CD012467-bbs2-0030" title="van derVoortPH , GerritsenRT , KuiperMA , EgbersPH , KingmaWP , BoermaEC . Filter run time in CVVH: pre- versus post-dilution and nadroparin versus regional heparin-protamine anticoagulation. Blood Purification2005;23(3):175-80. [MEDLINE: 15711037]">van der Voort 2005</a>; <a href="./references#CD012467-bbs2-0031" title="vanDoornKJ , HubloueI , VerbeelenD . Urea exchange efficacy during unfractionated heparin anticoagulation versus low molecular weight heparin (dalteparin) anticoagulation in continuous veno-venous hemofiltration [abstract]. In: 41st Congress. European Renal Association. European Dialysis and Transplantation Association; 2004 May 15-18; Lisbon, Portugal. 2004:384. [CENTRAL: CN-00509250] vanDoornKJ , HubloueI , VerbeelenD . Urea exchange efficacy during unfractionated heparin anticoagulation versus low molecular weight heparin (dalteparin) anticoagulation in continuous veno-venous hemofiltration [abstract no: 33]. Blood Purification2004;22(2):243. [CENTRAL: CN-01658168] ">van Doorn 2004</a>; <a href="./references#CD012467-bbs2-0033" title="VictorinoJA , OteroE , RohsigL , DornellesE , LouzadaM , StifftJ , et al. Low molecular weight heparin (LMWH) versus non-fractionated heparin (NFH) as anticoagulation system in continuous veno-veno hemodialysis (CVVH) in patients with acute renal (ARF) and respiratory failure (RF) [abstract no: 128]. In: American Thoracic Society International Conference; 2007 May 18-23; San Francisco (CA). 2007. [CENTRAL: CN-00645386] ">Victorino 2007</a>) as unclear risk of bias and 13 studies (38%) (<a href="./references#CD012467-bbs2-0005" title="SchilderL , NurmohamedS , BoschFH , PurmerIM , den BoerSS , KleppeCG , et al. Citrate anticoagulation versus systemic heparinisation in continuous venovenous hemofiltration in critically ill patients with acute kidney injury: a multi-center randomized clinical trial. Critical Care (London, England)2014;18(4):472. [MEDLINE: 25128022]SchilderL , NurmohamedSA , ter WeePM , PaauwNJ , GirbesAR , BeishuizenA , et al. Citrate confers less filter-induced complement activation and neutrophil degranulation than heparin when used for anticoagulation during continuous venovenous haemofiltration in critically ill patients. BMC Nephrology2014;15:19. [MEDLINE: 24438360]SchilderL , NurmohamedSA , ter WeePM , PaauwNJ , GirbesAR , BeishuizenA , et al. Putative novel mediators of acute kidney injury in critically ill patients: handling by continuous venovenous hemofiltration and effect of anticoagulation modalities. BMC Nephrology2015;16:178. [MEDLINE: 26519056]SchilderL , NurmohamedSA , ter WeePM , PaauwNJ , GirbesAR , BeishuizenA , et al. The plasma level and biomarker value of neutrophil gelatinase-associated lipocalin in critically ill patients with acute kidney injury are not affected by continuous venovenous hemofiltration and anticoagulation applied. Critical Care (London, England)2014;18(2):R78. [MEDLINE: 24755339]">CASH 2014</a>; <a href="./references#CD012467-bbs2-0014" title="HeinOV , vonHeymannC , DiehlT , ZiemerS , RoncoC , MorgeraS , et al. Intermittent hirudin versus continuous heparin for anticoagulation in continuous renal replacement therapy. Renal Failure2004;26(3):297-303. [MEDLINE: 15354980]">Hein 2004</a>; <a href="./references#CD012467-bbs2-0015" title="HetzelGR , SchmitzM , WissingH , RiesW , SchottG , HeeringPJ , et al. Regional citrate versus systemic heparin for anticoagulation in critically ill patients on continuous venovenous haemofiltration: a prospective randomized multicentre trial. Nephrology Dialysis Transplantation2011;26(1):232-9. [MEDLINE: 20876598]">Hetzel 2011</a>; <a href="./references#CD012467-bbs2-0016" title="JoannidisM , KountchevJ , GroteA , BellmanR , WiedermannCJ . Unfractioned versus low-molecular-weight heparin for anticoagulation in hemofiltration [abstract no: SU-PO880]. Journal of the American Society of Nephrology2003;14(Nov):728-9A. [CENTRAL: CN-00583249] JoannidisM , KountchevJ , RauchenzaunerM , SchusterschitzN , UlmerH , MayrA , et al. Enoxaparin vs. unfractionated heparin for anticoagulation during continuous veno-venous hemofiltration: a randomized controlled crossover study. Intensive Care Medicine2007;33(9):1571-9. [MEDLINE: 17563874]KountchevJ , GroteA , BellmannR , WiedermannC , JoannidisM . Unfractioned versus low-molecular-weight heparin (enoxaparin) for anticoagulation in CVVH [abstract no: MP459]. In: 41st Congress. European Renal Association. European Dialysis and Transplantation Association; 2004 May 15-18; Lisbon, Portugal. 2004:384. [CENTRAL: CN-00509287] ">Joannidis 2007</a>; <a href="./references#CD012467-bbs2-0019" title="KutsogiannisDJ , GibneyRT , StolleryD , GaoJ . Regional citrate versus systemic heparin anticoagulation for continuous renal replacement in critically ill patients. Kidney International2005;67(6):2361-7. [MEDLINE: 15882280]">Kutsogiannis 2005</a>; <a href="./references#CD012467-bbs2-0020" title="LangeneckerSA , FelfernigM , WerbaA , MuellerCM , ChiariA , ZimpferM . Anticoagulation with prostacyclin and heparin during continuous venovenous hemofiltration. Critical Care Medicine1994;22(11):1774-81. [MEDLINE: 7956281]">Langenecker 1994</a>; <a href="./references#CD012467-bbs2-0018" title="Kozek-LangeneckerSA , SpissCK , GamsjagerT , DomenigC , ZimpferM . Anticoagulation with prostaglandins and unfractionated heparin during continuous venovenous haemofiltration: a randomized controlled trial. Wiener Klinische Wochenschrift2002;114(3):96-101. [MEDLINE: 12060975]">Kozek‐Langenecker 2002</a>; <a href="./references#CD012467-bbs2-0021" title="LeeYK , LeeHW , ChoiKH , KimBS . Ability of nafamostat mesilate to prolong filter patency during continuous renal replacement therapy in patients at high risk of bleeding: a randomized controlled study. PLoS ONE [Electronic Resource]2014;9(10):e108737. [MEDLINE: 25302581]LeeYK , LeeHW , ChoiKH , KimBS . The effect of nafamostat mesilate in prolonging filter patency with patients on continuous renal replacement therapy [abstract no: MP403]. Nephrology Dialysis Transplantation2013;28(Suppl 1):i425. [EMBASE: 71076312]">Lee 2014b</a>; <a href="./references#CD012467-bbs2-0022" title="LinkA , GirndtM , SelejanS , RbahR , BohmM . Tirofiban preserves platelet loss during continuous renal replacement therapy in a randomised prospective open-blinded pilot study. Critical Care (London, England)2008;12(4):R111. [MEDLINE: 18759963]">Link 2008</a>; <a href="./references#CD012467-bbs2-0026" title="ReevesJH , CummingAR , GallagherL , O'BrienJL , SantamariaJD . A controlled trial of low-molecular-weight heparin (dalteparin) versus unfractionated heparin as anticoagulant during continuous venovenous hemodialysis with filtration. Critical Care Medicine1999;27(10):2224-8. [MEDLINE: 10548211]">Reeves 1999</a>; <a href="./references#CD012467-bbs2-0027" title="ReevesJH , GraanM . Randomised controlled trial: enoxaparin versus heparin in continuous renal replacement therapy [abstract no: 41]. Blood Purification2003;21(2):203. [CENTRAL: CN-00757740] ">Reeves 2003</a>; <a href="./references#CD012467-bbs2-0028" title="StuckerF , PonteB , TatawJ , MartinPY , WozniakH , PuginJ , et al. Efficacy and safety of citrate-based anticoagulation compared to heparin in patients with acute kidney injury requiring continuous renal replacement therapy: a randomized controlled trial. Critical Care (London, England)2015;19(1):91. [MEDLINE: 25881975]StuckerF , PuginJ , TattawJ , PonteB , BrochardL , MartinP , et al. Citrate-based anticoagulation in patients with AKI in the intensive care unit: a safe and efficacious method [abstract no: 0379]. Intensive Care Medicine2013;39(Suppl 2):S320. [EMBASE: 71446324]">Stucker 2015</a>; <a href="./references#CD012467-bbs2-0032" title="Vargas HeinO , vonHeymannC , LippsM , ZiemerS , RoncoC , NeumayerHH , et al. Hirudin versus heparin for anticoagulation in continuous renal replacement therapy. Intensive Care Medicine2001;27(4):673-9. [MEDLINE: 11403068]">Vargas Hein 2001</a>) as high risk of bias. </p> </section> </section> <section id="CD012467-sec-0059"> <h3 class="title" id="CD012467-sec-0059">Effects of interventions</h3> <p>See: <a href="./full#CD012467-tbl-0001"><b>Summary of findings 1</b> Citrate versus unfractionated heparin for continuous renal replacement therapy</a>; <a href="./full#CD012467-tbl-0002"><b>Summary of findings 2</b> Unfractionated heparin versus low molecular weight heparin for continuous renal replacement therapy</a>; <a href="./full#CD012467-tbl-0003"><b>Summary of findings 3</b> Unfractionated heparin versus no pharmacological anticoagulation for continuous renal replacement therapy</a> </p> <p>Summary of findings for the main comparisons (<a href="./full#CD012467-tbl-0001">summary of findings Table 1</a>; <a href="./full#CD012467-tbl-0002">summary of findings Table 2</a>; <a href="./full#CD012467-tbl-0003">summary of findings Table 3</a>).Ã‚Â Ã‚Â All the included comparisons and the data for all primary and secondary outcomes can be found in <a href="./appendices#CD012467-sec-0228">Appendix 4</a>. </p> <section id="CD012467-sec-0060"> <h4 class="title">Citrate versus unfractionated heparin</h4> <section id="CD012467-sec-0061"> <h5 class="title">Major bleeding</h5> <p>Compared to UFH, citrate probably reduces major bleeding events (<a href="./references#CD012467-fig-0008" title="">Analysis 1.1</a>.1; <a href="#CD012467-fig-0004">Figure 4</a> (7 studies, 535 participants, 702 observations): RR 0.22, 95% CI 0.08 to 0.62; I<sup>2</sup> = 21%, moderate certainty of evidence) (<a href="./references#CD012467-bbs2-0003" title="BetjesMG , OosteromD , vanAgterenM , vande WeteringJ . Regional citrate versus heparin anticoagulation during venovenous hemofiltration in patients at low risk for bleeding: similar hemofilter survival but significantly less bleeding [abstract no: TH-FC107]. Journal of the American Society of Nephrology2006;17(Abstracts):24A. [CENTRAL: CN-00671866] BetjesMG , vanOosteromD , vanAgterenM , vande WeteringJ . Regional citrate versus heparin anticoagulation during venovenous hemofiltration in patients at low risk for bleeding: similar hemofilter survival but significantly less bleeding. Journal of Nephrology2007;20(5):602-8. [MEDLINE: 17918147]">Betjes 2007</a>; <a href="./references#CD012467-bbs2-0005" title="SchilderL , NurmohamedS , BoschFH , PurmerIM , den BoerSS , KleppeCG , et al. Citrate anticoagulation versus systemic heparinisation in continuous venovenous hemofiltration in critically ill patients with acute kidney injury: a multi-center randomized clinical trial. Critical Care (London, England)2014;18(4):472. [MEDLINE: 25128022]SchilderL , NurmohamedSA , ter WeePM , PaauwNJ , GirbesAR , BeishuizenA , et al. Citrate confers less filter-induced complement activation and neutrophil degranulation than heparin when used for anticoagulation during continuous venovenous haemofiltration in critically ill patients. BMC Nephrology2014;15:19. [MEDLINE: 24438360]SchilderL , NurmohamedSA , ter WeePM , PaauwNJ , GirbesAR , BeishuizenA , et al. Putative novel mediators of acute kidney injury in critically ill patients: handling by continuous venovenous hemofiltration and effect of anticoagulation modalities. BMC Nephrology2015;16:178. [MEDLINE: 26519056]SchilderL , NurmohamedSA , ter WeePM , PaauwNJ , GirbesAR , BeishuizenA , et al. The plasma level and biomarker value of neutrophil gelatinase-associated lipocalin in critically ill patients with acute kidney injury are not affected by continuous venovenous hemofiltration and anticoagulation applied. Critical Care (London, England)2014;18(2):R78. [MEDLINE: 24755339]">CASH 2014</a>; <a href="./references#CD012467-bbs2-0015" title="HetzelGR , SchmitzM , WissingH , RiesW , SchottG , HeeringPJ , et al. Regional citrate versus systemic heparin for anticoagulation in critically ill patients on continuous venovenous haemofiltration: a prospective randomized multicentre trial. Nephrology Dialysis Transplantation2011;26(1):232-9. [MEDLINE: 20876598]">Hetzel 2011</a>; <a href="./references#CD012467-bbs2-0019" title="KutsogiannisDJ , GibneyRT , StolleryD , GaoJ . Regional citrate versus systemic heparin anticoagulation for continuous renal replacement in critically ill patients. Kidney International2005;67(6):2361-7. [MEDLINE: 15882280]">Kutsogiannis 2005</a>; <a href="./references#CD012467-bbs2-0023" title="MonchiM , BerghmansD , LedouxD , CanivetJL , DuboisB , DamasP . Citrate vs. heparin for anticoagulation in continuous venovenous hemofiltration: a prospective randomized study. Intensive Care Medicine2004;30(2):260-5. [MEDLINE: 14600809]">Monchi 2004</a>; <a href="./references#CD012467-bbs2-0028" title="StuckerF , PonteB , TatawJ , MartinPY , WozniakH , PuginJ , et al. Efficacy and safety of citrate-based anticoagulation compared to heparin in patients with acute kidney injury requiring continuous renal replacement therapy: a randomized controlled trial. Critical Care (London, England)2015;19(1):91. [MEDLINE: 25881975]StuckerF , PuginJ , TattawJ , PonteB , BrochardL , MartinP , et al. Citrate-based anticoagulation in patients with AKI in the intensive care unit: a safe and efficacious method [abstract no: 0379]. Intensive Care Medicine2013;39(Suppl 2):S320. [EMBASE: 71446324]">Stucker 2015</a>; <a href="./references#CD012467-bbs2-0029" title="TiranathanagulK , JearnsujitwimolO , SusantitaphongP , KijkriengkraikulN , LeelahavanichkulA , SrisawatN , et al. Regional citrate anticoagulation reduces polymorphonuclear cell degranulation in critically ill patients treated with continuous venovenous hemofiltration. Therapeutic Apheresis &amp; Dialysis2011;15(6):556-64. [MEDLINE: 22107692]">Tiranathanagul 2011</a>). Three studies (<a href="./references#CD012467-bbs2-0003" title="BetjesMG , OosteromD , vanAgterenM , vande WeteringJ . Regional citrate versus heparin anticoagulation during venovenous hemofiltration in patients at low risk for bleeding: similar hemofilter survival but significantly less bleeding [abstract no: TH-FC107]. Journal of the American Society of Nephrology2006;17(Abstracts):24A. [CENTRAL: CN-00671866] BetjesMG , vanOosteromD , vanAgterenM , vande WeteringJ . Regional citrate versus heparin anticoagulation during venovenous hemofiltration in patients at low risk for bleeding: similar hemofilter survival but significantly less bleeding. Journal of Nephrology2007;20(5):602-8. [MEDLINE: 17918147]">Betjes 2007</a>; <a href="./references#CD012467-bbs2-0019" title="KutsogiannisDJ , GibneyRT , StolleryD , GaoJ . Regional citrate versus systemic heparin anticoagulation for continuous renal replacement in critically ill patients. Kidney International2005;67(6):2361-7. [MEDLINE: 15882280]">Kutsogiannis 2005</a>; <a href="./references#CD012467-bbs2-0023" title="MonchiM , BerghmansD , LedouxD , CanivetJL , DuboisB , DamasP . Citrate vs. heparin for anticoagulation in continuous venovenous hemofiltration: a prospective randomized study. Intensive Care Medicine2004;30(2):260-5. [MEDLINE: 14600809]">Monchi 2004</a>) reported results of multiple enrolments of the same participants and we used the number of circuits as denominators of the event risk. One study reported a bleeding episode that required discontinuation of study anticoagulant within 72 hours and within 28 days (<a href="./references#CD012467-bbs2-0005" title="SchilderL , NurmohamedS , BoschFH , PurmerIM , den BoerSS , KleppeCG , et al. Citrate anticoagulation versus systemic heparinisation in continuous venovenous hemofiltration in critically ill patients with acute kidney injury: a multi-center randomized clinical trial. Critical Care (London, England)2014;18(4):472. [MEDLINE: 25128022]SchilderL , NurmohamedSA , ter WeePM , PaauwNJ , GirbesAR , BeishuizenA , et al. Citrate confers less filter-induced complement activation and neutrophil degranulation than heparin when used for anticoagulation during continuous venovenous haemofiltration in critically ill patients. BMC Nephrology2014;15:19. [MEDLINE: 24438360]SchilderL , NurmohamedSA , ter WeePM , PaauwNJ , GirbesAR , BeishuizenA , et al. Putative novel mediators of acute kidney injury in critically ill patients: handling by continuous venovenous hemofiltration and effect of anticoagulation modalities. BMC Nephrology2015;16:178. [MEDLINE: 26519056]SchilderL , NurmohamedSA , ter WeePM , PaauwNJ , GirbesAR , BeishuizenA , et al. The plasma level and biomarker value of neutrophil gelatinase-associated lipocalin in critically ill patients with acute kidney injury are not affected by continuous venovenous hemofiltration and anticoagulation applied. Critical Care (London, England)2014;18(2):R78. [MEDLINE: 24755339]">CASH 2014</a>). We used the outcome within 28 days for the analysis. </p> <div class="figure" id="CD012467-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Citrate versus UFH, outcome: 1.1 Major bleeding." data-id="CD012467-fig-0004" src="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/image_n/nCD012467-FIG-04.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Citrate versus UFH, outcome: 1.1 Major bleeding.</p> </div> </div> </div> <p>Compared to UFH plus protamine, citrate may reduce major bleeding events (<a href="./references#CD012467-fig-0008" title="">Analysis 1.1</a>.2; <a href="#CD012467-fig-0004">Figure 4</a> (3 studies, 252 participants, 262 observations): RR 0.34, 95% CI 0.01 to 8.24; low certainty of evidence) (<a href="./references#CD012467-bbs2-0010" title="FealyN , BaldwinI , JohnstoneM , EgiM , BellomoR . A pilot randomized controlled crossover study comparing regional heparinization to regional citrate anticoagulation for continuous venovenous hemofiltration. International Journal of Artificial Organs2007;30(4):301-7. [MEDLINE: 17520566]">Fealy 2007</a>; <a href="./references#CD012467-bbs2-0011" title="BrainMJ , RoodenburgOS , AdamsN , McCrackenP , HockingsL , MusgraveS , et al. Randomised trial of software algorithm driven regional citrate anticoagulation versus heparin in continuous renal replacement therapy: the Filter Life in Renal Replacement Therapy pilot trial. Critical Care &amp; Resuscitation2014;16(2):131-7. [MEDLINE: 24888284]">FLIRRT 2014</a>; <a href="./references#CD012467-bbs2-0013" title="GattasDJ , RajbhandariD , BradfordC , BuhrH , LoS , BellomoR . A randomized controlled trial of regional citrate versus regional heparin anticoagulation for continuous renal replacement therapy in critically ill adults. Critical Care Medicine2015;43(8):1622-9. [MEDLINE: 25853591]">Gattas 2015</a>). </p> </section> <section id="CD012467-sec-0062"> <h5 class="title">Death at 28 days</h5> <p>Compared to UFH, citrate probably makes little or no difference to death at 28 days (<a href="./references#CD012467-fig-0009" title="">Analysis 1.2</a>.1; <a href="#CD012467-fig-0005">Figure 5</a> (5 studies, 462 participants): RR 1.06, 95% CI 0.86 to 1.30; I<sup>2</sup> = 0%, moderate certainty of evidence) (<a href="./references#CD012467-bbs2-0005" title="SchilderL , NurmohamedS , BoschFH , PurmerIM , den BoerSS , KleppeCG , et al. Citrate anticoagulation versus systemic heparinisation in continuous venovenous hemofiltration in critically ill patients with acute kidney injury: a multi-center randomized clinical trial. Critical Care (London, England)2014;18(4):472. [MEDLINE: 25128022]SchilderL , NurmohamedSA , ter WeePM , PaauwNJ , GirbesAR , BeishuizenA , et al. Citrate confers less filter-induced complement activation and neutrophil degranulation than heparin when used for anticoagulation during continuous venovenous haemofiltration in critically ill patients. BMC Nephrology2014;15:19. [MEDLINE: 24438360]SchilderL , NurmohamedSA , ter WeePM , PaauwNJ , GirbesAR , BeishuizenA , et al. Putative novel mediators of acute kidney injury in critically ill patients: handling by continuous venovenous hemofiltration and effect of anticoagulation modalities. BMC Nephrology2015;16:178. [MEDLINE: 26519056]SchilderL , NurmohamedSA , ter WeePM , PaauwNJ , GirbesAR , BeishuizenA , et al. The plasma level and biomarker value of neutrophil gelatinase-associated lipocalin in critically ill patients with acute kidney injury are not affected by continuous venovenous hemofiltration and anticoagulation applied. Critical Care (London, England)2014;18(2):R78. [MEDLINE: 24755339]">CASH 2014</a>; <a href="./references#CD012467-bbs2-0015" title="HetzelGR , SchmitzM , WissingH , RiesW , SchottG , HeeringPJ , et al. Regional citrate versus systemic heparin for anticoagulation in critically ill patients on continuous venovenous haemofiltration: a prospective randomized multicentre trial. Nephrology Dialysis Transplantation2011;26(1):232-9. [MEDLINE: 20876598]">Hetzel 2011</a>; <a href="./references#CD012467-bbs2-0028" title="StuckerF , PonteB , TatawJ , MartinPY , WozniakH , PuginJ , et al. Efficacy and safety of citrate-based anticoagulation compared to heparin in patients with acute kidney injury requiring continuous renal replacement therapy: a randomized controlled trial. Critical Care (London, England)2015;19(1):91. [MEDLINE: 25881975]StuckerF , PuginJ , TattawJ , PonteB , BrochardL , MartinP , et al. Citrate-based anticoagulation in patients with AKI in the intensive care unit: a safe and efficacious method [abstract no: 0379]. Intensive Care Medicine2013;39(Suppl 2):S320. [EMBASE: 71446324]">Stucker 2015</a>; <a href="./references#CD012467-bbs2-0029" title="TiranathanagulK , JearnsujitwimolO , SusantitaphongP , KijkriengkraikulN , LeelahavanichkulA , SrisawatN , et al. Regional citrate anticoagulation reduces polymorphonuclear cell degranulation in critically ill patients treated with continuous venovenous hemofiltration. Therapeutic Apheresis &amp; Dialysis2011;15(6):556-64. [MEDLINE: 22107692]">Tiranathanagul 2011</a>; <a href="./references#CD012467-bbs2-0019" title="KutsogiannisDJ , GibneyRT , StolleryD , GaoJ . Regional citrate versus systemic heparin anticoagulation for continuous renal replacement in critically ill patients. Kidney International2005;67(6):2361-7. [MEDLINE: 15882280]">Kutsogiannis 2005</a>). </p> <div class="figure" id="CD012467-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Citrate versus UFH, outcome: 1.2 Death at 28 days." data-id="CD012467-fig-0005" src="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/image_n/nCD012467-FIG-05.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Citrate versus UFH, outcome: 1.2 Death at 28 days.</p> </div> </div> </div> <p>Compared to UFH plus protamine, citrate may make little or no difference to 28‐day mortality (<a href="./references#CD012467-fig-0009" title="">Analysis 1.2</a>.2; <a href="#CD012467-fig-0005">Figure 5</a> (2 studies, 242 participants): RR 1.11, 95% CI 0.76 to 1.64; I<sup>2</sup> = 0%, low certainty of evidence) (<a href="./references#CD012467-bbs2-0011" title="BrainMJ , RoodenburgOS , AdamsN , McCrackenP , HockingsL , MusgraveS , et al. Randomised trial of software algorithm driven regional citrate anticoagulation versus heparin in continuous renal replacement therapy: the Filter Life in Renal Replacement Therapy pilot trial. Critical Care &amp; Resuscitation2014;16(2):131-7. [MEDLINE: 24888284]">FLIRRT 2014</a>: <a href="./references#CD012467-bbs2-0013" title="GattasDJ , RajbhandariD , BradfordC , BuhrH , LoS , BellomoR . A randomized controlled trial of regional citrate versus regional heparin anticoagulation for continuous renal replacement therapy in critically ill adults. Critical Care Medicine2015;43(8):1622-9. [MEDLINE: 25853591]">Gattas 2015</a>). </p> <p><a href="./references#CD012467-bbs2-0019" title="KutsogiannisDJ , GibneyRT , StolleryD , GaoJ . Regional citrate versus systemic heparin anticoagulation for continuous renal replacement in critically ill patients. Kidney International2005;67(6):2361-7. [MEDLINE: 15882280]">Kutsogiannis 2005</a> reported patient survival after ICU and hospital discharge (3/16 patients in the citrate group compared to 4/14 patients in the UFH group) and we assumed that the relative survival ratio was similar to the relative risk ratio of death at 28 days. <a href="./references#CD012467-bbs2-0013" title="GattasDJ , RajbhandariD , BradfordC , BuhrH , LoS , BellomoR . A randomized controlled trial of regional citrate versus regional heparin anticoagulation for continuous renal replacement therapy in critically ill adults. Critical Care Medicine2015;43(8):1622-9. [MEDLINE: 25853591]">Gattas 2015</a> reported ICU deaths (28/105 in citrate group and 25/107 in UFH plus protamine group) and hospital deaths (33/105 in citrate and 31/107 in UFH plus protamine group) and we used hospital deaths for the meta‐analysis. <a href="./references#CD012467-bbs2-0003" title="BetjesMG , OosteromD , vanAgterenM , vande WeteringJ . Regional citrate versus heparin anticoagulation during venovenous hemofiltration in patients at low risk for bleeding: similar hemofilter survival but significantly less bleeding [abstract no: TH-FC107]. Journal of the American Society of Nephrology2006;17(Abstracts):24A. [CENTRAL: CN-00671866] BetjesMG , vanOosteromD , vanAgterenM , vande WeteringJ . Regional citrate versus heparin anticoagulation during venovenous hemofiltration in patients at low risk for bleeding: similar hemofilter survival but significantly less bleeding. Journal of Nephrology2007;20(5):602-8. [MEDLINE: 17918147]">Betjes 2007</a> did not report death of participants; however, they reported that one patient in the UFH group died due to haemothorax and irreversible circulatory shock. <a href="./references#CD012467-bbs2-0023" title="MonchiM , BerghmansD , LedouxD , CanivetJL , DuboisB , DamasP . Citrate vs. heparin for anticoagulation in continuous venovenous hemofiltration: a prospective randomized study. Intensive Care Medicine2004;30(2):260-5. [MEDLINE: 14600809]">Monchi 2004</a> did not measure death because they performed a cross‐over study design. </p> </section> <section id="CD012467-sec-0063"> <h5 class="title">Successful prevention of clotting in the first 24 hours</h5> <p>Compared to UFH, citrate probably makes little or no difference to successful prevention of clotting (<a href="./references#CD012467-fig-0010" title="">Analysis 1.3</a>.1; <a href="#CD012467-fig-0006">Figure 6</a> (3 studies, 88 participants, 211 observations): RR 1.44, 95% CI 1.10 to 1.87; I<sup>2</sup> = 0%, moderate certainty of evidence) (<a href="./references#CD012467-bbs2-0003" title="BetjesMG , OosteromD , vanAgterenM , vande WeteringJ . Regional citrate versus heparin anticoagulation during venovenous hemofiltration in patients at low risk for bleeding: similar hemofilter survival but significantly less bleeding [abstract no: TH-FC107]. Journal of the American Society of Nephrology2006;17(Abstracts):24A. [CENTRAL: CN-00671866] BetjesMG , vanOosteromD , vanAgterenM , vande WeteringJ . Regional citrate versus heparin anticoagulation during venovenous hemofiltration in patients at low risk for bleeding: similar hemofilter survival but significantly less bleeding. Journal of Nephrology2007;20(5):602-8. [MEDLINE: 17918147]">Betjes 2007</a>; <a href="./references#CD012467-bbs2-0029" title="TiranathanagulK , JearnsujitwimolO , SusantitaphongP , KijkriengkraikulN , LeelahavanichkulA , SrisawatN , et al. Regional citrate anticoagulation reduces polymorphonuclear cell degranulation in critically ill patients treated with continuous venovenous hemofiltration. Therapeutic Apheresis &amp; Dialysis2011;15(6):556-64. [MEDLINE: 22107692]">Tiranathanagul 2011</a>; <a href="./references#CD012467-bbs2-0023" title="MonchiM , BerghmansD , LedouxD , CanivetJL , DuboisB , DamasP . Citrate vs. heparin for anticoagulation in continuous venovenous hemofiltration: a prospective randomized study. Intensive Care Medicine2004;30(2):260-5. [MEDLINE: 14600809]">Monchi 2004</a>). </p> <div class="figure" id="CD012467-fig-0006"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 6</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Citrate versus UFH, outcome: 1.3 Successful prevention of clotting." data-id="CD012467-fig-0006" src="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/image_n/nCD012467-FIG-06.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Citrate versus UFH, outcome: 1.3 Successful prevention of clotting. </p> </div> </div> </div> <p>Compared to UFH plus protamine, citrate may make little or no difference to successful treatment of clotting (<a href="./references#CD012467-fig-0010" title="">Analysis 1.3</a>.2; <a href="#CD012467-fig-0006">Figure 6</a> (2 studies, 40 participants, 229Ã‚Â observations): RR 0.97, 95% CI 0.72Ã‚Â to 1.31; I<sup>2</sup> = 0%, low certainty of evidence) in the citrate group compared to UFH plus protamine (<a href="./references#CD012467-bbs2-0010" title="FealyN , BaldwinI , JohnstoneM , EgiM , BellomoR . A pilot randomized controlled crossover study comparing regional heparinization to regional citrate anticoagulation for continuous venovenous hemofiltration. International Journal of Artificial Organs2007;30(4):301-7. [MEDLINE: 17520566]">Fealy 2007</a>: <a href="./references#CD012467-bbs2-0011" title="BrainMJ , RoodenburgOS , AdamsN , McCrackenP , HockingsL , MusgraveS , et al. Randomised trial of software algorithm driven regional citrate anticoagulation versus heparin in continuous renal replacement therapy: the Filter Life in Renal Replacement Therapy pilot trial. Critical Care &amp; Resuscitation2014;16(2):131-7. [MEDLINE: 24888284]">FLIRRT 2014</a>). </p> <p><a href="./references#CD012467-bbs2-0023" title="MonchiM , BerghmansD , LedouxD , CanivetJL , DuboisB , DamasP . Citrate vs. heparin for anticoagulation in continuous venovenous hemofiltration: a prospective randomized study. Intensive Care Medicine2004;30(2):260-5. [MEDLINE: 14600809]">Monchi 2004</a> reported results of cross‐over treatment of the same participants and we used the number of circuits as denominators of the event risk. <a href="./references#CD012467-bbs2-0003" title="BetjesMG , OosteromD , vanAgterenM , vande WeteringJ . Regional citrate versus heparin anticoagulation during venovenous hemofiltration in patients at low risk for bleeding: similar hemofilter survival but significantly less bleeding [abstract no: TH-FC107]. Journal of the American Society of Nephrology2006;17(Abstracts):24A. [CENTRAL: CN-00671866] BetjesMG , vanOosteromD , vanAgterenM , vande WeteringJ . Regional citrate versus heparin anticoagulation during venovenous hemofiltration in patients at low risk for bleeding: similar hemofilter survival but significantly less bleeding. Journal of Nephrology2007;20(5):602-8. [MEDLINE: 17918147]">Betjes 2007</a> did not report the outcome; however, they reported the number of filters being successfully used for 72 hours and we used the outcome for the analysis. <a href="./references#CD012467-bbs2-0005" title="SchilderL , NurmohamedS , BoschFH , PurmerIM , den BoerSS , KleppeCG , et al. Citrate anticoagulation versus systemic heparinisation in continuous venovenous hemofiltration in critically ill patients with acute kidney injury: a multi-center randomized clinical trial. Critical Care (London, England)2014;18(4):472. [MEDLINE: 25128022]SchilderL , NurmohamedSA , ter WeePM , PaauwNJ , GirbesAR , BeishuizenA , et al. Citrate confers less filter-induced complement activation and neutrophil degranulation than heparin when used for anticoagulation during continuous venovenous haemofiltration in critically ill patients. BMC Nephrology2014;15:19. [MEDLINE: 24438360]SchilderL , NurmohamedSA , ter WeePM , PaauwNJ , GirbesAR , BeishuizenA , et al. Putative novel mediators of acute kidney injury in critically ill patients: handling by continuous venovenous hemofiltration and effect of anticoagulation modalities. BMC Nephrology2015;16:178. [MEDLINE: 26519056]SchilderL , NurmohamedSA , ter WeePM , PaauwNJ , GirbesAR , BeishuizenA , et al. The plasma level and biomarker value of neutrophil gelatinase-associated lipocalin in critically ill patients with acute kidney injury are not affected by continuous venovenous hemofiltration and anticoagulation applied. Critical Care (London, England)2014;18(2):R78. [MEDLINE: 24755339]">CASH 2014</a> did not report successful prevention of clotting; however, they reported the number of filters used within 72 hours: 1 filter (median) and 0 to 5 (range) for citrate and 2 (median) and 1 to 9 (range) for UFH. <a href="./references#CD012467-bbs2-0010" title="FealyN , BaldwinI , JohnstoneM , EgiM , BellomoR . A pilot randomized controlled crossover study comparing regional heparinization to regional citrate anticoagulation for continuous venovenous hemofiltration. International Journal of Artificial Organs2007;30(4):301-7. [MEDLINE: 17520566]">Fealy 2007</a> and <a href="./references#CD012467-bbs2-0011" title="BrainMJ , RoodenburgOS , AdamsN , McCrackenP , HockingsL , MusgraveS , et al. Randomised trial of software algorithm driven regional citrate anticoagulation versus heparin in continuous renal replacement therapy: the Filter Life in Renal Replacement Therapy pilot trial. Critical Care &amp; Resuscitation2014;16(2):131-7. [MEDLINE: 24888284]">FLIRRT 2014</a> reported results of multiple enrolments of the same participants and we used the number of circuits as the denominators of the event risk. </p> </section> <section id="CD012467-sec-0064"> <h5 class="title">Metabolic disturbances</h5> <p>Compared to UFH, citrate may lead to metabolic disturbances (<a href="./references#CD012467-fig-0011" title="">Analysis 1.4</a>.1 (5 studies, 341 participants, 369 observations): RR 2.88, 95% CI 1.12Ã‚Â to 7.39; I<sup>2</sup>= 0%, low certainty of evidence) (<a href="./references#CD012467-bbs2-0003" title="BetjesMG , OosteromD , vanAgterenM , vande WeteringJ . Regional citrate versus heparin anticoagulation during venovenous hemofiltration in patients at low risk for bleeding: similar hemofilter survival but significantly less bleeding [abstract no: TH-FC107]. Journal of the American Society of Nephrology2006;17(Abstracts):24A. [CENTRAL: CN-00671866] BetjesMG , vanOosteromD , vanAgterenM , vande WeteringJ . Regional citrate versus heparin anticoagulation during venovenous hemofiltration in patients at low risk for bleeding: similar hemofilter survival but significantly less bleeding. Journal of Nephrology2007;20(5):602-8. [MEDLINE: 17918147]">Betjes 2007</a>; <a href="./references#CD012467-bbs2-0005" title="SchilderL , NurmohamedS , BoschFH , PurmerIM , den BoerSS , KleppeCG , et al. Citrate anticoagulation versus systemic heparinisation in continuous venovenous hemofiltration in critically ill patients with acute kidney injury: a multi-center randomized clinical trial. Critical Care (London, England)2014;18(4):472. [MEDLINE: 25128022]SchilderL , NurmohamedSA , ter WeePM , PaauwNJ , GirbesAR , BeishuizenA , et al. Citrate confers less filter-induced complement activation and neutrophil degranulation than heparin when used for anticoagulation during continuous venovenous haemofiltration in critically ill patients. BMC Nephrology2014;15:19. [MEDLINE: 24438360]SchilderL , NurmohamedSA , ter WeePM , PaauwNJ , GirbesAR , BeishuizenA , et al. Putative novel mediators of acute kidney injury in critically ill patients: handling by continuous venovenous hemofiltration and effect of anticoagulation modalities. BMC Nephrology2015;16:178. [MEDLINE: 26519056]SchilderL , NurmohamedSA , ter WeePM , PaauwNJ , GirbesAR , BeishuizenA , et al. The plasma level and biomarker value of neutrophil gelatinase-associated lipocalin in critically ill patients with acute kidney injury are not affected by continuous venovenous hemofiltration and anticoagulation applied. Critical Care (London, England)2014;18(2):R78. [MEDLINE: 24755339]">CASH 2014</a>; <a href="./references#CD012467-bbs2-0019" title="KutsogiannisDJ , GibneyRT , StolleryD , GaoJ . Regional citrate versus systemic heparin anticoagulation for continuous renal replacement in critically ill patients. Kidney International2005;67(6):2361-7. [MEDLINE: 15882280]">Kutsogiannis 2005</a>; <a href="./references#CD012467-bbs2-0023" title="MonchiM , BerghmansD , LedouxD , CanivetJL , DuboisB , DamasP . Citrate vs. heparin for anticoagulation in continuous venovenous hemofiltration: a prospective randomized study. Intensive Care Medicine2004;30(2):260-5. [MEDLINE: 14600809]">Monchi 2004</a>; <a href="./references#CD012467-bbs2-0028" title="StuckerF , PonteB , TatawJ , MartinPY , WozniakH , PuginJ , et al. Efficacy and safety of citrate-based anticoagulation compared to heparin in patients with acute kidney injury requiring continuous renal replacement therapy: a randomized controlled trial. Critical Care (London, England)2015;19(1):91. [MEDLINE: 25881975]StuckerF , PuginJ , TattawJ , PonteB , BrochardL , MartinP , et al. Citrate-based anticoagulation in patients with AKI in the intensive care unit: a safe and efficacious method [abstract no: 0379]. Intensive Care Medicine2013;39(Suppl 2):S320. [EMBASE: 71446324]">Stucker 2015</a>).Ã‚Â  </p> <p>For citrate compared to UFH plus protamine, no included study reported the events of metabolic disturbances. </p> <p><a href="./references#CD012467-bbs2-0028" title="StuckerF , PonteB , TatawJ , MartinPY , WozniakH , PuginJ , et al. Efficacy and safety of citrate-based anticoagulation compared to heparin in patients with acute kidney injury requiring continuous renal replacement therapy: a randomized controlled trial. Critical Care (London, England)2015;19(1):91. [MEDLINE: 25881975]StuckerF , PuginJ , TattawJ , PonteB , BrochardL , MartinP , et al. Citrate-based anticoagulation in patients with AKI in the intensive care unit: a safe and efficacious method [abstract no: 0379]. Intensive Care Medicine2013;39(Suppl 2):S320. [EMBASE: 71446324]">Stucker 2015</a> compared citrate to UFH, and reported four patients in citrate group were switched to heparin during the study (one on account of worsening liver failure, one on account of a technical problem with calcium infusion, and two for clinically relevant hypocalcaemia) and five patients were switched from heparin to citrate (two patients with major bleeding and three because of recurrent filter clotting). We handledÃ‚Â the four patients (switched from citrate to heparin) as citrate group and the five (switched from heparin to citrate) as heparin group because the outcomes were measured before the switch. </p> </section> <section id="CD012467-sec-0065"> <h5 class="title">Hypernatraemia</h5> <p>It is uncertain if citrate compared to UFH increases hypernatraemia because the certainty of the evidence was very low (<a href="./references#CD012467-fig-0012" title="">Analysis 1.5</a>.1). For citrate compared to UFH plus protamine, no included study reported hypernatraemia. </p> <p>Three studies reported hypernatraemia as an outcome. <a href="./references#CD012467-bbs2-0005" title="SchilderL , NurmohamedS , BoschFH , PurmerIM , den BoerSS , KleppeCG , et al. Citrate anticoagulation versus systemic heparinisation in continuous venovenous hemofiltration in critically ill patients with acute kidney injury: a multi-center randomized clinical trial. Critical Care (London, England)2014;18(4):472. [MEDLINE: 25128022]SchilderL , NurmohamedSA , ter WeePM , PaauwNJ , GirbesAR , BeishuizenA , et al. Citrate confers less filter-induced complement activation and neutrophil degranulation than heparin when used for anticoagulation during continuous venovenous haemofiltration in critically ill patients. BMC Nephrology2014;15:19. [MEDLINE: 24438360]SchilderL , NurmohamedSA , ter WeePM , PaauwNJ , GirbesAR , BeishuizenA , et al. Putative novel mediators of acute kidney injury in critically ill patients: handling by continuous venovenous hemofiltration and effect of anticoagulation modalities. BMC Nephrology2015;16:178. [MEDLINE: 26519056]SchilderL , NurmohamedSA , ter WeePM , PaauwNJ , GirbesAR , BeishuizenA , et al. The plasma level and biomarker value of neutrophil gelatinase-associated lipocalin in critically ill patients with acute kidney injury are not affected by continuous venovenous hemofiltration and anticoagulation applied. Critical Care (London, England)2014;18(2):R78. [MEDLINE: 24755339]">CASH 2014</a> (serum sodium &gt; 150mmol/L) reported 4/66 events in the citrate group and 3/73 events in the UFH group. <a href="./references#CD012467-bbs2-0003" title="BetjesMG , OosteromD , vanAgterenM , vande WeteringJ . Regional citrate versus heparin anticoagulation during venovenous hemofiltration in patients at low risk for bleeding: similar hemofilter survival but significantly less bleeding [abstract no: TH-FC107]. Journal of the American Society of Nephrology2006;17(Abstracts):24A. [CENTRAL: CN-00671866] BetjesMG , vanOosteromD , vanAgterenM , vande WeteringJ . Regional citrate versus heparin anticoagulation during venovenous hemofiltration in patients at low risk for bleeding: similar hemofilter survival but significantly less bleeding. Journal of Nephrology2007;20(5):602-8. [MEDLINE: 17918147]">Betjes 2007</a> (serum sodium &gt; 155 mmol/L) and <a href="./references#CD012467-bbs2-0023" title="MonchiM , BerghmansD , LedouxD , CanivetJL , DuboisB , DamasP . Citrate vs. heparin for anticoagulation in continuous venovenous hemofiltration: a prospective randomized study. Intensive Care Medicine2004;30(2):260-5. [MEDLINE: 14600809]">Monchi 2004</a> (serum sodium &gt; 150 mmol/L) reported no hypernatraemia events. </p> </section> <section id="CD012467-sec-0066"> <h5 class="title">Hypocalcaemia</h5> <p>Compared to UFH, citrate probably leads to hypocalcaemia (<a href="./references#CD012467-fig-0013" title="">Analysis 1.6</a>.1 (5 studies, 372 participants, 400 observations): RR 4.51, 95% CI 1.31 to 15.55; I<sup>2</sup> = 0%, moderate certainty of evidence) (<a href="./references#CD012467-bbs2-0003" title="BetjesMG , OosteromD , vanAgterenM , vande WeteringJ . Regional citrate versus heparin anticoagulation during venovenous hemofiltration in patients at low risk for bleeding: similar hemofilter survival but significantly less bleeding [abstract no: TH-FC107]. Journal of the American Society of Nephrology2006;17(Abstracts):24A. [CENTRAL: CN-00671866] BetjesMG , vanOosteromD , vanAgterenM , vande WeteringJ . Regional citrate versus heparin anticoagulation during venovenous hemofiltration in patients at low risk for bleeding: similar hemofilter survival but significantly less bleeding. Journal of Nephrology2007;20(5):602-8. [MEDLINE: 17918147]">Betjes 2007</a>; <a href="./references#CD012467-bbs2-0015" title="HetzelGR , SchmitzM , WissingH , RiesW , SchottG , HeeringPJ , et al. Regional citrate versus systemic heparin for anticoagulation in critically ill patients on continuous venovenous haemofiltration: a prospective randomized multicentre trial. Nephrology Dialysis Transplantation2011;26(1):232-9. [MEDLINE: 20876598]">Hetzel 2011</a>; <a href="./references#CD012467-bbs2-0019" title="KutsogiannisDJ , GibneyRT , StolleryD , GaoJ . Regional citrate versus systemic heparin anticoagulation for continuous renal replacement in critically ill patients. Kidney International2005;67(6):2361-7. [MEDLINE: 15882280]">Kutsogiannis 2005</a>; <a href="./references#CD012467-bbs2-0023" title="MonchiM , BerghmansD , LedouxD , CanivetJL , DuboisB , DamasP . Citrate vs. heparin for anticoagulation in continuous venovenous hemofiltration: a prospective randomized study. Intensive Care Medicine2004;30(2):260-5. [MEDLINE: 14600809]">Monchi 2004</a>; <a href="./references#CD012467-bbs2-0028" title="StuckerF , PonteB , TatawJ , MartinPY , WozniakH , PuginJ , et al. Efficacy and safety of citrate-based anticoagulation compared to heparin in patients with acute kidney injury requiring continuous renal replacement therapy: a randomized controlled trial. Critical Care (London, England)2015;19(1):91. [MEDLINE: 25881975]StuckerF , PuginJ , TattawJ , PonteB , BrochardL , MartinP , et al. Citrate-based anticoagulation in patients with AKI in the intensive care unit: a safe and efficacious method [abstract no: 0379]. Intensive Care Medicine2013;39(Suppl 2):S320. [EMBASE: 71446324]">Stucker 2015</a>). Compared to UFH plus protamine, citrate may increase hypocalcaemia (<a href="./references#CD012467-fig-0013" title="">Analysis 1.6</a>.2 (1 study, 30 participants): RR 4.20, 95% CI 0.24 to 74.48; low certainty of evidence) (<a href="./references#CD012467-bbs2-0011" title="BrainMJ , RoodenburgOS , AdamsN , McCrackenP , HockingsL , MusgraveS , et al. Randomised trial of software algorithm driven regional citrate anticoagulation versus heparin in continuous renal replacement therapy: the Filter Life in Renal Replacement Therapy pilot trial. Critical Care &amp; Resuscitation2014;16(2):131-7. [MEDLINE: 24888284]">FLIRRT 2014</a>). </p> </section> <section id="CD012467-sec-0067"> <h5 class="title">Hypercalcaemia</h5> <p><a href="./references#CD012467-bbs2-0003" title="BetjesMG , OosteromD , vanAgterenM , vande WeteringJ . Regional citrate versus heparin anticoagulation during venovenous hemofiltration in patients at low risk for bleeding: similar hemofilter survival but significantly less bleeding [abstract no: TH-FC107]. Journal of the American Society of Nephrology2006;17(Abstracts):24A. [CENTRAL: CN-00671866] BetjesMG , vanOosteromD , vanAgterenM , vande WeteringJ . Regional citrate versus heparin anticoagulation during venovenous hemofiltration in patients at low risk for bleeding: similar hemofilter survival but significantly less bleeding. Journal of Nephrology2007;20(5):602-8. [MEDLINE: 17918147]">Betjes 2007</a> and <a href="./references#CD012467-bbs2-0005" title="SchilderL , NurmohamedS , BoschFH , PurmerIM , den BoerSS , KleppeCG , et al. Citrate anticoagulation versus systemic heparinisation in continuous venovenous hemofiltration in critically ill patients with acute kidney injury: a multi-center randomized clinical trial. Critical Care (London, England)2014;18(4):472. [MEDLINE: 25128022]SchilderL , NurmohamedSA , ter WeePM , PaauwNJ , GirbesAR , BeishuizenA , et al. Citrate confers less filter-induced complement activation and neutrophil degranulation than heparin when used for anticoagulation during continuous venovenous haemofiltration in critically ill patients. BMC Nephrology2014;15:19. [MEDLINE: 24438360]SchilderL , NurmohamedSA , ter WeePM , PaauwNJ , GirbesAR , BeishuizenA , et al. Putative novel mediators of acute kidney injury in critically ill patients: handling by continuous venovenous hemofiltration and effect of anticoagulation modalities. BMC Nephrology2015;16:178. [MEDLINE: 26519056]SchilderL , NurmohamedSA , ter WeePM , PaauwNJ , GirbesAR , BeishuizenA , et al. The plasma level and biomarker value of neutrophil gelatinase-associated lipocalin in critically ill patients with acute kidney injury are not affected by continuous venovenous hemofiltration and anticoagulation applied. Critical Care (London, England)2014;18(2):R78. [MEDLINE: 24755339]">CASH 2014</a> reported no hypercalcaemia events in either the UFH or citrate group (<a href="./references#CD012467-fig-0014" title="">Analysis 1.7</a>.1). </p> </section> <section id="CD012467-sec-0068"> <h5 class="title">Recovery of kidney function</h5> <p>Compared to UFH, citrate may make little or no difference to recovery of kidney function (<a href="./references#CD012467-fig-0015" title="">Analysis 1.8</a>.1 (2 studies, 214 participants): RR 1.04, 95% CI 0.89 to 1.21; I<sup>2</sup> = 0%, low certainty evidence) (<a href="./references#CD012467-bbs2-0005" title="SchilderL , NurmohamedS , BoschFH , PurmerIM , den BoerSS , KleppeCG , et al. Citrate anticoagulation versus systemic heparinisation in continuous venovenous hemofiltration in critically ill patients with acute kidney injury: a multi-center randomized clinical trial. Critical Care (London, England)2014;18(4):472. [MEDLINE: 25128022]SchilderL , NurmohamedSA , ter WeePM , PaauwNJ , GirbesAR , BeishuizenA , et al. Citrate confers less filter-induced complement activation and neutrophil degranulation than heparin when used for anticoagulation during continuous venovenous haemofiltration in critically ill patients. BMC Nephrology2014;15:19. [MEDLINE: 24438360]SchilderL , NurmohamedSA , ter WeePM , PaauwNJ , GirbesAR , BeishuizenA , et al. Putative novel mediators of acute kidney injury in critically ill patients: handling by continuous venovenous hemofiltration and effect of anticoagulation modalities. BMC Nephrology2015;16:178. [MEDLINE: 26519056]SchilderL , NurmohamedSA , ter WeePM , PaauwNJ , GirbesAR , BeishuizenA , et al. The plasma level and biomarker value of neutrophil gelatinase-associated lipocalin in critically ill patients with acute kidney injury are not affected by continuous venovenous hemofiltration and anticoagulation applied. Critical Care (London, England)2014;18(2):R78. [MEDLINE: 24755339]">CASH 2014</a>; <a href="./references#CD012467-bbs2-0028" title="StuckerF , PonteB , TatawJ , MartinPY , WozniakH , PuginJ , et al. Efficacy and safety of citrate-based anticoagulation compared to heparin in patients with acute kidney injury requiring continuous renal replacement therapy: a randomized controlled trial. Critical Care (London, England)2015;19(1):91. [MEDLINE: 25881975]StuckerF , PuginJ , TattawJ , PonteB , BrochardL , MartinP , et al. Citrate-based anticoagulation in patients with AKI in the intensive care unit: a safe and efficacious method [abstract no: 0379]. Intensive Care Medicine2013;39(Suppl 2):S320. [EMBASE: 71446324]">Stucker 2015</a>). </p> <p>Compared to UFH plus protamine, citrate may make little or no difference to recovery of kidney function (<a href="./references#CD012467-fig-0015" title="">Analysis 1.8</a>.2 (1 studies, 30 participants): RR 1.16, 95% CI 0.53 to 2.51; low certainty of evidence) (<a href="./references#CD012467-bbs2-0011" title="BrainMJ , RoodenburgOS , AdamsN , McCrackenP , HockingsL , MusgraveS , et al. Randomised trial of software algorithm driven regional citrate anticoagulation versus heparin in continuous renal replacement therapy: the Filter Life in Renal Replacement Therapy pilot trial. Critical Care &amp; Resuscitation2014;16(2):131-7. [MEDLINE: 24888284]">FLIRRT 2014</a>). </p> </section> <section id="CD012467-sec-0069"> <h5 class="title">Thrombocytopenia</h5> <p>Compared to UFH, citrate may reduce thrombocytopenia (<a href="./references#CD012467-fig-0016" title="">Analysis 1.9</a>.1 (3 studies, 412 participants): RR 0.39, 95% CI 0.14 to 1.03; I<sup>2</sup> = 0%, low certainty of evidence) (<a href="./references#CD012467-bbs2-0005" title="SchilderL , NurmohamedS , BoschFH , PurmerIM , den BoerSS , KleppeCG , et al. Citrate anticoagulation versus systemic heparinisation in continuous venovenous hemofiltration in critically ill patients with acute kidney injury: a multi-center randomized clinical trial. Critical Care (London, England)2014;18(4):472. [MEDLINE: 25128022]SchilderL , NurmohamedSA , ter WeePM , PaauwNJ , GirbesAR , BeishuizenA , et al. Citrate confers less filter-induced complement activation and neutrophil degranulation than heparin when used for anticoagulation during continuous venovenous haemofiltration in critically ill patients. BMC Nephrology2014;15:19. [MEDLINE: 24438360]SchilderL , NurmohamedSA , ter WeePM , PaauwNJ , GirbesAR , BeishuizenA , et al. Putative novel mediators of acute kidney injury in critically ill patients: handling by continuous venovenous hemofiltration and effect of anticoagulation modalities. BMC Nephrology2015;16:178. [MEDLINE: 26519056]SchilderL , NurmohamedSA , ter WeePM , PaauwNJ , GirbesAR , BeishuizenA , et al. The plasma level and biomarker value of neutrophil gelatinase-associated lipocalin in critically ill patients with acute kidney injury are not affected by continuous venovenous hemofiltration and anticoagulation applied. Critical Care (London, England)2014;18(2):R78. [MEDLINE: 24755339]">CASH 2014</a>; <a href="./references#CD012467-bbs2-0015" title="HetzelGR , SchmitzM , WissingH , RiesW , SchottG , HeeringPJ , et al. Regional citrate versus systemic heparin for anticoagulation in critically ill patients on continuous venovenous haemofiltration: a prospective randomized multicentre trial. Nephrology Dialysis Transplantation2011;26(1):232-9. [MEDLINE: 20876598]">Hetzel 2011</a>; <a href="./references#CD012467-bbs2-0028" title="StuckerF , PonteB , TatawJ , MartinPY , WozniakH , PuginJ , et al. Efficacy and safety of citrate-based anticoagulation compared to heparin in patients with acute kidney injury requiring continuous renal replacement therapy: a randomized controlled trial. Critical Care (London, England)2015;19(1):91. [MEDLINE: 25881975]StuckerF , PuginJ , TattawJ , PonteB , BrochardL , MartinP , et al. Citrate-based anticoagulation in patients with AKI in the intensive care unit: a safe and efficacious method [abstract no: 0379]. Intensive Care Medicine2013;39(Suppl 2):S320. [EMBASE: 71446324]">Stucker 2015</a>) for the comparison between citrate and UFH (<a href="#CD012467-tbl-0004">Table 1</a>). </p> <div class="table" id="CD012467-tbl-0004"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Thrombocytopenia and platelet counts</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Ã‚Â Study ID</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Ã‚Â Thrombocytopenia (n/N)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Ã‚Â Platelet count</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012467-bbs2-0005" title="SchilderL , NurmohamedS , BoschFH , PurmerIM , den BoerSS , KleppeCG , et al. Citrate anticoagulation versus systemic heparinisation in continuous venovenous hemofiltration in critically ill patients with acute kidney injury: a multi-center randomized clinical trial. Critical Care (London, England)2014;18(4):472. [MEDLINE: 25128022]SchilderL , NurmohamedSA , ter WeePM , PaauwNJ , GirbesAR , BeishuizenA , et al. Citrate confers less filter-induced complement activation and neutrophil degranulation than heparin when used for anticoagulation during continuous venovenous haemofiltration in critically ill patients. BMC Nephrology2014;15:19. [MEDLINE: 24438360]SchilderL , NurmohamedSA , ter WeePM , PaauwNJ , GirbesAR , BeishuizenA , et al. Putative novel mediators of acute kidney injury in critically ill patients: handling by continuous venovenous hemofiltration and effect of anticoagulation modalities. BMC Nephrology2015;16:178. [MEDLINE: 26519056]SchilderL , NurmohamedSA , ter WeePM , PaauwNJ , GirbesAR , BeishuizenA , et al. The plasma level and biomarker value of neutrophil gelatinase-associated lipocalin in critically ill patients with acute kidney injury are not affected by continuous venovenous hemofiltration and anticoagulation applied. Critical Care (London, England)2014;18(2):R78. [MEDLINE: 24755339]">CASH 2014</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Citrate: 0/66</p> <p>UFH: 6/73</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012467-bbs2-0015" title="HetzelGR , SchmitzM , WissingH , RiesW , SchottG , HeeringPJ , et al. Regional citrate versus systemic heparin for anticoagulation in critically ill patients on continuous venovenous haemofiltration: a prospective randomized multicentre trial. Nephrology Dialysis Transplantation2011;26(1):232-9. [MEDLINE: 20876598]">Hetzel 2011</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Citrate: 4/87</p> <p>UFH: 8/83</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012467-bbs2-0028" title="StuckerF , PonteB , TatawJ , MartinPY , WozniakH , PuginJ , et al. Efficacy and safety of citrate-based anticoagulation compared to heparin in patients with acute kidney injury requiring continuous renal replacement therapy: a randomized controlled trial. Critical Care (London, England)2015;19(1):91. [MEDLINE: 25881975]StuckerF , PuginJ , TattawJ , PonteB , BrochardL , MartinP , et al. Citrate-based anticoagulation in patients with AKI in the intensive care unit: a safe and efficacious method [abstract no: 0379]. Intensive Care Medicine2013;39(Suppl 2):S320. [EMBASE: 71446324]">Stucker 2015</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Citrate: 1/54</p> <p>UFH: 2/49</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012467-bbs2-0024" title="Oudemans-van StraatenHM , BosmanRJ , KoopmansM , van derVoortPH , WesterJP , van derSpoelJI , et al. Citrate anticoagulation for continuous venovenous hemofiltration. Critical Care Medicine2009;37(2):545-52. [MEDLINE: 19114912]">Oudemans‐van Straaten 2009</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Citrate: 3/97</p> <p>LMWH: 4/103</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012467-bbs2-0026" title="ReevesJH , CummingAR , GallagherL , O'BrienJL , SantamariaJD . A controlled trial of low-molecular-weight heparin (dalteparin) versus unfractionated heparin as anticoagulant during continuous venovenous hemodialysis with filtration. Critical Care Medicine1999;27(10):2224-8. [MEDLINE: 10548211]">Reeves 1999</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>UFH: 4/22 (1 confirmed as HIT)</p> <p>LMWH: 8/25 (3 confirmed as HIT)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The mean (Ã‚Â± SE) reduction in platelet count during HF was:</p> <p>UFH: 63 Ã‚Â± 25.8 x 10<sup>9</sup> </p> <p>LMWH: 41.8 Ã‚Â± 26.6 x 10<sup>9</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012467-bbs2-0004" title="BirnbaumJ , SpiesCD , KlotzE , HeinOV , MorgeraS , SchinkT , et al. Iloprost for additional anticoagulation in continuous renal replacement therapy--a pilot study. Renal Failure2007;29(3):271-7. [MEDLINE: 17497439]">Birnbaum 2007</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>UFH + PGI<sub>2</sub>: 1/10 </p> <p>UFH: 0/10</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>UFH + PGI<sub>2</sub>: drop to 16/nL in one patient due to sepsis </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012467-bbs2-0014" title="HeinOV , vonHeymannC , DiehlT , ZiemerS , RoncoC , MorgeraS , et al. Intermittent hirudin versus continuous heparin for anticoagulation in continuous renal replacement therapy. Renal Failure2004;26(3):297-303. [MEDLINE: 15354980]">Hein 2004</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hirudin: 0/12</p> <p>UFH: 2/14</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>UFH: 2 patients had bleeding complications and platelet counts were 69/nL and 17/nL</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>LMWH ‐ low molecular weight heparin; SE ‐ standard error; UFH ‐ unfractionated heparin</p> </div> </div> <p>For citrate compared to UFH plus protamine, no study reported thrombocytopenia.</p> <p>No study reported the detailedÃ‚Â platelet counts or the averageÃ‚Â of platelet counts in patients with thrombocytopenia. </p> </section> <section id="CD012467-sec-0070"> <h5 class="title">Catheter thrombotic events</h5> <p>Compared to UFH, citrate may make little or no difference to catheter thrombotic events (<a href="./references#CD012467-fig-0017" title="">Analysis 1.10</a>.1 (4 studies, 238 participants, 301 observations): RR 1.03, 95% CI 0.42 to 2.48; I<sup>2</sup> = 45%, low certainty evidence) (<a href="./references#CD012467-bbs2-0003" title="BetjesMG , OosteromD , vanAgterenM , vande WeteringJ . Regional citrate versus heparin anticoagulation during venovenous hemofiltration in patients at low risk for bleeding: similar hemofilter survival but significantly less bleeding [abstract no: TH-FC107]. Journal of the American Society of Nephrology2006;17(Abstracts):24A. [CENTRAL: CN-00671866] BetjesMG , vanOosteromD , vanAgterenM , vande WeteringJ . Regional citrate versus heparin anticoagulation during venovenous hemofiltration in patients at low risk for bleeding: similar hemofilter survival but significantly less bleeding. Journal of Nephrology2007;20(5):602-8. [MEDLINE: 17918147]">Betjes 2007</a>; <a href="./references#CD012467-bbs2-0005" title="SchilderL , NurmohamedS , BoschFH , PurmerIM , den BoerSS , KleppeCG , et al. Citrate anticoagulation versus systemic heparinisation in continuous venovenous hemofiltration in critically ill patients with acute kidney injury: a multi-center randomized clinical trial. Critical Care (London, England)2014;18(4):472. [MEDLINE: 25128022]SchilderL , NurmohamedSA , ter WeePM , PaauwNJ , GirbesAR , BeishuizenA , et al. Citrate confers less filter-induced complement activation and neutrophil degranulation than heparin when used for anticoagulation during continuous venovenous haemofiltration in critically ill patients. BMC Nephrology2014;15:19. [MEDLINE: 24438360]SchilderL , NurmohamedSA , ter WeePM , PaauwNJ , GirbesAR , BeishuizenA , et al. Putative novel mediators of acute kidney injury in critically ill patients: handling by continuous venovenous hemofiltration and effect of anticoagulation modalities. BMC Nephrology2015;16:178. [MEDLINE: 26519056]SchilderL , NurmohamedSA , ter WeePM , PaauwNJ , GirbesAR , BeishuizenA , et al. The plasma level and biomarker value of neutrophil gelatinase-associated lipocalin in critically ill patients with acute kidney injury are not affected by continuous venovenous hemofiltration and anticoagulation applied. Critical Care (London, England)2014;18(2):R78. [MEDLINE: 24755339]">CASH 2014</a>; <a href="./references#CD012467-bbs2-0019" title="KutsogiannisDJ , GibneyRT , StolleryD , GaoJ . Regional citrate versus systemic heparin anticoagulation for continuous renal replacement in critically ill patients. Kidney International2005;67(6):2361-7. [MEDLINE: 15882280]">Kutsogiannis 2005</a>; <a href="./references#CD012467-bbs2-0023" title="MonchiM , BerghmansD , LedouxD , CanivetJL , DuboisB , DamasP . Citrate vs. heparin for anticoagulation in continuous venovenous hemofiltration: a prospective randomized study. Intensive Care Medicine2004;30(2):260-5. [MEDLINE: 14600809]">Monchi 2004</a>). </p> <p>For citrate compared to UFH plus protamine, no study reported catheter thrombotic events. </p> </section> <section id="CD012467-sec-0071"> <h5 class="title">Adverse events</h5> <section id="CD012467-sec-0072"> <h6 class="title">Number of treatment attempts with dropouts due to adverse events (technique or patient‐dependent factors) </h6> <p>Compared to UFH, citrate may reduce the number of treatment attempts (per circuit) with dropouts due to adverse events (<a href="./references#CD012467-fig-0018" title="">Analysis 1.11</a>.1 (3 studies, 412 treatments): RR 0.47, 95% CI 0.15 to 1.49; I<sup>2</sup> = 47%, low certainty of evidence) (<a href="./references#CD012467-bbs2-0005" title="SchilderL , NurmohamedS , BoschFH , PurmerIM , den BoerSS , KleppeCG , et al. Citrate anticoagulation versus systemic heparinisation in continuous venovenous hemofiltration in critically ill patients with acute kidney injury: a multi-center randomized clinical trial. Critical Care (London, England)2014;18(4):472. [MEDLINE: 25128022]SchilderL , NurmohamedSA , ter WeePM , PaauwNJ , GirbesAR , BeishuizenA , et al. Citrate confers less filter-induced complement activation and neutrophil degranulation than heparin when used for anticoagulation during continuous venovenous haemofiltration in critically ill patients. BMC Nephrology2014;15:19. [MEDLINE: 24438360]SchilderL , NurmohamedSA , ter WeePM , PaauwNJ , GirbesAR , BeishuizenA , et al. Putative novel mediators of acute kidney injury in critically ill patients: handling by continuous venovenous hemofiltration and effect of anticoagulation modalities. BMC Nephrology2015;16:178. [MEDLINE: 26519056]SchilderL , NurmohamedSA , ter WeePM , PaauwNJ , GirbesAR , BeishuizenA , et al. The plasma level and biomarker value of neutrophil gelatinase-associated lipocalin in critically ill patients with acute kidney injury are not affected by continuous venovenous hemofiltration and anticoagulation applied. Critical Care (London, England)2014;18(2):R78. [MEDLINE: 24755339]">CASH 2014</a>; <a href="./references#CD012467-bbs2-0015" title="HetzelGR , SchmitzM , WissingH , RiesW , SchottG , HeeringPJ , et al. Regional citrate versus systemic heparin for anticoagulation in critically ill patients on continuous venovenous haemofiltration: a prospective randomized multicentre trial. Nephrology Dialysis Transplantation2011;26(1):232-9. [MEDLINE: 20876598]">Hetzel 2011</a>; <a href="./references#CD012467-bbs2-0028" title="StuckerF , PonteB , TatawJ , MartinPY , WozniakH , PuginJ , et al. Efficacy and safety of citrate-based anticoagulation compared to heparin in patients with acute kidney injury requiring continuous renal replacement therapy: a randomized controlled trial. Critical Care (London, England)2015;19(1):91. [MEDLINE: 25881975]StuckerF , PuginJ , TattawJ , PonteB , BrochardL , MartinP , et al. Citrate-based anticoagulation in patients with AKI in the intensive care unit: a safe and efficacious method [abstract no: 0379]. Intensive Care Medicine2013;39(Suppl 2):S320. [EMBASE: 71446324]">Stucker 2015</a>). </p> <p>It is uncertain whether citrate compared to UFH plus protamine makes little or no difference to numbers of treatment attempts (per circuit) and dropouts due to adverse events (<a href="./references#CD012467-fig-0018" title="">Analysis 1.11</a>.2) because the certainty of the evidence is very low (<a href="./references#CD012467-bbs2-0010" title="FealyN , BaldwinI , JohnstoneM , EgiM , BellomoR . A pilot randomized controlled crossover study comparing regional heparinization to regional citrate anticoagulation for continuous venovenous hemofiltration. International Journal of Artificial Organs2007;30(4):301-7. [MEDLINE: 17520566]">Fealy 2007</a>; <a href="./references#CD012467-bbs2-0011" title="BrainMJ , RoodenburgOS , AdamsN , McCrackenP , HockingsL , MusgraveS , et al. Randomised trial of software algorithm driven regional citrate anticoagulation versus heparin in continuous renal replacement therapy: the Filter Life in Renal Replacement Therapy pilot trial. Critical Care &amp; Resuscitation2014;16(2):131-7. [MEDLINE: 24888284]">FLIRRT 2014</a>; <a href="./references#CD012467-bbs2-0012" title="GarcesEO , VictorinoJA , ThomeFS , RohsigLM , DornellesE , LouzadaM , et al. Enoxaparin versus unfractioned heparin as anticoagulant for continuous venovenous hemodialysis: a randomized open-label trial. Renal Failure2010;32(3):320-7. [MEDLINE: 20370447]">Garces 2010</a>). </p> </section> <section id="CD012467-sec-0073"> <h6 class="title">Number of treatment attempts with adverse events (technique or patient‐dependent factors)</h6> <p>Compared to UFH, citrate may reduce the number of treatment attempts (per circuits) with any adverse events (<a href="./references#CD012467-fig-0019" title="">Analysis 1.12</a> (6 studies, 539 treatments): RR 0.59, 95% CI 0.36 to 0.99; I<sup>2</sup> = 62%, low certainty of evidence) (<a href="./references#CD012467-bbs2-0003" title="BetjesMG , OosteromD , vanAgterenM , vande WeteringJ . Regional citrate versus heparin anticoagulation during venovenous hemofiltration in patients at low risk for bleeding: similar hemofilter survival but significantly less bleeding [abstract no: TH-FC107]. Journal of the American Society of Nephrology2006;17(Abstracts):24A. [CENTRAL: CN-00671866] BetjesMG , vanOosteromD , vanAgterenM , vande WeteringJ . Regional citrate versus heparin anticoagulation during venovenous hemofiltration in patients at low risk for bleeding: similar hemofilter survival but significantly less bleeding. Journal of Nephrology2007;20(5):602-8. [MEDLINE: 17918147]">Betjes 2007</a>; <a href="./references#CD012467-bbs2-0005" title="SchilderL , NurmohamedS , BoschFH , PurmerIM , den BoerSS , KleppeCG , et al. Citrate anticoagulation versus systemic heparinisation in continuous venovenous hemofiltration in critically ill patients with acute kidney injury: a multi-center randomized clinical trial. Critical Care (London, England)2014;18(4):472. [MEDLINE: 25128022]SchilderL , NurmohamedSA , ter WeePM , PaauwNJ , GirbesAR , BeishuizenA , et al. Citrate confers less filter-induced complement activation and neutrophil degranulation than heparin when used for anticoagulation during continuous venovenous haemofiltration in critically ill patients. BMC Nephrology2014;15:19. [MEDLINE: 24438360]SchilderL , NurmohamedSA , ter WeePM , PaauwNJ , GirbesAR , BeishuizenA , et al. Putative novel mediators of acute kidney injury in critically ill patients: handling by continuous venovenous hemofiltration and effect of anticoagulation modalities. BMC Nephrology2015;16:178. [MEDLINE: 26519056]SchilderL , NurmohamedSA , ter WeePM , PaauwNJ , GirbesAR , BeishuizenA , et al. The plasma level and biomarker value of neutrophil gelatinase-associated lipocalin in critically ill patients with acute kidney injury are not affected by continuous venovenous hemofiltration and anticoagulation applied. Critical Care (London, England)2014;18(2):R78. [MEDLINE: 24755339]">CASH 2014</a>; <a href="./references#CD012467-bbs2-0015" title="HetzelGR , SchmitzM , WissingH , RiesW , SchottG , HeeringPJ , et al. Regional citrate versus systemic heparin for anticoagulation in critically ill patients on continuous venovenous haemofiltration: a prospective randomized multicentre trial. Nephrology Dialysis Transplantation2011;26(1):232-9. [MEDLINE: 20876598]">Hetzel 2011</a>; <a href="./references#CD012467-bbs2-0019" title="KutsogiannisDJ , GibneyRT , StolleryD , GaoJ . Regional citrate versus systemic heparin anticoagulation for continuous renal replacement in critically ill patients. Kidney International2005;67(6):2361-7. [MEDLINE: 15882280]">Kutsogiannis 2005</a>; <a href="./references#CD012467-bbs2-0023" title="MonchiM , BerghmansD , LedouxD , CanivetJL , DuboisB , DamasP . Citrate vs. heparin for anticoagulation in continuous venovenous hemofiltration: a prospective randomized study. Intensive Care Medicine2004;30(2):260-5. [MEDLINE: 14600809]">Monchi 2004</a>; <a href="./references#CD012467-bbs2-0028" title="StuckerF , PonteB , TatawJ , MartinPY , WozniakH , PuginJ , et al. Efficacy and safety of citrate-based anticoagulation compared to heparin in patients with acute kidney injury requiring continuous renal replacement therapy: a randomized controlled trial. Critical Care (London, England)2015;19(1):91. [MEDLINE: 25881975]StuckerF , PuginJ , TattawJ , PonteB , BrochardL , MartinP , et al. Citrate-based anticoagulation in patients with AKI in the intensive care unit: a safe and efficacious method [abstract no: 0379]. Intensive Care Medicine2013;39(Suppl 2):S320. [EMBASE: 71446324]">Stucker 2015</a>). </p> <p>It is uncertain whether citrate compares to UFH plus protamine reduces the number of treatment attempts with any adverse events (<a href="./references#CD012467-fig-0019" title="">Analysis 1.12</a>.2) because the certainty of the evidence is very low (<a href="./references#CD012467-bbs2-0010" title="FealyN , BaldwinI , JohnstoneM , EgiM , BellomoR . A pilot randomized controlled crossover study comparing regional heparinization to regional citrate anticoagulation for continuous venovenous hemofiltration. International Journal of Artificial Organs2007;30(4):301-7. [MEDLINE: 17520566]">Fealy 2007</a>; <a href="./references#CD012467-bbs2-0011" title="BrainMJ , RoodenburgOS , AdamsN , McCrackenP , HockingsL , MusgraveS , et al. Randomised trial of software algorithm driven regional citrate anticoagulation versus heparin in continuous renal replacement therapy: the Filter Life in Renal Replacement Therapy pilot trial. Critical Care &amp; Resuscitation2014;16(2):131-7. [MEDLINE: 24888284]">FLIRRT 2014</a>; <a href="./references#CD012467-bbs2-0012" title="GarcesEO , VictorinoJA , ThomeFS , RohsigLM , DornellesE , LouzadaM , et al. Enoxaparin versus unfractioned heparin as anticoagulant for continuous venovenous hemodialysis: a randomized open-label trial. Renal Failure2010;32(3):320-7. [MEDLINE: 20370447]">Garces 2010</a>). </p> </section> <section id="CD012467-sec-0074"> <h6 class="title">Number of patients with any adverse events</h6> <p>The number of patients who experienced any adverse events is tabulated in <a href="#CD012467-tbl-0005">Table 2</a> and <a href="#CD012467-tbl-0006">Table 3</a>. </p> <div class="table" id="CD012467-tbl-0005"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Adverse events: Citrate versus UFH</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study ID</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Adverse events</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Intervention: events/participants</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p><a href="./references#CD012467-bbs2-0003" title="BetjesMG , OosteromD , vanAgterenM , vande WeteringJ . Regional citrate versus heparin anticoagulation during venovenous hemofiltration in patients at low risk for bleeding: similar hemofilter survival but significantly less bleeding [abstract no: TH-FC107]. Journal of the American Society of Nephrology2006;17(Abstracts):24A. [CENTRAL: CN-00671866] BetjesMG , vanOosteromD , vanAgterenM , vande WeteringJ . Regional citrate versus heparin anticoagulation during venovenous hemofiltration in patients at low risk for bleeding: similar hemofilter survival but significantly less bleeding. Journal of Nephrology2007;20(5):602-8. [MEDLINE: 17918147]">Betjes 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>All bleeding events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Citrate: 0/27</p> <p>UFH: 9/21</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Alkalosis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Citrate: 0/27</p> <p>UFH: 2/21</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hypocalcaemia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Citrate: 2/27</p> <p>UFH: 0/21</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="7" valign=""> <p><a href="./references#CD012467-bbs2-0005" title="SchilderL , NurmohamedS , BoschFH , PurmerIM , den BoerSS , KleppeCG , et al. Citrate anticoagulation versus systemic heparinisation in continuous venovenous hemofiltration in critically ill patients with acute kidney injury: a multi-center randomized clinical trial. Critical Care (London, England)2014;18(4):472. [MEDLINE: 25128022]SchilderL , NurmohamedSA , ter WeePM , PaauwNJ , GirbesAR , BeishuizenA , et al. Citrate confers less filter-induced complement activation and neutrophil degranulation than heparin when used for anticoagulation during continuous venovenous haemofiltration in critically ill patients. BMC Nephrology2014;15:19. [MEDLINE: 24438360]SchilderL , NurmohamedSA , ter WeePM , PaauwNJ , GirbesAR , BeishuizenA , et al. Putative novel mediators of acute kidney injury in critically ill patients: handling by continuous venovenous hemofiltration and effect of anticoagulation modalities. BMC Nephrology2015;16:178. [MEDLINE: 26519056]SchilderL , NurmohamedSA , ter WeePM , PaauwNJ , GirbesAR , BeishuizenA , et al. The plasma level and biomarker value of neutrophil gelatinase-associated lipocalin in critically ill patients with acute kidney injury are not affected by continuous venovenous hemofiltration and anticoagulation applied. Critical Care (London, England)2014;18(2):R78. [MEDLINE: 24755339]">CASH 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Bleeding within 28 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Citrate: 3/66</p> <p>UFH: 10/73</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>HIT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Citrate: 0/66</p> <p>UFH: 6/73</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Citrate accumulation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Citrate: 4/66</p> <p>UFH: 0/73</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Miscellaneous</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Citrate: 1/66</p> <p>UFH: 3/73</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Alkalaemia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Citrate: 1/66</p> <p>UFH: 0/73</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hypernatraemia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Citrate: 4/66</p> <p>UFH: 3/73</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hypermagnesaemia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Citrate: 8/66</p> <p>UFH: 6/73</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p><a href="./references#CD012467-bbs2-0015" title="HetzelGR , SchmitzM , WissingH , RiesW , SchottG , HeeringPJ , et al. Regional citrate versus systemic heparin for anticoagulation in critically ill patients on continuous venovenous haemofiltration: a prospective randomized multicentre trial. Nephrology Dialysis Transplantation2011;26(1):232-9. [MEDLINE: 20876598]">Hetzel 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>HIT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Citrate: 4/87</p> <p>UFH: 8/83</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>All bleeding events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Citrate: 5/87</p> <p>UFH: 12/83</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Citrate accumulation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Citrate: 1/87</p> <p>UFH: 0/83</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p><a href="./references#CD012467-bbs2-0019" title="KutsogiannisDJ , GibneyRT , StolleryD , GaoJ . Regional citrate versus systemic heparin anticoagulation for continuous renal replacement in critically ill patients. Kidney International2005;67(6):2361-7. [MEDLINE: 15882280]">Kutsogiannis 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>All bleeding events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Citrate: 1/16</p> <p>UFH: 8/14</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Metabolic alkalosis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Citrate: 1/16</p> <p>UFH: 0/14</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hypocalcaemia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Citrate: 1/16</p> <p>UFH: 0/14</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p><a href="./references#CD012467-bbs2-0023" title="MonchiM , BerghmansD , LedouxD , CanivetJL , DuboisB , DamasP . Citrate vs. heparin for anticoagulation in continuous venovenous hemofiltration: a prospective randomized study. Intensive Care Medicine2004;30(2):260-5. [MEDLINE: 14600809]">Monchi 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>All bleeding events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Citrate: 0/26</p> <p>UFH: 1/23</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hypocalcaemia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Citrate: 1/26</p> <p>UFH: 0/23</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Alkalosis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Citrate: 1/26</p> <p>UFH: 0/23</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p><a href="./references#CD012467-bbs2-0028" title="StuckerF , PonteB , TatawJ , MartinPY , WozniakH , PuginJ , et al. Efficacy and safety of citrate-based anticoagulation compared to heparin in patients with acute kidney injury requiring continuous renal replacement therapy: a randomized controlled trial. Critical Care (London, England)2015;19(1):91. [MEDLINE: 25881975]StuckerF , PuginJ , TattawJ , PonteB , BrochardL , MartinP , et al. Citrate-based anticoagulation in patients with AKI in the intensive care unit: a safe and efficacious method [abstract no: 0379]. Intensive Care Medicine2013;39(Suppl 2):S320. [EMBASE: 71446324]">Stucker 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>All bleeding events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Citrate: 0/54</p> <p>UFH: 4/49</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>HIT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Citrate: 1/54</p> <p>UFH: 2/49</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Metabolic disorders</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Citrate: 14/54</p> <p>UFH: 3/49</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012467-bbs2-0029" title="TiranathanagulK , JearnsujitwimolO , SusantitaphongP , KijkriengkraikulN , LeelahavanichkulA , SrisawatN , et al. Regional citrate anticoagulation reduces polymorphonuclear cell degranulation in critically ill patients treated with continuous venovenous hemofiltration. Therapeutic Apheresis &amp; Dialysis2011;15(6):556-64. [MEDLINE: 22107692]">Tiranathanagul 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>All bleeding events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Citrate: 0/10</p> <p>UFH: 0/10</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>HIT‐ heparin‐induced thrombocytopenia; UFH ‐ unfractionated heparin</p> </div> </div> <div class="table" id="CD012467-tbl-0006"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Adverse events: Citrate versus UFH plus protamine</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study ID</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Adverse events</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Intervention: events/participants</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012467-bbs2-0010" title="FealyN , BaldwinI , JohnstoneM , EgiM , BellomoR . A pilot randomized controlled crossover study comparing regional heparinization to regional citrate anticoagulation for continuous venovenous hemofiltration. International Journal of Artificial Organs2007;30(4):301-7. [MEDLINE: 17520566]">Fealy 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>All bleeding events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Citrate: 0/11</p> <p>UFH: 0/11</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="10" valign=""> <p><a href="./references#CD012467-bbs2-0013" title="GattasDJ , RajbhandariD , BradfordC , BuhrH , LoS , BellomoR . A randomized controlled trial of regional citrate versus regional heparin anticoagulation for continuous renal replacement therapy in critically ill adults. Critical Care Medicine2015;43(8):1622-9. [MEDLINE: 25853591]">Gattas 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>All bleeding events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Citrate: 0/105</p> <p>UFH: 1/107</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hypercalcaemia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Citrate: 1/105</p> <p>UFH: 0/107</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Skin necrosis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Citrate: 0/105</p> <p>UFH: 1/107</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>HIT (confirmed)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Citrate: 0/105</p> <p>UFH: 2/107</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Acidosis, hypotension</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Citrate: 1/105</p> <p>UFH: 0/107</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>HIT (suspected)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Citrate: 0/105</p> <p>UFH: 3/107</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Bradycardia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Citrate: 0/105</p> <p>UFH: 1/107</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ventricular bigeminy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Citrate: 0/105</p> <p>UFH: 1/107</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ventricular fibrillation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Citrate: 0/105</p> <p>UFH: 1/107</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cardiac arrest (PEA)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Citrate: 0/105</p> <p>UFH: 1/107</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p><a href="./references#CD012467-bbs2-0011" title="BrainMJ , RoodenburgOS , AdamsN , McCrackenP , HockingsL , MusgraveS , et al. Randomised trial of software algorithm driven regional citrate anticoagulation versus heparin in continuous renal replacement therapy: the Filter Life in Renal Replacement Therapy pilot trial. Critical Care &amp; Resuscitation2014;16(2):131-7. [MEDLINE: 24888284]">FLIRRT 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Bleeding episodes requiring treatment cessation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Citrate: 0/19</p> <p>UFH: 0/11</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hypocalcaemia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Citrate: 3/19</p> <p>UFH: 0/11</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Prolonged APTT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Citrate: 0/19</p> <p>UFH: 1/11</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>APTT ‐ activated partial thromboplastin time; HIT ‐ heparin‐induced thrombocytopenia; PEA ‐ pulseless electrical activity; UFH ‐ unfractionated heparin </p> </div> </div> </section> </section> <section id="CD012467-sec-0075"> <h5 class="title">Cost to health care services</h5> <p>Due to inadequate data, it was uncertain whether UFH compared to citrate increased the cost to health care services. </p> <p><a href="http://CASH 2014" target="_blank">CASH 2014</a> reported a cost comparison of CRRT for citrate with UFH. TheÃ‚Â study reported the total cost forÃ‚Â the first 72 hours of CVVH was USD634 (ranging from 499 to 999) for citrate and USD760 (ranging from 367 to 1,511) for UFH. A cost forÃ‚Â replacement fluid was USD362 (ranging from 258 to 419) (citrate including replacement fluid) for citrate and USD491 (ranging from 136 to 843) for UFH. A costÃ‚Â for nursing staff to change filterÃ‚Â was USD22 (ranging from 22 to 109) for citrate and USD44 (ranging from 22 to 196) for UFH. A cost forÃ‚Â filter sets was USD97 (ranging from 97 to 487) for citrate and USD195 (ranging from 97 to 876) for UFH. A cost forÃ‚Â UFH was 0 for citrate and USD7.4 (ranging from 4.40 to 7.72) for UFH. A cost forÃ‚Â calcium gluconate was USD94 (ranging from 80 to 96) for citrate and 0 for UFH. </p> <p><a href="http://Fealy 2007" target="_blank">Fealy 2007</a> reported that citrate had a longer circuit lifeÃ‚Â than UFH plus protamine byÃ‚Â four hours and it would save one circuit every 54 hours (a saving of USD99). However, the citrate‐based replacement fluid and supplementation of calcium or magnesium cost higher than lactate‐based replacement fluid and UFH and protamine by USD111/day in their institute.Ã‚Â expensive in citrate than that of UFH plus protamine in their institute. As such, they suggested UFH plus protamine would save the total cost compared to citrate. </p> </section> <section id="CD012467-sec-0076"> <h5 class="title">Other outcomes</h5> <p>The following outcomes were not reported by any of the studies.</p> <p> <ul id="CD012467-list-0016"> <li> <p>Early termination with blood loss in the circuits</p> </li> <li> <p>Other adverse events (including allergic reactions, urticaria, and anaphylaxis).</p> </li> </ul> </p> </section> </section> <section id="CD012467-sec-0077"> <h4 class="title">Citrate versus low molecular weight heparin</h4> <section id="CD012467-sec-0078"> <h5 class="title">Major bleeding</h5> <p>Compared to LMWH, citrate probably reduced major bleeding (<a href="./references#CD012467-fig-0020" title="">Analysis 2.1</a>.1 (2 studies, 234 participants, 234 observations): RR 0.45, 95% CI 0.21 to 0.97; I<sup>2</sup> = 0%, moderate certainty of evidence) (<a href="./references#CD012467-bbs2-0024" title="Oudemans-van StraatenHM , BosmanRJ , KoopmansM , van derVoortPH , WesterJP , van derSpoelJI , et al. Citrate anticoagulation for continuous venovenous hemofiltration. Critical Care Medicine2009;37(2):545-52. [MEDLINE: 19114912]">Oudemans‐van Straaten 2009</a>; <a href="./references#CD012467-bbs2-0034" title="WuB , ZhangK , XuB , JiD , LiuZ , GongD . Randomized controlled trial to evaluate regional citrate anticoagulation plus low-dose of dalteparin in continuous veno-venous hemofiltration. Blood Purification2015;39(4):306-12. [MEDLINE: 26022434]ZhangK , GongD , JiD , XuB , IIuZ . Regional citrate plus low dose of low molecular weight heparins: a safe and more efficacy anticoagulation protocol for continuous veno - venous hemofiltration [abstract no: 71]. In: CCRT 2012. 17th International Conference on CRRT; 2012 Feb 14-17; San Diego (CA). 2012. [CENTRAL: CN-01658175] ">Wu 2015b</a>). </p> </section> <section id="CD012467-sec-0079"> <h5 class="title">Death</h5> <p>Data synthesis of available data (death at three months and death at an unknown time‐point) are shown in <a href="./references#CD012467-fig-0021" title="">Analysis 2.2</a> (<a href="./references#CD012467-bbs2-0024" title="Oudemans-van StraatenHM , BosmanRJ , KoopmansM , van derVoortPH , WesterJP , van derSpoelJI , et al. Citrate anticoagulation for continuous venovenous hemofiltration. Critical Care Medicine2009;37(2):545-52. [MEDLINE: 19114912]">Oudemans‐van Straaten 2009</a>; <a href="./references#CD012467-bbs2-0034" title="WuB , ZhangK , XuB , JiD , LiuZ , GongD . Randomized controlled trial to evaluate regional citrate anticoagulation plus low-dose of dalteparin in continuous veno-venous hemofiltration. Blood Purification2015;39(4):306-12. [MEDLINE: 26022434]ZhangK , GongD , JiD , XuB , IIuZ . Regional citrate plus low dose of low molecular weight heparins: a safe and more efficacy anticoagulation protocol for continuous veno - venous hemofiltration [abstract no: 71]. In: CCRT 2012. 17th International Conference on CRRT; 2012 Feb 14-17; San Diego (CA). 2012. [CENTRAL: CN-01658175] ">Wu 2015b</a>). We could not obtain the data for death at 28 days from the included studies, therefore it is uncertain whether citrate compared to LMWH reduces death at 28 days because the certainty of the evidence is very low. </p> </section> <section id="CD012467-sec-0080"> <h5 class="title">Successful prevention of clottingÃ‚Â in the first 24 hours</h5> <p>Available data for successful prevention of clotting within eight hours are shown in <a href="./references#CD012467-fig-0022" title="">Analysis 2.3</a> (<a href="./references#CD012467-bbs2-0034" title="WuB , ZhangK , XuB , JiD , LiuZ , GongD . Randomized controlled trial to evaluate regional citrate anticoagulation plus low-dose of dalteparin in continuous veno-venous hemofiltration. Blood Purification2015;39(4):306-12. [MEDLINE: 26022434]ZhangK , GongD , JiD , XuB , IIuZ . Regional citrate plus low dose of low molecular weight heparins: a safe and more efficacy anticoagulation protocol for continuous veno - venous hemofiltration [abstract no: 71]. In: CCRT 2012. 17th International Conference on CRRT; 2012 Feb 14-17; San Diego (CA). 2012. [CENTRAL: CN-01658175] ">Wu 2015b</a>). We could not obtain data on successful prevention of clotting within 24 hours from the included studies; therefore, it is uncertain whether citrate compared to LMWH makes little or no difference to successful prevention of clotting at 24 hours because the certainty of evidence was very low. </p> </section> <section id="CD012467-sec-0081"> <h5 class="title">Metabolic disturbances</h5> <p>It was uncertain whether citrate compared to LMWH leads to metabolic disturbances because the certainty of the evidence is very low (<a href="./references#CD012467-fig-0023" title="">Analysis 2.4</a>) (<a href="./references#CD012467-bbs2-0024" title="Oudemans-van StraatenHM , BosmanRJ , KoopmansM , van derVoortPH , WesterJP , van derSpoelJI , et al. Citrate anticoagulation for continuous venovenous hemofiltration. Critical Care Medicine2009;37(2):545-52. [MEDLINE: 19114912]">Oudemans‐van Straaten 2009</a>; <a href="./references#CD012467-bbs2-0034" title="WuB , ZhangK , XuB , JiD , LiuZ , GongD . Randomized controlled trial to evaluate regional citrate anticoagulation plus low-dose of dalteparin in continuous veno-venous hemofiltration. Blood Purification2015;39(4):306-12. [MEDLINE: 26022434]ZhangK , GongD , JiD , XuB , IIuZ . Regional citrate plus low dose of low molecular weight heparins: a safe and more efficacy anticoagulation protocol for continuous veno - venous hemofiltration [abstract no: 71]. In: CCRT 2012. 17th International Conference on CRRT; 2012 Feb 14-17; San Diego (CA). 2012. [CENTRAL: CN-01658175] ">Wu 2015b</a>). </p> </section> <section id="CD012467-sec-0082"> <h5 class="title">Hypernatraemia</h5> <p>It was uncertain whether citrate compared to LMWH leads to hypernatraemia because the certainty of the evidence is very low (<a href="./references#CD012467-fig-0024" title="">Analysis 2.5</a>) (<a href="./references#CD012467-bbs2-0024" title="Oudemans-van StraatenHM , BosmanRJ , KoopmansM , van derVoortPH , WesterJP , van derSpoelJI , et al. Citrate anticoagulation for continuous venovenous hemofiltration. Critical Care Medicine2009;37(2):545-52. [MEDLINE: 19114912]">Oudemans‐van Straaten 2009</a>; <a href="./references#CD012467-bbs2-0034" title="WuB , ZhangK , XuB , JiD , LiuZ , GongD . Randomized controlled trial to evaluate regional citrate anticoagulation plus low-dose of dalteparin in continuous veno-venous hemofiltration. Blood Purification2015;39(4):306-12. [MEDLINE: 26022434]ZhangK , GongD , JiD , XuB , IIuZ . Regional citrate plus low dose of low molecular weight heparins: a safe and more efficacy anticoagulation protocol for continuous veno - venous hemofiltration [abstract no: 71]. In: CCRT 2012. 17th International Conference on CRRT; 2012 Feb 14-17; San Diego (CA). 2012. [CENTRAL: CN-01658175] ">Wu 2015b</a>). </p> </section> <section id="CD012467-sec-0083"> <h5 class="title">Hypocalcaemia</h5> <p>Compared to LMWH, citrate may lead to hypocalcaemia (<a href="./references#CD012467-fig-0025" title="">Analysis 2.6</a> (2 studies, 234 participants, 234 observations): RR 3.29, 95% CI 0.81 to 13.46; low certainty of evidence) (<a href="./references#CD012467-bbs2-0024" title="Oudemans-van StraatenHM , BosmanRJ , KoopmansM , van derVoortPH , WesterJP , van derSpoelJI , et al. Citrate anticoagulation for continuous venovenous hemofiltration. Critical Care Medicine2009;37(2):545-52. [MEDLINE: 19114912]">Oudemans‐van Straaten 2009</a>; <a href="./references#CD012467-bbs2-0034" title="WuB , ZhangK , XuB , JiD , LiuZ , GongD . Randomized controlled trial to evaluate regional citrate anticoagulation plus low-dose of dalteparin in continuous veno-venous hemofiltration. Blood Purification2015;39(4):306-12. [MEDLINE: 26022434]ZhangK , GongD , JiD , XuB , IIuZ . Regional citrate plus low dose of low molecular weight heparins: a safe and more efficacy anticoagulation protocol for continuous veno - venous hemofiltration [abstract no: 71]. In: CCRT 2012. 17th International Conference on CRRT; 2012 Feb 14-17; San Diego (CA). 2012. [CENTRAL: CN-01658175] ">Wu 2015b</a>). </p> </section> <section id="CD012467-sec-0084"> <h5 class="title">Hypercalcaemia</h5> <p>Compared to LMWH, citrate may reduce hypercalcaemia (<a href="./references#CD012467-fig-0026" title="">Analysis 2.7</a> (1 study, 200 participants, 200 observations): RR 0.19, 95% CI 0.04 to 0.85, low certainty of evidence) (<a href="./references#CD012467-bbs2-0024" title="Oudemans-van StraatenHM , BosmanRJ , KoopmansM , van derVoortPH , WesterJP , van derSpoelJI , et al. Citrate anticoagulation for continuous venovenous hemofiltration. Critical Care Medicine2009;37(2):545-52. [MEDLINE: 19114912]">Oudemans‐van Straaten 2009</a>). </p> </section> <section id="CD012467-sec-0085"> <h5 class="title">Recovery of kidney function</h5> <p>It was uncertain whether citrate compared to LMWH makes little or no difference to the recovery of kidney function because the certainty of the evidence is very low (<a href="./references#CD012467-fig-0027" title="">Analysis 2.8</a>) (<a href="./references#CD012467-bbs2-0024" title="Oudemans-van StraatenHM , BosmanRJ , KoopmansM , van derVoortPH , WesterJP , van derSpoelJI , et al. Citrate anticoagulation for continuous venovenous hemofiltration. Critical Care Medicine2009;37(2):545-52. [MEDLINE: 19114912]">Oudemans‐van Straaten 2009</a>; <a href="./references#CD012467-bbs2-0034" title="WuB , ZhangK , XuB , JiD , LiuZ , GongD . Randomized controlled trial to evaluate regional citrate anticoagulation plus low-dose of dalteparin in continuous veno-venous hemofiltration. Blood Purification2015;39(4):306-12. [MEDLINE: 26022434]ZhangK , GongD , JiD , XuB , IIuZ . Regional citrate plus low dose of low molecular weight heparins: a safe and more efficacy anticoagulation protocol for continuous veno - venous hemofiltration [abstract no: 71]. In: CCRT 2012. 17th International Conference on CRRT; 2012 Feb 14-17; San Diego (CA). 2012. [CENTRAL: CN-01658175] ">Wu 2015b</a>). </p> </section> <section id="CD012467-sec-0086"> <h5 class="title">Thrombocytopenia</h5> <p>It was uncertain whether citrate compared to LMWH reduces thrombocytopenia because the certainty of the evidence is very low (<a href="./references#CD012467-fig-0028" title="">Analysis 2.9</a>) (<a href="./references#CD012467-bbs2-0024" title="Oudemans-van StraatenHM , BosmanRJ , KoopmansM , van derVoortPH , WesterJP , van derSpoelJI , et al. Citrate anticoagulation for continuous venovenous hemofiltration. Critical Care Medicine2009;37(2):545-52. [MEDLINE: 19114912]">Oudemans‐van Straaten 2009</a>) (<a href="#CD012467-tbl-0004">Table 1</a>). </p> <p><a href="./references#CD012467-bbs2-0034" title="WuB , ZhangK , XuB , JiD , LiuZ , GongD . Randomized controlled trial to evaluate regional citrate anticoagulation plus low-dose of dalteparin in continuous veno-venous hemofiltration. Blood Purification2015;39(4):306-12. [MEDLINE: 26022434]ZhangK , GongD , JiD , XuB , IIuZ . Regional citrate plus low dose of low molecular weight heparins: a safe and more efficacy anticoagulation protocol for continuous veno - venous hemofiltration [abstract no: 71]. In: CCRT 2012. 17th International Conference on CRRT; 2012 Feb 14-17; San Diego (CA). 2012. [CENTRAL: CN-01658175] ">Wu 2015b</a> reported that no cases of HIT. </p> <p>No study reported the detailedÃ‚Â platelet counts or the averageÃ‚Â of platelet counts in patients with thrombocytopenia.Ã‚Â  </p> </section> <section id="CD012467-sec-0087"> <h5 class="title">Adverse events</h5> <section id="CD012467-sec-0088"> <h6 class="title">Number of treatment cessations due to any adverse events (technique or patient‐dependent factors) </h6> <p>Compared to LMWH, citrate may reduce dropouts from treatment due to adverse events in the citrate group (<a href="./references#CD012467-fig-0029" title="">Analysis 2.10</a> (2 studies, 234 participants, 234 observations): RR 0.11, 95% CI 0.03 to 0.44, low certainty of evidence) (<a href="./references#CD012467-bbs2-0024" title="Oudemans-van StraatenHM , BosmanRJ , KoopmansM , van derVoortPH , WesterJP , van derSpoelJI , et al. Citrate anticoagulation for continuous venovenous hemofiltration. Critical Care Medicine2009;37(2):545-52. [MEDLINE: 19114912]">Oudemans‐van Straaten 2009</a>). <a href="./references#CD012467-bbs2-0034" title="WuB , ZhangK , XuB , JiD , LiuZ , GongD . Randomized controlled trial to evaluate regional citrate anticoagulation plus low-dose of dalteparin in continuous veno-venous hemofiltration. Blood Purification2015;39(4):306-12. [MEDLINE: 26022434]ZhangK , GongD , JiD , XuB , IIuZ . Regional citrate plus low dose of low molecular weight heparins: a safe and more efficacy anticoagulation protocol for continuous veno - venous hemofiltration [abstract no: 71]. In: CCRT 2012. 17th International Conference on CRRT; 2012 Feb 14-17; San Diego (CA). 2012. [CENTRAL: CN-01658175] ">Wu 2015b</a> reported there were no dropouts due to adverse events. </p> </section> </section> <section id="CD012467-sec-0089"> <h5 class="title">Number of treatment attempts with adverse events (technique or patient‐dependent factors)</h5> <p>We could not analyse this outcome due to inadequate reporting of adverse events.</p> <section id="CD012467-sec-0090"> <h6 class="title">Numbers of patients with any adverse events</h6> <p>The number of patients who experienced any adverse events is tabulated in <a href="#CD012467-tbl-0007">Table 4</a>. </p> <div class="table" id="CD012467-tbl-0007"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Adverse events: Citrate versus LMWH</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study ID</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Adverse events</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Intervention: events/participants</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012467-bbs2-0024" title="Oudemans-van StraatenHM , BosmanRJ , KoopmansM , van derVoortPH , WesterJP , van derSpoelJI , et al. Citrate anticoagulation for continuous venovenous hemofiltration. Critical Care Medicine2009;37(2):545-52. [MEDLINE: 19114912]">Oudemans‐van Straaten 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adverse events needing discontinuation of study anticoagulation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Citrate: 2/97</p> <p>LMWH: 20/103</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p><a href="./references#CD012467-bbs2-0034" title="WuB , ZhangK , XuB , JiD , LiuZ , GongD . Randomized controlled trial to evaluate regional citrate anticoagulation plus low-dose of dalteparin in continuous veno-venous hemofiltration. Blood Purification2015;39(4):306-12. [MEDLINE: 26022434]ZhangK , GongD , JiD , XuB , IIuZ . Regional citrate plus low dose of low molecular weight heparins: a safe and more efficacy anticoagulation protocol for continuous veno - venous hemofiltration [abstract no: 71]. In: CCRT 2012. 17th International Conference on CRRT; 2012 Feb 14-17; San Diego (CA). 2012. [CENTRAL: CN-01658175] ">Wu 2015b</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Bleeding</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Citrate: 2/15</p> <p>LMWH: 4/19</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hypocalcaemia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Citrate: 1/15</p> <p>LMWH: 0/19</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Metabolic acidosis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Citrate: 3/15</p> <p>LMWH: 0/19</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Severe metabolic acidosis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Citrate: 1/15</p> <p>LMWH: 0/19</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>LMWH ‐ low molecular weight heparin</p> </div> </div> </section> </section> <section id="CD012467-sec-0091"> <h5 class="title">Cost to health care services</h5> <p><a href="./references#CD012467-bbs2-0034" title="WuB , ZhangK , XuB , JiD , LiuZ , GongD . Randomized controlled trial to evaluate regional citrate anticoagulation plus low-dose of dalteparin in continuous veno-venous hemofiltration. Blood Purification2015;39(4):306-12. [MEDLINE: 26022434]ZhangK , GongD , JiD , XuB , IIuZ . Regional citrate plus low dose of low molecular weight heparins: a safe and more efficacy anticoagulation protocol for continuous veno - venous hemofiltration [abstract no: 71]. In: CCRT 2012. 17th International Conference on CRRT; 2012 Feb 14-17; San Diego (CA). 2012. [CENTRAL: CN-01658175] ">Wu 2015b</a> reported the mean cost of CRRT/patient/ day was USD601 Ã‚Â± 118 for the citrate group and USD594 Ã‚Â± 116 for LMWH group; however, the detailed method of the calculation was not clear. </p> </section> <section id="CD012467-sec-0092"> <h5 class="title">Other outcomes</h5> <p>The following outcomes were not reported.</p> <p> <ul id="CD012467-list-0017"> <li> <p>Early termination with blood loss in the circuits</p> </li> <li> <p>Catheter thrombotic events</p> </li> <li> <p>Adverse events (including allergic reactions, urticaria, and anaphylaxis).</p> </li> </ul> </p> </section> </section> <section id="CD012467-sec-0093"> <h4 class="title">Unfractionated heparin versus low molecular weight heparin</h4> <section id="CD012467-sec-0094"> <h5 class="title">Major bleeding</h5> <p>Compared to LMWH, UFH may reduce major bleeding (<a href="./references#CD012467-fig-0030" title="">Analysis 3.1</a>; <a href="#CD012467-fig-0007">Figure 7</a> (5 studies, 153 participants, 233 observations): RR 0.58, 95% CI 0.13 to 2.58; I<sup>2</sup> = 45%, low certainty of evidence) (<a href="./references#CD012467-bbs2-0016" title="JoannidisM , KountchevJ , GroteA , BellmanR , WiedermannCJ . Unfractioned versus low-molecular-weight heparin for anticoagulation in hemofiltration [abstract no: SU-PO880]. Journal of the American Society of Nephrology2003;14(Nov):728-9A. [CENTRAL: CN-00583249] JoannidisM , KountchevJ , RauchenzaunerM , SchusterschitzN , UlmerH , MayrA , et al. Enoxaparin vs. unfractionated heparin for anticoagulation during continuous veno-venous hemofiltration: a randomized controlled crossover study. Intensive Care Medicine2007;33(9):1571-9. [MEDLINE: 17563874]KountchevJ , GroteA , BellmannR , WiedermannC , JoannidisM . Unfractioned versus low-molecular-weight heparin (enoxaparin) for anticoagulation in CVVH [abstract no: MP459]. In: 41st Congress. European Renal Association. European Dialysis and Transplantation Association; 2004 May 15-18; Lisbon, Portugal. 2004:384. [CENTRAL: CN-00509287] ">Joannidis 2007</a>; <a href="./references#CD012467-bbs2-0026" title="ReevesJH , CummingAR , GallagherL , O'BrienJL , SantamariaJD . A controlled trial of low-molecular-weight heparin (dalteparin) versus unfractionated heparin as anticoagulant during continuous venovenous hemodialysis with filtration. Critical Care Medicine1999;27(10):2224-8. [MEDLINE: 10548211]">Reeves 1999</a>; <a href="./references#CD012467-bbs2-0027" title="ReevesJH , GraanM . Randomised controlled trial: enoxaparin versus heparin in continuous renal replacement therapy [abstract no: 41]. Blood Purification2003;21(2):203. [CENTRAL: CN-00757740] ">Reeves 2003</a>; <a href="./references#CD012467-bbs2-0033" title="VictorinoJA , OteroE , RohsigL , DornellesE , LouzadaM , StifftJ , et al. Low molecular weight heparin (LMWH) versus non-fractionated heparin (NFH) as anticoagulation system in continuous veno-veno hemodialysis (CVVH) in patients with acute renal (ARF) and respiratory failure (RF) [abstract no: 128]. In: American Thoracic Society International Conference; 2007 May 18-23; San Francisco (CA). 2007. [CENTRAL: CN-00645386] ">Victorino 2007</a>). In <a href="./references#CD012467-bbs2-0012" title="GarcesEO , VictorinoJA , ThomeFS , RohsigLM , DornellesE , LouzadaM , et al. Enoxaparin versus unfractioned heparin as anticoagulant for continuous venovenous hemodialysis: a randomized open-label trial. Renal Failure2010;32(3):320-7. [MEDLINE: 20370447]">Garces 2010</a> no participants experienced major bleeding defined as a fatal haemorrhagic event, bleeding in a critical organ such as intracranial, intra‐abdominal or pulmonary, or the need for transfusion of two or more units of packed red blood cells; however, five participants in the LMWH group experienced a minor bleeding episode (oozing or frank haemorrhage clinically detected in the mucosa of the mouth or nose, or around the tracheal tube, arterial lines, venous catheters, and in postoperative wounds). <a href="./references#CD012467-bbs2-0031" title="vanDoornKJ , HubloueI , VerbeelenD . Urea exchange efficacy during unfractionated heparin anticoagulation versus low molecular weight heparin (dalteparin) anticoagulation in continuous veno-venous hemofiltration [abstract]. In: 41st Congress. European Renal Association. European Dialysis and Transplantation Association; 2004 May 15-18; Lisbon, Portugal. 2004:384. [CENTRAL: CN-00509250] vanDoornKJ , HubloueI , VerbeelenD . Urea exchange efficacy during unfractionated heparin anticoagulation versus low molecular weight heparin (dalteparin) anticoagulation in continuous veno-venous hemofiltration [abstract no: 33]. Blood Purification2004;22(2):243. [CENTRAL: CN-01658168] ">van Doorn 2004</a> did not report the number of major bleeding episodes. For <a href="./references#CD012467-bbs2-0033" title="VictorinoJA , OteroE , RohsigL , DornellesE , LouzadaM , StifftJ , et al. Low molecular weight heparin (LMWH) versus non-fractionated heparin (NFH) as anticoagulation system in continuous veno-veno hemodialysis (CVVH) in patients with acute renal (ARF) and respiratory failure (RF) [abstract no: 128]. In: American Thoracic Society International Conference; 2007 May 18-23; San Francisco (CA). 2007. [CENTRAL: CN-00645386] ">Victorino 2007</a>, only the proportion of the participants with bleeding were reported, and we estimated the number of bleeding participants by integer estimation of bleeding participants (26.3% versus 0% of around 20 participants). </p> <div class="figure" id="CD012467-fig-0007"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 7</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 3 UFH versus LMWH, outcome: 3.1 Major bleeding." data-id="CD012467-fig-0007" src="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/image_n/nCD012467-FIG-07.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 3 UFH versus LMWH, outcome: 3.1 Major bleeding.</p> </div> </div> </div> </section> <section id="CD012467-sec-0095"> <h5 class="title">Death at 28 days</h5> <p>No study reported death at 28 days and we used the death during the study period for <a href="./references#CD012467-fig-0031" title="">Analysis 3.2</a>. It is uncertain whether UFH compared to LMWH reduces death at 28 days because the certainty of the evidence is very low. </p> </section> <section id="CD012467-sec-0096"> <h5 class="title">Successful prevention of clottingÃ‚Â in the first 24 hours</h5> <p>It is uncertain whether UFH compare to LMWH leads to successful prevention of clotting (<a href="./references#CD012467-fig-0032" title="">Analysis 3.3</a>) because the certainty of the evidence is very low. </p> </section> <section id="CD012467-sec-0097"> <h5 class="title">Thrombocytopenia</h5> <p>It was uncertain whether UFH compared to LMWH leads to thrombocytopenia (<a href="./references#CD012467-fig-0033" title="">Analysis 3.4</a>) because the certainty of the evidence is very low. <a href="./references#CD012467-bbs2-0026" title="ReevesJH , CummingAR , GallagherL , O'BrienJL , SantamariaJD . A controlled trial of low-molecular-weight heparin (dalteparin) versus unfractionated heparin as anticoagulant during continuous venovenous hemodialysis with filtration. Critical Care Medicine1999;27(10):2224-8. [MEDLINE: 10548211]">Reeves 1999</a> reported the event of thrombocytopenia (47 participants, RR 0.57, 95% CI 0.20 to 1.63). <a href="./references#CD012467-bbs2-0016" title="JoannidisM , KountchevJ , GroteA , BellmanR , WiedermannCJ . Unfractioned versus low-molecular-weight heparin for anticoagulation in hemofiltration [abstract no: SU-PO880]. Journal of the American Society of Nephrology2003;14(Nov):728-9A. [CENTRAL: CN-00583249] JoannidisM , KountchevJ , RauchenzaunerM , SchusterschitzN , UlmerH , MayrA , et al. Enoxaparin vs. unfractionated heparin for anticoagulation during continuous veno-venous hemofiltration: a randomized controlled crossover study. Intensive Care Medicine2007;33(9):1571-9. [MEDLINE: 17563874]KountchevJ , GroteA , BellmannR , WiedermannC , JoannidisM . Unfractioned versus low-molecular-weight heparin (enoxaparin) for anticoagulation in CVVH [abstract no: MP459]. In: 41st Congress. European Renal Association. European Dialysis and Transplantation Association; 2004 May 15-18; Lisbon, Portugal. 2004:384. [CENTRAL: CN-00509287] ">Joannidis 2007</a> reported no participants experienced thrombocytopenia during the randomised cross‐over study period. <a href="./references#CD012467-bbs2-0012" title="GarcesEO , VictorinoJA , ThomeFS , RohsigLM , DornellesE , LouzadaM , et al. Enoxaparin versus unfractioned heparin as anticoagulant for continuous venovenous hemodialysis: a randomized open-label trial. Renal Failure2010;32(3):320-7. [MEDLINE: 20370447]">Garces 2010</a> reported the proportion of thrombocytopenia with unclear denominator and we could not estimate the number of patients who experienced thrombocytopenia (<a href="#CD012467-tbl-0004">Table 1</a>). </p> <p><a href="./references#CD012467-bbs2-0026" title="ReevesJH , CummingAR , GallagherL , O'BrienJL , SantamariaJD . A controlled trial of low-molecular-weight heparin (dalteparin) versus unfractionated heparin as anticoagulant during continuous venovenous hemodialysis with filtration. Critical Care Medicine1999;27(10):2224-8. [MEDLINE: 10548211]">Reeves 1999</a> reported one HIT patients from four thrombocytopenia patients in a total of UFH 22 patients and threeÃ‚Â HIT patients from eightÃ‚Â thrombocytopenia patients in a total of LMWH 25Ã‚Â patients. </p> <p>No study reported the detailedÃ‚Â platelet counts or the averageÃ‚Â of platelet counts in patients with thrombocytopenia.Ã‚Â  </p> </section> <section id="CD012467-sec-0098"> <h5 class="title">Adverse events</h5> <section id="CD012467-sec-0099"> <h6 class="title">Number of patients who dropped out of treatment because of adverse events (technique or patient‐dependent factors) </h6> <p>Compared to LMWH, UFH may reduce the number of patients who dropped out of treatment because of adverse events (<a href="./references#CD012467-fig-0034" title="">Analysis 3.5</a> (2 studies, 77 patients, 117 observations): RR 0.29, 95% CI 0.02 to 3.53; low certainty evidence). </p> <p>One cross‐over RCT (<a href="./references#CD012467-bbs2-0016" title="JoannidisM , KountchevJ , GroteA , BellmanR , WiedermannCJ . Unfractioned versus low-molecular-weight heparin for anticoagulation in hemofiltration [abstract no: SU-PO880]. Journal of the American Society of Nephrology2003;14(Nov):728-9A. [CENTRAL: CN-00583249] JoannidisM , KountchevJ , RauchenzaunerM , SchusterschitzN , UlmerH , MayrA , et al. Enoxaparin vs. unfractionated heparin for anticoagulation during continuous veno-venous hemofiltration: a randomized controlled crossover study. Intensive Care Medicine2007;33(9):1571-9. [MEDLINE: 17563874]KountchevJ , GroteA , BellmannR , WiedermannC , JoannidisM . Unfractioned versus low-molecular-weight heparin (enoxaparin) for anticoagulation in CVVH [abstract no: MP459]. In: 41st Congress. European Renal Association. European Dialysis and Transplantation Association; 2004 May 15-18; Lisbon, Portugal. 2004:384. [CENTRAL: CN-00509287] ">Joannidis 2007</a>) reported 1/38 patients dropped out due to a major bleeding episode from the UFH group and 1/39 patients dropped out from the LMWH group. <a href="./references#CD012467-bbs2-0012" title="GarcesEO , VictorinoJA , ThomeFS , RohsigLM , DornellesE , LouzadaM , et al. Enoxaparin versus unfractioned heparin as anticoagulant for continuous venovenous hemodialysis: a randomized open-label trial. Renal Failure2010;32(3):320-7. [MEDLINE: 20370447]">Garces 2010</a> reported 5/19 patients from the LMWH group had minor bleeding and anticoagulation was stopped. </p> </section> <section id="CD012467-sec-0100"> <h6 class="title">Number of treatment attempts with adverse events (technique or patient‐dependent factors)</h6> <p>It was uncertain whether UFH compared to LMWH makes little or no difference to the number of treatment attempts with adverse events (<a href="./references#CD012467-fig-0035" title="">Analysis 3.6</a>) because the certainty of the evidence is very low. </p> <p>One cross‐over RCT reported 1/38 patients dropped out due to major bleeding episode and there was one minor bleeding episode in the UFH group and 1/39 patients dropped out due to major bleeding episode and there was one minor bleeding episode in the LMWH group (<a href="./references#CD012467-bbs2-0016" title="JoannidisM , KountchevJ , GroteA , BellmanR , WiedermannCJ . Unfractioned versus low-molecular-weight heparin for anticoagulation in hemofiltration [abstract no: SU-PO880]. Journal of the American Society of Nephrology2003;14(Nov):728-9A. [CENTRAL: CN-00583249] JoannidisM , KountchevJ , RauchenzaunerM , SchusterschitzN , UlmerH , MayrA , et al. Enoxaparin vs. unfractionated heparin for anticoagulation during continuous veno-venous hemofiltration: a randomized controlled crossover study. Intensive Care Medicine2007;33(9):1571-9. [MEDLINE: 17563874]KountchevJ , GroteA , BellmannR , WiedermannC , JoannidisM . Unfractioned versus low-molecular-weight heparin (enoxaparin) for anticoagulation in CVVH [abstract no: MP459]. In: 41st Congress. European Renal Association. European Dialysis and Transplantation Association; 2004 May 15-18; Lisbon, Portugal. 2004:384. [CENTRAL: CN-00509287] ">Joannidis 2007</a>). </p> </section> <section id="CD012467-sec-0101"> <h6 class="title">Number of patients with any adverse events</h6> <p>The number of patients who experienced any adverse events is tabulated in <a href="#CD012467-tbl-0008">Table 5</a>. </p> <div class="table" id="CD012467-tbl-0008"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Adverse events: LMWH versus UFH</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study ID</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Adverse events</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Intervention: events/participants</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012467-bbs2-0012" title="GarcesEO , VictorinoJA , ThomeFS , RohsigLM , DornellesE , LouzadaM , et al. Enoxaparin versus unfractioned heparin as anticoagulant for continuous venovenous hemodialysis: a randomized open-label trial. Renal Failure2010;32(3):320-7. [MEDLINE: 20370447]">Garces 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Bleeding</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>LMWH: 5/19</p> <p>UFH: 0/21</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><a href="./references#CD012467-bbs2-0016" title="JoannidisM , KountchevJ , GroteA , BellmanR , WiedermannCJ . Unfractioned versus low-molecular-weight heparin for anticoagulation in hemofiltration [abstract no: SU-PO880]. Journal of the American Society of Nephrology2003;14(Nov):728-9A. [CENTRAL: CN-00583249] JoannidisM , KountchevJ , RauchenzaunerM , SchusterschitzN , UlmerH , MayrA , et al. Enoxaparin vs. unfractionated heparin for anticoagulation during continuous veno-venous hemofiltration: a randomized controlled crossover study. Intensive Care Medicine2007;33(9):1571-9. [MEDLINE: 17563874]KountchevJ , GroteA , BellmannR , WiedermannC , JoannidisM . Unfractioned versus low-molecular-weight heparin (enoxaparin) for anticoagulation in CVVH [abstract no: MP459]. In: 41st Congress. European Renal Association. European Dialysis and Transplantation Association; 2004 May 15-18; Lisbon, Portugal. 2004:384. [CENTRAL: CN-00509287] ">Joannidis 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>All bleeding events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>LMWH: 2/37</p> <p>UFH: 2/37</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>HIT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>LMWH: 0/37</p> <p>UFH: 0/37</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p><a href="./references#CD012467-bbs2-0026" title="ReevesJH , CummingAR , GallagherL , O'BrienJL , SantamariaJD . A controlled trial of low-molecular-weight heparin (dalteparin) versus unfractionated heparin as anticoagulant during continuous venovenous hemodialysis with filtration. Critical Care Medicine1999;27(10):2224-8. [MEDLINE: 10548211]">Reeves 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Significant bleeding events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>LMWH: 2/25</p> <p>UFH: 4/22</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Trivial bleeding events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>LMWH: 3/25</p> <p>UFH: 3/22</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>HIT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>LMWH: 3/25</p> <p>UFH: 1/22</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012467-bbs2-0027" title="ReevesJH , GraanM . Randomised controlled trial: enoxaparin versus heparin in continuous renal replacement therapy [abstract no: 41]. Blood Purification2003;21(2):203. [CENTRAL: CN-00757740] ">Reeves 2003</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Major bleeding</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>LMWH: 1/15</p> <p>UFH: 4/14</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012467-bbs2-0031" title="vanDoornKJ , HubloueI , VerbeelenD . Urea exchange efficacy during unfractionated heparin anticoagulation versus low molecular weight heparin (dalteparin) anticoagulation in continuous veno-venous hemofiltration [abstract]. In: 41st Congress. European Renal Association. European Dialysis and Transplantation Association; 2004 May 15-18; Lisbon, Portugal. 2004:384. [CENTRAL: CN-00509250] vanDoornKJ , HubloueI , VerbeelenD . Urea exchange efficacy during unfractionated heparin anticoagulation versus low molecular weight heparin (dalteparin) anticoagulation in continuous veno-venous hemofiltration [abstract no: 33]. Blood Purification2004;22(2):243. [CENTRAL: CN-01658168] ">van Doorn 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No adverse events reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012467-bbs2-0033" title="VictorinoJA , OteroE , RohsigL , DornellesE , LouzadaM , StifftJ , et al. Low molecular weight heparin (LMWH) versus non-fractionated heparin (NFH) as anticoagulation system in continuous veno-veno hemodialysis (CVVH) in patients with acute renal (ARF) and respiratory failure (RF) [abstract no: 128]. In: American Thoracic Society International Conference; 2007 May 18-23; San Francisco (CA). 2007. [CENTRAL: CN-00645386] ">Victorino 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clinical bleeding</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>LMWH: 0/21</p> <p>UFH: 5/19</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>HIT ‐ heparin‐induced thrombocytopenia; LMWH ‐ low molecular weight heparin; UFH ‐ unfractionated heparin </p> </div> </div> </section> </section> <section id="CD012467-sec-0102"> <h5 class="title">Cost to health care services</h5> <p>It was uncertain whether LMWH increases the total cost to health care services because of inadequate data. <a href="http://Reeves 1999" target="_blank">Reeves 1999</a> reported the total daily cost of CRRT was USD18 more with LMWH than with UFH, and HF with the automatic system cost USD29 more per day than with the manual system, irrespective of the anticoagulant. </p> </section> <section id="CD012467-sec-0103"> <h5 class="title">Other outcomes</h5> <p>No other outcomes were reported for this comparison.</p> </section> </section> <section id="CD012467-sec-0104"> <h4 class="title">Unfractionated heparin versus no pharmacological anticoagulation</h4> <section id="CD012467-sec-0105"> <h5 class="title">Major bleeding</h5> <p>It is uncertain whether UFH reduces major bleeding because the certainty of the evidence is very low (<a href="./references#CD012467-fig-0036" title="">Analysis 4.1</a>) (<a href="./references#CD012467-bbs2-0002" title="BellomoR , TeedeH , BoyceN . Anticoagulant regimens in acute continuous hemodiafiltration: a comparative study. Intensive Care Medicine1993;19(6):329-32. [MEDLINE: 8227722]">Bellomo 1993</a>). </p> </section> <section id="CD012467-sec-0106"> <h5 class="title">Other outcomes</h5> <p>No other outcomes were reported for this comparison.</p> </section> </section> <section id="CD012467-sec-0107"> <h4 class="title">Unfractionated heparin plus protamine versus unfractionated heparin</h4> <section id="CD012467-sec-0108"> <h5 class="title">Major bleeding</h5> <p><a href="./references#CD012467-bbs2-0002" title="BellomoR , TeedeH , BoyceN . Anticoagulant regimens in acute continuous hemodiafiltration: a comparative study. Intensive Care Medicine1993;19(6):329-32. [MEDLINE: 8227722]">Bellomo 1993</a> reported no major bleeding occurred in the groups comparing UFH to UFH plus protamine in their cross‐over RCT (total of 54 patients with unclear allocation ratio). </p> </section> <section id="CD012467-sec-0109"> <h5 class="title">Other outcomes</h5> <p>No other outcomes were reported for this comparison.</p> </section> </section> <section id="CD012467-sec-0110"> <h4 class="title">Nafamostat mesilate versus no anticoagulation</h4> <section id="CD012467-sec-0111"> <h5 class="title">Major bleeding</h5> <p>Compared to no pharmacological anticoagulation, nafamostat mesilate may lead to slightly more major bleeding (<a href="./references#CD012467-fig-0037" title="">Analysis 5.1</a> (2 studies, 115 participants, 115 observations): RR 1.06, 95% CI 0.37 to 3.04; I<sup>2</sup> = 0%, low certainty of evidence) (<a href="./references#CD012467-bbs2-0006" title="ChoiJY , KangYJ , JangHM , JungHY , ChoJH , ParkSH , et al. Nafamostat mesilate as an anticoagulant during continuous renal replacement therapy in patients with high bleeding risk: a randomized clinical trial. Medicine2015;94(52):e2392. [MEDLINE: 26717390]">Choi 2015</a>; <a href="./references#CD012467-bbs2-0021" title="LeeYK , LeeHW , ChoiKH , KimBS . Ability of nafamostat mesilate to prolong filter patency during continuous renal replacement therapy in patients at high risk of bleeding: a randomized controlled study. PLoS ONE [Electronic Resource]2014;9(10):e108737. [MEDLINE: 25302581]LeeYK , LeeHW , ChoiKH , KimBS . The effect of nafamostat mesilate in prolonging filter patency with patients on continuous renal replacement therapy [abstract no: MP403]. Nephrology Dialysis Transplantation2013;28(Suppl 1):i425. [EMBASE: 71076312]">Lee 2014b</a>). </p> </section> <section id="CD012467-sec-0112"> <h5 class="title">Death at 28 days</h5> <p>Compared to no pharmacological anticoagulation, nafamostat mesilate may make little or no difference to death at 28 days (<a href="./references#CD012467-fig-0038" title="">Analysis 5.2</a>) (2 studies, 133 participants, 133 observations): RR 1.00, 95% CI 0.72 to 1.41; I<sup>2</sup> = 46%, low certainty of evidence) (<a href="./references#CD012467-bbs2-0006" title="ChoiJY , KangYJ , JangHM , JungHY , ChoJH , ParkSH , et al. Nafamostat mesilate as an anticoagulant during continuous renal replacement therapy in patients with high bleeding risk: a randomized clinical trial. Medicine2015;94(52):e2392. [MEDLINE: 26717390]">Choi 2015</a>; <a href="./references#CD012467-bbs2-0021" title="LeeYK , LeeHW , ChoiKH , KimBS . Ability of nafamostat mesilate to prolong filter patency during continuous renal replacement therapy in patients at high risk of bleeding: a randomized controlled study. PLoS ONE [Electronic Resource]2014;9(10):e108737. [MEDLINE: 25302581]LeeYK , LeeHW , ChoiKH , KimBS . The effect of nafamostat mesilate in prolonging filter patency with patients on continuous renal replacement therapy [abstract no: MP403]. Nephrology Dialysis Transplantation2013;28(Suppl 1):i425. [EMBASE: 71076312]">Lee 2014b</a>). <a href="./references#CD012467-bbs2-0006" title="ChoiJY , KangYJ , JangHM , JungHY , ChoJH , ParkSH , et al. Nafamostat mesilate as an anticoagulant during continuous renal replacement therapy in patients with high bleeding risk: a randomized clinical trial. Medicine2015;94(52):e2392. [MEDLINE: 26717390]">Choi 2015</a> reported death at various time points including 30 days; however, we could not estimate the number of survival patients and the denominator according to the reported data. Therefore, we used the in‐hospital death for the analysis (missing data due to the withdrawal of the informed consent by five patients from the nafamostat mesilate group were analysed as survival patients). In addition, we performed a sensitivity analysis of the case if the five patients had not survived. The direction of the intervention was not changed in the sensitivity analysis. </p> </section> <section id="CD012467-sec-0113"> <h5 class="title">Recovery of kidney function</h5> <p>It was uncertain whether Nafamostat mesilate compared to no anticoagulation leads to the recovery of kidney function (<a href="./references#CD012467-fig-0039" title="">Analysis 5.3</a>) because the certainty of the evidence is very low (<a href="./references#CD012467-bbs2-0006" title="ChoiJY , KangYJ , JangHM , JungHY , ChoJH , ParkSH , et al. Nafamostat mesilate as an anticoagulant during continuous renal replacement therapy in patients with high bleeding risk: a randomized clinical trial. Medicine2015;94(52):e2392. [MEDLINE: 26717390]">Choi 2015</a>). </p> </section> <section id="CD012467-sec-0114"> <h5 class="title">Catheter thrombotic event</h5> <p>It was uncertain whether nafamostat mesilate compared to no anticoagulation leads to catheter thrombotic events (<a href="./references#CD012467-fig-0040" title="">Analysis 5.4</a>) because the certainty of the evidence is very low (<a href="./references#CD012467-bbs2-0006" title="ChoiJY , KangYJ , JangHM , JungHY , ChoJH , ParkSH , et al. Nafamostat mesilate as an anticoagulant during continuous renal replacement therapy in patients with high bleeding risk: a randomized clinical trial. Medicine2015;94(52):e2392. [MEDLINE: 26717390]">Choi 2015</a>). </p> </section> <section id="CD012467-sec-0115"> <h5 class="title">Adverse events</h5> <section id="CD012467-sec-0116"> <h6 class="title">Number of treatment cessations due to any adverse events (technique or patient‐dependent factors) </h6> <p>It was uncertain whether nafamostat mesilate compared to no anticoagulation leads to treatment cessations due to any adverse events (<a href="./references#CD012467-fig-0041" title="">Analysis 5.5</a>) because the certainty of the evidence is very low (<a href="./references#CD012467-bbs2-0006" title="ChoiJY , KangYJ , JangHM , JungHY , ChoJH , ParkSH , et al. Nafamostat mesilate as an anticoagulant during continuous renal replacement therapy in patients with high bleeding risk: a randomized clinical trial. Medicine2015;94(52):e2392. [MEDLINE: 26717390]">Choi 2015</a>). </p> </section> <section id="CD012467-sec-0117"> <h6 class="title">Number of treatment attempts with adverse events (technique or patient‐dependent factors)</h6> <p>Compared to no pharmacological anticoagulation, nafamostat mesilate may lead to slightly more adverse events (<a href="./references#CD012467-fig-0042" title="">Analysis 5.6</a> (2 studies, 128 participants, 128 observations): RR 1.09Ã‚Â 95% CI 0.58 to 2.02; I<sup>2</sup> = 0%, low certainty of evidence) (<a href="./references#CD012467-bbs2-0006" title="ChoiJY , KangYJ , JangHM , JungHY , ChoJH , ParkSH , et al. Nafamostat mesilate as an anticoagulant during continuous renal replacement therapy in patients with high bleeding risk: a randomized clinical trial. Medicine2015;94(52):e2392. [MEDLINE: 26717390]">Choi 2015</a>; <a href="./references#CD012467-bbs2-0021" title="LeeYK , LeeHW , ChoiKH , KimBS . Ability of nafamostat mesilate to prolong filter patency during continuous renal replacement therapy in patients at high risk of bleeding: a randomized controlled study. PLoS ONE [Electronic Resource]2014;9(10):e108737. [MEDLINE: 25302581]LeeYK , LeeHW , ChoiKH , KimBS . The effect of nafamostat mesilate in prolonging filter patency with patients on continuous renal replacement therapy [abstract no: MP403]. Nephrology Dialysis Transplantation2013;28(Suppl 1):i425. [EMBASE: 71076312]">Lee 2014b</a>). </p> <section id="CD012467-sec-0118"> <p><b>Number of patients with any adverse events</b></p> <p>The number of patients who experienced any adverse events is tabulated in <a href="#CD012467-tbl-0009">Table 6</a>. </p> <div class="table" id="CD012467-tbl-0009"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">Adverse events: Nafamostat mesilate versus no anticoagulation</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study ID</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Adverse events</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Intervention: events/participants</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012467-bbs2-0006" title="ChoiJY , KangYJ , JangHM , JungHY , ChoJH , ParkSH , et al. Nafamostat mesilate as an anticoagulant during continuous renal replacement therapy in patients with high bleeding risk: a randomized clinical trial. Medicine2015;94(52):e2392. [MEDLINE: 26717390]">Choi 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>GI bleeding</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nafamostat mesilate: 2/31</p> <p>No anticoagulation: 0/24</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="8" valign=""> <p><a href="./references#CD012467-bbs2-0021" title="LeeYK , LeeHW , ChoiKH , KimBS . Ability of nafamostat mesilate to prolong filter patency during continuous renal replacement therapy in patients at high risk of bleeding: a randomized controlled study. PLoS ONE [Electronic Resource]2014;9(10):e108737. [MEDLINE: 25302581]LeeYK , LeeHW , ChoiKH , KimBS . The effect of nafamostat mesilate in prolonging filter patency with patients on continuous renal replacement therapy [abstract no: MP403]. Nephrology Dialysis Transplantation2013;28(Suppl 1):i425. [EMBASE: 71076312]">Lee 2014b</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>All adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nafamostat mesilate: 33/36</p> <p>No anticoagulation: 33/37</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Grade 1 pulmonary haemorrhage</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nafamostat mesilate: 1/36</p> <p>No anticoagulation: 0/37</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Grade 1 GI bleeding</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nafamostat mesilate: 0/36</p> <p>No anticoagulation: 1/37</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Grade 2 GI bleeding</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nafamostat mesilate: 0/36</p> <p>No anticoagulation: 2/37</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Grade 4 GI bleeding</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nafamostat mesilate: 1/36</p> <p>No anticoagulation: 0/37</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Grade 1 vaginal bleeding</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nafamostat mesilate: 1/36</p> <p>No anticoagulation: 0/37</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Variceal bleeding</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nafamostat mesilate: 0/36</p> <p>No anticoagulation: 1/37</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Catheter insertion site oozing</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nafamostat mesilate: 0/36</p> <p>No anticoagulation: 1/37</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>GI ‐ gastrointestinal</p> </div> </div> </section> </section> </section> <section id="CD012467-sec-0119"> <h5 class="title">Other outcomes</h5> <p>No other outcomes were reported for this comparison.</p> </section> </section> <section id="CD012467-sec-0120"> <h4 class="title">Prostaglandin I<sub>2</sub> versus unfractionated heparin </h4> <section id="CD012467-sec-0121"> <h5 class="title">Major bleeding</h5> <p><a href="./references#CD012467-bbs2-0020" title="LangeneckerSA , FelfernigM , WerbaA , MuellerCM , ChiariA , ZimpferM . Anticoagulation with prostacyclin and heparin during continuous venovenous hemofiltration. Critical Care Medicine1994;22(11):1774-81. [MEDLINE: 7956281]">Langenecker 1994</a> reported no major bleeding occurred in the groups comparing PGI<sub>2</sub> to UFH (27 patients analysed, 3 patients data missing) (<a href="./references#CD012467-fig-0043" title="">Analysis 6.1</a>). </p> </section> <section id="CD012467-sec-0122"> <h5 class="title">Successful prevention of clottingÃ‚Â in the first 24 hours</h5> <p>Compared to UFH, PGI<sub>2</sub> may make little or no difference to the successful prevention of clotting (<a href="./references#CD012467-fig-0044" title="">Analysis 6.2</a> (1 study, 23 participants): RR 1.09, 95% CI 0.64 to 1.87; low certainty of evidence) (<a href="./references#CD012467-bbs2-0001" title="ArcangeliA , RoccaB , SalvatoriG , CianciaM , De CristofaroR , AntonelliM . Heparin versus prostacyclin in continuous hemodiafiltration for acute renal failure: effects on platelet function in the systemic circulation and across the filter. Thrombosis Research2010;126(1):24-31. [MEDLINE: 20185164]">Arcangeli 2010</a>). </p> </section> <section id="CD012467-sec-0123"> <h5 class="title">Other outcomes</h5> <p>No other outcomes were reported for this comparison.</p> </section> </section> <section id="CD012467-sec-0124"> <h4 class="title">Unfractionated heparin plus prostaglandin I<sub>2</sub> versus prostaglandin I<sub>2</sub> </h4> <section id="CD012467-sec-0125"> <h5 class="title">Major bleeding</h5> <p><a href="./references#CD012467-bbs2-0020" title="LangeneckerSA , FelfernigM , WerbaA , MuellerCM , ChiariA , ZimpferM . Anticoagulation with prostacyclin and heparin during continuous venovenous hemofiltration. Critical Care Medicine1994;22(11):1774-81. [MEDLINE: 7956281]">Langenecker 1994</a> reported no major bleeding occurred during the study period (<a href="./references#CD012467-fig-0045" title="">Analysis 7.1</a>). </p> </section> <section id="CD012467-sec-0126"> <h5 class="title">Other outcomes</h5> <p>No other outcomes were reported for this comparison.</p> </section> </section> <section id="CD012467-sec-0127"> <h4 class="title">Unfractionated heparin plus prostaglandin I<sub>2</sub> versus unfractionated heparin </h4> <section id="CD012467-sec-0128"> <h5 class="title">Major bleeding</h5> <p>It was uncertain whether UFH plus PGI<sub> 2</sub> compared to UFH reduces major bleeding (<a href="./references#CD012467-fig-0046" title="">Analysis 8.1</a>) because the certainty of the evidence is very low (<a href="./references#CD012467-bbs2-0020" title="LangeneckerSA , FelfernigM , WerbaA , MuellerCM , ChiariA , ZimpferM . Anticoagulation with prostacyclin and heparin during continuous venovenous hemofiltration. Critical Care Medicine1994;22(11):1774-81. [MEDLINE: 7956281]">Langenecker 1994</a>; <a href="./references#CD012467-bbs2-0018" title="Kozek-LangeneckerSA , SpissCK , GamsjagerT , DomenigC , ZimpferM . Anticoagulation with prostaglandins and unfractionated heparin during continuous venovenous haemofiltration: a randomized controlled trial. Wiener Klinische Wochenschrift2002;114(3):96-101. [MEDLINE: 12060975]">Kozek‐Langenecker 2002</a>). </p> <p><a href="./references#CD012467-bbs2-0018" title="Kozek-LangeneckerSA , SpissCK , GamsjagerT , DomenigC , ZimpferM . Anticoagulation with prostaglandins and unfractionated heparin during continuous venovenous haemofiltration: a randomized controlled trial. Wiener Klinische Wochenschrift2002;114(3):96-101. [MEDLINE: 12060975]">Kozek‐Langenecker 2002</a> reported 3 bleeding events (3/17) in the UFH plus placebo group and no major bleeding occurred in the unfractionated UFH plus PGI<sub>2</sub> group (0/15). <a href="./references#CD012467-bbs2-0020" title="LangeneckerSA , FelfernigM , WerbaA , MuellerCM , ChiariA , ZimpferM . Anticoagulation with prostacyclin and heparin during continuous venovenous hemofiltration. Critical Care Medicine1994;22(11):1774-81. [MEDLINE: 7956281]">Langenecker 1994</a> (from the same research group) reported no major bleeding occurred (0/13 with 3 patients data missing in UFH, 0/19 in UFH plus PGI<sub>2</sub>). <a href="./references#CD012467-bbs2-0004" title="BirnbaumJ , SpiesCD , KlotzE , HeinOV , MorgeraS , SchinkT , et al. Iloprost for additional anticoagulation in continuous renal replacement therapy--a pilot study. Renal Failure2007;29(3):271-7. [MEDLINE: 17497439]">Birnbaum 2007</a> reported no bleeding events. </p> </section> <section id="CD012467-sec-0129"> <h5 class="title">Successful prevention of clottingÃ‚Â in the first 24 hours</h5> <p>Compared to UFH, UFH plus PGI<sub>2</sub> may lead to successful prevention of clotting (<a href="./references#CD012467-fig-0047" title="">Analysis 8.2</a> (2 studies, 158 participants): RR 1.91, 95% CI 1.32 to 2.78; I<sup>2</sup> = 0%; low certainty of evidence) (<a href="./references#CD012467-bbs2-0004" title="BirnbaumJ , SpiesCD , KlotzE , HeinOV , MorgeraS , SchinkT , et al. Iloprost for additional anticoagulation in continuous renal replacement therapy--a pilot study. Renal Failure2007;29(3):271-7. [MEDLINE: 17497439]">Birnbaum 2007</a>; <a href="./references#CD012467-bbs2-0018" title="Kozek-LangeneckerSA , SpissCK , GamsjagerT , DomenigC , ZimpferM . Anticoagulation with prostaglandins and unfractionated heparin during continuous venovenous haemofiltration: a randomized controlled trial. Wiener Klinische Wochenschrift2002;114(3):96-101. [MEDLINE: 12060975]">Kozek‐Langenecker 2002</a>). </p> </section> <section id="CD012467-sec-0130"> <h5 class="title">Thrombocytopenia</h5> <p>It was uncertain whether UFH and PGI<sub>2</sub> compare to UFH may lead to thrombocytopenia (<a href="./references#CD012467-fig-0048" title="">Analysis 8.3</a>) because the certainty of the evidence is very low (<a href="./references#CD012467-bbs2-0004" title="BirnbaumJ , SpiesCD , KlotzE , HeinOV , MorgeraS , SchinkT , et al. Iloprost for additional anticoagulation in continuous renal replacement therapy--a pilot study. Renal Failure2007;29(3):271-7. [MEDLINE: 17497439]">Birnbaum 2007</a>). <a href="./references#CD012467-bbs2-0004" title="BirnbaumJ , SpiesCD , KlotzE , HeinOV , MorgeraS , SchinkT , et al. Iloprost for additional anticoagulation in continuous renal replacement therapy--a pilot study. Renal Failure2007;29(3):271-7. [MEDLINE: 17497439]">Birnbaum 2007</a> reported 1/10 patients experienced thrombocytopenia of 16 /nL in the UFH plus PGI<sub>2</sub> group and no patient experienced thrombocytopenia inÃ‚Â the UFH group (<a href="#CD012467-tbl-0004">Table 1</a>). </p> </section> <section id="CD012467-sec-0131"> <h5 class="title">Catheter thrombotic events</h5> <p>It was uncertain whether UFH and PGI<sub>2</sub> compared to UFH may lead to catheter thrombotic events (<a href="./references#CD012467-fig-0049" title="">Analysis 8.4</a>) because the certainty of the evidence is very low (<a href="./references#CD012467-bbs2-0004" title="BirnbaumJ , SpiesCD , KlotzE , HeinOV , MorgeraS , SchinkT , et al. Iloprost for additional anticoagulation in continuous renal replacement therapy--a pilot study. Renal Failure2007;29(3):271-7. [MEDLINE: 17497439]">Birnbaum 2007</a>). </p> </section> <section id="CD012467-sec-0132"> <h5 class="title">Adverse events</h5> <section id="CD012467-sec-0133"> <h6 class="title">Number of treatment attempts with adverse events (technique or patient‐dependent factors)</h6> <p>It was uncertain whether UFH and PGI<sub>2</sub> compared to UFH may lead to more adverse events (<a href="./references#CD012467-fig-0050" title="">Analysis 8.5</a>) because the certainty of the evidence is very low (<a href="./references#CD012467-bbs2-0004" title="BirnbaumJ , SpiesCD , KlotzE , HeinOV , MorgeraS , SchinkT , et al. Iloprost for additional anticoagulation in continuous renal replacement therapy--a pilot study. Renal Failure2007;29(3):271-7. [MEDLINE: 17497439]">Birnbaum 2007</a>; <a href="./references#CD012467-bbs2-0018" title="Kozek-LangeneckerSA , SpissCK , GamsjagerT , DomenigC , ZimpferM . Anticoagulation with prostaglandins and unfractionated heparin during continuous venovenous haemofiltration: a randomized controlled trial. Wiener Klinische Wochenschrift2002;114(3):96-101. [MEDLINE: 12060975]">Kozek‐Langenecker 2002</a>). </p> </section> <section id="CD012467-sec-0134"> <h6 class="title">Number of patients with any adverse events</h6> <p>The number of patients who experienced any adverse events is tabulated in <a href="#CD012467-tbl-0010">Table 7</a>. </p> <div class="table" id="CD012467-tbl-0010"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 7.</span> <span class="table-title">Adverse events: UFH plus PGI2 versus UFH</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study ID</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Adverse events</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Intervention: events/participants</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><a href="./references#CD012467-bbs2-0018" title="Kozek-LangeneckerSA , SpissCK , GamsjagerT , DomenigC , ZimpferM . Anticoagulation with prostaglandins and unfractionated heparin during continuous venovenous haemofiltration: a randomized controlled trial. Wiener Klinische Wochenschrift2002;114(3):96-101. [MEDLINE: 12060975]">Kozek‐Langenecker 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Trivial bleeding</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>UFH plus PGI<sub>2</sub>: 1/15 </p> <p>UFH: 3/17</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Major bleeding</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>UFH plus PGI<sub>2</sub>: 0/15 </p> <p>UFH: 3/17</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>PG ‐ prostaglandin; UFH ‐ unfractionated heparin</p> </div> </div> </section> </section> <section id="CD012467-sec-0135"> <h5 class="title">Other outcomes</h5> <p>No other outcomes were reported for this comparison.</p> </section> </section> <section id="CD012467-sec-0136"> <h4 class="title">Unfractionated heparin plus protamine and prostaglandin I<sub>2</sub> versus unfractionated heparin </h4> <section id="CD012467-sec-0137"> <h5 class="title">Major bleeding</h5> <p>It was uncertain whether UFH plus protamine and PGI<sub>2</sub> compared to UFH may reduce major bleeding (<a href="./references#CD012467-fig-0051" title="">Analysis 9.1</a>) because the certainty of evidence was very low (<a href="./references#CD012467-bbs2-0009" title="FabbriLP , NuceraM , Al MalyanM , BecchiC . Regional anticoagulation and antiaggregation for CVVH in critically ill patients: a prospective, randomized, controlled pilot study. Acta Anaesthesiologica Scandinavica2010;54(1):92-7. [MEDLINE: 19650808]">Fabbri 2010</a>). </p> </section> <section id="CD012467-sec-0138"> <h5 class="title">Death at 28 days</h5> <p>It was uncertain whether UFH plus protamine and PGI<sub>2</sub> compared to UFH may reduce death at 28 days because the certainty of evidence was very low (<a href="./references#CD012467-bbs2-0009" title="FabbriLP , NuceraM , Al MalyanM , BecchiC . Regional anticoagulation and antiaggregation for CVVH in critically ill patients: a prospective, randomized, controlled pilot study. Acta Anaesthesiologica Scandinavica2010;54(1):92-7. [MEDLINE: 19650808]">Fabbri 2010</a>). </p> <p><a href="./references#CD012467-bbs2-0009" title="FabbriLP , NuceraM , Al MalyanM , BecchiC . Regional anticoagulation and antiaggregation for CVVH in critically ill patients: a prospective, randomized, controlled pilot study. Acta Anaesthesiologica Scandinavica2010;54(1):92-7. [MEDLINE: 19650808]">Fabbri 2010</a> reported death at 24 hours (<a href="./references#CD012467-fig-0052" title="">Analysis 9.2</a>) </p> </section> <section id="CD012467-sec-0139"> <h5 class="title">Successful prevention of clottingÃ‚Â in the first 24 hours</h5> <p>It was uncertain whether UFH plus protamine and PGI<sub>2</sub> compared to UFH may lead to successful prevention of clotting (<a href="./references#CD012467-fig-0053" title="">Analysis 9.3</a>.2) because the certainty of evidence was very low (<a href="./references#CD012467-bbs2-0009" title="FabbriLP , NuceraM , Al MalyanM , BecchiC . Regional anticoagulation and antiaggregation for CVVH in critically ill patients: a prospective, randomized, controlled pilot study. Acta Anaesthesiologica Scandinavica2010;54(1):92-7. [MEDLINE: 19650808]">Fabbri 2010</a>).Ã‚Â  </p> </section> <section id="CD012467-sec-0140"> <h5 class="title">Adverse events</h5> <section id="CD012467-sec-0141"> <h6 class="title">Number of patients with any adverse events</h6> <p>The number of patients who experienced any adverse events is tabulated in <a href="#CD012467-tbl-0011">Table 8</a>. </p> <div class="table" id="CD012467-tbl-0011"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 8.</span> <span class="table-title">Adverse events: UFH plus protamine plus PGI2 versus UFH</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study ID</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Adverse events</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Intervention: events/participants</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><a href="./references#CD012467-bbs2-0009" title="FabbriLP , NuceraM , Al MalyanM , BecchiC . Regional anticoagulation and antiaggregation for CVVH in critically ill patients: a prospective, randomized, controlled pilot study. Acta Anaesthesiologica Scandinavica2010;54(1):92-7. [MEDLINE: 19650808]">Fabbri 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Severe bleeding events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>UFH + protamine + PGI<sub>2</sub>: 2/46 </p> <p>UFH: 7/44</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mild to moderate bleeding events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>UFH + protamine + PGI<sub>2</sub>: 2/46 </p> <p>UFH: 4/44</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>PG ‐ prostaglandin; UFH ‐ unfractionated heparin</p> </div> </div> </section> <section id="CD012467-sec-0142"> <h6 class="title">Other outcomes</h6> <p>No other outcomes were reported for this comparison.</p> </section> </section> </section> <section id="CD012467-sec-0143"> <h4 class="title">Unfractionated heparin plus prostaglandin I<sub>2</sub> versus unfractionated heparin plus prostaglandin E<sub>1</sub> </h4> <section id="CD012467-sec-0144"> <h5 class="title">Major bleeding</h5> <p>It was uncertain whether UFH plus PGI<sub>2</sub> compared to UFH plus PGE<sub>1</sub> reduces major bleeding (<a href="./references#CD012467-fig-0054" title="">Analysis 10.1</a>) because the certainty of the evidence is very low (<a href="./references#CD012467-bbs2-0018" title="Kozek-LangeneckerSA , SpissCK , GamsjagerT , DomenigC , ZimpferM . Anticoagulation with prostaglandins and unfractionated heparin during continuous venovenous haemofiltration: a randomized controlled trial. Wiener Klinische Wochenschrift2002;114(3):96-101. [MEDLINE: 12060975]">Kozek‐Langenecker 2002</a>). </p> </section> <section id="CD012467-sec-0145"> <h5 class="title">Successful prevention of clotting</h5> <p>It was uncertain whether UFH plus PGI<sub>2</sub> compared to UFH plus PGE<sub>1</sub> leads to successful prevention of clotting (<a href="./references#CD012467-fig-0054" title="">Analysis 10.1</a>) because the certainty of the evidence is very low (<a href="./references#CD012467-bbs2-0018" title="Kozek-LangeneckerSA , SpissCK , GamsjagerT , DomenigC , ZimpferM . Anticoagulation with prostaglandins and unfractionated heparin during continuous venovenous haemofiltration: a randomized controlled trial. Wiener Klinische Wochenschrift2002;114(3):96-101. [MEDLINE: 12060975]">Kozek‐Langenecker 2002</a>). </p> </section> <section id="CD012467-sec-0146"> <h5 class="title">Adverse events</h5> <section id="CD012467-sec-0147"> <h6 class="title">Number of patients with any adverse events</h6> <p>The number of patients who experienced any adverse events is tabulated in <a href="#CD012467-tbl-0012">Table 9</a>. </p> <div class="table" id="CD012467-tbl-0012"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 9.</span> <span class="table-title">Adverse events: UFH plus PGI2 versus UFH plus PGE1 </span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study ID</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Adverse events</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Intervention: events/participants</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><a href="./references#CD012467-bbs2-0018" title="Kozek-LangeneckerSA , SpissCK , GamsjagerT , DomenigC , ZimpferM . Anticoagulation with prostaglandins and unfractionated heparin during continuous venovenous haemofiltration: a randomized controlled trial. Wiener Klinische Wochenschrift2002;114(3):96-101. [MEDLINE: 12060975]">Kozek‐Langenecker 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Trivial bleeding</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>UFH + PGI<sub>2</sub>: 1/15 </p> <p>UFH + PGE<sub>1</sub>: 1/18 </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Major bleeding</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>UFH + PGI<sub>2</sub>: 0/15 </p> <p>UFH + PGE<sub>1</sub>: 1/18 </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>PG ‐ prostaglandin; UFH ‐ unfractionated heparin</p> </div> </div> </section> </section> <section id="CD012467-sec-0148"> <h5 class="title">Other outcomes</h5> <p>No other outcomes were reported for this comparison</p> </section> </section> <section id="CD012467-sec-0149"> <h4 class="title">Unfractionated heparin plus prostaglandin E<sub>1</sub> versus unfractionated heparin </h4> <section id="CD012467-sec-0150"> <h5 class="title">Major bleeding</h5> <p>It was uncertain whether UFH plus PGE<sub>1</sub> compared to UFH reduces major bleeding (<a href="./references#CD012467-fig-0056" title="">Analysis 11.1</a>) because the certainty of the evidence is very low (<a href="./references#CD012467-bbs2-0018" title="Kozek-LangeneckerSA , SpissCK , GamsjagerT , DomenigC , ZimpferM . Anticoagulation with prostaglandins and unfractionated heparin during continuous venovenous haemofiltration: a randomized controlled trial. Wiener Klinische Wochenschrift2002;114(3):96-101. [MEDLINE: 12060975]">Kozek‐Langenecker 2002</a>). </p> </section> <section id="CD012467-sec-0151"> <h5 class="title">Successful prevention of clottingÃ‚Â in the first 24 hours</h5> <p>Compared to UFH, UFH plus PGE<sub>1</sub> may reduce the successful prevention of clotting (<a href="./references#CD012467-fig-0057" title="">Analysis 11.2</a> (1 study, 135 participants): RR 1.71, 95% CI 1.16 to 2.52) low certainty of evidence (<a href="./references#CD012467-bbs2-0018" title="Kozek-LangeneckerSA , SpissCK , GamsjagerT , DomenigC , ZimpferM . Anticoagulation with prostaglandins and unfractionated heparin during continuous venovenous haemofiltration: a randomized controlled trial. Wiener Klinische Wochenschrift2002;114(3):96-101. [MEDLINE: 12060975]">Kozek‐Langenecker 2002</a>). </p> </section> </section> <section id="CD012467-sec-0152"> <h4 class="title">Other outcomes</h4> <p>No other outcomes were reported for this comparison.</p> </section> <section id="CD012467-sec-0153"> <h4 class="title">Unfractionated heparin plus tirofiban versus unfractionated heparin</h4> <section id="CD012467-sec-0154"> <h5 class="title">Major bleeding</h5> <p>No major bleeding was reported (<a href="./references#CD012467-fig-0058" title="">Analysis 12.1</a>) (<a href="./references#CD012467-bbs2-0022" title="LinkA , GirndtM , SelejanS , RbahR , BohmM . Tirofiban preserves platelet loss during continuous renal replacement therapy in a randomised prospective open-blinded pilot study. Critical Care (London, England)2008;12(4):R111. [MEDLINE: 18759963]">Link 2008</a>). </p> </section> <section id="CD012467-sec-0155"> <h5 class="title">Death at 28 days</h5> <p>It was uncertain whether UFH plus tirofiban compared to UFH reduces death at 28 days (<a href="./references#CD012467-fig-0059" title="">Analysis 12.2</a>) because the certainty of the evidence is very low (<a href="./references#CD012467-bbs2-0022" title="LinkA , GirndtM , SelejanS , RbahR , BohmM . Tirofiban preserves platelet loss during continuous renal replacement therapy in a randomised prospective open-blinded pilot study. Critical Care (London, England)2008;12(4):R111. [MEDLINE: 18759963]">Link 2008</a>). In‐hospital or ICU deaths were reported and we used the in‐hospital death for <a href="./references#CD012467-fig-0059" title="">Analysis 12.2</a>. </p> </section> <section id="CD012467-sec-0156"> <h5 class="title">Adverse events</h5> <section id="CD012467-sec-0157"> <h6 class="title">Number of patients with any adverse events</h6> <p>The number of patients who experienced any adverse events is tabulated in <a href="#CD012467-tbl-0013">Table 10</a>. </p> <div class="table" id="CD012467-tbl-0013"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 10.</span> <span class="table-title">Adverse events: UFH plus tirofiban versus UFH</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study ID</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Adverse events</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Intervention: events/participants</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><a href="./references#CD012467-bbs2-0022" title="LinkA , GirndtM , SelejanS , RbahR , BohmM . Tirofiban preserves platelet loss during continuous renal replacement therapy in a randomised prospective open-blinded pilot study. Critical Care (London, England)2008;12(4):R111. [MEDLINE: 18759963]">Link 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Major bleeding</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>UFH: 0/20</p> <p>Tirofiban: 0/20</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Minor bleeding</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>UFH: 2/20</p> <p>Tirofiban: 1/20</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>UFH ‐ unfractionated heparin</p> </div> </div> </section> </section> <section id="CD012467-sec-0158"> <h5 class="title">Other outcomes</h5> <p>No other outcomes were reported for this comparison.</p> </section> </section> <section id="CD012467-sec-0159"> <h4 class="title">Bivalirudin versus unfractionated heparin</h4> <section id="CD012467-sec-0160"> <h5 class="title">Major bleeding</h5> <p>It was uncertain whether bivalirudin compared to UFH reduces bleeding (<a href="./references#CD012467-fig-0060" title="">Analysis 13.1</a>) because the certainty of the evidence is very low (<a href="./references#CD012467-bbs2-0017" title="KiserTH , MacLarenR , FishDN , HassellKL , TeitelbaumI . Bivalirudin versus unfractionated heparin for prevention of hemofilter occlusion during continuous renal replacement therapy. Pharmacotherapy2010;30(11):1117-26. [MEDLINE: 20973685]">Kiser 2010</a>). </p> </section> <section id="CD012467-sec-0161"> <h5 class="title">Death at 28 days</h5> <p>It was uncertain whether bivalirudin compared to UFH reduces death at 28 days (<a href="./references#CD012467-fig-0061" title="">Analysis 13.2</a>) because the certainty of the evidence is very low (<a href="./references#CD012467-bbs2-0017" title="KiserTH , MacLarenR , FishDN , HassellKL , TeitelbaumI . Bivalirudin versus unfractionated heparin for prevention of hemofilter occlusion during continuous renal replacement therapy. Pharmacotherapy2010;30(11):1117-26. [MEDLINE: 20973685]">Kiser 2010</a>). </p> </section> <section id="CD012467-sec-0162"> <h5 class="title">Recovery of kidney function</h5> <p>It was uncertain whether bivalirudin compared to UFH prevents recovery of kidney function (<a href="./references#CD012467-fig-0062" title="">Analysis 13.3</a>) because the certainty of the evidence is very low (<a href="./references#CD012467-bbs2-0017" title="KiserTH , MacLarenR , FishDN , HassellKL , TeitelbaumI . Bivalirudin versus unfractionated heparin for prevention of hemofilter occlusion during continuous renal replacement therapy. Pharmacotherapy2010;30(11):1117-26. [MEDLINE: 20973685]">Kiser 2010</a>). </p> </section> <section id="CD012467-sec-0163"> <h5 class="title">Adverse events</h5> <section id="CD012467-sec-0164"> <h6 class="title">Number of patients with any adverse events</h6> <p>The number of patients who experienced any adverse events is tabulated in <a href="#CD012467-tbl-0014">Table 11</a>. </p> <div class="table" id="CD012467-tbl-0014"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 11.</span> <span class="table-title">Adverse events: Bivalirudin versus UFH</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study ID</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Adverse events</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Intervention: events/participants</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><a href="./references#CD012467-bbs2-0017" title="KiserTH , MacLarenR , FishDN , HassellKL , TeitelbaumI . Bivalirudin versus unfractionated heparin for prevention of hemofilter occlusion during continuous renal replacement therapy. Pharmacotherapy2010;30(11):1117-26. [MEDLINE: 20973685]">Kiser 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Alveolar haemorrhage</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Bivalirudin: 0/5</p> <p>UFH: 1/5</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Deep vein thrombosis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Bivalirudin: 0/5</p> <p>UFH: 1/5</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>UFH ‐ unfractionated heparin</p> </div> </div> </section> <section id="CD012467-sec-0165"> <h6 class="title">Other outcomes</h6> <p>No other outcomes were reported for this comparison.</p> </section> </section> </section> <section id="CD012467-sec-0166"> <h4 class="title">Hirudin versus unfractionated heparin</h4> <section id="CD012467-sec-0167"> <h5 class="title">Major bleeding</h5> <p>It was uncertain whether hirudin compared to UFH leads to major bleeding (<a href="./references#CD012467-fig-0063" title="">Analysis 14.1</a>) because the certainty of the evidence is very low (<a href="./references#CD012467-bbs2-0032" title="Vargas HeinO , vonHeymannC , LippsM , ZiemerS , RoncoC , NeumayerHH , et al. Hirudin versus heparin for anticoagulation in continuous renal replacement therapy. Intensive Care Medicine2001;27(4):673-9. [MEDLINE: 11403068]">Vargas Hein 2001</a>; <a href="./references#CD012467-bbs2-0014" title="HeinOV , vonHeymannC , DiehlT , ZiemerS , RoncoC , MorgeraS , et al. Intermittent hirudin versus continuous heparin for anticoagulation in continuous renal replacement therapy. Renal Failure2004;26(3):297-303. [MEDLINE: 15354980]">Hein 2004</a>). </p> </section> <section id="CD012467-sec-0168"> <h5 class="title">Death at 28 days</h5> <p>It was uncertain whether hirudin compared to UFH leads to increased death at 28 days (<a href="./references#CD012467-fig-0064" title="">Analysis 14.2</a>) because the certainty of the evidence is very low (<a href="./references#CD012467-bbs2-0032" title="Vargas HeinO , vonHeymannC , LippsM , ZiemerS , RoncoC , NeumayerHH , et al. Hirudin versus heparin for anticoagulation in continuous renal replacement therapy. Intensive Care Medicine2001;27(4):673-9. [MEDLINE: 11403068]">Vargas Hein 2001</a>; <a href="./references#CD012467-bbs2-0014" title="HeinOV , vonHeymannC , DiehlT , ZiemerS , RoncoC , MorgeraS , et al. Intermittent hirudin versus continuous heparin for anticoagulation in continuous renal replacement therapy. Renal Failure2004;26(3):297-303. [MEDLINE: 15354980]">Hein 2004</a>). ICU death was reported. </p> </section> <section id="CD012467-sec-0169"> <h5 class="title">Thrombocytopenia</h5> <p>It was uncertain whether hirudin compared to UFH leads to thrombocytopenia (<a href="./references#CD012467-fig-0065" title="">Analysis 14.3</a>) because the certainty of the evidence is very low (<a href="./references#CD012467-bbs2-0014" title="HeinOV , vonHeymannC , DiehlT , ZiemerS , RoncoC , MorgeraS , et al. Intermittent hirudin versus continuous heparin for anticoagulation in continuous renal replacement therapy. Renal Failure2004;26(3):297-303. [MEDLINE: 15354980]">Hein 2004</a>).Ã‚Â One of 14 patients experienced thrombocytopenia of 69Ã‚Â /nL and 1/14 experienced 17 /nLÃ‚Â in the UFHÃ‚Â group and no patient experienced thrombocytopenia inÃ‚Â the hirudinÃ‚Â group (<a href="./references#CD012467-bbs2-0014" title="HeinOV , vonHeymannC , DiehlT , ZiemerS , RoncoC , MorgeraS , et al. Intermittent hirudin versus continuous heparin for anticoagulation in continuous renal replacement therapy. Renal Failure2004;26(3):297-303. [MEDLINE: 15354980]">Hein 2004</a>) (<a href="#CD012467-tbl-0004">Table 1</a>). </p> </section> <section id="CD012467-sec-0170"> <h5 class="title">Adverse events</h5> <section id="CD012467-sec-0171"> <h6 class="title">Number of patients with any adverse events</h6> <p>The number of patients who experienced any adverse events is tabulated in <a href="#CD012467-tbl-0015">Table 12</a>. </p> <div class="table" id="CD012467-tbl-0015"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 12.</span> <span class="table-title">Adverse events: Hirudin versus UFH</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study ID</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Adverse events</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Intervention: events/participants</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012467-bbs2-0032" title="Vargas HeinO , vonHeymannC , LippsM , ZiemerS , RoncoC , NeumayerHH , et al. Hirudin versus heparin for anticoagulation in continuous renal replacement therapy. Intensive Care Medicine2001;27(4):673-9. [MEDLINE: 11403068]">Vargas Hein 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Bleeding</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hirudin: 3/8</p> <p>UFH: 0/9</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012467-bbs2-0014" title="HeinOV , vonHeymannC , DiehlT , ZiemerS , RoncoC , MorgeraS , et al. Intermittent hirudin versus continuous heparin for anticoagulation in continuous renal replacement therapy. Renal Failure2004;26(3):297-303. [MEDLINE: 15354980]">Hein 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Bleeding</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hirudin: 0/12</p> <p>UFH: 2/14</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>UFH ‐ unfractionated heparin</p> </div> </div> </section> </section> <section id="CD012467-sec-0172"> <h5 class="title">Other outcomes</h5> <p>No other outcomes were reported for this comparison.</p> </section> </section> <section id="CD012467-sec-0173"> <h4 class="title">Low molecular weight dextran versus placebo (vehicle)</h4> <section id="CD012467-sec-0174"> <h5 class="title">Successful prevention of clottingÃ‚Â in the first 24 hours</h5> <p>It was uncertain whether low molecular weight dextran compared to placebo leads to successful prevention of clotting (<a href="./references#CD012467-fig-0066" title="">Analysis 15.1</a>) because the certainty of the evidence is very low (<a href="./references#CD012467-bbs2-0025" title="PalevskyPM , BurrR , MorelandL , TokiwaY , GreenbergA . Failure of low molecular weight dextran to prevent clotting during continuous renal replacement therapy. ASAIO Journal1995;41(4):847-9. [MEDLINE: 8589465]">Palevsky 1995</a>). </p> </section> <section id="CD012467-sec-0175"> <h5 class="title">Other outcomes</h5> <p>No other outcomes were reported for this comparison.</p> </section> </section> <section id="CD012467-sec-0176"> <h4 class="title">Dalteparin (low molecular weight heparin) versus nadroparinÃ‚Â (low molecular weight heparin) </h4> <section id="CD012467-sec-0177"> <h5 class="title">Major bleeding</h5> <p>No major bleeding was reported to have occurred in the study period (32 participants) (<a href="./references#CD012467-bbs2-0008" title="dePontAC , Oudemans-van StraatenHM , RoozendaalKJ , ZandstraDF . Nadroparin versus dalteparin anticoagulation in high-volume, continuous venovenous hemofiltration: a double-blind, randomized, crossover study. Critical Care Medicine2000;28(2):421-5. [MEDLINE: 10708177]">de Pont 2000</a>). </p> </section> <section id="CD012467-sec-0178"> <h5 class="title">Successful prevention of clottingÃ‚Â in the first 24 hours</h5> <p>It was uncertain whether dalteparin (LMWH) compared to nadroparin (LMWH) leads to successful prevention of clotting (<a href="./references#CD012467-fig-0067" title="">Analysis 16.1</a>) because the certainty of the evidence is very low. </p> </section> <section id="CD012467-sec-0179"> <h5 class="title">Adverse events</h5> <section id="CD012467-sec-0180"> <h6 class="title">Number of patients with any adverse events</h6> <p>The number of patients who experienced any adverse events is tabulated in <a href="#CD012467-tbl-0016">Table 13</a>. </p> <div class="table" id="CD012467-tbl-0016"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 13.</span> <span class="table-title">Adverse events: Dalteparin (LMWH) versus nadoparin (LMWH)</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study ID</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Adverse events</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Intervention: events/participants</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012467-bbs2-0008" title="dePontAC , Oudemans-van StraatenHM , RoozendaalKJ , ZandstraDF . Nadroparin versus dalteparin anticoagulation in high-volume, continuous venovenous hemofiltration: a double-blind, randomized, crossover study. Critical Care Medicine2000;28(2):421-5. [MEDLINE: 10708177]">de Pont 2000</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>All bleeding events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nadroparin: 2/32</p> <p>Dalteparin: 1/32</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>LMWH ‐ low molecular weight heparin</p> </div> </div> </section> </section> <section id="CD012467-sec-0181"> <h5 class="title">Other outcomes</h5> <p>No other outcomes were reported for this comparison.</p> </section> </section> <section id="CD012467-sec-0182"> <h4 class="title">Citrate plus low molecular weight heparin versus citrate</h4> <section id="CD012467-sec-0183"> <h5 class="title">Major bleeding</h5> <p>It was uncertain whether citrate plus LMWH compared to citrate reduced major bleeding (<a href="./references#CD012467-fig-0068" title="">Analysis 17.1</a>) because the certainty of the evidence is very low. </p> </section> <section id="CD012467-sec-0184"> <h5 class="title">Death at 28 days</h5> <p>It was uncertain whether citrate plus LMWH compared to citrate reduced 28‐day mortality (<a href="./references#CD012467-fig-0069" title="">Analysis 17.2</a>) because the certainty of the evidence is very low. </p> </section> <section id="CD012467-sec-0185"> <h5 class="title">Successful prevention of clottingÃ‚Â in the first 24 hours</h5> <p>It was uncertain whether citrate plus LMWH compared to citrate makes little or no difference to successful prevention of clotting (<a href="./references#CD012467-fig-0070" title="">Analysis 17.3</a>) because the certainty of evidence was very low. </p> <p>Only data for successful prevention of clotting within eight hours was available and are shown in <a href="./references#CD012467-fig-0070" title="">Analysis 17.3</a> (<a href="./references#CD012467-bbs2-0034" title="WuB , ZhangK , XuB , JiD , LiuZ , GongD . Randomized controlled trial to evaluate regional citrate anticoagulation plus low-dose of dalteparin in continuous veno-venous hemofiltration. Blood Purification2015;39(4):306-12. [MEDLINE: 26022434]ZhangK , GongD , JiD , XuB , IIuZ . Regional citrate plus low dose of low molecular weight heparins: a safe and more efficacy anticoagulation protocol for continuous veno - venous hemofiltration [abstract no: 71]. In: CCRT 2012. 17th International Conference on CRRT; 2012 Feb 14-17; San Diego (CA). 2012. [CENTRAL: CN-01658175] ">Wu 2015b</a>). </p> </section> <section id="CD012467-sec-0186"> <h5 class="title">Metabolic disturbances</h5> <p>It was uncertain whether citrate plus LMWH compared to citrate leads to metabolic disturbances because the certainty of the evidence is very low (<a href="./references#CD012467-fig-0071" title="">Analysis 17.4</a>) (<a href="./references#CD012467-bbs2-0034" title="WuB , ZhangK , XuB , JiD , LiuZ , GongD . Randomized controlled trial to evaluate regional citrate anticoagulation plus low-dose of dalteparin in continuous veno-venous hemofiltration. Blood Purification2015;39(4):306-12. [MEDLINE: 26022434]ZhangK , GongD , JiD , XuB , IIuZ . Regional citrate plus low dose of low molecular weight heparins: a safe and more efficacy anticoagulation protocol for continuous veno - venous hemofiltration [abstract no: 71]. In: CCRT 2012. 17th International Conference on CRRT; 2012 Feb 14-17; San Diego (CA). 2012. [CENTRAL: CN-01658175] ">Wu 2015b</a>). </p> </section> <section id="CD012467-sec-0187"> <h5 class="title">Hypernatraemia</h5> <p><a href="./references#CD012467-bbs2-0034" title="WuB , ZhangK , XuB , JiD , LiuZ , GongD . Randomized controlled trial to evaluate regional citrate anticoagulation plus low-dose of dalteparin in continuous veno-venous hemofiltration. Blood Purification2015;39(4):306-12. [MEDLINE: 26022434]ZhangK , GongD , JiD , XuB , IIuZ . Regional citrate plus low dose of low molecular weight heparins: a safe and more efficacy anticoagulation protocol for continuous veno - venous hemofiltration [abstract no: 71]. In: CCRT 2012. 17th International Conference on CRRT; 2012 Feb 14-17; San Diego (CA). 2012. [CENTRAL: CN-01658175] ">Wu 2015b</a> reported there were no cases of hypernatraemia (<a href="./references#CD012467-fig-0072" title="">Analysis 17.5</a>). </p> </section> <section id="CD012467-sec-0188"> <h5 class="title">Hypocalcaemia</h5> <p>It was uncertain whether citrate plus LMWH compared to citrate leads to hypocalcaemia because the certainty of the evidence is very low (<a href="./references#CD012467-fig-0073" title="">Analysis 17.6</a>) (<a href="./references#CD012467-bbs2-0034" title="WuB , ZhangK , XuB , JiD , LiuZ , GongD . Randomized controlled trial to evaluate regional citrate anticoagulation plus low-dose of dalteparin in continuous veno-venous hemofiltration. Blood Purification2015;39(4):306-12. [MEDLINE: 26022434]ZhangK , GongD , JiD , XuB , IIuZ . Regional citrate plus low dose of low molecular weight heparins: a safe and more efficacy anticoagulation protocol for continuous veno - venous hemofiltration [abstract no: 71]. In: CCRT 2012. 17th International Conference on CRRT; 2012 Feb 14-17; San Diego (CA). 2012. [CENTRAL: CN-01658175] ">Wu 2015b</a>). </p> </section> <section id="CD012467-sec-0189"> <h5 class="title">Early termination with blood loss in the circuits</h5> <p>No study reported this outcome.</p> </section> <section id="CD012467-sec-0190"> <h5 class="title">Recovery of kidney function</h5> <p>It was uncertain whether citrate plus LMWH compared to citrate make little or no difference to the recovery of kidney function because the certainty of the evidence is very low (<a href="./references#CD012467-fig-0074" title="">Analysis 17.7</a>) (<a href="./references#CD012467-bbs2-0034" title="WuB , ZhangK , XuB , JiD , LiuZ , GongD . Randomized controlled trial to evaluate regional citrate anticoagulation plus low-dose of dalteparin in continuous veno-venous hemofiltration. Blood Purification2015;39(4):306-12. [MEDLINE: 26022434]ZhangK , GongD , JiD , XuB , IIuZ . Regional citrate plus low dose of low molecular weight heparins: a safe and more efficacy anticoagulation protocol for continuous veno - venous hemofiltration [abstract no: 71]. In: CCRT 2012. 17th International Conference on CRRT; 2012 Feb 14-17; San Diego (CA). 2012. [CENTRAL: CN-01658175] ">Wu 2015b</a>). </p> </section> <section id="CD012467-sec-0191"> <h5 class="title">Thrombocytopenia</h5> <p><a href="./references#CD012467-bbs2-0034" title="WuB , ZhangK , XuB , JiD , LiuZ , GongD . Randomized controlled trial to evaluate regional citrate anticoagulation plus low-dose of dalteparin in continuous veno-venous hemofiltration. Blood Purification2015;39(4):306-12. [MEDLINE: 26022434]ZhangK , GongD , JiD , XuB , IIuZ . Regional citrate plus low dose of low molecular weight heparins: a safe and more efficacy anticoagulation protocol for continuous veno - venous hemofiltration [abstract no: 71]. In: CCRT 2012. 17th International Conference on CRRT; 2012 Feb 14-17; San Diego (CA). 2012. [CENTRAL: CN-01658175] ">Wu 2015b</a> reported there were no cases of thrombocytopenia (<a href="./references#CD012467-fig-0075" title="">Analysis 17.8</a>). </p> </section> <section id="CD012467-sec-0192"> <h5 class="title">Adverse events</h5> <section id="CD012467-sec-0193"> <h6 class="title">Number of treatment cessations due to any adverse events (technique or patient‐dependent factors) </h6> <p><a href="./references#CD012467-bbs2-0034" title="WuB , ZhangK , XuB , JiD , LiuZ , GongD . Randomized controlled trial to evaluate regional citrate anticoagulation plus low-dose of dalteparin in continuous veno-venous hemofiltration. Blood Purification2015;39(4):306-12. [MEDLINE: 26022434]ZhangK , GongD , JiD , XuB , IIuZ . Regional citrate plus low dose of low molecular weight heparins: a safe and more efficacy anticoagulation protocol for continuous veno - venous hemofiltration [abstract no: 71]. In: CCRT 2012. 17th International Conference on CRRT; 2012 Feb 14-17; San Diego (CA). 2012. [CENTRAL: CN-01658175] ">Wu 2015b</a> reported there were no dropouts due to adverse events (<a href="./references#CD012467-fig-0076" title="">Analysis 17.9</a>). </p> </section> <section id="CD012467-sec-0194"> <h6 class="title">Number of treatment attempts with adverse events (technique or patient‐dependent factors)</h6> <p>We could not analyse this outcome due to inadequate reporting of adverse events.</p> </section> <section id="CD012467-sec-0195"> <h6 class="title">Number of patients with any adverse events</h6> <p>The number of patients who experienced any adverse events is tabulated in <a href="#CD012467-tbl-0017">Table 14</a>. </p> <div class="table" id="CD012467-tbl-0017"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 14.</span> <span class="table-title">Adverse events: Citrate plus LMWH versus citrate</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study ID</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Adverse events</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Intervention: events/participants</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p><a href="./references#CD012467-bbs2-0034" title="WuB , ZhangK , XuB , JiD , LiuZ , GongD . Randomized controlled trial to evaluate regional citrate anticoagulation plus low-dose of dalteparin in continuous veno-venous hemofiltration. Blood Purification2015;39(4):306-12. [MEDLINE: 26022434]ZhangK , GongD , JiD , XuB , IIuZ . Regional citrate plus low dose of low molecular weight heparins: a safe and more efficacy anticoagulation protocol for continuous veno - venous hemofiltration [abstract no: 71]. In: CCRT 2012. 17th International Conference on CRRT; 2012 Feb 14-17; San Diego (CA). 2012. [CENTRAL: CN-01658175] ">Wu 2015b</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Bleeding</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Citrate + LMWH: 1/19</p> <p>Citrate: 2/15</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hypocalcaemia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Citrate + LMWH: 0/19</p> <p>Citrate: 1/15</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Metabolic acidosis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Citrate + LMWH: 4/19</p> <p>Citrate: 3/15</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Severe metabolic acidosis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Citrate + LMWH: 0/19</p> <p>Citrate: 1/15</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>LMWH ‐ low molecular weight heparin</p> </div> </div> </section> </section> <section id="CD012467-sec-0196"> <h5 class="title">Cost to health care services</h5> <p>One study reported the mean cost of CRRT per patient per day was USD511Ã‚Â±60 for citrate plus the LMWH group and USD601Ã‚Â±118Ã‚Â for the citrate group (<a href="./references#CD012467-bbs2-0034" title="WuB , ZhangK , XuB , JiD , LiuZ , GongD . Randomized controlled trial to evaluate regional citrate anticoagulation plus low-dose of dalteparin in continuous veno-venous hemofiltration. Blood Purification2015;39(4):306-12. [MEDLINE: 26022434]ZhangK , GongD , JiD , XuB , IIuZ . Regional citrate plus low dose of low molecular weight heparins: a safe and more efficacy anticoagulation protocol for continuous veno - venous hemofiltration [abstract no: 71]. In: CCRT 2012. 17th International Conference on CRRT; 2012 Feb 14-17; San Diego (CA). 2012. [CENTRAL: CN-01658175] ">Wu 2015b</a>); however, the detailed method of the calculation was not clear. </p> </section> <section id="CD012467-sec-0197"> <h5 class="title">Other outcomes</h5> <p>No other outcomes were reported for this comparison.</p> </section> </section> <section id="CD012467-sec-0198"> <h4 class="title">Citrate plus low molecular weight heparin versus low molecular weight heparin</h4> <section id="CD012467-sec-0199"> <h5 class="title">Major bleeding</h5> <p>It was uncertain whether citrate plus LMWH compared to LMWH reduces major bleeding (<a href="./references#CD012467-fig-0077" title="">Analysis 18.1</a>) </p> </section> <section id="CD012467-sec-0200"> <h5 class="title">Death at 28 days</h5> <p>It was uncertain whether citrate plus LMWH compared to LMWH reduces 28‐day mortality (<a href="./references#CD012467-fig-0078" title="">Analysis 18.2</a>) because the certainty of the evidence is very low. </p> </section> <section id="CD012467-sec-0201"> <h5 class="title">Successful prevention of clottingÃ‚Â in the first 24 hours</h5> <p>It was uncertain whether citrate plus LMWH compared to LMWH makes little or no difference to successful prevention of clotting (<a href="./references#CD012467-fig-0079" title="">Analysis 18.3</a>) because the certainty of evidence was very low. </p> <p>Only data for successful prevention of clotting within eight hours was available and are shown in <a href="./references#CD012467-fig-0079" title="">Analysis 18.3</a> (<a href="./references#CD012467-bbs2-0034" title="WuB , ZhangK , XuB , JiD , LiuZ , GongD . Randomized controlled trial to evaluate regional citrate anticoagulation plus low-dose of dalteparin in continuous veno-venous hemofiltration. Blood Purification2015;39(4):306-12. [MEDLINE: 26022434]ZhangK , GongD , JiD , XuB , IIuZ . Regional citrate plus low dose of low molecular weight heparins: a safe and more efficacy anticoagulation protocol for continuous veno - venous hemofiltration [abstract no: 71]. In: CCRT 2012. 17th International Conference on CRRT; 2012 Feb 14-17; San Diego (CA). 2012. [CENTRAL: CN-01658175] ">Wu 2015b</a>). </p> </section> <section id="CD012467-sec-0202"> <h5 class="title">Metabolic disturbances</h5> <p>It was uncertain whether citrate plus LMWH compared to LMWH leads to metabolic disturbances because the certainty of the evidence is very low (<a href="./references#CD012467-fig-0080" title="">Analysis 18.4</a>) (<a href="./references#CD012467-bbs2-0034" title="WuB , ZhangK , XuB , JiD , LiuZ , GongD . Randomized controlled trial to evaluate regional citrate anticoagulation plus low-dose of dalteparin in continuous veno-venous hemofiltration. Blood Purification2015;39(4):306-12. [MEDLINE: 26022434]ZhangK , GongD , JiD , XuB , IIuZ . Regional citrate plus low dose of low molecular weight heparins: a safe and more efficacy anticoagulation protocol for continuous veno - venous hemofiltration [abstract no: 71]. In: CCRT 2012. 17th International Conference on CRRT; 2012 Feb 14-17; San Diego (CA). 2012. [CENTRAL: CN-01658175] ">Wu 2015b</a>). </p> </section> <section id="CD012467-sec-0203"> <h5 class="title">Hypernatraemia</h5> <p><a href="./references#CD012467-bbs2-0034" title="WuB , ZhangK , XuB , JiD , LiuZ , GongD . Randomized controlled trial to evaluate regional citrate anticoagulation plus low-dose of dalteparin in continuous veno-venous hemofiltration. Blood Purification2015;39(4):306-12. [MEDLINE: 26022434]ZhangK , GongD , JiD , XuB , IIuZ . Regional citrate plus low dose of low molecular weight heparins: a safe and more efficacy anticoagulation protocol for continuous veno - venous hemofiltration [abstract no: 71]. In: CCRT 2012. 17th International Conference on CRRT; 2012 Feb 14-17; San Diego (CA). 2012. [CENTRAL: CN-01658175] ">Wu 2015b</a> reported there were no cases of hypernatraemia (<a href="./references#CD012467-fig-0081" title="">Analysis 18.5</a>). </p> </section> <section id="CD012467-sec-0204"> <h5 class="title">Hypocalcaemia</h5> <p><a href="./references#CD012467-bbs2-0034" title="WuB , ZhangK , XuB , JiD , LiuZ , GongD . Randomized controlled trial to evaluate regional citrate anticoagulation plus low-dose of dalteparin in continuous veno-venous hemofiltration. Blood Purification2015;39(4):306-12. [MEDLINE: 26022434]ZhangK , GongD , JiD , XuB , IIuZ . Regional citrate plus low dose of low molecular weight heparins: a safe and more efficacy anticoagulation protocol for continuous veno - venous hemofiltration [abstract no: 71]. In: CCRT 2012. 17th International Conference on CRRT; 2012 Feb 14-17; San Diego (CA). 2012. [CENTRAL: CN-01658175] ">Wu 2015b</a> reported there were no cases of hypocalcaemia (<a href="./references#CD012467-fig-0082" title="">Analysis 18.6</a>). </p> </section> <section id="CD012467-sec-0205"> <h5 class="title">Recovery of kidney function</h5> <p>It was uncertain whether citrate plus LMWH compare to LMWH make little or no difference to recovery of kidney function because the certainty of the evidence is very low (<a href="./references#CD012467-fig-0083" title="">Analysis 18.7</a>) (<a href="./references#CD012467-bbs2-0034" title="WuB , ZhangK , XuB , JiD , LiuZ , GongD . Randomized controlled trial to evaluate regional citrate anticoagulation plus low-dose of dalteparin in continuous veno-venous hemofiltration. Blood Purification2015;39(4):306-12. [MEDLINE: 26022434]ZhangK , GongD , JiD , XuB , IIuZ . Regional citrate plus low dose of low molecular weight heparins: a safe and more efficacy anticoagulation protocol for continuous veno - venous hemofiltration [abstract no: 71]. In: CCRT 2012. 17th International Conference on CRRT; 2012 Feb 14-17; San Diego (CA). 2012. [CENTRAL: CN-01658175] ">Wu 2015b</a>). </p> </section> <section id="CD012467-sec-0206"> <h5 class="title">Thrombocytopenia</h5> <p><a href="./references#CD012467-bbs2-0034" title="WuB , ZhangK , XuB , JiD , LiuZ , GongD . Randomized controlled trial to evaluate regional citrate anticoagulation plus low-dose of dalteparin in continuous veno-venous hemofiltration. Blood Purification2015;39(4):306-12. [MEDLINE: 26022434]ZhangK , GongD , JiD , XuB , IIuZ . Regional citrate plus low dose of low molecular weight heparins: a safe and more efficacy anticoagulation protocol for continuous veno - venous hemofiltration [abstract no: 71]. In: CCRT 2012. 17th International Conference on CRRT; 2012 Feb 14-17; San Diego (CA). 2012. [CENTRAL: CN-01658175] ">Wu 2015b</a> reported there were no cases of thrombocytopenia (<a href="./references#CD012467-fig-0084" title="">Analysis 18.8</a>). </p> </section> <section id="CD012467-sec-0207"> <h5 class="title">Adverse events</h5> <section id="CD012467-sec-0208"> <h6 class="title">Number of treatment cessations due to any adverse events (technique or patient‐dependent factors) </h6> <p><a href="./references#CD012467-bbs2-0034" title="WuB , ZhangK , XuB , JiD , LiuZ , GongD . Randomized controlled trial to evaluate regional citrate anticoagulation plus low-dose of dalteparin in continuous veno-venous hemofiltration. Blood Purification2015;39(4):306-12. [MEDLINE: 26022434]ZhangK , GongD , JiD , XuB , IIuZ . Regional citrate plus low dose of low molecular weight heparins: a safe and more efficacy anticoagulation protocol for continuous veno - venous hemofiltration [abstract no: 71]. In: CCRT 2012. 17th International Conference on CRRT; 2012 Feb 14-17; San Diego (CA). 2012. [CENTRAL: CN-01658175] ">Wu 2015b</a> reported there were no dropouts due to adverse events (<a href="./references#CD012467-fig-0085" title="">Analysis 18.9</a>). </p> </section> <section id="CD012467-sec-0209"> <h6 class="title">Number of treatment attempts with adverse events (technique or patient‐dependent factors)</h6> <p>We could not analyse this outcome due to inadequate reporting of adverse events.</p> </section> <section id="CD012467-sec-0210"> <h6 class="title">Number of patients with any adverse events</h6> <p>The number of patients who experienced any adverse events is tabulated in <a href="#CD012467-tbl-0018">Table 15</a>. </p> <div class="table" id="CD012467-tbl-0018"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 15.</span> <span class="table-title">Adverse events: Citrate plus LMWH versus LMWH</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study ID</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Adverse events</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Intervention: events/participants</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p><a href="./references#CD012467-bbs2-0034" title="WuB , ZhangK , XuB , JiD , LiuZ , GongD . Randomized controlled trial to evaluate regional citrate anticoagulation plus low-dose of dalteparin in continuous veno-venous hemofiltration. Blood Purification2015;39(4):306-12. [MEDLINE: 26022434]ZhangK , GongD , JiD , XuB , IIuZ . Regional citrate plus low dose of low molecular weight heparins: a safe and more efficacy anticoagulation protocol for continuous veno - venous hemofiltration [abstract no: 71]. In: CCRT 2012. 17th International Conference on CRRT; 2012 Feb 14-17; San Diego (CA). 2012. [CENTRAL: CN-01658175] ">Wu 2015b</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Bleeding</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Citrate + LMWH: 1/19</p> <p>LMWH: 4/19</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hypocalcaemia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Citrate + LMWH: 0/19</p> <p>LMWH: 0/19</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Metabolic acidosis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Citrate + LMWH: 4/19</p> <p>LMWH: 0/19</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Severe metabolic acidosis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Citrate + LMWH: 0/19</p> <p>LMWH: 0/19</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>LMWH ‐ low molecular weight heparin</p> </div> </div> </section> </section> <section id="CD012467-sec-0211"> <h5 class="title">Cost to health care services</h5> <p>One study reported the mean cost of CRRT/patient/day was USD511 Ã‚Â± 60 for the citrate plus LMWH group and USD594 Ã‚Â± 116 for the citrate group (<a href="./references#CD012467-bbs2-0034" title="WuB , ZhangK , XuB , JiD , LiuZ , GongD . Randomized controlled trial to evaluate regional citrate anticoagulation plus low-dose of dalteparin in continuous veno-venous hemofiltration. Blood Purification2015;39(4):306-12. [MEDLINE: 26022434]ZhangK , GongD , JiD , XuB , IIuZ . Regional citrate plus low dose of low molecular weight heparins: a safe and more efficacy anticoagulation protocol for continuous veno - venous hemofiltration [abstract no: 71]. In: CCRT 2012. 17th International Conference on CRRT; 2012 Feb 14-17; San Diego (CA). 2012. [CENTRAL: CN-01658175] ">Wu 2015b</a>); however, the detailed method of the calculation was not clear. </p> </section> <section id="CD012467-sec-0212"> <h5 class="title">Other outcomes</h5> <p>No other outcomes were reported for this comparison.</p> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD012467-sec-0213" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD012467-sec-0213"></div> <section id="CD012467-sec-0214"> <h3 class="title" id="CD012467-sec-0214">Summary of main results</h3> <p>This review summarizes 34 studies involving 1960Ã‚Â participants with CRRT that reported the effects of a variety of pharmacological interventions on critical care and CRRT‐related outcomes. All studies were in adults or unknown age; no studies were identified that evaluated therapy for children with CRRT. The cause AKI of involved patients were highly heterogeneous. The most common interventions were heparin‐derivatives and citrate. Other interventions included protamine, PGI2, PGE1, bivalirudin, hirudin, and low molecular weight dextran. For the comparison of citrate to no anticoagulation, no completed study was identified. Risks of bias in the included studies were often high or unclear, and due to these risks combined with imprecision in effect estimates, we frequently evaluated the certainty of evidence as low or very low.Ã‚Â  </p> <p>In general, currently available evidence does not support the superiority of any anticoagulant to another; however, citrate probably has a lower bleeding risk and increases successful prevention of clotting compared to UFH. For death, compared to UFH, citrate probably makes little or no difference. It was uncertain whether citrate compares to no anticoagulation increases or reduces bleeding, successfully prevent clotting or mortality. All other anticoagulants including LMWH were not proven to reduce or increase the risk of bleeding nor successfully prevent clotting compared to citrate or to no anticoagulation. </p> </section> <section id="CD012467-sec-0215"> <h3 class="title" id="CD012467-sec-0215">Overall completeness and applicability of evidence</h3> <p>We conducted this systematic review using Cochrane standard methods to capture a comprehensive, overview of all pharmacological interventions to prevent clotting of CRRT circuits. The body of the evidence showed that we do not have adequate data with high certainty to determine the safest pharmacological intervention to maintain the patency of CRRT circuits. </p> <p>Currently, citrate, UFH or no anticoagulation are used most frequently to prevent clotting of circuits in CRRT (<a href="./references#CD012467-bbs2-0062" title="DavenportA . Anticoagulation for continuous renal replacement therapy. UpToDate2018;Topic 16855 Version 12.0.">Davenport 2018</a>; <a href="./references#CD012467-bbs2-0088" title="TolwaniAJ , WilleKM . Anticoagulation for continuous renal replacement therapy. Seminars in Dialysis2009;22(2):141-5. [MEDLINE: 19426417]">Tolwani 2009</a>). We found RCTs of citrate versus UFH (eight completed studies). However, we found only one small completed study (<a href="./references#CD012467-bbs2-0002" title="BellomoR , TeedeH , BoyceN . Anticoagulant regimens in acute continuous hemodiafiltration: a comparative study. Intensive Care Medicine1993;19(6):329-32. [MEDLINE: 8227722]">Bellomo 1993</a>) that compared UFH versus no anticoagulation and only two studies (<a href="./references#CD012467-bbs2-0056" title="SrisawatN . Immunomodulation effect of regional citrate anticoagulation in acute kidney injury requiring continuous renal replacement therapy. www.clinicaltrials.gov/ct2/show/NCT02423642 (first received 22 April 2015). ">NCT02423642</a>; <a href="./references#CD012467-bbs2-0060" title="ArcaroliJ . Clinical evaluation of use of prismocitrate 18 in patients undergoing acute continuous renal replacement therapy (CRRT). www.clinicaltrials.gov/ct2/show/NCT02860130 (first received 9 August 2016). ">NCT02860130</a>) that compared citrate versus no anticoagulation. We could not obtain the results of the recently completed study (<a href="./references#CD012467-bbs2-0056" title="SrisawatN . Immunomodulation effect of regional citrate anticoagulation in acute kidney injury requiring continuous renal replacement therapy. www.clinicaltrials.gov/ct2/show/NCT02423642 (first received 22 April 2015). ">NCT02423642</a>) and one ongoing studies we found compared citrate versus no anticoagulation was terminated due to low recruitment (<a href="./references#CD012467-bbs2-0060" title="ArcaroliJ . Clinical evaluation of use of prismocitrate 18 in patients undergoing acute continuous renal replacement therapy (CRRT). www.clinicaltrials.gov/ct2/show/NCT02860130 (first received 9 August 2016). ">NCT02860130</a>). </p> <p>We excluded several studies comparing different dosages of particular treatments (<a href="./references#CD012467-bbs2-0037" title="AnsteyC , CampbellV , RichardsonA . A comparison between two dilute citrate solutions (15 vs. 18 mmol/l) in continuous renal replacement therapy: the Base Excess and Renal Substitution Solution study. Blood Purification2016;42(3):194-201. [MEDLINE: 27352175]">Anstey 2016</a>; <a href="./references#CD012467-bbs2-0038" title="HenrikssonBA . Evaluation of lifespan in AN69ST with two different heparinization strategies. www.isrctn.com/ISRCTN01121161 (first received 13 March 2013). ">ISRCTN01121161</a>; <a href="./references#CD012467-bbs2-0039" title="Kozek-LangeneckerSA , KettnerSC , OismuellerC , GonanoC , SpeiserW , ZimpferM . Anticoagulation with prostaglandin E1 and unfractionated heparin during continuous venovenous hemofiltration. Critical Care Medicine1998;26(7):1208-12. [MEDLINE: 9671370]">Kozek‐Langenecker 1998</a>; <a href="./references#CD012467-bbs2-0042" title="LeslieGD , JacobsIG , ClarkeGM . Proximally delivered dilute heparin does not improve circuit life in continuous venovenous haemodiafiltration. Intensive Care Medicine1996;22(11):1261-4. [MEDLINE: 9120123]">Leslie 1996</a>; <a href="./references#CD012467-bbs2-0046" title="BoerW . Magnesium balance of citrate-based continuous venovenous hemofiltration, effect of citrate dose. www.clinicaltrials.gov/ct2/show/NCT02194569 (first received 18 July 2014). ">NCT02194569</a>) in order to assess the drug‐class effect. Formal methodologies of applicability assessment of relative ratio or absolute risk difference for different dose comparison have not been established. Further studies are needed to assess the dosing of single pharmacological interventions. </p> <p>Studies that comprehensively address the cost for health care services were lacking. Most studies reported on the treatment cost or described only a part of the cost, which was vulnerable to investigators' or study sponsors' conflict of interest. Therefore, we decided these results should not be in the Summary of Findings table to avoid misinterpretation. Guidance for primary research that addresses the overall costs of CRRT is desperately needed. </p> <p>Several ongoing or unpublished studies were identified that met our inclusion criteria: <a href="./references#CD012467-bbs2-0058" title="NCT01839578. Regional citrate versus systemic heparin anticoagulation for super high-flux continuous hemodialysis in septic shock: effect on middle molecular weight molecules clearances. www.clinicaltrials.gov/ct2/show/NCT01839578 (first received 25 April 2013). ">NCT01839578</a> (citrate versus UFH); <a href="./references#CD012467-bbs2-0056" title="SrisawatN . Immunomodulation effect of regional citrate anticoagulation in acute kidney injury requiring continuous renal replacement therapy. www.clinicaltrials.gov/ct2/show/NCT02423642 (first received 22 April 2015). ">NCT02423642</a> (citrate versus UFH or no anticoagulation); <a href="./references#CD012467-bbs2-0059" title="ZarbockA . Regional citrate versus systemic heparin anticoagulation for continuous renal replacement therapy in critically ill patients with acute kidney injury. www.clinicaltrials.gov/ct2/show/NCT02669589 (first received 1 February 2016). ">NCT02669589</a> (citrate versus UFH). Since the certainty of the evidence is moderate or low for the outcomes we assessed with the completed studies, the estimates of the treatment effect might change after the dissemination of these studies' results. </p> <p>One limitation of our review is data availability. We planned to synthesise the data from cross‐over or multiple‐enrolment studies using only the first intervention; however, such information was not available and we performed our analysis based on whatever data the authors provided, using the total number of circuits as the denominator as a priori defined review protocol.Ã‚Â  </p> <p>Additionally, the effects of the anticoagulants on “successful prevention of clotting” were documented often using different outcome measures, such as filter survival time, which limited our ability to combine studies. The reason why we chose “successful prevention of clotting” instead of “filter life” is because it is a patient‐oriented outcome and what is important to answer here is which pharmacological intervention is more likely to prevent a clot of the circuit during treatment. Also, the 24‐hour timeframe is suggested to assess the need for anticoagulation therapy in literature. </p> </section> <section id="CD012467-sec-0216"> <h3 class="title" id="CD012467-sec-0216">Quality of the evidence</h3> <p>Overall, most studies had high or unclear risks of bias for some or most domains (<a href="#CD012467-fig-0002">Figure 2</a>). The GRADE assessments for each outcome are presented individually in the <a href="./full#CD012467-tbl-0001">summary of findings Table 1</a>; <a href="./full#CD012467-tbl-0002">summary of findings Table 2</a>; <a href="./full#CD012467-tbl-0003">summary of findings Table 3</a> or result section. </p> </section> <section id="CD012467-sec-0217"> <h3 class="title" id="CD012467-sec-0217">Potential biases in the review process</h3> <p>We identified 34 completed studies of which 3 were available only in an abstract format (all investigated LMWH vs UFH). We could not obtain additional information through follow‐up with the authors. There might be potential bias influenced by data availability or publication status. </p> </section> <section id="CD012467-sec-0218"> <h3 class="title" id="CD012467-sec-0218">Agreements and disagreements with other studies or reviews</h3> <p>There have been several reviews that compared the major anticoagulants (e.g. citrate versus UFH) (<a href="./references#CD012467-bbs2-0062" title="DavenportA . Anticoagulation for continuous renal replacement therapy. UpToDate2018;Topic 16855 Version 12.0.">Davenport 2018</a>; <a href="./references#CD012467-bbs2-0073" title="Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group. KDIGO Clinical Practice Guideline for Acute Kidney Injury. Kidney international - Supplement2012;2(1):1-138. [DOI: 10.1038/kisup.2012.1]">KDIGO 2012</a>; <a href="./references#CD012467-bbs2-0076" title="LiuC , MaoZ , KangH , HuJ , ZhouF . Regional citrate versus heparin anticoagulation for continuous renal replacement therapy in critically ill patients: a meta-analysis with trial sequential analysis of randomized controlled trials. Critical Care (London, England)2016;20(1):144. [MEDLINE: 27176622]">Liu 2016</a>). </p> <p><a href="./references#CD012467-bbs2-0076" title="LiuC , MaoZ , KangH , HuJ , ZhouF . Regional citrate versus heparin anticoagulation for continuous renal replacement therapy in critically ill patients: a meta-analysis with trial sequential analysis of randomized controlled trials. Critical Care (London, England)2016;20(1):144. [MEDLINE: 27176622]">Liu 2016</a> systematically reviewed citrate versus UFH with or without protamine or LMWH of CRRT. They compared citrate versus UFH with or without protamine or LMWH and reported that citrate further prolonged circuit lifespan and reduced the risk of bleeding, bud there was showed no difference in mortality. They concluded that "citrate should be recommended as the priority anticoagulant for critically ill patients who require CRRT". <a href="./references#CD012467-bbs2-0088" title="TolwaniAJ , WilleKM . Anticoagulation for continuous renal replacement therapy. Seminars in Dialysis2009;22(2):141-5. [MEDLINE: 19426417]">Tolwani 2009</a> reviewed (not systematically) and summarised studies of all anticoagulation methods and stated that citrate decreased the rate of clotting and citrate reduced the risks of bleeding compared with systemic heparin. </p> <p><a href="./references#CD012467-bbs2-0062" title="DavenportA . Anticoagulation for continuous renal replacement therapy. UpToDate2018;Topic 16855 Version 12.0.">Davenport 2018</a> reviewed and summarised studies of all anticoagulation methods for CRRT and recommended that citrate should be used for CRRT anticoagulation. The authors suggested that they use pharmacological anticoagulation if the haemofilter was clotted without anticoagulation within 24 hours. They proposed to use citrate rather than UFH if citrate is available and the patient has no contraindication. The review recommended that citrate is better than heparin for prevention of clotting and is less likely to cause bleeding. However, they stated citrate does not have a survival benefit compared with heparin. A clinical practice guideline from KDIGO also recommended citrate use if there was no risk of the citrate accumulation (<a href="./references#CD012467-bbs2-0073" title="Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group. KDIGO Clinical Practice Guideline for Acute Kidney Injury. Kidney international - Supplement2012;2(1):1-138. [DOI: 10.1038/kisup.2012.1]">KDIGO 2012</a>). </p> <p>The current systematic review supports these findings. However, for the comparison of citrate versus UFH plus protamine, LMWH or other pharmacological anticoagulants, there were few studies and little data available for clinically relevant outcomes and the certainty of the evidence was mostly low or very low. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD012467-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/urn:x-wiley:14651858:media:CD012467:CD012467-FIG-01" target="_blank"><b></b></a></p> </div><img alt="Flow chart of study selection" data-id="CD012467-fig-0001" src="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/image_n/nCD012467-FIG-01.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/image_t/tCD012467-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Flow chart of study selection</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/full#CD012467-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/image_n/nCD012467-FIG-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012467-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/urn:x-wiley:14651858:media:CD012467:CD012467-FIG-02" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD012467-fig-0002" src="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/image_n/nCD012467-FIG-02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/image_t/tCD012467-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/full#CD012467-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/image_n/nCD012467-FIG-02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012467-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/urn:x-wiley:14651858:media:CD012467:CD012467-FIG-03" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD012467-fig-0003" src="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/image_n/nCD012467-FIG-03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/image_t/tCD012467-FIG-03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/full#CD012467-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/image_n/nCD012467-FIG-03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012467-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/urn:x-wiley:14651858:media:CD012467:CD012467-FIG-04" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Citrate versus UFH, outcome: 1.1 Major bleeding." data-id="CD012467-fig-0004" src="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/image_n/nCD012467-FIG-04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/image_t/tCD012467-FIG-04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Citrate versus UFH, outcome: 1.1 Major bleeding.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/full#CD012467-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/image_n/nCD012467-FIG-04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012467-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/urn:x-wiley:14651858:media:CD012467:CD012467-FIG-05" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Citrate versus UFH, outcome: 1.2 Death at 28 days." data-id="CD012467-fig-0005" src="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/image_n/nCD012467-FIG-05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/image_t/tCD012467-FIG-05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Citrate versus UFH, outcome: 1.2 Death at 28 days.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/full#CD012467-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/image_n/nCD012467-FIG-05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012467-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/urn:x-wiley:14651858:media:CD012467:CD012467-FIG-06" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Citrate versus UFH, outcome: 1.3 Successful prevention of clotting." data-id="CD012467-fig-0006" src="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/image_n/nCD012467-FIG-06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/image_t/tCD012467-FIG-06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 6</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Citrate versus UFH, outcome: 1.3 Successful prevention of clotting. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/full#CD012467-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/image_n/nCD012467-FIG-06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012467-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/urn:x-wiley:14651858:media:CD012467:CD012467-FIG-07" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 3 UFH versus LMWH, outcome: 3.1 Major bleeding." data-id="CD012467-fig-0007" src="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/image_n/nCD012467-FIG-07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/image_t/tCD012467-FIG-07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 7</div> <div class="figure-caption"> <p>Forest plot of comparison: 3 UFH versus LMWH, outcome: 3.1 Major bleeding.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/full#CD012467-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/image_n/nCD012467-FIG-07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012467-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/urn:x-wiley:14651858:media:CD012467:CD012467-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Citrate versus UFH, Outcome 1: Major bleeding" data-id="CD012467-fig-0008" src="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/image_n/nCD012467-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/image_t/tCD012467-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: Citrate versus UFH, Outcome 1: Major bleeding</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/references#CD012467-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/image_n/nCD012467-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012467-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/urn:x-wiley:14651858:media:CD012467:CD012467-CMP-001.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Citrate versus UFH, Outcome 2: Death at 28 days" data-id="CD012467-fig-0009" src="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/image_n/nCD012467-CMP-001.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/image_t/tCD012467-CMP-001.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1: Citrate versus UFH, Outcome 2: Death at 28 days</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/references#CD012467-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/image_n/nCD012467-CMP-001.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012467-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/urn:x-wiley:14651858:media:CD012467:CD012467-CMP-001.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Citrate versus UFH, Outcome 3: Successful prevention of clotting" data-id="CD012467-fig-0010" src="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/image_n/nCD012467-CMP-001.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/image_t/tCD012467-CMP-001.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1: Citrate versus UFH, Outcome 3: Successful prevention of clotting</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/references#CD012467-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/image_n/nCD012467-CMP-001.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012467-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/urn:x-wiley:14651858:media:CD012467:CD012467-CMP-001.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Citrate versus UFH, Outcome 4: Metabolic disturbances" data-id="CD012467-fig-0011" src="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/image_n/nCD012467-CMP-001.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/image_t/tCD012467-CMP-001.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1: Citrate versus UFH, Outcome 4: Metabolic disturbances</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/references#CD012467-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/image_n/nCD012467-CMP-001.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012467-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/urn:x-wiley:14651858:media:CD012467:CD012467-CMP-001.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Citrate versus UFH, Outcome 5: Hypernatraemia" data-id="CD012467-fig-0012" src="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/image_n/nCD012467-CMP-001.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/image_t/tCD012467-CMP-001.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1: Citrate versus UFH, Outcome 5: Hypernatraemia</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/references#CD012467-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/image_n/nCD012467-CMP-001.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012467-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/urn:x-wiley:14651858:media:CD012467:CD012467-CMP-001.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Citrate versus UFH, Outcome 6: Hypocalcaemia" data-id="CD012467-fig-0013" src="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/image_n/nCD012467-CMP-001.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/image_t/tCD012467-CMP-001.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1: Citrate versus UFH, Outcome 6: Hypocalcaemia</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/references#CD012467-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/image_n/nCD012467-CMP-001.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012467-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/urn:x-wiley:14651858:media:CD012467:CD012467-CMP-001.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Citrate versus UFH, Outcome 7: Hypercalcaemia" data-id="CD012467-fig-0014" src="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/image_n/nCD012467-CMP-001.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/image_t/tCD012467-CMP-001.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1: Citrate versus UFH, Outcome 7: Hypercalcaemia</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/references#CD012467-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/image_n/nCD012467-CMP-001.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012467-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/urn:x-wiley:14651858:media:CD012467:CD012467-CMP-001.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Citrate versus UFH, Outcome 8: Recovery of kidney function" data-id="CD012467-fig-0015" src="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/image_n/nCD012467-CMP-001.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/image_t/tCD012467-CMP-001.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1: Citrate versus UFH, Outcome 8: Recovery of kidney function</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/references#CD012467-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/image_n/nCD012467-CMP-001.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012467-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/urn:x-wiley:14651858:media:CD012467:CD012467-CMP-001.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Citrate versus UFH, Outcome 9: Thrombocytopenia" data-id="CD012467-fig-0016" src="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/image_n/nCD012467-CMP-001.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/image_t/tCD012467-CMP-001.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1: Citrate versus UFH, Outcome 9: Thrombocytopenia</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/references#CD012467-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/image_n/nCD012467-CMP-001.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012467-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/urn:x-wiley:14651858:media:CD012467:CD012467-CMP-001.10" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Citrate versus UFH, Outcome 10: Catheter thrombotic events" data-id="CD012467-fig-0017" src="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/image_n/nCD012467-CMP-001.10.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/image_t/tCD012467-CMP-001.10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.10</div> <div class="figure-caption"> <p>Comparison 1: Citrate versus UFH, Outcome 10: Catheter thrombotic events</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/references#CD012467-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/image_n/nCD012467-CMP-001.10.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012467-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/urn:x-wiley:14651858:media:CD012467:CD012467-CMP-001.11" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Citrate versus UFH, Outcome 11: Treatment cessation due to any adverse event" data-id="CD012467-fig-0018" src="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/image_n/nCD012467-CMP-001.11.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/image_t/tCD012467-CMP-001.11.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.11</div> <div class="figure-caption"> <p>Comparison 1: Citrate versus UFH, Outcome 11: Treatment cessation due to any adverse event </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/references#CD012467-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/image_n/nCD012467-CMP-001.11.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012467-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/urn:x-wiley:14651858:media:CD012467:CD012467-CMP-001.12" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Citrate versus UFH, Outcome 12: Treatment attempts with any adverse events" data-id="CD012467-fig-0019" src="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/image_n/nCD012467-CMP-001.12.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/image_t/tCD012467-CMP-001.12.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.12</div> <div class="figure-caption"> <p>Comparison 1: Citrate versus UFH, Outcome 12: Treatment attempts with any adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/references#CD012467-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/image_n/nCD012467-CMP-001.12.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012467-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/urn:x-wiley:14651858:media:CD012467:CD012467-CMP-002.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Citrate versus LMWH, Outcome 1: Major bleeding" data-id="CD012467-fig-0020" src="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/image_n/nCD012467-CMP-002.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/image_t/tCD012467-CMP-002.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2: Citrate versus LMWH, Outcome 1: Major bleeding</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/references#CD012467-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/image_n/nCD012467-CMP-002.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012467-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/urn:x-wiley:14651858:media:CD012467:CD012467-CMP-002.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Citrate versus LMWH, Outcome 2: Death" data-id="CD012467-fig-0021" src="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/image_n/nCD012467-CMP-002.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/image_t/tCD012467-CMP-002.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2: Citrate versus LMWH, Outcome 2: Death</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/references#CD012467-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/image_n/nCD012467-CMP-002.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012467-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/urn:x-wiley:14651858:media:CD012467:CD012467-CMP-002.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Citrate versus LMWH, Outcome 3: Successful prevention of clotting" data-id="CD012467-fig-0022" src="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/image_n/nCD012467-CMP-002.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/image_t/tCD012467-CMP-002.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2: Citrate versus LMWH, Outcome 3: Successful prevention of clotting</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/references#CD012467-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/image_n/nCD012467-CMP-002.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012467-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/urn:x-wiley:14651858:media:CD012467:CD012467-CMP-002.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Citrate versus LMWH, Outcome 4: Metabolic disturbances" data-id="CD012467-fig-0023" src="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/image_n/nCD012467-CMP-002.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/image_t/tCD012467-CMP-002.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2: Citrate versus LMWH, Outcome 4: Metabolic disturbances</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/references#CD012467-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/image_n/nCD012467-CMP-002.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012467-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/urn:x-wiley:14651858:media:CD012467:CD012467-CMP-002.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Citrate versus LMWH, Outcome 5: Hypernatraemia" data-id="CD012467-fig-0024" src="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/image_n/nCD012467-CMP-002.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/image_t/tCD012467-CMP-002.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2: Citrate versus LMWH, Outcome 5: Hypernatraemia</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/references#CD012467-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/image_n/nCD012467-CMP-002.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012467-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/urn:x-wiley:14651858:media:CD012467:CD012467-CMP-002.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Citrate versus LMWH, Outcome 6: Hypocalcaemia" data-id="CD012467-fig-0025" src="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/image_n/nCD012467-CMP-002.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/image_t/tCD012467-CMP-002.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.6</div> <div class="figure-caption"> <p>Comparison 2: Citrate versus LMWH, Outcome 6: Hypocalcaemia</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/references#CD012467-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/image_n/nCD012467-CMP-002.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012467-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/urn:x-wiley:14651858:media:CD012467:CD012467-CMP-002.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Citrate versus LMWH, Outcome 7: Hypercalcaemia" data-id="CD012467-fig-0026" src="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/image_n/nCD012467-CMP-002.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/image_t/tCD012467-CMP-002.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.7</div> <div class="figure-caption"> <p>Comparison 2: Citrate versus LMWH, Outcome 7: Hypercalcaemia</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/references#CD012467-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/image_n/nCD012467-CMP-002.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012467-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/urn:x-wiley:14651858:media:CD012467:CD012467-CMP-002.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Citrate versus LMWH, Outcome 8: Recovery of kidney function" data-id="CD012467-fig-0027" src="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/image_n/nCD012467-CMP-002.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/image_t/tCD012467-CMP-002.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.8</div> <div class="figure-caption"> <p>Comparison 2: Citrate versus LMWH, Outcome 8: Recovery of kidney function</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/references#CD012467-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/image_n/nCD012467-CMP-002.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012467-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/urn:x-wiley:14651858:media:CD012467:CD012467-CMP-002.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Citrate versus LMWH, Outcome 9: Thrombocytopenia" data-id="CD012467-fig-0028" src="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/image_n/nCD012467-CMP-002.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/image_t/tCD012467-CMP-002.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.9</div> <div class="figure-caption"> <p>Comparison 2: Citrate versus LMWH, Outcome 9: Thrombocytopenia</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/references#CD012467-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/image_n/nCD012467-CMP-002.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012467-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/urn:x-wiley:14651858:media:CD012467:CD012467-CMP-002.10" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Citrate versus LMWH, Outcome 10: Treatment cessation due to any adverse event" data-id="CD012467-fig-0029" src="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/image_n/nCD012467-CMP-002.10.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/image_t/tCD012467-CMP-002.10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.10</div> <div class="figure-caption"> <p>Comparison 2: Citrate versus LMWH, Outcome 10: Treatment cessation due to any adverse event </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/references#CD012467-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/image_n/nCD012467-CMP-002.10.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012467-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/urn:x-wiley:14651858:media:CD012467:CD012467-CMP-003.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: UFH versus LMWH, Outcome 1: Major bleeding" data-id="CD012467-fig-0030" src="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/image_n/nCD012467-CMP-003.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/image_t/tCD012467-CMP-003.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3: UFH versus LMWH, Outcome 1: Major bleeding</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/references#CD012467-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/image_n/nCD012467-CMP-003.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012467-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/urn:x-wiley:14651858:media:CD012467:CD012467-CMP-003.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: UFH versus LMWH, Outcome 2: Death (unknown time frame)" data-id="CD012467-fig-0031" src="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/image_n/nCD012467-CMP-003.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/image_t/tCD012467-CMP-003.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3: UFH versus LMWH, Outcome 2: Death (unknown time frame)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/references#CD012467-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/image_n/nCD012467-CMP-003.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012467-fig-0032"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/urn:x-wiley:14651858:media:CD012467:CD012467-CMP-003.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: UFH versus LMWH, Outcome 3: Successful prevention of clotting" data-id="CD012467-fig-0032" src="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/image_n/nCD012467-CMP-003.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/image_t/tCD012467-CMP-003.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3: UFH versus LMWH, Outcome 3: Successful prevention of clotting</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/references#CD012467-fig-0032">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/image_n/nCD012467-CMP-003.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012467-fig-0033"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/urn:x-wiley:14651858:media:CD012467:CD012467-CMP-003.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: UFH versus LMWH, Outcome 4: Thrombocytopenia" data-id="CD012467-fig-0033" src="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/image_n/nCD012467-CMP-003.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/image_t/tCD012467-CMP-003.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.4</div> <div class="figure-caption"> <p>Comparison 3: UFH versus LMWH, Outcome 4: Thrombocytopenia</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/references#CD012467-fig-0033">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/image_n/nCD012467-CMP-003.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012467-fig-0034"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/urn:x-wiley:14651858:media:CD012467:CD012467-CMP-003.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: UFH versus LMWH, Outcome 5: Treatment cessation due to any adverse event" data-id="CD012467-fig-0034" src="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/image_n/nCD012467-CMP-003.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/image_t/tCD012467-CMP-003.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.5</div> <div class="figure-caption"> <p>Comparison 3: UFH versus LMWH, Outcome 5: Treatment cessation due to any adverse event</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/references#CD012467-fig-0034">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/image_n/nCD012467-CMP-003.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012467-fig-0035"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/urn:x-wiley:14651858:media:CD012467:CD012467-CMP-003.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: UFH versus LMWH, Outcome 6: Any adverse event" data-id="CD012467-fig-0035" src="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/image_n/nCD012467-CMP-003.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/image_t/tCD012467-CMP-003.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.6</div> <div class="figure-caption"> <p>Comparison 3: UFH versus LMWH, Outcome 6: Any adverse event</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/references#CD012467-fig-0035">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/image_n/nCD012467-CMP-003.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012467-fig-0036"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/urn:x-wiley:14651858:media:CD012467:CD012467-CMP-004.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: UFH versus no anticoagulation, Outcome 1: Major bleeding" data-id="CD012467-fig-0036" src="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/image_n/nCD012467-CMP-004.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/image_t/tCD012467-CMP-004.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4: UFH versus no anticoagulation, Outcome 1: Major bleeding</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/references#CD012467-fig-0036">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/image_n/nCD012467-CMP-004.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012467-fig-0037"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/urn:x-wiley:14651858:media:CD012467:CD012467-CMP-005.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Nafamostat mesilate versus no anticoagulation, Outcome 1: Major bleeding" data-id="CD012467-fig-0037" src="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/image_n/nCD012467-CMP-005.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/image_t/tCD012467-CMP-005.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.1</div> <div class="figure-caption"> <p>Comparison 5: Nafamostat mesilate versus no anticoagulation, Outcome 1: Major bleeding</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/references#CD012467-fig-0037">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/image_n/nCD012467-CMP-005.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012467-fig-0038"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/urn:x-wiley:14651858:media:CD012467:CD012467-CMP-005.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Nafamostat mesilate versus no anticoagulation, Outcome 2: Death at 28 days" data-id="CD012467-fig-0038" src="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/image_n/nCD012467-CMP-005.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/image_t/tCD012467-CMP-005.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.2</div> <div class="figure-caption"> <p>Comparison 5: Nafamostat mesilate versus no anticoagulation, Outcome 2: Death at 28 days </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/references#CD012467-fig-0038">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/image_n/nCD012467-CMP-005.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012467-fig-0039"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/urn:x-wiley:14651858:media:CD012467:CD012467-CMP-005.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Nafamostat mesilate versus no anticoagulation, Outcome 3: Recovery of kidney function" data-id="CD012467-fig-0039" src="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/image_n/nCD012467-CMP-005.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/image_t/tCD012467-CMP-005.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.3</div> <div class="figure-caption"> <p>Comparison 5: Nafamostat mesilate versus no anticoagulation, Outcome 3: Recovery of kidney function </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/references#CD012467-fig-0039">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/image_n/nCD012467-CMP-005.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012467-fig-0040"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/urn:x-wiley:14651858:media:CD012467:CD012467-CMP-005.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Nafamostat mesilate versus no anticoagulation, Outcome 4: Catheter thrombotic events" data-id="CD012467-fig-0040" src="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/image_n/nCD012467-CMP-005.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/image_t/tCD012467-CMP-005.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.4</div> <div class="figure-caption"> <p>Comparison 5: Nafamostat mesilate versus no anticoagulation, Outcome 4: Catheter thrombotic events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/references#CD012467-fig-0040">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/image_n/nCD012467-CMP-005.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012467-fig-0041"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/urn:x-wiley:14651858:media:CD012467:CD012467-CMP-005.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Nafamostat mesilate versus no anticoagulation, Outcome 5: Treatment cessation due to any adverse event" data-id="CD012467-fig-0041" src="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/image_n/nCD012467-CMP-005.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/image_t/tCD012467-CMP-005.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.5</div> <div class="figure-caption"> <p>Comparison 5: Nafamostat mesilate versus no anticoagulation, Outcome 5: Treatment cessation due to any adverse event </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/references#CD012467-fig-0041">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/image_n/nCD012467-CMP-005.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012467-fig-0042"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/urn:x-wiley:14651858:media:CD012467:CD012467-CMP-005.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Nafamostat mesilate versus no anticoagulation, Outcome 6: Treatment attempts with any adverse events" data-id="CD012467-fig-0042" src="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/image_n/nCD012467-CMP-005.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/image_t/tCD012467-CMP-005.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.6</div> <div class="figure-caption"> <p>Comparison 5: Nafamostat mesilate versus no anticoagulation, Outcome 6: Treatment attempts with any adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/references#CD012467-fig-0042">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/image_n/nCD012467-CMP-005.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012467-fig-0043"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/urn:x-wiley:14651858:media:CD012467:CD012467-CMP-006.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: PGI2 versus UFH, Outcome 1: Major bleeding" data-id="CD012467-fig-0043" src="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/image_n/nCD012467-CMP-006.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/image_t/tCD012467-CMP-006.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.1</div> <div class="figure-caption"> <p>Comparison 6: PGI<sub>2</sub> versus UFH, Outcome 1: Major bleeding </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/references#CD012467-fig-0043">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/image_n/nCD012467-CMP-006.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012467-fig-0044"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/urn:x-wiley:14651858:media:CD012467:CD012467-CMP-006.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: PGI2 versus UFH, Outcome 2: Successful prevention of clotting" data-id="CD012467-fig-0044" src="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/image_n/nCD012467-CMP-006.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/image_t/tCD012467-CMP-006.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.2</div> <div class="figure-caption"> <p>Comparison 6: PGI<sub>2</sub> versus UFH, Outcome 2: Successful prevention of clotting </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/references#CD012467-fig-0044">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/image_n/nCD012467-CMP-006.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012467-fig-0045"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/urn:x-wiley:14651858:media:CD012467:CD012467-CMP-007.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: UFH plus PGI2 versus PGI2, Outcome 1: Major bleeding" data-id="CD012467-fig-0045" src="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/image_n/nCD012467-CMP-007.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/image_t/tCD012467-CMP-007.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.1</div> <div class="figure-caption"> <p>Comparison 7: UFH plus PGI<sub>2</sub> versus PGI<sub>2</sub>, Outcome 1: Major bleeding </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/references#CD012467-fig-0045">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/image_n/nCD012467-CMP-007.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012467-fig-0046"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/urn:x-wiley:14651858:media:CD012467:CD012467-CMP-008.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 8: UFH plus PGI2 versus UFH, Outcome 1: Major bleeding" data-id="CD012467-fig-0046" src="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/image_n/nCD012467-CMP-008.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/image_t/tCD012467-CMP-008.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.1</div> <div class="figure-caption"> <p>Comparison 8: UFH plus PGI<sub>2</sub> versus UFH, Outcome 1: Major bleeding </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/references#CD012467-fig-0046">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/image_n/nCD012467-CMP-008.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012467-fig-0047"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/urn:x-wiley:14651858:media:CD012467:CD012467-CMP-008.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 8: UFH plus PGI2 versus UFH, Outcome 2: Successful prevention of clotting" data-id="CD012467-fig-0047" src="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/image_n/nCD012467-CMP-008.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/image_t/tCD012467-CMP-008.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.2</div> <div class="figure-caption"> <p>Comparison 8: UFH plus PGI<sub>2</sub> versus UFH, Outcome 2: Successful prevention of clotting </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/references#CD012467-fig-0047">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/image_n/nCD012467-CMP-008.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012467-fig-0048"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/urn:x-wiley:14651858:media:CD012467:CD012467-CMP-008.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 8: UFH plus PGI2 versus UFH, Outcome 3: Thrombocytopenia" data-id="CD012467-fig-0048" src="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/image_n/nCD012467-CMP-008.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/image_t/tCD012467-CMP-008.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.3</div> <div class="figure-caption"> <p>Comparison 8: UFH plus PGI<sub>2</sub> versus UFH, Outcome 3: Thrombocytopenia </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/references#CD012467-fig-0048">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/image_n/nCD012467-CMP-008.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012467-fig-0049"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/urn:x-wiley:14651858:media:CD012467:CD012467-CMP-008.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 8: UFH plus PGI2 versus UFH, Outcome 4: Catheter thrombotic events" data-id="CD012467-fig-0049" src="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/image_n/nCD012467-CMP-008.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/image_t/tCD012467-CMP-008.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.4</div> <div class="figure-caption"> <p>Comparison 8: UFH plus PGI<sub>2</sub> versus UFH, Outcome 4: Catheter thrombotic events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/references#CD012467-fig-0049">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/image_n/nCD012467-CMP-008.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012467-fig-0050"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/urn:x-wiley:14651858:media:CD012467:CD012467-CMP-008.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 8: UFH plus PGI2 versus UFH, Outcome 5: Any adverse event" data-id="CD012467-fig-0050" src="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/image_n/nCD012467-CMP-008.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/image_t/tCD012467-CMP-008.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.5</div> <div class="figure-caption"> <p>Comparison 8: UFH plus PGI<sub>2</sub> versus UFH, Outcome 5: Any adverse event </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/references#CD012467-fig-0050">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/image_n/nCD012467-CMP-008.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012467-fig-0051"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/urn:x-wiley:14651858:media:CD012467:CD012467-CMP-009.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 9: UFH plus protamine and PGI2 versus UFH, Outcome 1: Major bleeding" data-id="CD012467-fig-0051" src="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/image_n/nCD012467-CMP-009.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/image_t/tCD012467-CMP-009.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.1</div> <div class="figure-caption"> <p>Comparison 9: UFH plus protamine and PGI<sub>2</sub> versus UFH, Outcome 1: Major bleeding </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/references#CD012467-fig-0051">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/image_n/nCD012467-CMP-009.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012467-fig-0052"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/urn:x-wiley:14651858:media:CD012467:CD012467-CMP-009.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 9: UFH plus protamine and PGI2 versus UFH, Outcome 2: Death at 24 hours" data-id="CD012467-fig-0052" src="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/image_n/nCD012467-CMP-009.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/image_t/tCD012467-CMP-009.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.2</div> <div class="figure-caption"> <p>Comparison 9: UFH plus protamine and PGI<sub>2</sub> versus UFH, Outcome 2: Death at 24 hours </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/references#CD012467-fig-0052">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/image_n/nCD012467-CMP-009.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012467-fig-0053"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/urn:x-wiley:14651858:media:CD012467:CD012467-CMP-009.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 9: UFH plus protamine and PGI2 versus UFH, Outcome 3: Successful prevention of clotting" data-id="CD012467-fig-0053" src="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/image_n/nCD012467-CMP-009.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/image_t/tCD012467-CMP-009.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.3</div> <div class="figure-caption"> <p>Comparison 9: UFH plus protamine and PGI<sub>2</sub> versus UFH, Outcome 3: Successful prevention of clotting </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/references#CD012467-fig-0053">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/image_n/nCD012467-CMP-009.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012467-fig-0054"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/urn:x-wiley:14651858:media:CD012467:CD012467-CMP-010.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 10: UFH plus PGI2 versus UFH plus PGE1, Outcome 1: Major bleeding" data-id="CD012467-fig-0054" src="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/image_n/nCD012467-CMP-010.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/image_t/tCD012467-CMP-010.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.1</div> <div class="figure-caption"> <p>Comparison 10: UFH plus PGI<sub>2</sub> versus UFH plus PGE<sub>1</sub>, Outcome 1: Major bleeding </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/references#CD012467-fig-0054">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/image_n/nCD012467-CMP-010.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012467-fig-0055"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/urn:x-wiley:14651858:media:CD012467:CD012467-CMP-010.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 10: UFH plus PGI2 versus UFH plus PGE1, Outcome 2: Successful prevention of clotting" data-id="CD012467-fig-0055" src="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/image_n/nCD012467-CMP-010.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/image_t/tCD012467-CMP-010.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.2</div> <div class="figure-caption"> <p>Comparison 10: UFH plus PGI<sub>2</sub> versus UFH plus PGE<sub>1</sub>, Outcome 2: Successful prevention of clotting </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/references#CD012467-fig-0055">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/image_n/nCD012467-CMP-010.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012467-fig-0056"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/urn:x-wiley:14651858:media:CD012467:CD012467-CMP-011.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 11: UFH plus PGE1 versus UFH, Outcome 1: Major bleeding" data-id="CD012467-fig-0056" src="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/image_n/nCD012467-CMP-011.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/image_t/tCD012467-CMP-011.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.1</div> <div class="figure-caption"> <p>Comparison 11: UFH plus PGE<sub>1</sub> versus UFH, Outcome 1: Major bleeding </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/references#CD012467-fig-0056">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/image_n/nCD012467-CMP-011.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012467-fig-0057"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/urn:x-wiley:14651858:media:CD012467:CD012467-CMP-011.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 11: UFH plus PGE1 versus UFH, Outcome 2: Successful prevention of clotting" data-id="CD012467-fig-0057" src="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/image_n/nCD012467-CMP-011.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/image_t/tCD012467-CMP-011.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.2</div> <div class="figure-caption"> <p>Comparison 11: UFH plus PGE<sub>1</sub> versus UFH, Outcome 2: Successful prevention of clotting </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/references#CD012467-fig-0057">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/image_n/nCD012467-CMP-011.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012467-fig-0058"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/urn:x-wiley:14651858:media:CD012467:CD012467-CMP-012.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 12: UFH plus tirofiban versus UFH, Outcome 1: Major bleeding" data-id="CD012467-fig-0058" src="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/image_n/nCD012467-CMP-012.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/image_t/tCD012467-CMP-012.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 12.1</div> <div class="figure-caption"> <p>Comparison 12: UFH plus tirofiban versus UFH, Outcome 1: Major bleeding</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/references#CD012467-fig-0058">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/image_n/nCD012467-CMP-012.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012467-fig-0059"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/urn:x-wiley:14651858:media:CD012467:CD012467-CMP-012.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 12: UFH plus tirofiban versus UFH, Outcome 2: Death at 28 days" data-id="CD012467-fig-0059" src="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/image_n/nCD012467-CMP-012.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/image_t/tCD012467-CMP-012.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 12.2</div> <div class="figure-caption"> <p>Comparison 12: UFH plus tirofiban versus UFH, Outcome 2: Death at 28 days</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/references#CD012467-fig-0059">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/image_n/nCD012467-CMP-012.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012467-fig-0060"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/urn:x-wiley:14651858:media:CD012467:CD012467-CMP-013.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 13: Bivalirudin versus UFH, Outcome 1: Major bleeding" data-id="CD012467-fig-0060" src="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/image_n/nCD012467-CMP-013.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/image_t/tCD012467-CMP-013.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 13.1</div> <div class="figure-caption"> <p>Comparison 13: Bivalirudin versus UFH, Outcome 1: Major bleeding</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/references#CD012467-fig-0060">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/image_n/nCD012467-CMP-013.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012467-fig-0061"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/urn:x-wiley:14651858:media:CD012467:CD012467-CMP-013.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 13: Bivalirudin versus UFH, Outcome 2: Death at 28 days" data-id="CD012467-fig-0061" src="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/image_n/nCD012467-CMP-013.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/image_t/tCD012467-CMP-013.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 13.2</div> <div class="figure-caption"> <p>Comparison 13: Bivalirudin versus UFH, Outcome 2: Death at 28 days</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/references#CD012467-fig-0061">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/image_n/nCD012467-CMP-013.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012467-fig-0062"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/urn:x-wiley:14651858:media:CD012467:CD012467-CMP-013.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 13: Bivalirudin versus UFH, Outcome 3: Recovery of kidney function" data-id="CD012467-fig-0062" src="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/image_n/nCD012467-CMP-013.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/image_t/tCD012467-CMP-013.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 13.3</div> <div class="figure-caption"> <p>Comparison 13: Bivalirudin versus UFH, Outcome 3: Recovery of kidney function</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/references#CD012467-fig-0062">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/image_n/nCD012467-CMP-013.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012467-fig-0063"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/urn:x-wiley:14651858:media:CD012467:CD012467-CMP-014.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 14: Hirudin versus UFH, Outcome 1: Major bleeding" data-id="CD012467-fig-0063" src="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/image_n/nCD012467-CMP-014.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/image_t/tCD012467-CMP-014.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 14.1</div> <div class="figure-caption"> <p>Comparison 14: Hirudin versus UFH, Outcome 1: Major bleeding</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/references#CD012467-fig-0063">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/image_n/nCD012467-CMP-014.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012467-fig-0064"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/urn:x-wiley:14651858:media:CD012467:CD012467-CMP-014.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 14: Hirudin versus UFH, Outcome 2: Death at 28 days" data-id="CD012467-fig-0064" src="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/image_n/nCD012467-CMP-014.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/image_t/tCD012467-CMP-014.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 14.2</div> <div class="figure-caption"> <p>Comparison 14: Hirudin versus UFH, Outcome 2: Death at 28 days</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/references#CD012467-fig-0064">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/image_n/nCD012467-CMP-014.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012467-fig-0065"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/urn:x-wiley:14651858:media:CD012467:CD012467-CMP-014.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 14: Hirudin versus UFH, Outcome 3: Thrombocytopenia" data-id="CD012467-fig-0065" src="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/image_n/nCD012467-CMP-014.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/image_t/tCD012467-CMP-014.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 14.3</div> <div class="figure-caption"> <p>Comparison 14: Hirudin versus UFH, Outcome 3: Thrombocytopenia</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/references#CD012467-fig-0065">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/image_n/nCD012467-CMP-014.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012467-fig-0066"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/urn:x-wiley:14651858:media:CD012467:CD012467-CMP-015.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 15: Low molecular weight dextran versus placebo, Outcome 1: Successful prevention of clotting" data-id="CD012467-fig-0066" src="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/image_n/nCD012467-CMP-015.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/image_t/tCD012467-CMP-015.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 15.1</div> <div class="figure-caption"> <p>Comparison 15: Low molecular weight dextran versus placebo, Outcome 1: Successful prevention of clotting </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/references#CD012467-fig-0066">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/image_n/nCD012467-CMP-015.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012467-fig-0067"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/urn:x-wiley:14651858:media:CD012467:CD012467-CMP-016.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 16: Dalteparin (LMWH) versus nadroparin (LMWH), Outcome 1: Successful prevention of clotting" data-id="CD012467-fig-0067" src="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/image_n/nCD012467-CMP-016.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/image_t/tCD012467-CMP-016.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 16.1</div> <div class="figure-caption"> <p>Comparison 16: Dalteparin (LMWH) versus nadroparin (LMWH), Outcome 1: Successful prevention of clotting </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/references#CD012467-fig-0067">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/image_n/nCD012467-CMP-016.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012467-fig-0068"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/urn:x-wiley:14651858:media:CD012467:CD012467-CMP-017.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 17: Citrate plus LMWH versus citrate, Outcome 1: Major bleeding" data-id="CD012467-fig-0068" src="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/image_n/nCD012467-CMP-017.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/image_t/tCD012467-CMP-017.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 17.1</div> <div class="figure-caption"> <p>Comparison 17: Citrate plus LMWH versus citrate, Outcome 1: Major bleeding</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/references#CD012467-fig-0068">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/image_n/nCD012467-CMP-017.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012467-fig-0069"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/urn:x-wiley:14651858:media:CD012467:CD012467-CMP-017.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 17: Citrate plus LMWH versus citrate, Outcome 2: Death at 28 days" data-id="CD012467-fig-0069" src="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/image_n/nCD012467-CMP-017.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/image_t/tCD012467-CMP-017.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 17.2</div> <div class="figure-caption"> <p>Comparison 17: Citrate plus LMWH versus citrate, Outcome 2: Death at 28 days</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/references#CD012467-fig-0069">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/image_n/nCD012467-CMP-017.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012467-fig-0070"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/urn:x-wiley:14651858:media:CD012467:CD012467-CMP-017.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 17: Citrate plus LMWH versus citrate, Outcome 3: Successful prevention of clotting" data-id="CD012467-fig-0070" src="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/image_n/nCD012467-CMP-017.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/image_t/tCD012467-CMP-017.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 17.3</div> <div class="figure-caption"> <p>Comparison 17: Citrate plus LMWH versus citrate, Outcome 3: Successful prevention of clotting </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/references#CD012467-fig-0070">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/image_n/nCD012467-CMP-017.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012467-fig-0071"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/urn:x-wiley:14651858:media:CD012467:CD012467-CMP-017.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 17: Citrate plus LMWH versus citrate, Outcome 4: Metabolic disturbances" data-id="CD012467-fig-0071" src="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/image_n/nCD012467-CMP-017.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/image_t/tCD012467-CMP-017.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 17.4</div> <div class="figure-caption"> <p>Comparison 17: Citrate plus LMWH versus citrate, Outcome 4: Metabolic disturbances</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/references#CD012467-fig-0071">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/image_n/nCD012467-CMP-017.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012467-fig-0072"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/urn:x-wiley:14651858:media:CD012467:CD012467-CMP-017.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 17: Citrate plus LMWH versus citrate, Outcome 5: Hypernatraemia" data-id="CD012467-fig-0072" src="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/image_n/nCD012467-CMP-017.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/image_t/tCD012467-CMP-017.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 17.5</div> <div class="figure-caption"> <p>Comparison 17: Citrate plus LMWH versus citrate, Outcome 5: Hypernatraemia</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/references#CD012467-fig-0072">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/image_n/nCD012467-CMP-017.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012467-fig-0073"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/urn:x-wiley:14651858:media:CD012467:CD012467-CMP-017.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 17: Citrate plus LMWH versus citrate, Outcome 6: Hypocalcaemia" data-id="CD012467-fig-0073" src="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/image_n/nCD012467-CMP-017.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/image_t/tCD012467-CMP-017.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 17.6</div> <div class="figure-caption"> <p>Comparison 17: Citrate plus LMWH versus citrate, Outcome 6: Hypocalcaemia</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/references#CD012467-fig-0073">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/image_n/nCD012467-CMP-017.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012467-fig-0074"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/urn:x-wiley:14651858:media:CD012467:CD012467-CMP-017.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 17: Citrate plus LMWH versus citrate, Outcome 7: Recovery of kidney function" data-id="CD012467-fig-0074" src="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/image_n/nCD012467-CMP-017.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/image_t/tCD012467-CMP-017.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 17.7</div> <div class="figure-caption"> <p>Comparison 17: Citrate plus LMWH versus citrate, Outcome 7: Recovery of kidney function</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/references#CD012467-fig-0074">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/image_n/nCD012467-CMP-017.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012467-fig-0075"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/urn:x-wiley:14651858:media:CD012467:CD012467-CMP-017.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 17: Citrate plus LMWH versus citrate, Outcome 8: Thrombocytopenia" data-id="CD012467-fig-0075" src="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/image_n/nCD012467-CMP-017.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/image_t/tCD012467-CMP-017.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 17.8</div> <div class="figure-caption"> <p>Comparison 17: Citrate plus LMWH versus citrate, Outcome 8: Thrombocytopenia</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/references#CD012467-fig-0075">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/image_n/nCD012467-CMP-017.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012467-fig-0076"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/urn:x-wiley:14651858:media:CD012467:CD012467-CMP-017.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 17: Citrate plus LMWH versus citrate, Outcome 9: Treatment cessation due to any adverse event" data-id="CD012467-fig-0076" src="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/image_n/nCD012467-CMP-017.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/image_t/tCD012467-CMP-017.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 17.9</div> <div class="figure-caption"> <p>Comparison 17: Citrate plus LMWH versus citrate, Outcome 9: Treatment cessation due to any adverse event </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/references#CD012467-fig-0076">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/image_n/nCD012467-CMP-017.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012467-fig-0077"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/urn:x-wiley:14651858:media:CD012467:CD012467-CMP-018.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 18: Citrate plus LMWH versus LMWH, Outcome 1: Major bleeding" data-id="CD012467-fig-0077" src="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/image_n/nCD012467-CMP-018.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/image_t/tCD012467-CMP-018.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 18.1</div> <div class="figure-caption"> <p>Comparison 18: Citrate plus LMWH versus LMWH, Outcome 1: Major bleeding</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/references#CD012467-fig-0077">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/image_n/nCD012467-CMP-018.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012467-fig-0078"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/urn:x-wiley:14651858:media:CD012467:CD012467-CMP-018.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 18: Citrate plus LMWH versus LMWH, Outcome 2: Death at 28 days" data-id="CD012467-fig-0078" src="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/image_n/nCD012467-CMP-018.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/image_t/tCD012467-CMP-018.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 18.2</div> <div class="figure-caption"> <p>Comparison 18: Citrate plus LMWH versus LMWH, Outcome 2: Death at 28 days</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/references#CD012467-fig-0078">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/image_n/nCD012467-CMP-018.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012467-fig-0079"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/urn:x-wiley:14651858:media:CD012467:CD012467-CMP-018.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 18: Citrate plus LMWH versus LMWH, Outcome 3: Successful prevention of clotting" data-id="CD012467-fig-0079" src="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/image_n/nCD012467-CMP-018.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/image_t/tCD012467-CMP-018.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 18.3</div> <div class="figure-caption"> <p>Comparison 18: Citrate plus LMWH versus LMWH, Outcome 3: Successful prevention of clotting </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/references#CD012467-fig-0079">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/image_n/nCD012467-CMP-018.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012467-fig-0080"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/urn:x-wiley:14651858:media:CD012467:CD012467-CMP-018.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 18: Citrate plus LMWH versus LMWH, Outcome 4: Metabolic disturbances" data-id="CD012467-fig-0080" src="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/image_n/nCD012467-CMP-018.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/image_t/tCD012467-CMP-018.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 18.4</div> <div class="figure-caption"> <p>Comparison 18: Citrate plus LMWH versus LMWH, Outcome 4: Metabolic disturbances</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/references#CD012467-fig-0080">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/image_n/nCD012467-CMP-018.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012467-fig-0081"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/urn:x-wiley:14651858:media:CD012467:CD012467-CMP-018.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 18: Citrate plus LMWH versus LMWH, Outcome 5: Hypernatraemia" data-id="CD012467-fig-0081" src="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/image_n/nCD012467-CMP-018.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/image_t/tCD012467-CMP-018.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 18.5</div> <div class="figure-caption"> <p>Comparison 18: Citrate plus LMWH versus LMWH, Outcome 5: Hypernatraemia</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/references#CD012467-fig-0081">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/image_n/nCD012467-CMP-018.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012467-fig-0082"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/urn:x-wiley:14651858:media:CD012467:CD012467-CMP-018.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 18: Citrate plus LMWH versus LMWH, Outcome 6: Hypocalcaemia" data-id="CD012467-fig-0082" src="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/image_n/nCD012467-CMP-018.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/image_t/tCD012467-CMP-018.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 18.6</div> <div class="figure-caption"> <p>Comparison 18: Citrate plus LMWH versus LMWH, Outcome 6: Hypocalcaemia</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/references#CD012467-fig-0082">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/image_n/nCD012467-CMP-018.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012467-fig-0083"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/urn:x-wiley:14651858:media:CD012467:CD012467-CMP-018.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 18: Citrate plus LMWH versus LMWH, Outcome 7: Recovery of kidney function" data-id="CD012467-fig-0083" src="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/image_n/nCD012467-CMP-018.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/image_t/tCD012467-CMP-018.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 18.7</div> <div class="figure-caption"> <p>Comparison 18: Citrate plus LMWH versus LMWH, Outcome 7: Recovery of kidney function</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/references#CD012467-fig-0083">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/image_n/nCD012467-CMP-018.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012467-fig-0084"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/urn:x-wiley:14651858:media:CD012467:CD012467-CMP-018.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 18: Citrate plus LMWH versus LMWH, Outcome 8: Thrombocytopenia" data-id="CD012467-fig-0084" src="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/image_n/nCD012467-CMP-018.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/image_t/tCD012467-CMP-018.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 18.8</div> <div class="figure-caption"> <p>Comparison 18: Citrate plus LMWH versus LMWH, Outcome 8: Thrombocytopenia</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/references#CD012467-fig-0084">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/image_n/nCD012467-CMP-018.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012467-fig-0085"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/urn:x-wiley:14651858:media:CD012467:CD012467-CMP-018.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 18: Citrate plus LMWH versus LMWH, Outcome 9: Treatment cessation due to any adverse event" data-id="CD012467-fig-0085" src="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/image_n/nCD012467-CMP-018.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/image_t/tCD012467-CMP-018.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 18.9</div> <div class="figure-caption"> <p>Comparison 18: Citrate plus LMWH versus LMWH, Outcome 9: Treatment cessation due to any adverse event </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/references#CD012467-fig-0085">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/media/CDSR/CD012467/image_n/nCD012467-CMP-018.09.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD012467-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Citrate versus unfractionated heparin for continuous renal replacement therapy</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Citrate versus UFH for CRRT</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> CRRT<br/><b>Setting:</b> ICU<br/><b>Intervention:</b> citrate<br/><b>Comparison:</b> UFH </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>No. of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with UFH</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with citrate</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Major bleeding</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>102 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>22 per 1,000<br/>(8 to 63) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.22<br/>(0.08 to 0.62) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>535 (7)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE <sup>1 2</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Death at 28 days</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>384 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>407 per 1,000<br/>(330 to 500) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.06<br/>(0.86 to 1.30) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>462 (5)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE <sup>3</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Successful prevention of clotting</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>257 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>370 per 1,000<br/>(283 to 481) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.44<br/>(1.10 to 1.87) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>88 (3)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE <sup>2</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Treatment cessation due to adverse events</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>141 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>66 per 1,000<br/>(21 to 211) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.47<br/>(0.15 to 1.49) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>412 (3)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>2 4</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Recovery of kidney function</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>583 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>607 per 1,000<br/>(519 to 706) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.04<br/>(0.89 to 1.21) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>214 (2)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>2 4</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Thrombocytopenia</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>78 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>30 per 1,000<br/>(11 to 80) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.39<br/>(0.14 to 1.03) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>412 (3)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>2 4</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cost to health care services</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>UFH:</b> unfractionated heparin; <b>CRRT:</b> continuous renal replacement therapy; <b>ICU:</b> intensive care unit; <b>CI:</b> confidence interval; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p>Reasons for downgrading the evidence</p> <p><sup>1</sup> Indirectness: including bleeding events of unclear severity </p> <p><sup>2</sup> Study limitations </p> <p><sup>3</sup> Imprecision: risk estimate consistent with both appreciable benefit and harm </p> <p><sup>4</sup> Imprecision: risk estimate includes null effect and estimate consistent with both appreciable benefit and harm </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Citrate versus unfractionated heparin for continuous renal replacement therapy</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/full#CD012467-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD012467-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Unfractionated heparin versus low molecular weight heparin for continuous renal replacement therapy</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>UFH versus LMWH for CRRT</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> CRRT<br/><b>Setting:</b> ICU<br/><b>Intervention:</b> UFH<br/><b>Comparison:</b> LMWH </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>No. of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with LMWH</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with UFH</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Major bleeding</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>103 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>60 per 1,000<br/>(13 to 267) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.58<br/>(0.13 to 2.58) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>153 (5)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1 2 3</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Death: unknown time frame</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>857 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>669 per 1,000<br/>(437 to 1,000) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.78<br/>(0.51 to 1.18) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29 (1)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>1 3 4</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Successful prevention of clotting</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>760 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>722 per 1,000<br/>(532 to 996) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.95<br/>(0.70 to 1.31) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>54 (1)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>1 3 4</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Treatment cessation due to adverse events</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>105 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>31 per 1,000<br/>(2 to 372) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.29<br/>(0.02 to 3.53) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>77 (2)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1 3</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Recovery of kidney function</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>not reported</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Thrombocytopenia</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>127 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>72 per 1,000<br/>(25 to 207) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.57<br/>(0.20 to 1.63) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>124 (2)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>1 3 4</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cost to health care services</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>UFH:</b> unfractionated heparin; <b>LMWH:</b> low molecular weight heparin; <b>CRRT:</b> continuous renal replacement therapy; <b>ICU:</b> intensive care unit; <b>CI:</b> confidence interval; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p>Reasons for downgrading the evidence</p> <p><sup>1</sup> Study limitations </p> <p><sup>2</sup> Severe heterogeneity: point estimates varied widely </p> <p><sup>3</sup> Imprecision: risk estimate includes null effect and estimate consistent with both appreciable benefit and harm </p> <p><sup>4</sup> Total number of events small </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Unfractionated heparin versus low molecular weight heparin for continuous renal replacement therapy</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/full#CD012467-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD012467-tbl-0003"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Unfractionated heparin versus no pharmacological anticoagulation for continuous renal replacement therapy</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>UFH versus no pharmacological anticoagulation for CRRT</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> CRRT<br/><b>Setting:</b> ICU<br/><b>Intervention:</b> UFH<br/><b>Comparison:</b> no anticoagulation </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>No. of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with no anticoagulation</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with UFH</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Major bleeding</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>200 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>100 per 1,000<br/>(10 to 934) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.50<br/>(0.05 to 4.67) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10 (1)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>1 2 3</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Death at 28 days</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>not reported</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Successful prevention of clotting</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>not reported</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Treatment cessation due of adverse events</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>not reported</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Recovery of kidney function</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>not reported</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Thrombocytopenia</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>not reported</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cost to health care services</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>not reported</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>UFH:</b> unfractionated heparin; <b>CRRT:</b> continuous renal replacement therapy; <b>ICU:</b> intensive care unit; <b>CI:</b> confidence interval; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p>Reasons for downgrading the evidence</p> <p><sup>1</sup> Study limitations </p> <p><sup>2</sup> Imprecision: risk estimate includes null effect and estimate consistent with both appreciable benefit and harm </p> <p><sup>3</sup> Total number of events small </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Unfractionated heparin versus no pharmacological anticoagulation for continuous renal replacement therapy</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/full#CD012467-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD012467-tbl-0004"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Thrombocytopenia and platelet counts</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Ã‚Â Study ID</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Ã‚Â Thrombocytopenia (n/N)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Ã‚Â Platelet count</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012467-bbs2-0005" title="SchilderL , NurmohamedS , BoschFH , PurmerIM , den BoerSS , KleppeCG , et al. Citrate anticoagulation versus systemic heparinisation in continuous venovenous hemofiltration in critically ill patients with acute kidney injury: a multi-center randomized clinical trial. Critical Care (London, England)2014;18(4):472. [MEDLINE: 25128022]SchilderL , NurmohamedSA , ter WeePM , PaauwNJ , GirbesAR , BeishuizenA , et al. Citrate confers less filter-induced complement activation and neutrophil degranulation than heparin when used for anticoagulation during continuous venovenous haemofiltration in critically ill patients. BMC Nephrology2014;15:19. [MEDLINE: 24438360]SchilderL , NurmohamedSA , ter WeePM , PaauwNJ , GirbesAR , BeishuizenA , et al. Putative novel mediators of acute kidney injury in critically ill patients: handling by continuous venovenous hemofiltration and effect of anticoagulation modalities. BMC Nephrology2015;16:178. [MEDLINE: 26519056]SchilderL , NurmohamedSA , ter WeePM , PaauwNJ , GirbesAR , BeishuizenA , et al. The plasma level and biomarker value of neutrophil gelatinase-associated lipocalin in critically ill patients with acute kidney injury are not affected by continuous venovenous hemofiltration and anticoagulation applied. Critical Care (London, England)2014;18(2):R78. [MEDLINE: 24755339]">CASH 2014</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Citrate: 0/66</p> <p>UFH: 6/73</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012467-bbs2-0015" title="HetzelGR , SchmitzM , WissingH , RiesW , SchottG , HeeringPJ , et al. Regional citrate versus systemic heparin for anticoagulation in critically ill patients on continuous venovenous haemofiltration: a prospective randomized multicentre trial. Nephrology Dialysis Transplantation2011;26(1):232-9. [MEDLINE: 20876598]">Hetzel 2011</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Citrate: 4/87</p> <p>UFH: 8/83</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012467-bbs2-0028" title="StuckerF , PonteB , TatawJ , MartinPY , WozniakH , PuginJ , et al. Efficacy and safety of citrate-based anticoagulation compared to heparin in patients with acute kidney injury requiring continuous renal replacement therapy: a randomized controlled trial. Critical Care (London, England)2015;19(1):91. [MEDLINE: 25881975]StuckerF , PuginJ , TattawJ , PonteB , BrochardL , MartinP , et al. Citrate-based anticoagulation in patients with AKI in the intensive care unit: a safe and efficacious method [abstract no: 0379]. Intensive Care Medicine2013;39(Suppl 2):S320. [EMBASE: 71446324]">Stucker 2015</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Citrate: 1/54</p> <p>UFH: 2/49</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012467-bbs2-0024" title="Oudemans-van StraatenHM , BosmanRJ , KoopmansM , van derVoortPH , WesterJP , van derSpoelJI , et al. Citrate anticoagulation for continuous venovenous hemofiltration. Critical Care Medicine2009;37(2):545-52. [MEDLINE: 19114912]">Oudemans‐van Straaten 2009</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Citrate: 3/97</p> <p>LMWH: 4/103</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012467-bbs2-0026" title="ReevesJH , CummingAR , GallagherL , O'BrienJL , SantamariaJD . A controlled trial of low-molecular-weight heparin (dalteparin) versus unfractionated heparin as anticoagulant during continuous venovenous hemodialysis with filtration. Critical Care Medicine1999;27(10):2224-8. [MEDLINE: 10548211]">Reeves 1999</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>UFH: 4/22 (1 confirmed as HIT)</p> <p>LMWH: 8/25 (3 confirmed as HIT)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The mean (Ã‚Â± SE) reduction in platelet count during HF was:</p> <p>UFH: 63 Ã‚Â± 25.8 x 10<sup>9</sup> </p> <p>LMWH: 41.8 Ã‚Â± 26.6 x 10<sup>9</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012467-bbs2-0004" title="BirnbaumJ , SpiesCD , KlotzE , HeinOV , MorgeraS , SchinkT , et al. Iloprost for additional anticoagulation in continuous renal replacement therapy--a pilot study. Renal Failure2007;29(3):271-7. [MEDLINE: 17497439]">Birnbaum 2007</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>UFH + PGI<sub>2</sub>: 1/10 </p> <p>UFH: 0/10</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>UFH + PGI<sub>2</sub>: drop to 16/nL in one patient due to sepsis </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012467-bbs2-0014" title="HeinOV , vonHeymannC , DiehlT , ZiemerS , RoncoC , MorgeraS , et al. Intermittent hirudin versus continuous heparin for anticoagulation in continuous renal replacement therapy. Renal Failure2004;26(3):297-303. [MEDLINE: 15354980]">Hein 2004</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hirudin: 0/12</p> <p>UFH: 2/14</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>UFH: 2 patients had bleeding complications and platelet counts were 69/nL and 17/nL</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="3"> <div class="table-footnote"> <p>LMWH ‐ low molecular weight heparin; SE ‐ standard error; UFH ‐ unfractionated heparin</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Thrombocytopenia and platelet counts</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/full#CD012467-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD012467-tbl-0005"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Adverse events: Citrate versus UFH</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study ID</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Adverse events</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Intervention: events/participants</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p><a href="./references#CD012467-bbs2-0003" title="BetjesMG , OosteromD , vanAgterenM , vande WeteringJ . Regional citrate versus heparin anticoagulation during venovenous hemofiltration in patients at low risk for bleeding: similar hemofilter survival but significantly less bleeding [abstract no: TH-FC107]. Journal of the American Society of Nephrology2006;17(Abstracts):24A. [CENTRAL: CN-00671866] BetjesMG , vanOosteromD , vanAgterenM , vande WeteringJ . Regional citrate versus heparin anticoagulation during venovenous hemofiltration in patients at low risk for bleeding: similar hemofilter survival but significantly less bleeding. Journal of Nephrology2007;20(5):602-8. [MEDLINE: 17918147]">Betjes 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>All bleeding events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Citrate: 0/27</p> <p>UFH: 9/21</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Alkalosis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Citrate: 0/27</p> <p>UFH: 2/21</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hypocalcaemia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Citrate: 2/27</p> <p>UFH: 0/21</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="7" valign=""> <p><a href="./references#CD012467-bbs2-0005" title="SchilderL , NurmohamedS , BoschFH , PurmerIM , den BoerSS , KleppeCG , et al. Citrate anticoagulation versus systemic heparinisation in continuous venovenous hemofiltration in critically ill patients with acute kidney injury: a multi-center randomized clinical trial. Critical Care (London, England)2014;18(4):472. [MEDLINE: 25128022]SchilderL , NurmohamedSA , ter WeePM , PaauwNJ , GirbesAR , BeishuizenA , et al. Citrate confers less filter-induced complement activation and neutrophil degranulation than heparin when used for anticoagulation during continuous venovenous haemofiltration in critically ill patients. BMC Nephrology2014;15:19. [MEDLINE: 24438360]SchilderL , NurmohamedSA , ter WeePM , PaauwNJ , GirbesAR , BeishuizenA , et al. Putative novel mediators of acute kidney injury in critically ill patients: handling by continuous venovenous hemofiltration and effect of anticoagulation modalities. BMC Nephrology2015;16:178. [MEDLINE: 26519056]SchilderL , NurmohamedSA , ter WeePM , PaauwNJ , GirbesAR , BeishuizenA , et al. The plasma level and biomarker value of neutrophil gelatinase-associated lipocalin in critically ill patients with acute kidney injury are not affected by continuous venovenous hemofiltration and anticoagulation applied. Critical Care (London, England)2014;18(2):R78. [MEDLINE: 24755339]">CASH 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Bleeding within 28 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Citrate: 3/66</p> <p>UFH: 10/73</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>HIT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Citrate: 0/66</p> <p>UFH: 6/73</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Citrate accumulation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Citrate: 4/66</p> <p>UFH: 0/73</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Miscellaneous</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Citrate: 1/66</p> <p>UFH: 3/73</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Alkalaemia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Citrate: 1/66</p> <p>UFH: 0/73</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hypernatraemia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Citrate: 4/66</p> <p>UFH: 3/73</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hypermagnesaemia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Citrate: 8/66</p> <p>UFH: 6/73</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p><a href="./references#CD012467-bbs2-0015" title="HetzelGR , SchmitzM , WissingH , RiesW , SchottG , HeeringPJ , et al. Regional citrate versus systemic heparin for anticoagulation in critically ill patients on continuous venovenous haemofiltration: a prospective randomized multicentre trial. Nephrology Dialysis Transplantation2011;26(1):232-9. [MEDLINE: 20876598]">Hetzel 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>HIT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Citrate: 4/87</p> <p>UFH: 8/83</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>All bleeding events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Citrate: 5/87</p> <p>UFH: 12/83</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Citrate accumulation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Citrate: 1/87</p> <p>UFH: 0/83</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p><a href="./references#CD012467-bbs2-0019" title="KutsogiannisDJ , GibneyRT , StolleryD , GaoJ . Regional citrate versus systemic heparin anticoagulation for continuous renal replacement in critically ill patients. Kidney International2005;67(6):2361-7. [MEDLINE: 15882280]">Kutsogiannis 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>All bleeding events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Citrate: 1/16</p> <p>UFH: 8/14</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Metabolic alkalosis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Citrate: 1/16</p> <p>UFH: 0/14</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hypocalcaemia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Citrate: 1/16</p> <p>UFH: 0/14</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p><a href="./references#CD012467-bbs2-0023" title="MonchiM , BerghmansD , LedouxD , CanivetJL , DuboisB , DamasP . Citrate vs. heparin for anticoagulation in continuous venovenous hemofiltration: a prospective randomized study. Intensive Care Medicine2004;30(2):260-5. [MEDLINE: 14600809]">Monchi 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>All bleeding events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Citrate: 0/26</p> <p>UFH: 1/23</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hypocalcaemia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Citrate: 1/26</p> <p>UFH: 0/23</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Alkalosis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Citrate: 1/26</p> <p>UFH: 0/23</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p><a href="./references#CD012467-bbs2-0028" title="StuckerF , PonteB , TatawJ , MartinPY , WozniakH , PuginJ , et al. Efficacy and safety of citrate-based anticoagulation compared to heparin in patients with acute kidney injury requiring continuous renal replacement therapy: a randomized controlled trial. Critical Care (London, England)2015;19(1):91. [MEDLINE: 25881975]StuckerF , PuginJ , TattawJ , PonteB , BrochardL , MartinP , et al. Citrate-based anticoagulation in patients with AKI in the intensive care unit: a safe and efficacious method [abstract no: 0379]. Intensive Care Medicine2013;39(Suppl 2):S320. [EMBASE: 71446324]">Stucker 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>All bleeding events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Citrate: 0/54</p> <p>UFH: 4/49</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>HIT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Citrate: 1/54</p> <p>UFH: 2/49</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Metabolic disorders</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Citrate: 14/54</p> <p>UFH: 3/49</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012467-bbs2-0029" title="TiranathanagulK , JearnsujitwimolO , SusantitaphongP , KijkriengkraikulN , LeelahavanichkulA , SrisawatN , et al. Regional citrate anticoagulation reduces polymorphonuclear cell degranulation in critically ill patients treated with continuous venovenous hemofiltration. Therapeutic Apheresis &amp; Dialysis2011;15(6):556-64. [MEDLINE: 22107692]">Tiranathanagul 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>All bleeding events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Citrate: 0/10</p> <p>UFH: 0/10</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="3"> <div class="table-footnote"> <p>HIT‐ heparin‐induced thrombocytopenia; UFH ‐ unfractionated heparin</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Adverse events: Citrate versus UFH</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/full#CD012467-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD012467-tbl-0006"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Adverse events: Citrate versus UFH plus protamine</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study ID</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Adverse events</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Intervention: events/participants</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012467-bbs2-0010" title="FealyN , BaldwinI , JohnstoneM , EgiM , BellomoR . A pilot randomized controlled crossover study comparing regional heparinization to regional citrate anticoagulation for continuous venovenous hemofiltration. International Journal of Artificial Organs2007;30(4):301-7. [MEDLINE: 17520566]">Fealy 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>All bleeding events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Citrate: 0/11</p> <p>UFH: 0/11</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="10" valign=""> <p><a href="./references#CD012467-bbs2-0013" title="GattasDJ , RajbhandariD , BradfordC , BuhrH , LoS , BellomoR . A randomized controlled trial of regional citrate versus regional heparin anticoagulation for continuous renal replacement therapy in critically ill adults. Critical Care Medicine2015;43(8):1622-9. [MEDLINE: 25853591]">Gattas 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>All bleeding events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Citrate: 0/105</p> <p>UFH: 1/107</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hypercalcaemia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Citrate: 1/105</p> <p>UFH: 0/107</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Skin necrosis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Citrate: 0/105</p> <p>UFH: 1/107</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>HIT (confirmed)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Citrate: 0/105</p> <p>UFH: 2/107</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Acidosis, hypotension</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Citrate: 1/105</p> <p>UFH: 0/107</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>HIT (suspected)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Citrate: 0/105</p> <p>UFH: 3/107</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Bradycardia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Citrate: 0/105</p> <p>UFH: 1/107</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ventricular bigeminy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Citrate: 0/105</p> <p>UFH: 1/107</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ventricular fibrillation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Citrate: 0/105</p> <p>UFH: 1/107</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cardiac arrest (PEA)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Citrate: 0/105</p> <p>UFH: 1/107</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p><a href="./references#CD012467-bbs2-0011" title="BrainMJ , RoodenburgOS , AdamsN , McCrackenP , HockingsL , MusgraveS , et al. Randomised trial of software algorithm driven regional citrate anticoagulation versus heparin in continuous renal replacement therapy: the Filter Life in Renal Replacement Therapy pilot trial. Critical Care &amp; Resuscitation2014;16(2):131-7. [MEDLINE: 24888284]">FLIRRT 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Bleeding episodes requiring treatment cessation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Citrate: 0/19</p> <p>UFH: 0/11</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hypocalcaemia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Citrate: 3/19</p> <p>UFH: 0/11</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Prolonged APTT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Citrate: 0/19</p> <p>UFH: 1/11</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="3"> <div class="table-footnote"> <p>APTT ‐ activated partial thromboplastin time; HIT ‐ heparin‐induced thrombocytopenia; PEA ‐ pulseless electrical activity; UFH ‐ unfractionated heparin </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Adverse events: Citrate versus UFH plus protamine</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/full#CD012467-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD012467-tbl-0007"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Adverse events: Citrate versus LMWH</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study ID</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Adverse events</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Intervention: events/participants</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012467-bbs2-0024" title="Oudemans-van StraatenHM , BosmanRJ , KoopmansM , van derVoortPH , WesterJP , van derSpoelJI , et al. Citrate anticoagulation for continuous venovenous hemofiltration. Critical Care Medicine2009;37(2):545-52. [MEDLINE: 19114912]">Oudemans‐van Straaten 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adverse events needing discontinuation of study anticoagulation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Citrate: 2/97</p> <p>LMWH: 20/103</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p><a href="./references#CD012467-bbs2-0034" title="WuB , ZhangK , XuB , JiD , LiuZ , GongD . Randomized controlled trial to evaluate regional citrate anticoagulation plus low-dose of dalteparin in continuous veno-venous hemofiltration. Blood Purification2015;39(4):306-12. [MEDLINE: 26022434]ZhangK , GongD , JiD , XuB , IIuZ . Regional citrate plus low dose of low molecular weight heparins: a safe and more efficacy anticoagulation protocol for continuous veno - venous hemofiltration [abstract no: 71]. In: CCRT 2012. 17th International Conference on CRRT; 2012 Feb 14-17; San Diego (CA). 2012. [CENTRAL: CN-01658175] ">Wu 2015b</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Bleeding</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Citrate: 2/15</p> <p>LMWH: 4/19</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hypocalcaemia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Citrate: 1/15</p> <p>LMWH: 0/19</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Metabolic acidosis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Citrate: 3/15</p> <p>LMWH: 0/19</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Severe metabolic acidosis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Citrate: 1/15</p> <p>LMWH: 0/19</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="3"> <div class="table-footnote"> <p>LMWH ‐ low molecular weight heparin</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Adverse events: Citrate versus LMWH</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/full#CD012467-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD012467-tbl-0008"> <div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Adverse events: LMWH versus UFH</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study ID</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Adverse events</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Intervention: events/participants</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012467-bbs2-0012" title="GarcesEO , VictorinoJA , ThomeFS , RohsigLM , DornellesE , LouzadaM , et al. Enoxaparin versus unfractioned heparin as anticoagulant for continuous venovenous hemodialysis: a randomized open-label trial. Renal Failure2010;32(3):320-7. [MEDLINE: 20370447]">Garces 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Bleeding</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>LMWH: 5/19</p> <p>UFH: 0/21</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><a href="./references#CD012467-bbs2-0016" title="JoannidisM , KountchevJ , GroteA , BellmanR , WiedermannCJ . Unfractioned versus low-molecular-weight heparin for anticoagulation in hemofiltration [abstract no: SU-PO880]. Journal of the American Society of Nephrology2003;14(Nov):728-9A. [CENTRAL: CN-00583249] JoannidisM , KountchevJ , RauchenzaunerM , SchusterschitzN , UlmerH , MayrA , et al. Enoxaparin vs. unfractionated heparin for anticoagulation during continuous veno-venous hemofiltration: a randomized controlled crossover study. Intensive Care Medicine2007;33(9):1571-9. [MEDLINE: 17563874]KountchevJ , GroteA , BellmannR , WiedermannC , JoannidisM . Unfractioned versus low-molecular-weight heparin (enoxaparin) for anticoagulation in CVVH [abstract no: MP459]. In: 41st Congress. European Renal Association. European Dialysis and Transplantation Association; 2004 May 15-18; Lisbon, Portugal. 2004:384. [CENTRAL: CN-00509287] ">Joannidis 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>All bleeding events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>LMWH: 2/37</p> <p>UFH: 2/37</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>HIT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>LMWH: 0/37</p> <p>UFH: 0/37</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p><a href="./references#CD012467-bbs2-0026" title="ReevesJH , CummingAR , GallagherL , O'BrienJL , SantamariaJD . A controlled trial of low-molecular-weight heparin (dalteparin) versus unfractionated heparin as anticoagulant during continuous venovenous hemodialysis with filtration. Critical Care Medicine1999;27(10):2224-8. [MEDLINE: 10548211]">Reeves 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Significant bleeding events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>LMWH: 2/25</p> <p>UFH: 4/22</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Trivial bleeding events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>LMWH: 3/25</p> <p>UFH: 3/22</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>HIT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>LMWH: 3/25</p> <p>UFH: 1/22</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012467-bbs2-0027" title="ReevesJH , GraanM . Randomised controlled trial: enoxaparin versus heparin in continuous renal replacement therapy [abstract no: 41]. Blood Purification2003;21(2):203. [CENTRAL: CN-00757740] ">Reeves 2003</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Major bleeding</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>LMWH: 1/15</p> <p>UFH: 4/14</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012467-bbs2-0031" title="vanDoornKJ , HubloueI , VerbeelenD . Urea exchange efficacy during unfractionated heparin anticoagulation versus low molecular weight heparin (dalteparin) anticoagulation in continuous veno-venous hemofiltration [abstract]. In: 41st Congress. European Renal Association. European Dialysis and Transplantation Association; 2004 May 15-18; Lisbon, Portugal. 2004:384. [CENTRAL: CN-00509250] vanDoornKJ , HubloueI , VerbeelenD . Urea exchange efficacy during unfractionated heparin anticoagulation versus low molecular weight heparin (dalteparin) anticoagulation in continuous veno-venous hemofiltration [abstract no: 33]. Blood Purification2004;22(2):243. [CENTRAL: CN-01658168] ">van Doorn 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No adverse events reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012467-bbs2-0033" title="VictorinoJA , OteroE , RohsigL , DornellesE , LouzadaM , StifftJ , et al. Low molecular weight heparin (LMWH) versus non-fractionated heparin (NFH) as anticoagulation system in continuous veno-veno hemodialysis (CVVH) in patients with acute renal (ARF) and respiratory failure (RF) [abstract no: 128]. In: American Thoracic Society International Conference; 2007 May 18-23; San Francisco (CA). 2007. [CENTRAL: CN-00645386] ">Victorino 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clinical bleeding</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>LMWH: 0/21</p> <p>UFH: 5/19</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="3"> <div class="table-footnote"> <p>HIT ‐ heparin‐induced thrombocytopenia; LMWH ‐ low molecular weight heparin; UFH ‐ unfractionated heparin </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Adverse events: LMWH versus UFH</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/full#CD012467-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD012467-tbl-0009"> <div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">Adverse events: Nafamostat mesilate versus no anticoagulation</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study ID</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Adverse events</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Intervention: events/participants</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012467-bbs2-0006" title="ChoiJY , KangYJ , JangHM , JungHY , ChoJH , ParkSH , et al. Nafamostat mesilate as an anticoagulant during continuous renal replacement therapy in patients with high bleeding risk: a randomized clinical trial. Medicine2015;94(52):e2392. [MEDLINE: 26717390]">Choi 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>GI bleeding</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nafamostat mesilate: 2/31</p> <p>No anticoagulation: 0/24</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="8" valign=""> <p><a href="./references#CD012467-bbs2-0021" title="LeeYK , LeeHW , ChoiKH , KimBS . Ability of nafamostat mesilate to prolong filter patency during continuous renal replacement therapy in patients at high risk of bleeding: a randomized controlled study. PLoS ONE [Electronic Resource]2014;9(10):e108737. [MEDLINE: 25302581]LeeYK , LeeHW , ChoiKH , KimBS . The effect of nafamostat mesilate in prolonging filter patency with patients on continuous renal replacement therapy [abstract no: MP403]. Nephrology Dialysis Transplantation2013;28(Suppl 1):i425. [EMBASE: 71076312]">Lee 2014b</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>All adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nafamostat mesilate: 33/36</p> <p>No anticoagulation: 33/37</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Grade 1 pulmonary haemorrhage</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nafamostat mesilate: 1/36</p> <p>No anticoagulation: 0/37</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Grade 1 GI bleeding</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nafamostat mesilate: 0/36</p> <p>No anticoagulation: 1/37</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Grade 2 GI bleeding</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nafamostat mesilate: 0/36</p> <p>No anticoagulation: 2/37</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Grade 4 GI bleeding</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nafamostat mesilate: 1/36</p> <p>No anticoagulation: 0/37</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Grade 1 vaginal bleeding</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nafamostat mesilate: 1/36</p> <p>No anticoagulation: 0/37</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Variceal bleeding</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nafamostat mesilate: 0/36</p> <p>No anticoagulation: 1/37</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Catheter insertion site oozing</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nafamostat mesilate: 0/36</p> <p>No anticoagulation: 1/37</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="3"> <div class="table-footnote"> <p>GI ‐ gastrointestinal</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">Adverse events: Nafamostat mesilate versus no anticoagulation</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/full#CD012467-tbl-0009">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD012467-tbl-0010"> <div class="table-heading"><span class="table-label">Table 7.</span> <span class="table-title">Adverse events: UFH plus PGI2 versus UFH</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study ID</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Adverse events</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Intervention: events/participants</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><a href="./references#CD012467-bbs2-0018" title="Kozek-LangeneckerSA , SpissCK , GamsjagerT , DomenigC , ZimpferM . Anticoagulation with prostaglandins and unfractionated heparin during continuous venovenous haemofiltration: a randomized controlled trial. Wiener Klinische Wochenschrift2002;114(3):96-101. [MEDLINE: 12060975]">Kozek‐Langenecker 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Trivial bleeding</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>UFH plus PGI<sub>2</sub>: 1/15 </p> <p>UFH: 3/17</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Major bleeding</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>UFH plus PGI<sub>2</sub>: 0/15 </p> <p>UFH: 3/17</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="3"> <div class="table-footnote"> <p>PG ‐ prostaglandin; UFH ‐ unfractionated heparin</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 7.</span> <span class="table-title">Adverse events: UFH plus PGI2 versus UFH</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/full#CD012467-tbl-0010">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD012467-tbl-0011"> <div class="table-heading"><span class="table-label">Table 8.</span> <span class="table-title">Adverse events: UFH plus protamine plus PGI2 versus UFH</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study ID</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Adverse events</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Intervention: events/participants</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><a href="./references#CD012467-bbs2-0009" title="FabbriLP , NuceraM , Al MalyanM , BecchiC . Regional anticoagulation and antiaggregation for CVVH in critically ill patients: a prospective, randomized, controlled pilot study. Acta Anaesthesiologica Scandinavica2010;54(1):92-7. [MEDLINE: 19650808]">Fabbri 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Severe bleeding events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>UFH + protamine + PGI<sub>2</sub>: 2/46 </p> <p>UFH: 7/44</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mild to moderate bleeding events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>UFH + protamine + PGI<sub>2</sub>: 2/46 </p> <p>UFH: 4/44</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="3"> <div class="table-footnote"> <p>PG ‐ prostaglandin; UFH ‐ unfractionated heparin</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 8.</span> <span class="table-title">Adverse events: UFH plus protamine plus PGI2 versus UFH</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/full#CD012467-tbl-0011">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD012467-tbl-0012"> <div class="table-heading"><span class="table-label">Table 9.</span> <span class="table-title">Adverse events: UFH plus PGI2 versus UFH plus PGE1 </span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study ID</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Adverse events</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Intervention: events/participants</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><a href="./references#CD012467-bbs2-0018" title="Kozek-LangeneckerSA , SpissCK , GamsjagerT , DomenigC , ZimpferM . Anticoagulation with prostaglandins and unfractionated heparin during continuous venovenous haemofiltration: a randomized controlled trial. Wiener Klinische Wochenschrift2002;114(3):96-101. [MEDLINE: 12060975]">Kozek‐Langenecker 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Trivial bleeding</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>UFH + PGI<sub>2</sub>: 1/15 </p> <p>UFH + PGE<sub>1</sub>: 1/18 </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Major bleeding</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>UFH + PGI<sub>2</sub>: 0/15 </p> <p>UFH + PGE<sub>1</sub>: 1/18 </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="3"> <div class="table-footnote"> <p>PG ‐ prostaglandin; UFH ‐ unfractionated heparin</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 9.</span> <span class="table-title">Adverse events: UFH plus PGI2 versus UFH plus PGE1 </span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/full#CD012467-tbl-0012">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD012467-tbl-0013"> <div class="table-heading"><span class="table-label">Table 10.</span> <span class="table-title">Adverse events: UFH plus tirofiban versus UFH</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study ID</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Adverse events</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Intervention: events/participants</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><a href="./references#CD012467-bbs2-0022" title="LinkA , GirndtM , SelejanS , RbahR , BohmM . Tirofiban preserves platelet loss during continuous renal replacement therapy in a randomised prospective open-blinded pilot study. Critical Care (London, England)2008;12(4):R111. [MEDLINE: 18759963]">Link 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Major bleeding</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>UFH: 0/20</p> <p>Tirofiban: 0/20</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Minor bleeding</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>UFH: 2/20</p> <p>Tirofiban: 1/20</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="3"> <div class="table-footnote"> <p>UFH ‐ unfractionated heparin</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 10.</span> <span class="table-title">Adverse events: UFH plus tirofiban versus UFH</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/full#CD012467-tbl-0013">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD012467-tbl-0014"> <div class="table-heading"><span class="table-label">Table 11.</span> <span class="table-title">Adverse events: Bivalirudin versus UFH</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study ID</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Adverse events</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Intervention: events/participants</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><a href="./references#CD012467-bbs2-0017" title="KiserTH , MacLarenR , FishDN , HassellKL , TeitelbaumI . Bivalirudin versus unfractionated heparin for prevention of hemofilter occlusion during continuous renal replacement therapy. Pharmacotherapy2010;30(11):1117-26. [MEDLINE: 20973685]">Kiser 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Alveolar haemorrhage</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Bivalirudin: 0/5</p> <p>UFH: 1/5</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Deep vein thrombosis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Bivalirudin: 0/5</p> <p>UFH: 1/5</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="3"> <div class="table-footnote"> <p>UFH ‐ unfractionated heparin</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 11.</span> <span class="table-title">Adverse events: Bivalirudin versus UFH</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/full#CD012467-tbl-0014">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD012467-tbl-0015"> <div class="table-heading"><span class="table-label">Table 12.</span> <span class="table-title">Adverse events: Hirudin versus UFH</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study ID</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Adverse events</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Intervention: events/participants</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012467-bbs2-0032" title="Vargas HeinO , vonHeymannC , LippsM , ZiemerS , RoncoC , NeumayerHH , et al. Hirudin versus heparin for anticoagulation in continuous renal replacement therapy. Intensive Care Medicine2001;27(4):673-9. [MEDLINE: 11403068]">Vargas Hein 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Bleeding</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hirudin: 3/8</p> <p>UFH: 0/9</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012467-bbs2-0014" title="HeinOV , vonHeymannC , DiehlT , ZiemerS , RoncoC , MorgeraS , et al. Intermittent hirudin versus continuous heparin for anticoagulation in continuous renal replacement therapy. Renal Failure2004;26(3):297-303. [MEDLINE: 15354980]">Hein 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Bleeding</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hirudin: 0/12</p> <p>UFH: 2/14</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="3"> <div class="table-footnote"> <p>UFH ‐ unfractionated heparin</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 12.</span> <span class="table-title">Adverse events: Hirudin versus UFH</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/full#CD012467-tbl-0015">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD012467-tbl-0016"> <div class="table-heading"><span class="table-label">Table 13.</span> <span class="table-title">Adverse events: Dalteparin (LMWH) versus nadoparin (LMWH)</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study ID</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Adverse events</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Intervention: events/participants</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012467-bbs2-0008" title="dePontAC , Oudemans-van StraatenHM , RoozendaalKJ , ZandstraDF . Nadroparin versus dalteparin anticoagulation in high-volume, continuous venovenous hemofiltration: a double-blind, randomized, crossover study. Critical Care Medicine2000;28(2):421-5. [MEDLINE: 10708177]">de Pont 2000</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>All bleeding events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nadroparin: 2/32</p> <p>Dalteparin: 1/32</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="3"> <div class="table-footnote"> <p>LMWH ‐ low molecular weight heparin</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 13.</span> <span class="table-title">Adverse events: Dalteparin (LMWH) versus nadoparin (LMWH)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/full#CD012467-tbl-0016">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD012467-tbl-0017"> <div class="table-heading"><span class="table-label">Table 14.</span> <span class="table-title">Adverse events: Citrate plus LMWH versus citrate</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study ID</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Adverse events</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Intervention: events/participants</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p><a href="./references#CD012467-bbs2-0034" title="WuB , ZhangK , XuB , JiD , LiuZ , GongD . Randomized controlled trial to evaluate regional citrate anticoagulation plus low-dose of dalteparin in continuous veno-venous hemofiltration. Blood Purification2015;39(4):306-12. [MEDLINE: 26022434]ZhangK , GongD , JiD , XuB , IIuZ . Regional citrate plus low dose of low molecular weight heparins: a safe and more efficacy anticoagulation protocol for continuous veno - venous hemofiltration [abstract no: 71]. In: CCRT 2012. 17th International Conference on CRRT; 2012 Feb 14-17; San Diego (CA). 2012. [CENTRAL: CN-01658175] ">Wu 2015b</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Bleeding</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Citrate + LMWH: 1/19</p> <p>Citrate: 2/15</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hypocalcaemia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Citrate + LMWH: 0/19</p> <p>Citrate: 1/15</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Metabolic acidosis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Citrate + LMWH: 4/19</p> <p>Citrate: 3/15</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Severe metabolic acidosis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Citrate + LMWH: 0/19</p> <p>Citrate: 1/15</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="3"> <div class="table-footnote"> <p>LMWH ‐ low molecular weight heparin</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 14.</span> <span class="table-title">Adverse events: Citrate plus LMWH versus citrate</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/full#CD012467-tbl-0017">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD012467-tbl-0018"> <div class="table-heading"><span class="table-label">Table 15.</span> <span class="table-title">Adverse events: Citrate plus LMWH versus LMWH</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study ID</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Adverse events</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Intervention: events/participants</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p><a href="./references#CD012467-bbs2-0034" title="WuB , ZhangK , XuB , JiD , LiuZ , GongD . Randomized controlled trial to evaluate regional citrate anticoagulation plus low-dose of dalteparin in continuous veno-venous hemofiltration. Blood Purification2015;39(4):306-12. [MEDLINE: 26022434]ZhangK , GongD , JiD , XuB , IIuZ . Regional citrate plus low dose of low molecular weight heparins: a safe and more efficacy anticoagulation protocol for continuous veno - venous hemofiltration [abstract no: 71]. In: CCRT 2012. 17th International Conference on CRRT; 2012 Feb 14-17; San Diego (CA). 2012. [CENTRAL: CN-01658175] ">Wu 2015b</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Bleeding</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Citrate + LMWH: 1/19</p> <p>LMWH: 4/19</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hypocalcaemia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Citrate + LMWH: 0/19</p> <p>LMWH: 0/19</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Metabolic acidosis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Citrate + LMWH: 4/19</p> <p>LMWH: 0/19</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Severe metabolic acidosis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Citrate + LMWH: 0/19</p> <p>LMWH: 0/19</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="3"> <div class="table-footnote"> <p>LMWH ‐ low molecular weight heparin</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 15.</span> <span class="table-title">Adverse events: Citrate plus LMWH versus LMWH</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/full#CD012467-tbl-0018">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012467-tbl-0019"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Citrate versus UFH</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 Major bleeding <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.1 Citrate versus UFH</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>702</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.22 [0.08, 0.62]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.2 Citrate versus UFH plus protamine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>262</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.34 [0.01, 8.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.2 Death at 28 days <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.1 Citrate versus UFH</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>462</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.06 [0.86, 1.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.2 Citrate versus UFH plus protamine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>242</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.11 [0.76, 1.64]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.3 Successful prevention of clotting <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.1 Citrate versus UFH</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>211</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.44 [1.10, 1.87]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.2 Citrate versus UFH plus protamine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>229</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.72, 1.31]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.4 Metabolic disturbances <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.1 Citrate versus UFH</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>369</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.88 [1.12, 7.39]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.5 Hypernatraemia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.1 Citrate versus UFH</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>236</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.47 [0.34, 6.35]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.6 Hypocalcaemia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6.1 Citrate versus UFH</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>400</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.51 [1.31, 15.55]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6.2 Citrate versus UFH plus protamine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.20 [0.24, 74.48]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.7 Hypercalcaemia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>158</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.7.1 Citrate versus UFH</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>158</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.8 Recovery of kidney function <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.8.1 Citrate versus UFH</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>214</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.04 [0.89, 1.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.8.2 Citrate versus UFH plus protamine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.16 [0.53, 2.51]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.9 Thrombocytopenia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.9.1 Citrate versus UFH</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>412</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.39 [0.14, 1.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.10 Catheter thrombotic events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.10.1 Citrate versus UFH</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>301</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.42, 2.48]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.11 Treatment cessation due to any adverse event <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.11.1 Citrate versus UFH</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>412</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.47 [0.15, 1.49]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.11.2 Citrate versus UFH plus protamine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1129</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.28, 3.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.12 Treatment attempts with any adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.12.1 Citrate versus UHF</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>539</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.59 [0.36, 0.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.12.2 Citrate versus UFH plus protamine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1129</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.71 [0.13, 3.80]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Citrate versus UFH</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/references#CD012467-tbl-0019">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012467-tbl-0020"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Citrate versus LMWH</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.1 Major bleeding <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>234</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.45 [0.21, 0.97]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.2 Death <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>253</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.79 [0.61, 1.02]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.3 Successful prevention of clotting <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.4 Metabolic disturbances <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>234</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.57 [0.12, 20.97]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.5 Hypernatraemia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>234</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.18 [0.13, 77.23]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.6 Hypocalcaemia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>234</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.29 [0.81, 13.46]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.7 Hypercalcaemia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.8 Recovery of kidney function <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>253</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.38, 2.67]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.9 Thrombocytopenia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>234</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [0.18, 3.47]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.10 Treatment cessation due to any adverse event <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>234</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.11 [0.03, 0.44]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Citrate versus LMWH</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/references#CD012467-tbl-0020">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012467-tbl-0021"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">UFH versus LMWH</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.1 Major bleeding <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>233</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.58 [0.13, 2.58]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.2 Death (unknown time frame) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.3 Successful prevention of clotting <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.4 Thrombocytopenia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>124</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.57 [0.20, 1.63]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.5 Treatment cessation due to any adverse event <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>117</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.29 [0.02, 3.53]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.6 Any adverse event <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">UFH versus LMWH</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/references#CD012467-tbl-0021">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012467-tbl-0022"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">UFH versus no anticoagulation</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.1 Major bleeding <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">UFH versus no anticoagulation</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/references#CD012467-tbl-0022">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012467-tbl-0023"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Nafamostat mesilate versus no anticoagulation</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.1 Major bleeding <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>115</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.06 [0.37, 3.04]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.2 Death at 28 days <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>133</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.72, 1.41]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.3 Recovery of kidney function <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.4 Catheter thrombotic events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.5 Treatment cessation due to any adverse event <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.6 Treatment attempts with any adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>128</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.09 [0.58, 2.02]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Nafamostat mesilate versus no anticoagulation</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/references#CD012467-tbl-0023">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012467-tbl-0024"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">PGI2 versus UFH</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.1 Major bleeding <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.2 Successful prevention of clotting <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">PGI2 versus UFH</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/references#CD012467-tbl-0024">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012467-tbl-0025"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">UFH plus PGI2 versus PGI2 </span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.1 Major bleeding <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">UFH plus PGI2 versus PGI2 </span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/references#CD012467-tbl-0025">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012467-tbl-0026"> <div class="table-heading"><span class="table-label">Comparison 8.</span> <span class="table-title">UFH plus PGI2 versus UFH</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8.1 Major bleeding <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>81</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.16 [0.01, 2.88]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8.2 Successful prevention of clotting <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>158</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.83 [1.27, 2.63]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8.3 Thrombocytopenia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8.4 Catheter thrombotic events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8.5 Any adverse event <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.19 [0.03, 1.40]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 8.</span> <span class="table-title">UFH plus PGI2 versus UFH</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/references#CD012467-tbl-0026">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012467-tbl-0027"> <div class="table-heading"><span class="table-label">Comparison 9.</span> <span class="table-title">UFH plus protamine and PGI2 versus UFH</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9.1 Major bleeding <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9.2 Death at 24 hours <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9.3 Successful prevention of clotting <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 9.</span> <span class="table-title">UFH plus protamine and PGI2 versus UFH</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/references#CD012467-tbl-0027">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012467-tbl-0028"> <div class="table-heading"><span class="table-label">Comparison 10.</span> <span class="table-title">UFH plus PGI2 versus UFH plus PGE1 </span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10.1 Major bleeding <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10.2 Successful prevention of clotting <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 10.</span> <span class="table-title">UFH plus PGI2 versus UFH plus PGE1 </span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/references#CD012467-tbl-0028">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012467-tbl-0029"> <div class="table-heading"><span class="table-label">Comparison 11.</span> <span class="table-title">UFH plus PGE1 versus UFH</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11.1 Major bleeding <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.31 [0.04, 2.74]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11.2 Successful prevention of clotting <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>135</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.71 [1.16, 2.52]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 11.</span> <span class="table-title">UFH plus PGE1 versus UFH</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/references#CD012467-tbl-0029">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012467-tbl-0030"> <div class="table-heading"><span class="table-label">Comparison 12.</span> <span class="table-title">UFH plus tirofiban versus UFH</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12.1 Major bleeding <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12.2 Death at 28 days <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 12.</span> <span class="table-title">UFH plus tirofiban versus UFH</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/references#CD012467-tbl-0030">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012467-tbl-0031"> <div class="table-heading"><span class="table-label">Comparison 13.</span> <span class="table-title">Bivalirudin versus UFH</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13.1 Major bleeding <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13.2 Death at 28 days <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13.3 Recovery of kidney function <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 13.</span> <span class="table-title">Bivalirudin versus UFH</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/references#CD012467-tbl-0031">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012467-tbl-0032"> <div class="table-heading"><span class="table-label">Comparison 14.</span> <span class="table-title">Hirudin versus UFH</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14.1 Major bleeding <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.37 [0.04, 43.22]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14.2 Death at 28 days <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.24 [0.63, 2.43]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14.3 Thrombocytopenia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 14.</span> <span class="table-title">Hirudin versus UFH</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/references#CD012467-tbl-0032">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012467-tbl-0033"> <div class="table-heading"><span class="table-label">Comparison 15.</span> <span class="table-title">Low molecular weight dextran versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15.1 Successful prevention of clotting <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 15.</span> <span class="table-title">Low molecular weight dextran versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/references#CD012467-tbl-0033">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012467-tbl-0034"> <div class="table-heading"><span class="table-label">Comparison 16.</span> <span class="table-title">Dalteparin (LMWH) versus nadroparin (LMWH)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">16.1 Successful prevention of clotting <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 16.</span> <span class="table-title">Dalteparin (LMWH) versus nadroparin (LMWH)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/references#CD012467-tbl-0034">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012467-tbl-0035"> <div class="table-heading"><span class="table-label">Comparison 17.</span> <span class="table-title">Citrate plus LMWH versus citrate</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">17.1 Major bleeding <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">17.2 Death at 28 days <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">17.3 Successful prevention of clotting <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">17.4 Metabolic disturbances <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">17.5 Hypernatraemia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">17.6 Hypocalcaemia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">17.7 Recovery of kidney function <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">17.8 Thrombocytopenia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">17.9 Treatment cessation due to any adverse event <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 17.</span> <span class="table-title">Citrate plus LMWH versus citrate</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/references#CD012467-tbl-0035">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012467-tbl-0036"> <div class="table-heading"><span class="table-label">Comparison 18.</span> <span class="table-title">Citrate plus LMWH versus LMWH</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">18.1 Major bleeding <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">18.2 Death at 28 days <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">18.3 Successful prevention of clotting <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">18.4 Metabolic disturbances <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">18.5 Hypernatraemia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">18.6 Hypocalcaemia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">18.7 Recovery of kidney function <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">18.8 Thrombocytopenia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">18.9 Treatment cessation due to any adverse event <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 18.</span> <span class="table-title">Citrate plus LMWH versus LMWH</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012467.pub3/references#CD012467-tbl-0036">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD012467.pub3&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD012467-note-0030">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD012467-note-0028">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD012467-note-0029">Français</a> </li> <li class="section-language"> <a class="" href="hr#CD012467-note-0027">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ja#CD012467-note-0026">日本語</a> </li> <li class="section-language"> <a class="" href="ms#CD012467-note-0025">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="ru#CD012467-note-0024">Русский</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD012467-note-0023">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738735355000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738735355000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012467\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012467\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012467\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012467\x2epub3"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012467\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012467\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012467\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012467\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012467\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012467\x2epub3"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012467\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012467\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012467\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012467\x2epub3"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012467\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012467\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012467\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012467\x2epub3"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=jU9oKp1Y&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012467.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD012467.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD012467.pub3/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD012467.pub3/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012467.pub3%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740714512512"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD012467.pub3/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740714512516"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD012467.pub3/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918d707b1b689377',t:'MTc0MDcxNDUxMi4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 